

11/28/00
JC520 U.S. PTO

11-29-00

seq/A

PATENT APPLICATION

jc520 U.S. PTO
09/724126
11/28/00



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No: 01017/35966A

PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. 1.53

*Box Patent Application
Commissioner for Patents
Washington, D.C. 20231*

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): Han et al.

Title: The Human E3 α Ubiquitin Ligase Family

1. Type of Application


- This is a new application for a
 - utility patent.
 - design patent.
- This is a continuation-in-part application of prior application no.

2. Application Papers Enclosed

- 1 Title Page
- 106 Pages of Specification (excluding Claims, Abstract, Drawings & Sequence Listing)
- 11 Page(s) of Claims
- 1 Page(s) of Abstract
- 16 Sheet(s) of Drawings (Figs. 1 to 12)
 - Formal
 - Informal
- 57 Page(s) of Sequence Listing

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Patent Application Transmittal and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on November 28, 2000, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EM578444884US.


Sharon M. Sintich

3. Declaration or Oath

- Enclosed
 - Executed by (check all applicable boxes)
 - Inventor(s)
 - Legal representative of inventor(s)
(37 CFR 1.42 or 1.43)
 - Joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached
 - The petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 are enclosed.
See Item 5D below for fee.
 - Not enclosed - the undersigned attorney or agent is authorized to file this application on behalf of the applicant(s). An executed declaration will follow.

4. Small Entity Status

- Applicant claims small entity status. See 37 CFR 1.27.
- A small entity statement is(are) attached.

5. Additional Papers Enclosed

- Preliminary Amendment
- Information Disclosure Statement
- Declaration of Biological Deposit
- Computer readable copy of sequence listing containing nucleotide and/or amino acid sequence
- Microfiche computer program
- Associate Power of Attorney
- Verified translation of a non-English patent application
- An assignment of the invention
- Return receipt postcard
- Other--Statement of Sequence Listing

6. Priority Applications Under 35 USC 119

Certified copies of applications from which priority under 35 USC 119 is claimed are listed below and

are attached.
 will follow.

COUNTRY	APPLICATION NO.	FILED
US	60/187,911	March 8, 2000

7. Filing Fee Calculation (37 CFR 1.16)

A. Utility Application

CLAIMS AS FILED - INCLUDING PRELIMINARY AMENDMENT (IF ANY)						
			SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	NO. FILED	NO. EXTRA	RATE	FEES	RATE	FEES
BASIC FEE				\$355.00		\$710.00
TOTAL	97 -20	= 77	X 9 =	\$	X 18 =	\$1,386.00
INDEP.	15 - 3	= 12	X 40 =	\$	X 80 =	\$960.00
<input checked="" type="checkbox"/> First Presentation of Multiple Dependent Claim			+ 135 =	\$	+ 270 =	\$270.00
Filing Fee:				\$	OR	\$3,326.00

B. Design Application (\$160.00/\$320.00) Filing Fee: \$ _____

C. Plant Application (\$245.00/\$490.00) Filing Fee: \$ _____

D. Other Fees

Recording Assignment [Fee -- \$40.00 per assignment] \$ _____

Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached [Fee -- \$130.00] \$ _____

Other \$ _____

Total Fees Enclosed \$3,326.00

8. Method of Payment of Fees

Enclosed check in the amount of: \$3,326.00

Charge Deposit Account No. 13-2855 in the amount of: \$ _____
A copy of this Transmittal is enclosed.

Not enclosed

9. Deposit Account and Refund Authorization

The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required during the pendency of this application under 37 CFR 1.16 or 37 CFR 1.17 or under other applicable rules (except payment of issue fees), to Deposit Account No. 13-2855. A copy of this Transmittal is enclosed.

Please refund any overpayment to Marshall, O'Toole, Gerstein, Murray & Borun at the address below.

10. Correspondence Address


Customer No.: 04743

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300
(312) 474-0448 (Telefacsimile)

By:

David W. Clough
Reg. No: 36,107



November 28, 2000

JOINT INVENTORS

"EXPRESS MAIL" mailing label No.
EM578444884US.

Date of Deposit: November 28, 2000

I hereby certify that this paper (or fee) is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, D.C. 20231


Sharon M. Sintich

APPLICATION FOR UNITED STATES LETTERS PATENT

S P E C I F I C A T I O N

TO ALL WHOM IT MAY CONCERN:

Be it known that we, Hui-Quan Han a citizen of the United States of America, residing at 3353 Crossland Street, Thousand Oaks, California, 91362, and Keith Kwak a citizen of the United States of America, residing at 1699 Amarelle Street, Thousand Oaks, California, 91320, have invented new and useful The Human E3 α Ubiquitin Ligase Family, of which the following is a specification.

THE HUMAN E3 α UBIQUITIN LIGASE FAMILY

RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119 from U.S.
5 provisional patent application Serial No. 60/187,911 filed March 8, 2000.

FIELD OF THE INVENTION

The present invention includes novel human E3 α ubiquitin ligase polypeptides (huE3 α I and huE3 α II) and nucleic acid molecules encoding the same. The invention also relates to vectors, host cells, selective binding agents, such as antibodies, and methods for producing huE3 α polypeptides. Also provided for are methods for the diagnosis, treatment, amelioration and/or prevention of diseases associated with huE3 α polypeptides, as well as methods for identifying modulators of huE3 α ligase activity.

BACKGROUND OF THE INVENTION

Technical advances in the identification, cloning, expression and manipulation of nucleic acid molecules and deciphering of the human genome have greatly accelerated the discovery of novel therapeutics based upon deciphering of the human genome. Rapid nucleic acid sequencing techniques can now generate sequence information at unprecedented rates and, coupled with computational analyses, allow the assembly of overlapping sequences into the partial and entire genomes as well as the identification of polypeptide-encoding regions. A comparison of a predicted amino acid sequence against a database compilation of known amino acid sequences can allow one to determine the extent of homology to previously identified sequences and/or structural landmarks. The cloning and expression of a polypeptide-encoding region of a nucleic acid molecule provides a polypeptide product for structural and functional analyses. The manipulation of nucleic acid molecules and encoded polypeptides to create variants and derivatives thereof may confer advantageous properties on a product for use as a therapeutic.

In spite of significant technical advances in genome research over the past decade, the potential for the development of novel therapeutics based on the human genome is still largely unrealized. Many genes encoding potentially beneficial

polypeptide therapeutics, or those encoding polypeptides which may act as "targets" for therapeutic molecules, have still not been identified. In addition, structural and functional analyses of polypeptide products from many human genes have not been undertaken.

5 Accordingly, it is an object of the invention to identify novel polypeptides and nucleic acid molecules encoding the same which have diagnostic or therapeutic benefit.

10 Most types of intracellular proteins are degraded through the ubiquitin-proteosome pathway. In this system, proteins are marked for proteosomal degradation by the conjugation of ubiquitin molecules to the protein. Conjugation of the ubiquitin molecule initially involves activation by the E1 enzyme. Upon activation the ubiquitin molecule is transferred to the E2 enzyme which serves as a carrier-protein. The E2 enzyme interacts with a specific E3 ligase family member. The E3 ligase binds to proteins targeted for degradation and catalyzes the transfer of ubiquitin from the E2 carrier enzyme to the target protein. Since the target protein binds to the ligase prior to conjugation, E3 ligase is the rate limiting step for ubiquitin conjugation and determines the specificity of the system. The ubiquitin chain serves as a degradation marker for the 26S proteosome (See Ciechanover, *EMBO J.*, 17: 7151-7160, 1998).

15 There are only a few known E3 ligases and the sequence homology between them is low. The E3 α family is the main family of intracellular ubiquitin ligases and is involved in N-end rule pathway of protein degradation. The N-end rule states that there is a strong relation between the *in vivo* half-life of a protein and the identity of its N-terminal amino acids. Accordingly, E3 α enzyme binds directly to the primary destabilizing N-terminal amino acid and catalyzes ubiquitin conjugation thereby targeting the protein for degradation. E3 α family members also recognize non-N-end rule substrates (See Ciechanover, *EMBO J.*, 17: 7151-7160, 1998).

20 The E3 α enzyme family currently consists of intracellular enzymes isolated from rabbit (Reiss and Hershko, *J. Biol. Chem.* 265: 3685-3690, 1990), mouse (Kwon *et al.*, *Proc. Natl. Acad. Sci., U.S.A.* 95: 7898-7903, 1999), yeast (Bartel *et al.*, *EMBO J.*, 9: 3179-3189, 1990) and the *C. elegans* (Wilson *et al.*, *Nature*, 368: 32-38, 1994; Genebank Accession No. U88308) counterparts termed UBR-1. Comparison of these known sequences indicates regions of high similarity regions (I-V) which suggest

the existence of a distinct family. The regions of similarity contain essential residues for the recognition of N-end rule substrates. In region I, the residues Cys-145, Val-146, Gly-173, and Asp-176 are known to be necessary for type-1 substrate binding in yeast and are conserved in the mouse. In regions II and III, residues Asp-318, His-321, and Glu-560 are essential for type-2 substrate binding in yeast and are also conserved in the mouse. In addition, there is a conserved zinc-finger domain in region I and a conserved RING-H2 domain in region IV (Kwon *et al.*, *Proc. Natl. Acad. Sci., U.S.A.*, 95: 7898-7903, 1999).

The full length mouse E3 α cDNA sequence and a partial human E3 α nucleotide sequence (\approx 1 kb) have recently been cloned and characterized as described in US 5,861,312 and Kwon *et al.* (*Proc. Natl. Acad. U.S.A.*, 95: 7898-7908, 1999). The full length mouse E3 α cDNA sequence is 5271 bp in length and encodes a 1757 amino acid polypeptide. The mouse E3 α gene is localized to the central region of chromosome 2 and is highly expressed in skeletal muscle, heart and brain. The partial human E3 α sequence was used to characterize tissue expression and chromosomal localization. This analysis indicated that the human E3 α gene is located on chromosome 15q and exhibits a similar expression pattern as mouse E3 α with high expression in skeletal muscle, heart and brain. As described herein, the present invention discloses two novel, full length, human E3 α sequences (huE3 α I and huE3 α II) and a novel, full length mouse E3 α sequence (muE3 α II). Expression of huE3 α I and huE3 α II mRNA is highly enriched in skeletal muscle tissues. Functionally, huE3 α polypeptides are intracellular enzymes that control protein conjugation and degradation.

Increased proteolysis through the ubiquitin-proteosome pathway has been determined to be a major cause of rapid muscle wasting in many pathological states including but not limited to fasting, metabolic acidosis, muscle denervation, kidney failure, renal cachexia, uremia, diabetes mellitus, sepsis, AIDS wasting syndrome, cancer cachexia, negative nitrogen balance cachexia, burns and Cushing's syndrome (See Mitch and Goldberg, *New England J. Med.*, 335: 1897-1905, 1996). Studies in animal models have shown that muscle wasting disorders are associated with increased ubiquitin content in muscles, increased levels of mRNA transcripts encoding ubiquitin, E2 enzyme and proteosome subunit mRNA, and increased ubiquitin-conjugation to muscle-proteins (See Lecker *et al.*, *J. Nutr.*, 129: 227S-237S, 1999). In this context, the N-end rule

pathway has been shown to play a role in muscle atrophy. E3 α inhibitors, such as dipeptides and methyl ester, reduce the level of ubiquitin conjugation in atrophying rat muscles caused by sepsis, fasting and cancer cachexia (Solomon *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 95: 12602-12607, 1999). These observations indicate that E3 α plays a role in the overall increase in ubiquitination that is associated with and may mediate muscle atrophy in catabolic and other disease states.

Thus, identification of members of the N-end rule protein degradation pathway has led to a better understanding of protein degradation in human cells and the mechanisms of protein degradation in pathological condition which involve muscle atrophy. Identification of the two novel human E3 α ubiquitin ligase genes and polypeptides, as described herein, will further clarify the understanding of these processes and facilitate the development of therapies for pathological conditions which involve abnormal or excessive protein degradation including conditions which involve atrophy of muscle.

SUMMARY OF THE INVENTION

The present invention relates to novel human E3 α nucleic acid molecules and polypeptides encoded by these nucleic acid molecules.

The invention provides isolated nucleic acid molecules comprising or consisting of a nucleotide sequence selected from the group consisting of:

- a) the nucleotide sequence as set forth in SEQ ID NOS: 1 or 3 ;
- b) a nucleotide sequence encoding the polypeptide set forth in SEQ ID NOS: 2 and 4;
- c) a nucleotide sequence which hybridizes under moderate or highly stringent conditions to the compliments of (a) or (b); and
- d) a nucleotide complementary to (a) - (c)

The invention also provides isolated nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of:

- a) a nucleotide sequence encoding a polypeptide that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the polypeptide set forth in SEQ ID NOS: 2 or 4, wherein the polypeptide has an activity of the polypeptide set forth in SEQ

ID NOS: 2 or 4 and the percent identity for these nucleic acid sequences are determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm;

5 b) a nucleotide sequence encoding an allelic variant or splice variant of the

nucleotide sequence as set forth in SEQ ID NOS: 1 or 3;

c) the nucleotide sequence of the DNA insert in ATCC Deposit No. PTA-
1489 or PTA-1490;

10 d) a nucleotide sequence of SEQ ID NOS: 1; 3; (a); or (b) encoding a
polypeptide fragment of at least about 25 amino acid residues, wherein the polypeptide
has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

e) a nucleotide sequence of SEQ ID NOS: 1, 3, or (a)-(c) comprising a
fragment of at least about 16 nucleotides;

f) a nucleotide sequence which hybridizes under moderately or highly
stringent conditions to the complement of any of (a)-(e); and

15 g) a nucleotide sequence complementary to any of (a)-(d).

The invention also provides isolated nucleic acid molecules comprising
a nucleotide sequence selected from the group consisting of:

a) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS:
20 2 or 4 with at least one conservative amino acid substitution, wherein the polypeptide has
an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

b) a nucleotide sequence encoding a polypeptide set forth in SEQ ID
NOS: 2 or 4 with at least one amino acid insertion, wherein the polypeptide has an
activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

25 c) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS:
2 or 4 with at least one amino acid deletion, wherein the polypeptide has an activity of
the polypeptide set forth in SEQ ID NOS: 2 or 4;

d) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS:
30 2 or 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an
activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

e) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NOS:
2 or 4 with at least one modification selected from the group consisting of amino acid

substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

f) a nucleotide sequence of (a)-(e) comprising a fragment of at least about

5 16 nucleotides;

g) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(f); and

h) a nucleotide sequence complementary to any of (a)-(e).

10 The invention also provides isolated polypeptides comprising the amino acid sequence selected from the group consisting of:

a) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4;

b) the mature amino acid sequence as set forth in SEQ ID NOS: 2 or 4 comprising a mature amino terminus at residues 1, and optionally further comprising an amino terminal methionine;

c) an amino acid sequence that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the amino acid sequence of the polypeptide of SEQ ID NOS: 2 or 4 wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4 and the percent identity for these amino acid sequences are determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm.

d) a fragment of the amino acid sequence set forth in SEQ ID NOS: 2 or 4 comprising at least about 25, 50, 75, 100, or greater than 100 amino acid residues, wherein the fragment has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

e) the amino acid sequence encoded by the DNA insert of ATCC Deposit No. PTA-1489 or PTA-1490;

f) an amino acid sequence for an ortholog of SEQ ID NOS: 2 or 4; including the murine ortholog set out as SEQ ID NO: 6.

30 g) an allelic variant or splice variant of (a), (b), (e) or (f);

The present invention also provides isolated polypeptides comprising the amino acid sequence selected from the group consisting of:

- a) the amino acid as sequence set forth in SEQ ID NOS: 2 or 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- b) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- c) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- d) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4; and
- e) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4, with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4.

The present invention provides expression vectors comprising the nucleic acid molecules set forth herein, host cells comprising the expression vectors of the invention, and a method of producing a human E3 α polypeptide comprising culturing the host cells and optionally isolating the polypeptide so produced. An another embodiment provides for viral vectors comprising the nucleic acid molecules of the inventions. Further provided is a process for determining whether a compound inhibits huE3 α polypeptide activity or production comprising exposing a host cell expressing huE3 α polypeptide to the compound, and measuring huE3 α polypeptide activity or production in said cell.

A transgenic non-human animal comprising a nucleic acid molecule encoding a huE3 α polypeptide is also encompassed by the invention. The huE3 α nucleic acid molecules are introduced into the animal in a manner that allows expression and

increased levels of a huE3 α polypeptide, which may include increased circulating levels. The transgenic non-human animal is preferably a mammal, and more preferably a rodent, such as a rat or a mouse.

Also provided are derivatives of the huE3 α polypeptides of the present invention, fusion polypeptides comprising the huE3 α polypeptides of the invention, and selective binding agents such as antibodies capable of specifically binding the polypeptides of the invention.

Pharmaceutical compositions comprising the nucleotides, polypeptides, or selective binding agents of the present invention and a carrier, adjuvant, solubilizer, stabilizer, anti-oxidant, or other pharmaceutically acceptable formulation agent are also encompassed by the invention. The pharmaceutical compositions include therapeutically effective amounts of the nucleotides or polypeptides of the present invention, and involve methods of using the polypeptides and nucleic acid molecules.

The huE3 α polypeptides and nucleic acid molecules of the present invention may be used for therapeutic or diagnostic purposes to treat, prevent, and/or detect diseases or disorders, including those recited herein.

Methods of regulating expression and modulating (*i.e.*, increasing or decreasing) levels of a huE3 α polypeptide are also encompassed by the invention. One method comprises administering to an animal a nucleic acid molecule encoding a huE3 α polypeptide. In another method, a nucleic acid molecule comprising elements that regulate or modulate the expression of a huE3 α polypeptide may be administered. Examples of these methods include gene therapy, cell therapy and antisense therapy as further described herein. Further provided is a method of identifying a compound which binds to a huE3 α polypeptide comprising.

A device, comprising a membrane suitable for implantation and host cells expressing a huE3 α polypeptide encapsulated within said membrane, wherein said membrane is permeable to said protein product and impermeable to materials detrimental to said cells is also encompassed by the present invention.

30 BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the alignment of the amino acid sequences for huE3 α I, huE3 α II, muE3 α I and muE3 α II (SEQ ID NOS: 2, 4, 15 and 6, respectively).

Figure 2 shows the results of a human multiple tissue Northern blot detecting huE3 α II expression.

Figure 3 shows the results of a human multiple tissue Northern blot detecting huE3 α I expression.

Figure 4 shows that transfection of 293T cells with huE3 α I and huE3II cDNA stimulates the ubiquitination of endogenous proteins and exogenously added α -lactalbumin in cell lysates. The left panel shows the results of gel-shift assays of ubiquitinated proteins. The high molecular weight bands (above 18 kDa for endogenous proteins and above 33 kDa for α -lactalbumin) are identified as “ 125 I-Ubiquitin-protein conjugates”. The left panel plots the quantitative measurement of ubiquinated proteins measured by a PhosphoImager.

Figure 5 shows that transfection of C₂C₁₂ and L6 myotube cells with huE3 α I and huE3II cDNA stimulates the ubiquitination of endogenous proteins cell lysates. The left panel shows the ubiquitinated high molecular weight bands (above 18 kDa for endogenous proteins) as “ 125 I-Ubiquitin-protein conjugates”. The left panel plots the quantitative measurement of ubiquinated proteins measured by a PhosphoImager.

Figure 6 shows the 125 I-ubiquitin conjugation to endogenous muscle proteins and its sensitivity to selective inhibitors of E3 α in muscle extracts from control and YAH-tumor bearing rats. Gel-shift assays of muscle extracts from control and tumor-bearing rats revealed the ubiquitinated high molecular weight bands (above 18 kDa) denoted as “ 125 I-Ubiquitin-protein conjugates”. The left panel is muscle extracts collected 3 days post-implantation and the right panel is muscle extracts collected 5 days post-implantation.

Figure 7 shows the ubiquitin conjugation to 125 I- α -lactalbumin in extracts from atrophying muscles in YAH-tumor bearing rats as western blots of muscle extracts from control and tumor-bearing rats with the ubiquitinated high molecular weight bands (above 33 kDa) as “ 125 I-Lactalbumin-ubiquitin conjugation”. The left panel is muscle extracts collected 3 days post-implantation and the right panel is muscle extracts collected 5 days post-implantation.

Figure 8 shows Northern blot analysis of E3 α I and E3 α II expression in skeletal muscle in YAH-130 experimental cachexia model. The RNA expression

from pair-fed control rats and tumor-bearing rats were compared 3 days (3d) and 5 days (5d) post-implantation.

Figure 9 shows Northern blot analysis of E3 α I and E3 α II expression in skeletal (gastrocnemius) muscle and cardiac muscle in the C26 experimental cachexia model. The RNA expression from pair-fed control rats and tumor-bearing mice were compared 12 days (12d) and 17 days (17d) post-implantation.

Figure 10 shows induction of E3 α II expression by proinflammatory cytokines TNF α and IL-6 in C₂C₁₂ myotube cultures on Northern blots. The RNA levels of E3 α II (upper panel) and E3 α I (lower panel) were detected 3 or 5 days after treatment with TNF α (left panel) and IL-6 (right panel).

Figure 11 shows that IL-6 treatment causes a time-dependent acceleration of ubiquitination in differentiated C₂C₁₂ cells. This data exhibits the results of a gel-shift assay showing the ubiquitinated high molecular weight bands denoted as “¹²⁵I-ubiquitin protein conjugates” (left panel) and is quantitated by a PhosphoImager in the right panel.

Figure 12 shows that TNF α treatment causes a does-dependent acceleration of ubiquitination in differentiated C₂C₁₂ cells. This data is displayed as gel-shift assay results with the ubiquitinated high molecular weight bands denoted as “¹²⁵I-ubiquitin protein conjugates” (left panel) and is quantitated by a PhosphoImager in the right panel.

DETAILED DESCRIPTION OF THE INVENTION

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described therein. All references cited in this application are expressly incorporated by reference herein.

Definitions

The term “huE3 α ” encompasses two novel orthologs of human E3 α ubiquitin ligase described herein including huE3 α I polynucleotide and polypeptide (SEQ ID NOS: 1 and 2, respectively) and huE3 α II polynucleotide and polypeptide (SEQ ID NOS: 3 and 4, respectively).

The term "huE3 α nucleic acid molecule" or "polynucleotide" refers to a nucleic acid molecules including a nucleotide sequence as set forth in SEQ ID NOS: 1 or 3, a nucleotide sequence encoding the polypeptide set forth in SEQ ID NOS: 2 or 4, a nucleotide sequence of the DNA insert in ATCC deposit nos. PTA-5 1489 or PTA-1490, or nucleic acid molecule related thereto. Related nucleic acid molecules include a nucleotide sequence that is at least about 70 percent identical to the nucleotide sequence as shown in SEQ ID NOS: 1 or 3, or comprise or consist essentially of a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide set forth in SEQ ID NOS: 2 or 4. In preferred 10 embodiments, these nucleotide sequences are about 75 percent, or about 80 percent, or about 85 percent, or about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the nucleotide sequence as shown in SEQ ID NOS: 1 or 3, or the nucleotide sequences encode a polypeptide that is about 75 percent, or about 80 percent, or about 85 percent, or about 90 percent, or about 95, 96, 97, 98, or 99 15 percent identical to the polypeptide sequence as set forth in SEQ ID NOS: 2 or 4.

Related nucleic acid molecules also include fragments of the huE3 α I or hu E3 α II nucleic acid molecules which fragments contain at least about 10 contiguous nucleotides, or about 15, or about 20, or about 25, or about 50, or about 75, or about 100, or greater than about 100 contiguous nucleotides of a huE3 α nucleic 20 acid molecule of SEQ ID NOS: 1 or 3. Related nucleic acid molecules also include fragments of the above huE3 α nucleic acid molecules which encode a polypeptide of at least about 25 amino acid residues, or about 50, or about 75, or about 100, or greater than about 100 amino acid residues of the huE3 α polypeptide of SEQ ID NOS: 2 or 4. Related nucleic acid molecules also include a nucleotide sequence 25 encoding a polypeptide comprising or consisting essentially of a substitution, modification, addition and/or a deletion of one or more amino acid residues compared to the polypeptide set forth in SEQ ID NOS: 2 or 4. In addition, related huE3 α nucleic acid molecules include those molecules which comprise nucleotide sequences which hybridize under moderately or highly stringent conditions as defined herein 30 with the fully complementary sequence of any of the huE3 α nucleic acid molecules of SEQ ID NOS: 1 or 3.

In preferred embodiments, the related nucleic acid molecules comprise sequences which hybridize under moderately or highly stringent conditions with a molecule having a sequence as shown in SEQ ID NOS: 1 or 3, or of a molecule encoding a polypeptide, which polypeptide comprises the sequence as shown in SEQ ID NOS: 2 or 4, or of a nucleic acid fragment as defined herein, or of a nucleic acid fragment encoding a polypeptide as defined herein or the complement of any or the forgoing molecules. It is also understood that related nucleic acid molecules include allelic or splice variants of a huE3 α nucleic acid molecule of SEQ ID NOS: 1 or 3, and include sequences which are complementary to any of the above nucleotide sequences. The related encoded polypeptides possess at least one activity of the polypeptide depicted in SEQ ID NOS: 2 or 4.

The term "isolated nucleic acid molecule" refers to a nucleic acid molecule of the invention that is free from at least one contaminating nucleic acid molecule with which it is naturally associated. Preferably, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating mammalian nucleic acid molecule(s) which would interfere with its use in polypeptide production or its therapeutic, diagnostic, or preventative use.

A "nucleic acid sequence" or "nucleic acid molecule" as used herein refer to a DNA or RNA sequence. The terms encompasses molecules formed from any of the known base analogs of DNA and RNA such as, but not limited to 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinyl-cytosine, pseudouracil, 5-(carboxyhydroxymethyl) uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxy-methylamino-methyluracil, dihydrouracil, inosine, N6-iso-pentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5' -methoxycarbonyl-methyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-

methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.

The term “operably linked” is used as recognized in the art to refer to an arrangement of flanking sequences wherein the flanking sequences so described are configured or assembled so as to perform their usual function. Thus, a flanking sequence operably linked to a coding sequence may be capable of effecting the replication, transcription and/or translation of the coding sequence. For example, a coding sequence is operably linked to a promoter when the promoter is capable of directing transcription of that coding sequence. A flanking sequence need not be contiguous with the coding sequence, so long as it functions correctly. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.

The term “pharmaceutically acceptable carrier” or “physiologically acceptable carrier” as used herein refer to one or more formulation materials suitable for accomplishing or enhancing delivery of the huE3 α polypeptide , huE3 α nucleic acid molecule, or huE3 α selective binding agent as a pharmaceutical composition.

The term “allelic variant” refers to one of several possible naturally occurring alternate forms of a gene occupying a given locus on a chromosome of an organism or a population of organisms.

The term “splice variant” refers to a nucleic acid molecule, usually RNA, which is generated by alternative processing of intron sequences in an RNA transcript of huE3 α polypeptide amino acid sequence.

The term “expression vector” refers to a vector which is suitable for transformation of a host cell and contains nucleic acid sequences which direct and/or control the expression of inserted heterologous nucleic acid sequences. Expression includes, but is not limited to, processes such as transcription, translation, and RNA splicing, if introns are present.

The term “vector” is used as recognized in the art to refer to any molecule (*e.g.*, nucleic acid, plasmid, or virus) used to transfer coding information to a host cell.

The term "transformation" as used herein refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transfection or transduction, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.

10 The term "transfection" is used to refer to the uptake of foreign or exogenous DNA by a cell, and a cell has been "transfected" when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, for example, Graham *et al.*, *Virology*, 52: 456, 1973; Sambrook *et al.*, *Molecular Cloning, A*

15 *Laboratory Manual*, Cold Spring Harbor Laboratories, New York, 1989; Davis *et al.*, *Basic Methods in Molecular Biology*, Elsevier, 1986; and Chu *et al.*, *Gene*, 13: 197, 1981. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

20 The term "transduction" is used to refer to the transfer of genes from one bacterium to another, usually by a phage. "Transduction" also refers to the acquisition and transfer of eukaryotic cellular sequences by retroviruses.

25 The term "host cell" is used to refer to a cell which has been transformed, or is capable of being transformed, by a vector bearing a selected gene of interest which is then expressed by the cell. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so long as the selected gene is present.

30 The term "highly stringent conditions" refers to those conditions that are designed to permit hybridization of DNA strands whose sequences are highly complementary, and to exclude hybridization of significantly mismatched DNAs. Hybridization stringency is principally determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of "highly stringent conditions" for hybridization and washing are 0.015 M sodium chloride,

0.0015 M sodium citrate at 65-68°C or 0.015 M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42°C. See Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989); Anderson *et al.*, *Nucleic Acid Hybridisation: A Practical Approach*, Ch. 4, IRL Press Limited (Oxford, England).

More stringent conditions (such as higher temperature, lower ionic strength, higher formamide, or other denaturing agent) may also be used, however, the rate of hybridization will be affected. Other agents may be included in the hybridization and washing buffers for the purpose of reducing non-specific and/or background hybridization. Examples are 0.1% bovine serum albumin, 0.1% polyvinyl-pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecylsulfate, NaDODSO₄, or SDS, ficoll, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, although another suitable agents can also be used. The concentration and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are usually carried out at pH 6.8-7.4, however, at typical ionic strength conditions, the rate of hybridization is nearly independent of pH. (See Anderson *et al.*, *Nucleic Acid Hybridisation: a Practical Approach*, Ch. 4, IRL Press Limited (Oxford, England)).

Factors affecting the stability of DNA duplex include base composition, length, and degree of base pair mismatch. Hybridization conditions can be adjusted by one skilled in the art in order to accommodate these variables and allow DNAs of different sequence relatedness to form hybrids. The melting temperature of a perfectly matched DNA duplex can be estimated by the following equation:

$$T_m(\text{°C}) = 81.5 + 16.6(\log[\text{Na}^+]) + 0.41(\%G+C) - 600/N - 0.72(\%\text{formamide})$$

where N is the length of the duplex formed, [Na⁺] is the molar concentration of the sodium ion in the hybridization or washing solution, %G+C is the percentage of (guanine+cytosine) bases in the hybrid. For imperfectly matched hybrids, the melting temperature is reduced by approximately 1°C for each 1% mismatch.

The term "moderately stringent conditions" refers to conditions under which a DNA duplex with a greater degree of base pair mismatching than could occur under "highly stringent conditions" is able to form. Examples of typical "moderately

stringent conditions" are 0.015M sodium chloride, 0.0015 M sodium citrate at 50-65°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 20% formamide at 37-50°C. By way of example, a "moderately stringent" condition of 50°C in 0.015 M sodium ion will allow about a 21% mismatch.

It will be appreciated by those skilled in the art that there is no absolute distinction between "highly" and "moderately" stringent conditions. For example, at 0.015M sodium ion (no formamide), the melting temperature of perfectly matched long DNA is about 71°C. With a wash at 65°C (at the same ionic strength), this would allow for approximately a 6% mismatch. To capture more distantly related sequences, one skilled in the art can simply lower the temperature or raise the ionic strength.

A good estimate of the melting temperature in 1 M NaCl* for oligonucleotide probes up to about 20 nt is given by:

$$T_m = 2^\circ\text{C per A-T base pair} + 4^\circ\text{C per G-C base pair}$$

*The sodium ion concentration in 6x salt sodium citrate (SSC) is 1M. See Suggs et al., *Developmental Biology Using Purified Genes*, p. 683, Brown and Fox (eds.) (1981).

High stringency washing conditions for oligonucleotides are usually at a temperature of 0-5°C below the Tm of the oligonucleotide in 6x SSC, 0.1% SDS for longer nucleotides.

The term "huE3 α polypeptide" refers to a polypeptide comprising the amino acid sequence of huE3 α I or huE3 α II (SEQ ID NOS: 2 or 4, respectively), and related polypeptides having a natural sequence or mutated sequence. Related polypeptides include: allelic variants; splice variants; fragments; derivatives; substitution, deletion, and insertion variants; fusion polypeptides; and orthologs of the huE3 α polypeptides of SEQ ID NOS: 2 or 4, which possess at least one activity of the polypeptide depicted in SEQ ID NOS: 2 or 4. Human E3 α polypeptides may be mature polypeptides, as defined herein, and may or may not have an amino terminal methionine residue, depending on the method by which they are prepared.

The term "huE3 α polypeptide fragment" refers to a polypeptide that comprises less than the full length amino acid sequence of a huE3 α I or huE3 α II polypeptide set forth in SEQ ID NOS: 2 or 4, respectively. Such huE3 α fragments can be 6 amino acids or more in length, and may arise, for example, from a truncation at the

amino terminus (with or without a leader sequence), a truncation at the carboxy terminus, and/or an internal deletion of one or more residues from the amino acid sequence. Human E3 α fragments may result from alternative RNA splicing or from *in vivo* protease activity. Membrane-bound forms of huE3 α are also contemplated by the present invention. In preferred embodiments, truncations and/or deletions comprise about 10 amino acids, or about 20 amino acids, or about 50 amino acids, or about 75 amino acids, or about 100 amino acids, or more than about 100 amino acids. The polypeptide fragments so produced will comprise about 25 contiguous amino acids, or about 50 amino acids, or about 75 amino acids, or about 100 amino acids, or about 150 amino acids, or about 200 amino acids. Such huE3 α polypeptide fragments may optionally comprise an amino terminal methionine residue. It will be appreciated that such fragments can also be used, for example, to generate antibodies to huE3 α polypeptides.

The term "huE3 α polypeptide variants" refers to huE3 α polypeptides which contain one or more amino acid sequence substitutions, deletions, and/or additions as compared to the huE3 α polypeptide amino acid sequence set forth as huE3 α I or huE3 α II (SEQ ID NOS: 2 or 4, respectively). Variants may be naturally occurring or artificially constructed. Such huE3 α polypeptide variants may be prepared from the corresponding nucleic acid molecules encoding said variants, which have a DNA sequence that varies accordingly from the DNA sequences for wild type huE3 α polypeptides as set forth in SEQ ID NOS: 1 or 3. In preferred embodiments, the variants have from 1 to 3, or from 1 to 5, or from 1 to 10, or from 1 to 20, or from 1 to 25, or from 1 to 50, or from 1 to 75, or from 1 to 100, or more than 100 amino acid substitutions, insertions, additions and/or deletions, wherein the substitutions may be conservative, or non-conservative, or any combination thereof.

One skilled in the art will be able to determine suitable variants of the native huE3 α polypeptide using well known techniques. For example, one may predict suitable areas of the molecule that may be changed without destroying biological activity. Also, one skilled in the art will realize that even areas that may be important for biological activity or for structure may be subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.

For predicting suitable areas of the molecule that may be changed without destroying activity, one skilled in the art may target areas not believed to be important for activity. For example, when similar polypeptides with similar activities from the same species or from other species are known, one skilled in the art may compare the amino acid sequence of huE3 α polypeptide to such similar polypeptides. After making such a comparison, one skilled in the art can determine residues and portions of the molecules that are conserved among similar polypeptides. One skilled in the art would know that changes in areas of the huE3 α molecule that are not conserved would be less likely to adversely affect the biological activity and/or structure of a huE3 α polypeptide.

One skilled in the art would also know that, even in relatively conserved regions, one may substitute chemically similar amino acids for the naturally occurring residues while retaining activity (conservative amino acid residue substitutions).

Additionally, one skilled in the art can review structure-function studies identifying residues in similar polypeptides that are important for activity or structure. In view of such a comparison, one skilled in the art can predict the importance of amino acid residues in a huE3 α polypeptide that correspond to amino acid residues that are important for activity or structure in similar polypeptides. One skilled in the art may opt for chemically similar amino acid substitutions for such predicted important amino acid residues of huE3 α polypeptides.

If available, one skilled in the art can also analyze the three-dimensional structure and amino acid sequence in relation to that structure in similar polypeptides. In view of that information, one skilled in the art may predict the alignment of amino acid residues of huE3 α polypeptide with respect to its three dimensional structure. One skilled in the art may choose not to make radical changes to amino acid residues predicted to be on the surface of the protein, since such residues may be involved in important interactions with other molecules.

Additional methods of predicting secondary structure include "threading" (Jones *et al.*, *Current Opin. Struct. Biol.*, 7(3):377-87 (1997); Sippl *et al.*, *Structure*, 4(1):15-9 (1996)), "profile analysis" (Bowie *et al.*, *Science*, 253:164-170 (1991); Gribskov *et al.*, *Meth. Enzym.*, 183:146-159 (1990); Gribskov *et al.*, *Proc. Nat. Acad. Sci.*, 84(13):4355-4358 (1987)), and "evolutionary linkage" (See Home, *supra*, and Brenner, *supra* 1997).

Moreover, one skilled in the art may generate test variants containing a single amino acid substitution at each amino acid residue. The variants could be screened using activity assays described herein. Such variants could be used to gather information about suitable variants. For example, if one discovered that a change to a particular amino acid residue resulted in destroyed, undesirably reduced, or unsuitable activity, variants with such a change would be avoided. In other words, based on information gathered from such routine experiments, one skilled in the art can readily determine the amino acids where further substitutions should be avoided either alone or in combination with other mutations.

In making such changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a its hydropathic index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte *et al.*, *J. Mol. Biol.*, 157: 105-131, 1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functionally equivalent protein or peptide thereby created is intended for use in immunological embodiments, as in the present case.

The U.S. Patent No. 4,554,101 states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, *i.e.*, with a biological property of the protein. As detailed in U.S. Patent No. 4,554,101, the following hydrophilicity

values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ± 1); glutamate (+3.0 ± 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ± 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4).

In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those which are within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred. One may also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. Through the methods disclosed in U.S. Patent No. 4,554,101 one of skill in the art is able to identify epitopes from within a given amino acid sequence. These regions are also referred to as "epitopic core regions".

Numerous scientific publications have been devoted to the prediction of secondary structure, and to the identification of epitopes, from analyses of amino acid sequences. See Chou *et al.*, *Biochemistry*, 13(2): 222-245, 1974; Chou *et al.*, *Biochemistry*, 113(2): 211-222, 1974; Chou *et al.*, *Adv. Enzymol. Relat. Areas Mol. Biol.*, 47: 45-148, 1978; Chou *et al.*, *Ann. Rev. Biochem.*, 47: 251-276 and Chou *et al.*, *Biophys. J.*, 26: 367-384, 1979. Moreover, computer programs are currently available to assist with predicting antigenic portions and epitopic core regions of proteins. Examples include those programs based upon the Jameson-Wolf analysis (Jameson *et al.*, *Comput. Appl. Biosci.*, 4(1): 181-186, 1998 and Wolf *et al.*, *Comput. Appl. Biosci.*, 4(1): 187-191, 1988, the program PepPlot® (Brutlag *et al.*, *CABS*, 6: 237-245 1990, and Weinberger *et al.*, *Science*, 228: 740-742, 1985) and other new programs for protein tertiary structure prediction (Fetrow *et al.*, *Biotechnology*, 11: 479-483 1993).

In preferred embodiments, the variants have from 1 to 3, or from 1 to 5, or from 1 to 10, or from 1 to 15, or from 1 to 20, or from 1 to 25, or from 1 to 50, or from 1 to 75, or from 1 to 100, or more than 100 amino acid substitutions, insertions, additions and/or deletions, wherein the substitutions may be conservative, as described herein, or non-conservative, or any combination thereof. In addition, the variants can have additions of amino acid residues either at the carboxy terminus or at the amino terminus (with or without a leader sequence).

Preferred huE3 α polypeptide variants include glycosylation variants wherein the number and/or type of glycosylation sites has been altered compared to native huE3 α polypeptide. In one embodiment, huE3 α polypeptide variants comprise a greater or a lesser number of N-linked glycosylation sites. An N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue designated as X may be any amino acid residue except proline. The substitution(s) of amino acid residues to create this sequence provides a potential new site for the addition of an N-linked carbohydrate chain. Alternatively, substitutions which eliminate this sequence will remove an existing N-linked carbohydrate chain.

Also provided is a rearrangement of N-linked carbohydrate chains wherein one or more N-linked glycosylation sites (typically those that are naturally occurring) are eliminated and one or more new N-linked sites are created. Additional preferred huE3 α variants include cysteine variants, wherein one or more cysteine residues are deleted or substituted with another amino acid (*e.g.*, serine). Cysteine variants are useful when huE3 α polypeptides must be refolded into a biologically active conformation such as after the isolation of insoluble inclusion bodies. Cysteine variants generally have fewer cysteine residues than the native protein, and typically have an even number to minimize interactions resulting from unpaired cysteines.

The term “huE3 α fusion polypeptide” refers to a fusion of huE3 α I or huE3 α II polypeptide, fragment, and/or variant thereof, with a heterologous peptide or polypeptide. IN addition, the polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 4 or huE3 α polypeptide variant many be fused to a homologous polypeptide to form a homodimer or to a heterologous polypeptide to form a heterodimer. Heterologous peptides and polypeptides include, but are not limited to: an epitope to allow for the detection and/or isolation of a huE3 α fusion polypeptide; a transmembrane receptor protein or a portion thereof, such as an extracellular domain, or a transmembrane and intracellular domain; a ligand or a portion thereof which binds to a transmembrane receptor protein; an enzyme or portion thereof which is catalytically active; a polypeptide or peptide which promotes oligomerization, such as a leucine zipper domain; a polypeptide or peptide which increases stability, such as an immunoglobulin constant region, and a polypeptide which has a therapeutic activity different from the huE3 α polypeptide.

In addition, a huE3 α polypeptide may be fused to itself or to a fragment, variant, or derivative thereof. Fusions can be made either at the amino terminus or at the carboxy terminus of a huE3 α polypeptide. Fusions may be direct with no linker or adapter molecule or indirect using through a linker or adapter molecule. A linker or adapter molecule may be one or more amino acid residues, typically from 20 amino acids residues, or up to about 50 amino acid residues. A linker or adapter molecule may also be designed with a cleavage site for a DNA restriction endonuclease or for a protease to allow for the separation of the fused moieties. It will be appreciated that once constructed, the fusion polypeptides can be derivatized according to the methods described herein.

In a further embodiment of the invention, a huE3 α polypeptide, including a fragment, variant, and/or derivative, is fused to an Fc region of human IgG. Antibodies comprise two functionally independent parts, a variable domain known as "Fab", which binds antigens, and a constant domain known as "Fc", which is involved in effector functions such as complement activation and attack by phagocytic cells. An Fc has a long serum half-life, whereas an Fab is short-lived (Capon *et al.*, *Nature*, 337: 525-31, 1989). When constructed together with a therapeutic protein, an Fc domain can provide longer half-life or incorporate such functions as Fc receptor binding, protein A binding, complement fixation and perhaps even placental transfer (Capon *et al.*, *Nature*, 337: 525-31, 1989). Table I summarizes the use of certain Fc fusions known in the art, including materials and methods applicable to the production of fused huE3 α polypeptides.

25

30

Table I
Fc Fusion with Therapeutic Proteins

	Form of Fc	Fusion partner	Therapeutic implications	Reference
5	IgG1	N-terminus of CD30-L	Hodgkin's disease; anaplastic lymphoma; T-cell leukemia	U.S. Patent No. 5,480,981
	Murine Fc γ 2a	IL-10	anti-inflammatory; transplant rejection	Zheng <i>et al.</i> , <i>J. Immunol.</i> , 154: 5590-600, 1995
	IgG1	TNF receptor	septic shock	Fisher <i>et al.</i> , <i>N. Engl. J. Med.</i> , 334: 1697-1702, 1996; Van Zee <i>et al.</i> , <i>J. Immunol.</i> , 156: 2221-30, 1996
10	IgG, IgA, IgM, or IgE (excluding the first domain)	TNF receptor	inflammation, autoimmune disorders	U.S. Pat. No. 5,808,029, issued September 15, 1998
15	IgG1	CD4 receptor	AIDS	Capon <i>et al.</i> , <i>Nature</i> 337: 525-31, 1989
	IgG1, IgG3	N-terminus of IL-2	anti cancer, antiviral	Harvill <i>et al.</i> , <i>Immunotech.</i> , 1: 95-105, 1995
	IgG1	C-terminus of OPG	osteoarthritis; bone density	WO 97/23614, published July 3, 1997
	IgG1	N-terminus of leptin	anti-obesity	PCT/US 97/23183, filed December 11, 1997
20	Human Ig Cy1	CTLA-4	autoimmune disorders	Linsley, <i>J. Exp. Med.</i> , 174: 561-9, 1991

In one example, all or portion of the human IgG hinge, CH2 and CH3 regions may be fused at either the N-terminus or C-terminus of the huE3 α polypeptides using methods known to the skilled artisan. In another example, a portion of a hinge regions and CH2 and CH3 regions may be fused. The resulting huE3 α Fc-fusion polypeptide may be purified by use of a Protein A affinity column. Peptides and proteins fused to an Fc region have been found to exhibit a substantially greater half-life *in vivo* than the unfused counterpart. Also, a fusion to an Fc region allows for dimerization/multimerization of the fusion polypeptide. The Fc region may be a naturally occurring Fc region, or may be altered to improve certain qualities, such as therapeutic qualities, circulation time, reduce aggregation, etc.

The term "huE3 α polypeptide derivatives" refers to huE3 α I or huE3 α II polypeptides, fragments, or variants, as defined herein, that have been chemically modified. The derivatives are modified in a manner that is different from naturally occurring huE3 α , polypeptides either in the type or location of the molecules attached to the polypeptide. Derivatives may further include molecules formed by the deletion of one or more chemical groups which are naturally attached to the huE3 α polypeptide.

For example, the polypeptides may be modified by the covalent attachment of one or more polymers, including, but not limited to, water soluble polymers, N-linked or O-linked carbohydrates, sugars, phosphates, and/or other such molecules. For example, the polymer selected is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. The polymer may be of any molecular weight, and may be branched or unbranched. Included within the scope of suitable polymers is a mixture of polymers. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.

Suitable water soluble polymers or mixtures thereof include, but are not limited to, polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran (such as low molecular weight dextran, of, for example about 6 kD), cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (*e.g.*, glycerol) and polyvinyl alcohol. Also encompassed by the present invention are bifunctional PEG crosslinking molecules which may be used to prepare covalently attached huE3 α multimers.

For the acylation reactions, the polymer(s) selected should have a single reactive ester group. For reductive alkylation, the polymer(s) selected should have a single reactive aldehyde group. A reactive aldehyde is, for example, polyethylene glycol propionaldehyde, which is water stable, or mono C₁-C₁₀ alkoxy or aryloxy derivatives thereof (*see* U.S. Patent No. 5,252,714).

The pegylation of huE3 α polypeptides may be carried out by any of the pegylation reactions known in the art, as described for example in the following references: Francis *et al.*, *Focus on Growth Factors*, 3: 4-10, 1992; EP 0154316; EP 0401384 and U.S. Patent No. 4,179,337. Pegylation may be carried out via an acylation

reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer) as described herein.

Polyethylene glycol (PEG) is a water-soluble polymer suitable for use herein. As used herein, the terms "polyethylene glycol" and "PEG" are meant to encompass any of the forms of PEG that have been used to derivatize proteins, including mono-(C₁-C₁₀) alkoxy- or aryloxy-polyethylene glycol.

In general, chemical derivatization may be performed under any suitable conditions used to react a biologically active substance with an activated polymer molecule. Methods for preparing pegylated huE3 α polypeptides will generally comprise the steps of (a) reacting the polypeptide with polyethylene glycol (such as a reactive ester or aldehyde derivative of PEG) under conditions whereby huE3 α polypeptide becomes attached to one or more PEG groups, and (b) obtaining the reaction product(s). In general, the optimal reaction conditions for the acylation reactions will be determined based on known parameters and the desired result. For example, the larger the ratio of PEG:protein, the greater the percentage of poly-pegylated product. In one embodiment, the huE3 α polypeptide derivative may have a single PEG moiety at the amino terminus. See, for example, U.S. Patent No. 5,234,784.

Generally, conditions which may be alleviated or modulated by the administration of the present huE3 α polypeptide derivative include those described herein for huE3 α polypeptides. However, the huE3 α polypeptide derivative disclosed herein may have additional activities, enhanced or reduced biological activity, or other characteristics, such as increased or decreased half-life, as compared to the non-derivatized molecules.

The terms "biologically active huE3 α polypeptides", "biologically active huE3 α polypeptide fragments", "biologically active huE3 α polypeptide variants", and "biologically active huE3 α polypeptide derivatives" refer to huE3 α I or huE3 α II polypeptides having at least one activity characteristic of a human E3 α ubiquitin ligase, such as the activity of the polynucleotide set forth in SEQ ID NOS: 2 or 4. In general, huE3 α polypeptides, fragments, variants, and derivatives thereof, will have at least one activity characteristic of a huE3 α polypeptide such as depicted in SEQ ID NOS: 2 or 4. In addition, a huE3 α polypeptide may be active as an immunogen, that is, the polypeptide contains at least one epitope to which antibodies may be raised.

5 "Naturally occurring" or "native" when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells, and the like, refers to materials which are found in nature and are not manipulated by man. Similarly, "non-naturally occurring" or "non-native" as used herein refers to a material that is not found in nature or that has been structurally modified or synthesized by man.

10 The term "isolated polypeptide" refers to a polypeptide of the present invention that is free from at least one contaminating polypeptide that is found in its natural environment. Preferably, the isolated polypeptide is substantially free from any other contaminating mammalian polypeptides which would interfere with its therapeutic, preventative, or diagnostic use.

15 The term "ortholog" refers to a polypeptide that corresponds to a polypeptide identified from a different species that corresponds to huE3 α polypeptide amino acid sequence. For example, mouse and human E3 α polypeptides are considered orthologs.

20 The term "mature huE3 α polypeptide" refers to a polypeptide lacking a leader sequence. A mature polypeptide may also include other modifications such as proteolytic processing of the amino terminus (with or without a leader sequence) and/or the carboxy terminus, cleavage of a smaller polypeptide from a larger precursor, N-linked and/or O-linked glycosylation, and the like. An exemplary mature huE3 α polypeptide is depicted by SEQ ID NOS: 2 or 4.

25 The terms "effective amount" and "therapeutically effective amount" refer to the amount of a huE3 α polypeptide or huE3 α nucleic acid molecule used to support an observable level of one or more biological activities of the huE3 α polypeptides as set forth herein.

30 The term "selective binding agent" refers to a molecule or molecules having specificity for huE3 α molecules. Selective binding agents include antibodies, such as polyclonal antibodies, monoclonal antibodies (mAbs), chimeric antibodies, CDR-grafted antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, as well as fragments, regions, or derivatives thereof

which are provided by known techniques, including, but not limited to enzymatic cleavage, peptide synthesis, or recombinant techniques.

As used herein, the terms, "specific" and "specificity" refer to the ability of the selective binding agents to bind to human huE3 α polypeptides. It will be appreciated, however, that the selective binding agents may also bind orthologs of huE3 α , polypeptides, that is, interspecies versions of E3 α , such as mouse and rat E3 α polypeptides. A preferred embodiment relates to antibodies that are highly specific to huE3 α polypeptides yet do not cross-react (that is, they fail to bind) with specificity to non-huE3 α polypeptides.

The term "antigen" refers to a molecule or a portion of a molecule capable of being bound by a selective binding agent, such as an antibody, which is additionally capable of inducing an animal to produce antibodies capable of binding to an epitope of that antigen. An antigen can have one or more epitopes. The specific binding reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which can be evoked by other antigens.

Human E3 α polypeptides, fragments, variants, and derivatives may be used to prepare huE3 α selective binding agents using methods known in the art. Thus, antibodies and antibody fragments that bind huE3 α polypeptides are within the scope of the present invention. Antibody fragments include those portions of the antibody which bind to an epitope on the huE3 α polypeptide. Examples of such fragments include Fab and F(ab') fragments generated by enzymatic cleavage of full-length antibodies. Other binding fragments include those generated by recombinant DNA techniques, such as the expression of recombinant plasmids containing nucleic acid sequences encoding antibody variable regions. These antibodies may be, for example, polyclonal monospecific polyclonal, monoclonal, recombinant, chimeric, humanized, human, single chain, and/or bispecific.

Relatedness of Nucleic Acid Molecules and/or Polypeptides

The term "identity", as known in the art, refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic

acid molecules, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between nucleic acid molecule or polypeptide sequences, as the case may be, as determined by the match between strings of two or more nucleotide or two or more amino acid sequences. "Identity" measures the percent of identical matches between two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer programs (*i.e.*, "algorithms").

The term "similarity" is a related concept, but in contrast to "identity", refers to a measure of similarity which includes both identical matches and conservative substitution matches. If two polypeptide sequences have, for example, 10/20 identical amino acids, and the remainder are all non-conservative substitutions, then the percent identity and similarity would both be 50%. If in the same example, there are 5 more positions where there are conservative substitutions, then the percent identity remains 50%, but the percent similarity would be 75% (15/20). Therefore, in cases where there are conservative substitutions, the degree of similarity between two polypeptide sequences will be higher than the percent identity between those two sequences.

The term "isolated nucleic acid molecule" refers to a nucleic acid molecule of the invention that (1) has been separated from at least about 50 percent of proteins, lipids, carbohydrates or other materials with which it is naturally found when total DNA is isolated from the source cells, (2) is not linked to all or a portion of a polynucleotide to which the "isolated nucleic acid molecule" is linked in nature, (3) is operably linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature as part of a larger polynucleotide sequence. Preferably, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating nucleic acid molecule(s) or other contaminants that are found in its natural environment that would interfere with its use in polypeptide production or its therapeutic, diagnostic, prophylactic or research use.

The term "isolated polypeptide" refers to a polypeptide of the present invention that (1) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates or other materials with which it is naturally found when isolated from the source cell, (2) is not linked (by covalent or noncovalent interaction) to all or

a portion of a polypeptide to which the "isolated polypeptide" is linked in nature, (3) is operably linked (by covalent or noncovalent interaction) to a polypeptide with which it is not linked in nature, or (4) does not occur in nature. Preferably, the isolated polypeptide is substantially free from any other contaminating polypeptides or other contaminants that are found in its natural environment that would interfere with its therapeutic, diagnostic, prophylactic or research use.

The term "conservative amino acid substitution" refers to a substitution of a native amino acid residue with a nonnative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. For example, a conservative substitution results from the replacement of a non-polar residue in a polypeptide with any other non-polar residue. Furthermore, any native residue in the polypeptide may also be substituted with alanine, as has been previously described for "alanine scanning mutagenesis." General rules for conservative amino acid substitutions are set forth in Table II.

15

Table II
Amino Acid Substitutions

	Original Residues	Exemplary Substitutions	Preferred Substitutions
5	Ala	Val, Leu, Ile	Val
	Arg	Lys, Gln, Asn	Lys
	Asn	Gln	Gln
	Asp	Glu	Glu
10	Cys	Ser, Ala	Ser
	Gln	Asn	Asn
	Glu	Asp	Asp
	Gly	Pro, Ala	Ala
15	His	Asn, Gln, Lys, Arg	Arg
	Ile	Leu, Val, Met, Ala, Phe, Norleucine	Leu
	Leu	Norleucine, Ile, Val, Met, Ala, Phe	Ile
	Lys	Arg, 1,4 Diamino-butyric Acid, Gln, Asn	Arg
20	Met	Leu, Phe, Ile	Leu
	Phe	Leu, Val, Ile, Ala, Tyr	Leu
	Pro	Ala	Gly
	Ser	Thr, Ala, Cys	Thr
25	Thr	Ser	Ser
	Trp	Tyr, Phe	Tyr
	Tyr	Trp, Phe, Thr, Ser	Phe
	Val	Ile, Met, Leu, Phe, Ala, Norleucine	Leu

Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics, and other reversed or inverted forms of amino acid moieties. It will be appreciated by those skilled in the art the nucleic acid and polypeptide molecules

described herein may be chemically synthesized as well as produced by recombinant means.

Conservative modifications to the amino acid sequence (and the corresponding modifications to the encoding nucleotides) will produce huE3 α polypeptides having functional and chemical characteristics similar to those of naturally occurring huE3 α polypeptides. In contrast, substantial modifications in the functional and/or chemical characteristics of huE3 α polypeptides may be accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues may be divided into classes based on common side chain properties:

- 1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;
- 2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- 3) acidic: Asp, Glu;
- 4) basic: His, Lys, Arg;
- 5) residues that influence chain orientation: Gly, Pro; and
- 6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class. Such substituted residues may be introduced into regions of the human E3 α polypeptide that are homologous with non-human E3 α polypeptides, or into the non-homologous regions of the molecule.

Identity and similarity of related nucleic acid molecules and polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M.

Stockton Press, New York, 1991; and Carillo *et al.*, *SIAM J. Applied Math.*, 48: 1073, 1988.

Preferred methods to determine identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are described in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux *et al.*, *Nucl. Acid. Res.*, 12: 387, 1984; Genetics Computer Group, University of Wisconsin, Madison, WI), BLASTP, BLASTN, and FASTA (Altschul *et al.*, *J. Mol. Biol.*, 215: 403-410, 1990). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (*BLAST Manual*, Altschul *et al.* NCB/NLM/NIH Bethesda, MD 20894; Altschul *et al.*, *supra*). The well known Smith Waterman algorithm may also be used to determine identity.

Certain alignment schemes for aligning two amino acid sequences may result in the matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full length sequences. Accordingly, in a preferred embodiment, the selected alignment method (GAP program) will result in an alignment that spans at least 50 contiguous amino acids of the target polypeptide.

For example, using the computer algorithm GAP (Genetics Computer Group, University of Wisconsin, Madison, WI), two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the "matched span", as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal; the "average diagonal" is the average of the diagonal of the comparison matrix being used; the "diagonal" is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix (see Dayhoff *et al.*, *Atlas of Protein Sequence and Structure*, vol. 5, supp.3 (1978) for the PAM 250 comparison matrix; Henikoff *et al.*, *Proc. Natl. Acad. Sci USA*, 89: 10915-10919, 1992 for the BLOSUM 62 comparison matrix) is also used by the algorithm.

Preferred parameters for a polypeptide sequence comparison include the following:

Algorithm: Needleman *et al.*, *J. Mol. Biol.*, 48, 443-453, 1970;

Comparison matrix: BLOSUM 62 from Henikoff *et al.*, *Proc. Natl. Acad. Sci. USA*, 89: 10915-10919, 1992)

5 Gap Penalty: 12

Gap Length Penalty: 4

Threshold of Similarity: 0

The GAP program is useful with the above parameters. The aforementioned parameters are the default parameters for polypeptide comparisons (along with no penalty for end gaps) using the GAP algorithm.

Preferred parameters for nucleic acid molecule sequence comparisons include the following:

Algorithm: Needleman *et al.*, *J. Mol Biol.*, 48: 443-453, 1970;

15 Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

The GAP program is also useful with the above parameters. The aforementioned parameters are the default parameters for nucleic acid molecule comparisons.

Other exemplary algorithms, gap opening penalties, gap extension penalties, comparison matrices, thresholds of similarity, etc. may be used by those of skill in the art, including those set forth in the Program Manual, Wisconsin Package, Version 9, September, 1997. The particular choices to be made will be apparent to those of skill in the art and will depend on the specific comparison to be made, such as DNA to DNA, protein to protein, protein to DNA; and additionally, whether the comparison is between given pairs of sequences (in which case GAP or BestFit are generally preferred) or between one sequence and a large database of sequences (in which case FASTA or BLASTA are preferred).

Synthesis

It will be appreciated by those skilled in the art the nucleic acid and polypeptide molecules described herein may be produced by recombinant and other means.

5

Nucleic Acid Molecules

Recombinant DNA methods used herein are generally those set forth in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), and/or Ausubel *et al.*, eds., *Current Protocols in Molecular Biology*, Green Publishers Inc. and Wiley and Sons, NY (1994). The present invention provides for nucleic acid molecules as described herein and methods for obtaining the molecules. Human E3 α (huE3 α) refers to the nucleotide sequence of either huE3 α I or huE3 α II. A gene or cDNA encoding a huE3 α polypeptide or fragment thereof may be obtained by hybridization screening of a genomic or cDNA library, or by PCR amplification. Where a gene encoding a huE3 α polypeptide has been identified from one species, all or a portion of that gene may be used as a probe to identify corresponding genes from other species (orthologs) or related genes from the same species (homologs). The probes or primers may be used to screen cDNA libraries from various tissue sources believed to express the huE3 α gene. In addition, part or all of a nucleic acid molecule having the sequence as set forth in SEQ ID NOS: 1 or 3 may be used to screen a genomic library to identify and isolate a gene encoding a huE3 α polypeptide. Typically, conditions of moderate or high stringency will be employed for screening to minimize the number of false positives obtained from the screen.

25 Nucleic acid molecules encoding huE3 α polypeptides may also be
identified by expression cloning which employs the detection of positive clones based
upon a property of the expressed protein. Typically, nucleic acid libraries are screened
by the binding of an antibody or other binding partner (*e.g.*, receptor or ligand) to
cloned proteins which are expressed and displayed on a host cell surface. The antibody
or binding partner is modified with a detectable label to identify those cells expressing
the desired clone.
30

Additional methods of predicting secondary structure include “threading” (Jones *et al.*, *Current Opin. Struct. Biol.*, 7(3):377-87 (1997); Sippl *et al.*, *Structure*, 4(1):15-9 (1996)), “profile analysis” (Bowie *et al.*, *Science*, 253:164-170 (1991); Gribskov *et al.*, *Meth. Enzym.*, 183:146-159 (1990); Gribskov *et al.*, *Proc. Nat. Acad. Sci.*, 84(13):4355-4358 (1987)), and “evolutionary linkage” (See Home, *supra*, and Brenner, *supra* 1997).

Another means of preparing a nucleic acid molecule encoding a huE3 α polypeptide, including a fragment or variant, is chemical synthesis using methods well known to the skilled artisan such as those described by Engels *et al.*, *Angew. Chem. Int'l. Ed.*, 28: 716-734, 1989. These methods include, *inter alia*, the phosphotriester, phosphoramidite, and H-phosphonate methods for nucleic acid synthesis. A preferred method for such chemical synthesis is polymer-supported synthesis using standard phosphoramidite chemistry. Typically, the DNA encoding the huE3 α polypeptide will be several hundred nucleotides in length. Nucleic acids larger than about 100 nucleotides can be synthesized as several fragments using these methods. The fragments can then be ligated together to form the full length huE3 α polypeptide. Usually, the DNA fragment encoding the amino terminus of the polypeptide will have an ATG, which encodes a methionine residue. This methionine may or may not be present on the mature form of the huE3 α polypeptide, depending on whether the polypeptide produced in the host cell is designed to be secreted from that cell.

In some cases, it may be desirable to prepare nucleic acid molecules encoding huE3 α polypeptide variants. Nucleic acid molecules encoding variants may be produced using site directed mutagenesis, PCR amplification, or other appropriate methods, where the primer(s) have the desired point mutations (see Sambrook *et al.*, *supra*, and Ausubel *et al.*, *supra*, for descriptions of mutagenesis techniques). Chemical synthesis using methods described by Engels *et al.*, *supra*, may also be used to prepare such variants. Other methods known to the skilled artisan may be used as well.

In certain embodiments, nucleic acid variants contain codons which have been altered for the optimal expression of a huE3 α polypeptide in a given host cell. Particular codon alterations will depend upon the huE3 α polypeptide(s) and host cell(s) selected for expression. Such “codon optimization” can be carried out by a variety of methods, for example, by selecting codons which are preferred for use in highly

expressed genes in a given host cell. Computer algorithms which incorporate codon frequency tables such as "Ecohigh.cod" for codon preference of highly expressed bacterial genes may be used and are provided by the University of Wisconsin Package Version 9.0, Genetics Computer Group, Madison, WI. Other useful codon frequency tables include "Celegans_high.cod", "Celegans_low.cod", "Drosophila_high.cod", "Human_high.cod", "Maize_high.cod", and "Yeast_high.cod".

In other embodiments, nucleic acid molecules encode huE3 α variants with conservative amino acid substitutions as described herein, huE3 α variants comprising an addition and/or a deletion of one or more N-linked or O-linked glycosylation sites, huE3 α variants having deletions and/or substitutions of one or more cysteine residues, or huE3 α polypeptide fragments as described herein. In addition, nucleic acid molecules may encode any combination of huE3 α variants, fragments, and fusion polypeptides described herein.

Vectors and Host Cells

A nucleic acid molecule encoding a huE3 α polypeptide is inserted into an appropriate expression vector using standard ligation techniques wherein huE3 α refers to either the polypeptide sequence of huE3 α I or huE3 α II. The vector is typically selected to be functional in the particular host cell employed (*i.e.*, the vector is compatible with the host cell machinery such that amplification of the gene and/or expression of the gene can occur). A nucleic acid molecule encoding a huE3 α polypeptide may be amplified/expressed in prokaryotic, yeast, insect (baculovirus systems), and/or eukaryotic host cells. Selection of the host cell will depend in part on whether a huE3 α polypeptide is to be post-translationally modified (*e.g.*, glycosylated and/or phosphorylated). If so, yeast, insect, or mammalian host cells are preferable. For a review of expression vectors, see *Meth. Enz.*, v.185, D.V. Goeddel, ed. Academic Press Inc., San Diego, CA (1990).

Typically, expression vectors used in any of the host cells will contain sequences for plasmid maintenance and for cloning and expression of exogenous nucleotide sequences. Such sequences, collectively referred to as "flanking sequences" in certain embodiments will typically include one or more of the following nucleotides: a promoter, one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, a complete intron sequence containing a donor and acceptor

splice site, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. Each of these sequences is discussed below.

5 Optionally, the vector may contain a "tag"-encoding sequence, *i.e.*, an oligonucleotide sequence located at the 5' or 3' end of the huE3 α polypeptide coding sequence; the oligonucleotide molecule encodes polyHis (such as hexaHis), or another "tag" such as FLAG, HA (hemagglutinin influenza virus) or *myc* for which commercially available antibodies exist. This tag is typically fused to the polypeptide upon expression of the polypeptide, and can serve as a means for affinity purification of the huE3 α polypeptide from the host cell. Affinity purification can be accomplished, for example, by column chromatography using antibodies against the tag as an affinity matrix. Optionally, the tag can subsequently be removed from the purified huE3 α polypeptide by various means such as using certain peptidases for cleavage.

10 Flanking sequences may be homologous (*i.e.*, from the same species and/or strain as the host cell), heterologous (*i.e.*, from a species other than the host cell species or strain), hybrid (*i.e.*, a combination of flanking sequences from more than one source), or synthetic, or the flanking sequences may be native sequences which normally function to regulate huE3 α polypeptide expression. As such, the source of a flanking sequence may be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequences is functional in, and can be activated by, the host cell machinery.

15 The flanking sequences useful in the vectors of this invention may be obtained by any of several methods well known in the art. Typically, flanking sequences useful herein other than endogenous huE3 α gene flanking sequences will have been previously identified by mapping and/or by restriction endonuclease digestion and can thus be isolated from the proper tissue source using the appropriate restriction endonucleases. In some cases, the full nucleotide sequence of one or more flanking sequence may be known. Here, the flanking sequence may be synthesized using the methods described herein for nucleic acid synthesis or cloning.

Where all or only a portion of the flanking sequence is known, it may be obtained using PCR and/or by screening a genomic library with suitable oligonucleotide and/or flanking sequence fragments from the same or another species.

5 Where the flanking sequence is not known, a fragment of DNA containing a flanking sequence may be isolated from a larger piece of DNA that may contain, for example, a coding sequence or even another gene or genes. Isolation may be accomplished by restriction endonuclease digestion to produce the proper DNA fragment followed by isolation using agarose gel purification, Qiagen® column chromatography (Chatsworth, CA), or other methods known to the skilled artisan. The selection of suitable enzymes

10 to accomplish this purpose will be readily apparent to one of ordinary skill in the art.

An origin of replication is typically a part of those prokaryotic expression vectors purchased commercially, and the origin aids in the amplification of the vector in a host cell. Amplification of the vector to a certain copy number can, in some cases, be important for the optimal expression of the huE3 α polypeptide. If the vector of choice does not contain an origin of replication site, one may be chemically synthesized based on a known sequence, and ligated into the vector. For example, the origin of replication from the plasmid pBR322 (Product No. 303-3s, New England Biolabs, Beverly, MA) is suitable for most gram-negative bacteria and various origins (e.g.; SV40, polyoma, adenovirus, vesicular stomatitis virus (VSV) or papillomaviruses such as HPV or BPV) are useful for cloning vectors in mammalian cells.

15 Generally, the origin of replication component is not needed for mammalian expression vectors (for example, the SV40 origin is often used only because it contains the early promoter).

20

A transcription termination sequence is typically located 3' of the end of a polypeptide coding region and serves to terminate transcription. Usually, a transcription termination sequence in prokaryotic cells is a G-C rich fragment followed by a poly T sequence. While the sequence is easily cloned from a library or even purchased commercially as part of a vector, it can also be readily synthesized using methods for nucleic acid synthesis such as those described herein.

25 A selectable marker gene element encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium. Typical selection marker genes encode proteins that (a) confer resistance to antibiotics or other

toxins, *e.g.*, ampicillin, tetracycline, or kanamycin for prokaryotic host cells, (b) complement auxotrophic deficiencies of the cell; or (c) supply critical nutrients not available from complex media. Preferred selectable markers are the kanamycin resistance gene, the ampicillin resistance gene, and the tetracycline resistance gene.
5 A neomycin resistance gene may also be used for selection in prokaryotic and eukaryotic host cells.

Other selection genes may be used to amplify the gene which will be expressed. Amplification is the process wherein genes which are in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Examples of suitable 10 selectable markers for mammalian cells include dihydrofolate reductase (DHFR) and thymidine kinase. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of the selection gene present in the vector. Selection pressure is imposed by culturing the transformed cells under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to the amplification of both the 15 selection gene and the DNA that encodes huE3 α polypeptides. As a result, increased quantities of huE3 α polypeptides are synthesized from the amplified DNA.

A ribosome binding site is usually necessary for translation initiation of 20 mRNA and is characterized by a Shine-Dalgarno sequence (prokaryotes) or a Kozak sequence (eukaryotes). The element is typically located 3' to the promoter and 5' to the coding sequence of the huE3 α polypeptide to be expressed. The Shine-Dalgarno sequence is varied but is typically a polypurine (*i.e.*, having a high A-G content). Many Shine-Dalgarno sequences have been identified, each of which can be readily 25 synthesized using methods set forth above and used in a prokaryotic vector.

A leader, or signal, sequence may be used to direct a huE3 α polypeptide out of the host cell. Typically, a nucleotide sequence encoding the signal sequence is positioned in the coding region of the huE3 α nucleic acid molecule, or directly at the 30 5' end of the huE3 α polypeptide coding region. Many signal sequences have been identified, and any of those that are functional in the selected host cell may be used in conjunction with the huE3 α nucleic acid molecule. Therefore, a signal sequence may be homologous (naturally occurring) or heterologous to the huE3 α gene or cDNA.

Additionally, a signal sequence may be chemically synthesized using methods described herein. In most cases, the secretion of a huE3 α polypeptide from the host cell via the presence of a signal peptide will result in the removal of the signal peptide from the huE3 α polypeptide. The signal sequence may be a component of the vector, or it may be a part of huE3 α DNA that is inserted into the vector.

Included within the scope of this invention is the use of either a nucleotide sequence encoding a native huE3 α signal sequence joined to a huE3 α polypeptide coding region or a nucleotide sequence encoding a heterologous signal sequence joined to a huE3 α polypeptide coding region. The heterologous signal sequence selected should be one that is recognized and processed, *i.e.*, cleaved by a signal peptidase, by the host cell. For prokaryotic host cells that do not recognize and process the native huE3 α signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, or heat-stable enterotoxin II leaders. For yeast secretion, the native huE3 α signal sequence may be substituted by the yeast invertase, alpha factor, or acid phosphatase leaders. In mammalian cell expression the native signal sequence is satisfactory, although other mammalian signal sequences may be suitable.

In some cases, such as where glycosylation is desired in a eukaryotic host cell expression system, one may manipulate the various presequences to improve glycosylation or yield. For example, one may alter the peptidase cleavage site of a particular signal peptide, or add presequences, which also may affect glycosylation. The final protein product may have, in the -1 position (relative to the first amino acid of the mature protein) one or more additional amino acids incident to expression, which may not have been totally removed. For example, the final protein product may have one or two amino acid residues found in the peptidase cleavage site, attached to the N-terminus. Alternatively, use of some enzyme cleavage sites may result in a slightly truncated form of the desired huE3 α polypeptide, if the enzyme cuts at such area within the mature polypeptide.

In many cases, transcription of a nucleic acid molecule is increased by the presence of one or more introns in the vector; this is particularly true where a polypeptide is produced in eukaryotic host cells, especially mammalian host cells. The introns used may be naturally occurring within the huE3 α gene, especially where the

gene used is a full length genomic sequence or a fragment thereof. Where the intron is not naturally occurring within the gene (as for most cDNAs), the intron(s) may be obtained from another source. The position of the intron with respect to flanking sequences and the huE3 α gene is generally important, as the intron must be expressed to be effective. Thus, when a huE3 α cDNA molecule is being expressed, the preferred position for the intron is 3' to the transcription start site, and 5' to the polyA transcription termination sequence. Preferably, the intron or introns will be located on one side or the other (*i.e.*, 5' or 3') of the cDNA such that it does not interrupt the coding sequence. Any intron from any source, including any viral, prokaryotic and eukaryotic (plant or animal) organisms, may be used to practice this invention, provided that it is compatible with the host cell(s) into which it is inserted. Also included herein are synthetic introns. Optionally, more than one intron may be used in the vector.

The expression and cloning vectors of the present invention will each typically contain a promoter that is recognized by the host organism and operably linked to the molecule encoding a huE3 α polypeptide. Promoters are untranscribed sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of the structural gene. Promoters are conventionally grouped into one of two classes, inducible promoters and constitutive promoters. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as the presence or absence of a nutrient or a change in temperature. Constitutive promoters, on the other hand, initiate continual gene product production; that is, there is little or no control over gene expression. A large number of promoters, recognized by a variety of potential host cells, are well known. A suitable promoter is operably linked to the DNA encoding a huE3 α polypeptide by removing the promoter from the source DNA by restriction enzyme digestion and inserting the desired promoter sequence into the vector. The native huE3 α promoter sequence may be used to direct amplification and/or expression of huE3 α DNA. A heterologous promoter is preferred, however, if it permits greater transcription and higher yields of the expressed protein as compared to the native promoter, and if it is compatible with the host cell system that has been selected for use.

Promoters suitable for use with prokaryotic hosts include the beta-lactamase and lactose promoter systems; alkaline phosphatase, a tryptophan (trp) promoter system; and hybrid promoters such as the tac promoter. Other known bacterial promoters are also suitable. Their sequences have been published, thereby enabling one skilled in the art to ligate them to the desired DNA sequence(s), using linkers or adapters as needed to supply any useful restriction sites.

Suitable promoters for use with yeast hosts are also well known in the art. Yeast enhancers are advantageously used with yeast promoters. Suitable promoters for use with mammalian host cells are well known and include, but are not limited to, those obtained from the genomes of viruses such as polyoma virus, fowl pox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40). Other suitable mammalian promoters include heterologous mammalian promoters, e.g., heat-shock promoters and the actin promoter.

Additional promoters which may be of interest in controlling huE3 α gene transcription include, but are not limited to: the SV40 early promoter region (Bernoist and Chambon, *Nature*, 290: 304-310, 1981); the CMV promoter; the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto *et al.*, *Cell*, 22: 787-797, 1980); the herpes thymidine kinase promoter (Wagner *et al.*, *Proc. Natl. Acad. Sci. USA*, 78: 144-1445, 1981); the regulatory sequences of the metallothioneine gene (Brinster *et al.*, *Nature*, 296: 39-42, 1982); prokaryotic expression vectors such as the beta-lactamase promoter (Villa-Kamaroff, *et al.*, *Proc. Natl. Acad. Sci. USA*, 75: 3727-3731, 1978); or the tac promoter (DeBoer, *et al.*, *Proc. Natl. Acad. Sci. USA*, 80: 21-25, 1983). Also of interest are the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: the elastase I gene control region which is active in pancreatic acinar cells (Swift *et al.*, *Cell*, 38: 639-646, 1984; Ornitz *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, 50: 399-409, 1986; MacDonald, *Hepatology*, 7: 425-515, 1987); the insulin gene control region which is active in pancreatic beta cells (Hanahan, *Nature*, 315: 115-122, 1985); the immunoglobulin gene control region which is active in lymphoid cells (Grosschedl *et al.*, *Cell*, 38: 647-658 (1984); Adames *et al.*, *Nature*, 318: 533-538 (1985); Alexander *et al.*, *Mol. Cell. Biol.*, 7: 1436-1444,

1987); the mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, *Cell*, 45: 485-495, 1986); the albumin gene control region which is active in liver (Pinkert *et al.*, *Genes and Devel.*, 1: 268-276, 1987); the alphafetoprotein gene control region which is active in liver (Krumlauf *et al.*, *Mol. Cell. Biol.*, 5: 1639-1648, 1985; Hammer *et al.*, *Science*, 235: 53-58, 1987); the alpha 1-antitrypsin gene control region which is active in the liver (Kelsey *et al.*, *Genes and Devel.*, 1: 161-171, 1987); the beta-globin gene control region which is active in myeloid cells (Mogram *et al.*, *Nature*, 315: 338-340, 1985; Kollias *et al.*, *Cell*, 46: 89-94, 1986); the myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead *et al.*, *Cell*, 48: 703-712, 1987); the myosin light chain-2 gene control region which is active in skeletal muscle (Sani, *Nature*, 314: 283-286, 1985); and the gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason *et al.*, *Science*, 234: 1372-1378, 1986).

An enhancer sequence may be inserted into the vector to increase the transcription of a DNA encoding a huE3 α polypeptide of the present invention by higher eukaryotes. Enhancers are cis-acting elements of DNA, usually about 10-300 bp in length, that act on the promoter to increase its transcription. Enhancers are relatively orientation and position independent. They have been found 5' and 3' to the transcription unit. Several enhancer sequences available from mammalian genes are known (*e.g.*, globin, elastase, albumin, alpha-feto-protein and insulin). Typically, however, an enhancer from a virus will be used. The SV40 enhancer, the cytomegalovirus early promoter enhancer, the polyoma enhancer, and adenovirus enhancers are exemplary enhancing elements for the activation of eukaryotic promoters. While an enhancer may be spliced into the vector at a position 5' or 3' to huE3 α DNA, it is typically located at a site 5' from the promoter.

Expression vectors of the invention may be constructed from a starting vector such as a commercially available vector. Such vectors may or may not contain all of the desired flanking sequences. Where one or more of the desired flanking sequences are not already present in the vector, they may be individually obtained and ligated into the vector. Methods used for obtaining each of the flanking sequences are well known to one skilled in the art.

Preferred vectors for practicing this invention are those which are compatible with bacterial, insect, and mammalian host cells. Such vectors include, *inter alia*, pCRII, pCR3, and pcDNA3.1 (Invitrogen Company, Carlsbad, CA), pBSII (Stratagene Company, La Jolla, CA), pET15 (Novagen, Madison, WI), pGEX (Pharmacia Biotech, Piscataway, NJ), pEGFP-N2 (Clontech, Palo Alto, CA), pETL (BlueBacII; Invitrogen), pDSR-alpha (PCT Publication No. WO90/14363) and pFastBacDual (Gibco/BRL, Grand Island, NY).

Additional suitable vectors include, but are not limited to, cosmids, plasmids, or modified viruses, but it will be appreciated that the vector system must be compatible with the selected host cell. Such vectors include, but are not limited to plasmids such as Bluescript® plasmid derivatives (a high copy number ColE1-based phagemid, Stratagene Cloning Systems Inc., La Jolla CA), PCR cloning plasmids designed for cloning Taq-amplified PCR products (*e.g.*, TOPO™ TA Cloning® Kit, PCR2.1® plasmid derivatives, Invitrogen, Carlsbad, CA), and mammalian, yeast, or virus vectors such as a baculovirus expression system (pBacPAK plasmid derivatives, Clontech, Palo Alto, CA). The recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, or other known techniques.

After the vector has been constructed and a nucleic acid molecule encoding a huE3 α polypeptide has been inserted into the proper site of the vector, the completed vector may be inserted into a suitable host cell for amplification and/or polypeptide expression. Host cells may be prokaryotic host cells (such as *E. coli*) or eukaryotic host cells (such as a yeast cell, an insect cell, or a vertebrate cell). The host cell, when cultured under appropriate conditions, synthesizes a huE3 α polypeptide which can subsequently be collected from the culture medium (if the host cell secretes it into the medium) or directly from the host cell producing it (if it is not secreted). The selection of an appropriate host cell will depend upon various factors, such as desired expression levels, polypeptide modifications that are desirable or necessary for activity, such as glycosylation or phosphorylation, and ease of folding into a biologically active molecule.

A number of suitable host cells are known in the art and many are available from the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209. Examples include, but are not limited to, mammalian cells, such as Chinese hamster ovary cells (CHO) (ATCC No. CCL61) CHO DHFR-cells (Urlaub *et al.*, *Proc. Natl. Acad. Sci. USA*, 97: 4216-4220, 1980), human

embryonic kidney (HEK) 293 or 293T cells (ATCC No. CRL1573), or 3T3 cells (ATCC No. CCL92). The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. Other suitable mammalian cell lines, are the monkey COS-1 (ATCC No. CRL1650) and COS-7 cell lines (ATCC No. CRL1651), and the CV-1 cell line (ATCC No. CCL70). Further exemplary mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, as well as primary explants, are also suitable. Candidate cells may be genotypically deficient in the selection gene, or may contain a dominantly acting selection gene. Other suitable mammalian cell lines include but are not limited to, mouse neuroblastoma N2A cells, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines, which are available from the American Type Culture Collection, Manassas, VA. Each of these cell lines is known by and available to those skilled in the art of protein expression.

Similarly useful as host cells suitable for the present invention are bacterial cells. For example, the various strains of *E. coli* (e.g., HB101, (ATCC No. 33694) DH5 α , DH10, and MC1061 (ATCC No. 53338)) are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis*, *Pseudomonas spp.*, other *Bacillus spp.*, *Streptomyces spp.*, and the like may also be employed in this method.

Many strains of yeast cells known to those skilled in the art are also available as host cells for the expression of the polypeptides of the present invention. Preferred yeast cells include, for example, *Saccharomyces cerevisiae* and *Pichia pastoris*.

Additionally, where desired, insect cell systems may be utilized in the methods of the present invention. Such systems are described for example in Kitts *et al.*, *Biotechniques*, 14: 810-817 (1993); Lucklow, *Curr. Opin. Biotechnol.*, 4: 564-572, 1993; and Lucklow *et al.* *J. Virol.*, 67: 4566-4579, 1993. Preferred insect cells are Sf-9 and Hi5 (Invitrogen, Carlsbad, CA).

The transformation of an expression vector for a huE3 α polypeptide into a selected host cell may be accomplished by well known methods including methods such as transfection, infection, calcium chloride, electroporation, microinjection, lipofection or the DEAE-dextran method or other known techniques. The method selected will in part be a function of the type of host cell to be used. These methods and

other suitable methods are well known to the skilled artisan, and are set forth, for example, in Sambrook *et al.*, *supra*.

One may also use transgenic animals to express glycosylated huE3 α polypeptides. For example, one may use a transgenic milk-producing animal (a cow or goat, for example) and obtain the present glycosylated polypeptide in the animal milk. One may also use plants to produce huE3 α polypeptides, however, in general, the glycosylation occurring in plants is different from that produced in mammalian cells, and may result in a glycosylated product which is not suitable for human therapeutic use.

10 **Polypeptide Production**

Host cells comprising a huE3 α expression vector may be cultured using standard media well known to the skilled artisan. The huE3 α expression vector refers a vector which expresses either huE3 α I or huE3 α II. The media will usually contain all nutrients necessary for the growth and survival of the cells. Suitable media for culturing *E. coli* cells include, for example, Luria Broth (LB) and/or Terrific Broth (TB). Suitable media for culturing eukaryotic cells are, Roswell Park Memorial Institute medium 1640 (RPMI 1640), Minimal Essential Medium (MEM), and/or Dulbecco's Modified Eagle Medium (DMEM), all of which may be supplemented with serum and/or growth factors as indicated by the particular cell line being cultured. A suitable medium for insect cultures is Grace's medium supplemented with yeastolate, lactalbumin hydrolysate, and/or fetal calf serum as necessary.

Typically, an antibiotic or other compound useful for selective growth of transformed cells is added as a supplement to the media. The compound to be used will be dictated by the selectable marker element present on the plasmid with which the host cell was transformed. For example, where the selectable marker element is kanamycin resistance, the compound added to the culture medium will be kanamycin. Other compounds for selective growth include ampicillin, tetracycline, and neomycin.

The amount of a huE3 α polypeptide produced by a host cell can be evaluated using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, High Performance Liquid Chromatography (HPLC) separation, immunoprecipitation, and/or activity assays such as DNA binding gel shift assays.

If a huE3 α polypeptide has been designed to be secreted from the host cells, the majority of polypeptide may be found in the cell culture medium. If however, the huE3 α polypeptide is not secreted from the host cells, it will be present in the cytoplasm and/or the nucleus (for eukaryotic host cells) or in the cytosol (for bacterial host cells).

For a huE3 α polypeptide situated in the host cell cytoplasm and/or nucleus, the host cells are typically first disrupted mechanically or with a detergent to release the intracellular contents into a buffered solution. Human E3 α polypeptide can then be isolated from this solution.

The purification of a huE3 α polypeptide from solution can be accomplished using a variety of techniques. If the polypeptide has been synthesized such that it contains a tag such as Hexahistidine (huE3 α polypeptide/hexaHis) or other small peptide such as FLAG (Eastman Kodak Co., New Haven, CT) or *myc* (Invitrogen, Carlsbad, CA) at either its carboxyl or amino terminus, it may essentially be purified in a one-step process by passing the solution through an affinity column where the column matrix has a high affinity for the tag or for the polypeptide directly (*i.e.*, a monoclonal antibody specifically recognizing and binding to the huE3 α polypeptide). For example, polyhistidine binds with great affinity and specificity to nickel, thus an affinity column of nickel (such as the Qiagen® nickel columns) can be used for purification of huE3 α polypeptide/polyHis. See for example, Ausubel *et al.*, eds., *Current Protocols in Molecular Biology*, Section 10.11.8, John Wiley & Sons, New York (1993).

Where a huE3 α polypeptide is prepared without a tag attached, and no antibodies are available, other well known procedures for purification can be used. Such procedures include, without limitation, ion exchange chromatography, molecular sieve chromatography, High Performance Liquid Chromatography (HPLC), native gel electrophoresis in combination with gel elution, and preparative isoelectric focusing ("Isoprime" machine/technique, Hoefer Scientific, San Francisco, CA). In some cases, two or more of these techniques may be combined to achieve increased purity.

If a huE3 α polypeptide is produced intracellularly, the intracellular material (including inclusion bodies for gram-negative bacteria) can be extracted from the host cell using any standard technique known to the skilled artisan. For example, the host cells can be lysed to release the contents of the periplasm/cytoplasm by French press, homogenization, and/or sonication followed by centrifugation.

If a huE3 α polypeptide has formed inclusion bodies in the cytosol, the inclusion bodies can often bind to the inner and/or outer cellular membranes and thus will be found primarily in the pellet material after centrifugation. The pellet material can then be treated at pH extremes or with chaotropic agent such as a detergent, guanidine, guanidine derivatives, urea, or urea derivatives in the presence of a reducing agent such as dithiothreitol at alkaline pH or tris carboxyethyl phosphine at acid pH to release, break apart, and solubilize the inclusion bodies. The solubized huE3 α polypeptide can then be analyzed using gel electrophoresis, immunoprecipitation or the like. If it is desired to isolate the huE3 α polypeptide, isolation may be accomplished using standard methods such as those described herein and in Marston *et al.*, *Meth. Enz.*, 182: 264-275 1990.

In some cases, a huE3 α polypeptide may not be biologically active upon isolation. Various methods for “refolding” or converting the polypeptide to its tertiary structure and generating disulfide linkages, can be used to restore biological activity. Such methods include exposing the solubilized polypeptide to a pH usually above 7 and in the presence of a particular concentration of a chaotrope. The selection of chaotrope is very similar to the choices used for inclusion body solubilization, but usually the chaotrope is used at a lower concentration and is not necessarily the same as chaotropes used for the solubilization. In most cases the refolding/oxidation solution will also contain a reducing agent or the reducing agent plus its oxidized form in a specific ratio to generate a particular redox potential allowing for disulfide shuffling to occur in the formation of the protein’s cysteine bridge(s). Some of the commonly used redox couples include cysteine/cystamine, glutathione (GSH)/dithiobis GSH, cupric chloride, dithiothreitol(DTT)/ dithiane DTT, and 2-2mercaptoethanol(β ME)/dithi(β ME). A cosolvent may be used to increase the efficiency of the refolding, and the more common reagents used for this purpose include glycerol, polyethylene glycol of various molecular weights, arginine and the like.

If inclusion bodies are not formed to a significant degree upon expression of a huE3 α polypeptide, then the polypeptide will be found primarily in the supernatant after centrifugation of the cell homogenate. The polypeptide may be further isolated from the supernatant using methods such as those described herein.

In situations where it is preferable to partially or completely purify a huE3 α polypeptide such that it is partially or substantially free of contaminants, standard methods known to those skilled in the art may be used. Such methods include, without limitation, separation by electrophoresis followed by electroelution, various types of

chromatography (affinity, immunoaffinity, molecular sieve, and/or ion exchange), and/or high pressure liquid chromatography. In some cases, it may be preferable to use more than one of these methods for complete purification.

Human E3 α polypeptides, including fragments, variants, and/or derivatives thereof may also be prepared by chemical synthesis methods (such as solid phase peptide synthesis) using techniques known in the art, such as those set forth by Merrifield *et al.*, *J. Am. Chem. Soc.*, 85 :2149, 1963, Houghten *et al.*, *Proc Natl Acad. Sci. USA*, 82: 5132 1985, and Stewart and Young, *Solid Phase Peptide Synthesis*, Pierce Chemical Co., Rockford, IL (1984). Such polypeptides may be synthesized with or without a methionine on the amino terminus. Chemically synthesized huE3 α polypeptides may be oxidized using methods set forth in these references to form disulfide bridges. Chemically synthesized huE3 α polypeptides are expected to have comparable biological activity to the corresponding huE3 α polypeptides produced recombinantly or purified from natural sources, and thus may be used interchangeably with a recombinant or natural huE3 α polypeptide.

Another means of obtaining a huE3 α polypeptide is via purification from biological samples such as source tissues and/or fluids in which the huE3 α polypeptide is naturally found. Such purification can be conducted using methods for protein purification as described herein. The presence of the huE3 α polypeptide during purification may be monitored using, for example, using an antibody prepared against recombinantly produced huE3 α polypeptide or peptide fragments thereof.

A number of additional methods for producing nucleic acids and polypeptides are known in the art, and the methods can be used to produce polypeptides having specificity for h2520-109. See for example, Roberts *et al.*, *Proc. Natl. Acad. Sci U.S.A.*, 94:12297-12303, 1997, which describes the production of fusion proteins between an mRNA and its encoded peptide. See also Roberts, R., *Curr. Opin. Chem. Biol.*, 3:268-273, 1999. Additionally, U.S. Patent No. 5,824,469 describes methods of obtaining oligonucleotides capable of carrying out a specific biological function. The procedure involves generating a heterogeneous pool of oligonucleotides, each having a 5' randomized sequence, a central preselected sequence, and a 3' randomized sequence. The resulting heterogeneous pool is introduced into a population of cells that do not exhibit the desired biological function. Subpopulations of the cells are then screened for those which exhibit a predetermined biological function. From that subpopulation, oligonucleotides capable of carrying out the desired biological function are isolated.

U.S. Patent Nos. 5,763,192; 5,814,476; 5,723,323; and 5,817,483 describe processes for producing peptides or polypeptides. This is done by producing stochastic genes or fragments thereof, and then introducing these genes into host cells which produce one or more proteins encoded by the stochastic genes. The host cells are then screened to identify those clones producing peptides or polypeptides having the desired activity.

Another method for producing peptides or polypeptides is described in PCT/US98/20094 (WO99/15650) filed by Athersys, Inc. Known as "Random Activation of Gene Expression for Gene Discovery" (RAGE-GD), the process involves the activation of endogenous gene expression or over-expression of a gene by in situ recombination methods. For example, expression of an endogenous gene is activated or increased by integrating a regulatory sequence into the target cell which is capable of activating expression of the gene by non-homologous or illegitimate recombination. The target DNA is first subjected to radiation, and a genetic promoter inserted. The promoter eventually locates a break at the front of a gene, initiating transcription of the gene. This results in expression of the desired peptide or polypeptide.

It will be appreciated that these methods can also be used to create comprehensive IL-17 like protein expression libraries, which can subsequently be used for high throughput phenotypic screening in a variety of assays, such as biochemical assays, cellular assays, and whole organism assays (*e.g.*, plant, mouse, etc.).

Chemical Derivatives

Chemically modified derivatives of the h2520-109 polypeptides may be prepared by one skilled in the art, given the disclosures set forth herein below. h2520-109 polypeptide derivatives are modified in a manner that is different, either in the type or location of the molecules naturally attached to the polypeptide. Derivatives may include molecules formed by the deletion of one or more naturally-attached chemical groups. The polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or a h2520-109 polypeptide variant, may be modified by the covalent attachment of one or more polymers. For example, the polymer selected is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Included within the scope of suitable polymers is a mixture of polymers. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.

The polymers each may be of any molecular weight and may be branched or unbranched. The polymers each typically have an average molecular weight of between about 2 kDa to about 100 kDa (the term "about" indicating that in preparations of a water soluble polymer, some molecules will weigh more, some less, than the stated molecular weight). The average molecular weight of each polymer is preferably between about 5 kDa and about 50 kDa, more preferably between about 12 kDa and about 40 kDa and most preferably between about 20 kDa to about 35 kDa. Suitable water soluble polymers or mixtures thereof include, but are not limited to, N-linked or O-linked carbohydrates; sugars; phosphates; polyethylene glycol (PEG) (including the forms of PEG that have been used to derivatize proteins, including mono-(C1-C10) alkoxy- or aryloxy-polyethylene glycol), monomethoxy-polyethylene glycol; dextran (such as low molecular weight dextran of, for example about 6 kD; cellulose, or other carbohydrate-based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol. Also encompassed by the present invention are bifunctional crosslinking molecules which may be used to prepare covalently attached multimers of the polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a h2520-109 polypeptide variant.

In general, chemical derivatization may be performed under any suitable condition used to react a protein with an activated polymer molecule. Methods for preparing chemical derivatives of polypeptides will generally comprise the steps of (a) reacting the polypeptide with the activated polymer molecule (such as a reactive ester or aldehyde derivative of the polymer molecule) under conditions whereby the polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or a h2520-109 polypeptide variant becomes attached to one or more polymer molecules, and (b) obtaining the reaction product(s). The optimal reaction conditions will be determined based on known parameters and the desired result. For example, the larger the ratio of polymer molecules:protein, the greater the percentage of attached polymer molecule. In one embodiment, the h2520-109 polypeptide derivative may have a single polymer molecule moiety at the amino terminus. (See, for example, U.S. Patent No. 5,234,784). The pegylation of the polypeptide may be specifically carried out by any of the pegylation reactions known in the art, as described for example in the following references: Francis *et al.*, *Focus on Growth Factors*, 3:4-10 (1992); EP 0154316; EP 0401384 and U.S. Patent No. 4,179,337. For example, pegylation may be carried out via

an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer) as described herein. For the acylation reactions, the polymer(s) selected should have a single reactive ester group. For reductive alkylation, the polymer(s) selected should have a single reactive aldehyde group. A reactive aldehyde is, for example, polyethylene glycol propionaldehyde, which is water stable, or mono C1-C10 alkoxy or aryloxy derivatives thereof (see U.S. Patent No. 5,252,714).

In another embodiment, h2520-109 polypeptides may be chemically coupled to biotin, and the biotin/h2520-109 polypeptide molecules which are conjugated are then allowed to bind to avidin, resulting in tetravalent avidin/biotin/h2520-109 polypeptide molecules. h2520-109 polypeptides may also be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugates precipitated with anti-DNP or anti-TNP-IgM to form decameric conjugates with a valency of 10.

Generally, conditions which may be alleviated or modulated by the administration of the present h2520-109 polypeptide derivatives include those described herein for h2520-109 polypeptides. However, the h2520-109 polypeptide derivatives disclosed herein may have additional activities, enhanced or reduced biological activity, or other characteristics, such as increased or decreased half-life, as compared to the non-derivatized molecules.

Selective Binding Agents

As used herein, the term "selective binding agent" refers to a molecule which has specificity for one or more huE3 α polypeptides. Suitable selective binding agents include, but are not limited to, antibodies and derivatives thereof, polypeptides, and small molecules. Suitable selective binding agents may be prepared using methods known in the art. An exemplary huE3 α polypeptide selective binding agent of the present invention is capable of binding a certain portion of the huE3 α polypeptide thereby inhibiting the binding of a cofactor to the huE3 α polypeptide.

Human E3 α polypeptides, fragments, variants, and derivatives may be used to prepare selective binding agents (such as antibodies) using methods known in the art; wherein huE3 α polypeptide refers to either huE3 α I or huE3 α II polypeptide. Thus, selective binding agents such as antibodies and antibody fragments that bind huE3 α polypeptides are within the scope of the present invention. The antibodies may

be polyclonal, monospecific polyclonal, monoclonal, recombinant, chimeric, humanized, human, single chain, and/or bispecific.

5 Polyclonal antibodies directed toward a huE3 α polypeptide generally are raised in animals (e.g., rabbits or mice) by multiple subcutaneous or intraperitoneal injections of huE3 α polypeptide and an adjuvant. It may be useful to conjugate a huE3 α polypeptide, or a variant, fragment, or derivative thereof to a carrier protein that is immunogenic in the species to be immunized, such as keyhole limpet heocyanin, serum, albumin, bovine thyroglobulin, or soybean trypsin inhibitor. Also, aggregating agents such as alum are used to enhance the immune response. After immunization, the animals
10 are bled and the serum is assayed for anti-huE3 α antibody titer.

Monoclonal antibodies directed toward huE3 α polypeptides are produced using any method which provides for the production of antibody molecules by continuous cell lines in culture. Examples of suitable methods for preparing monoclonal antibodies include the hybridoma methods of Kohler *et al.*, *Nature*, 256: 495-497, 1975 and the human B-cell hybridoma method, Kozbor, *J. Immunol.*, 133: 3001, 1984; Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987). Also provided by the invention are hybridoma cell lines which produce monoclonal antibodies reactive with huE3 α polypeptides.
15
20

Monoclonal antibodies of the invention may be modified for use as therapeutics. One embodiment is a "chimeric" antibody in which a portion of the heavy and/or light chain is identical with or homologous to a corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to a corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass. Also included are fragments of such antibodies, so long as they exhibit the desired biological activity. See, U.S. Patent No. 4,816,567; Morrison *et al.*, *Proc. Natl. Acad. Sci.*, 81: 6851-6855 (1985).
25

In another embodiment, a monoclonal antibody of the invention is a "humanized" antibody. Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. Humanization can be performed following methods known in the art (Jones *et al.*, *Nature* 321: 522-525, 1986; Riechmann *et al.*, *Nature*, 332: 323-327 (1988); Verhoeyen *et al.*, *Science* 239:1534-30

1536, 1988), by substituting rodent complementarity-determining regions (CDRs) for the corresponding regions of a human antibody.

Also encompassed by the invention are human antibodies which bind huE3 α polypeptides, fragments, variants and/or derivatives. Such antibodies are produced by immunization with a huE3 α antigen (*i.e.*, having at least 6 contiguous amino acids), optionally conjugated to a carrier, of transgenic animals (*e.g.*, mice) that are capable of producing a repertoire of human antibodies in the absence of endogenous immunoglobulin production. *See*, for example, Jakobovits *et al.*, *Proc. Natl. Acad. Sci.*, 90: 2551-2555, 1993; Jakobovits *et al.*, *Nature* 362: 255-258, 1993; Brugermann *et al.*, *Year in Immuno.*, 7: 33 (1993). In one method, such transgenic animals are produced by incapacitating the endogenous loci encoding the heavy and light immunoglobulin chains therein, and inserting loci encoding human heavy and light chain proteins into the genome thereof. Partially modified animals, that is those having less than the full complement of modifications, are then cross-bred to obtain an animal having all of the desired immune system modifications. When administered an immunogen, these transgenic animals produce antibodies with human variable regions, including human (*rather than e.g., murine*) antibodies which are immunospecific for these antigens. *See* PCT application Nos. PCT/US96/05928 and PCT/US93/06926. Additional methods are described in U.S. Patent No. 5,545,807, PCT application Nos. PCT/US91/245, PCT/GB89/01207, and in EP 546073B1 and EP 546073A1.

Human antibodies can also be produced from phage-display libraries (Hoogenboom *et al.*, *J. Mol. Biol.* 227: 381 1991; Marks *et al.*, *J. Mol. Biol.* 222: 581, 1991). These processes mimic immune selection through the display of antibody repertoires on the surface of filamentous bacteriophage, and subsequent selection of phage by their binding to an antigen of choice. One such technique is described in PCT Application WO99/10494, filed in the name of Adams *et al.*, which describes the isolation of high affinity and functional agonistic antibodies for MPL- and msk-receptors using such an approach.

Chimeric, CDR grafted, and humanized antibodies are typically produced by recombinant methods. Nucleic acids encoding the antibodies are introduced into host cells and expressed using materials and procedures described herein. In a preferred embodiment, the antibodies are produced in mammalian host cells, such as CHO cells. Human antibodies may be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells as described herein.

For diagnostic applications, in certain embodiments, anti-huE3 α antibodies typically will be labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as ^3H , ^{14}C , ^{32}P , 5 ^{35}S , or ^{125}I , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase, β -galactosidase, or horseradish peroxidase (Bayer *et al.*, *Meth. Enz.*, 184: 138-163 1990).

The anti-huE3 α antibodies of the invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (Sola, *Monoclonal Antibodies: A Manual of Techniques*, pp. 147-158 (CRC Press, Inc., 1987)) for the detection and quantitation of huE3 α polypeptides. The antibodies will bind huE3 α polypeptides with an affinity which is appropriate for the assay method being employed.

Competitive binding assays rely on the ability of a labeled standard (*e.g.*, a huE3 α polypeptide, or an immunologically reactive portion thereof) to compete with the test sample analyte (a huE3 α polypeptide) for binding with a limited amount of antihuE3 α antibody. The amount of a huE3 α polypeptide in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies typically are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays typically involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected and/or quantitated. In a sandwich assay, the test sample analyte is typically bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three part complex. *See, e.g.*, U.S. Patent No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assays). For example, one type of sandwich assay is an enzyme-linked immunosorbent assay (ELISA), in which case the detectable moiety is an enzyme.

The selective binding agents, including anti-h2520-109 antibodies, are also useful for *in vivo* imaging. An antibody labeled with a detectable moiety may be

administered to an animal, preferably into the bloodstream, and the presence and location of the labeled antibody in the host is assayed. The antibody may be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

5 Selective binding agents of the invention, including anti-h2520-109 antibodies, may be used as therapeutics. These therapeutic agents are generally agonists or antagonists, in that they either enhance or reduce, respectively, at least one of the biological activities of a h2520-109 polypeptide. In one embodiment, antagonist antibodies of the invention are antibodies or binding fragments thereof which are capable of specifically binding to a h2520-109 polypeptide and which are capable of inhibiting or eliminating the functional activity of a h2520-109 polypeptide *in vivo* or *in vitro*. In preferred embodiments, the selective binding agent, *e.g.*, an antagonist antibody will inhibit the functional activity of a h2520-109 polypeptide by at least about 50%, and preferably by at least about 80%. In another embodiment, the selective binding agent may be an antibody that is capable of interacting with a h2520-109 binding partner (a ligand, co-factor, or receptor) thereby inhibiting or eliminating h2520-109 activity *in vitro* or *in vivo*. Selective binding agents, including agonist and antagonist anti-h2520-109 antibodies are identified by screening assays which are well known in the art.

10 The invention also relates to a kit comprising huE3 α selective binding agents (such as antibodies) and other reagents useful for detecting huE3 α levels in biological samples. Such reagents may include a secondary antibody, a detectable label, blocking serum, positive and negative control samples, and detection reagents.

Genetically Engineered Non-Human Animals

15 Additionally included within the scope of the present invention are non-human animals such as mice, rats, or other rodents, rabbits, goats, or sheep, or other farm animals, in which the gene (or genes) encoding a native E3 α ubiquitin ligase polypeptide (such as E3 α I or E3 α II) has (have) been disrupted ("knocked out") such that the level of expression of this gene or genes is (are) significantly decreased or completely abolished. Such animals may be prepared using techniques and methods such as those described in U.S. Patent No. 5,557,032.

20 The present invention further includes non-human animals such as mice, rats, or other rodents, rabbits, goats, or sheep, or other farm animals, in which either the native form of the E3 α ubiquitin ligase polypeptide gene(s) for that animal or a

heterologous E3 α ubiquitin ligase polypeptide gene(s) is (are) over expressed by the animal, thereby creating a “transgenic” animal. Such transgenic animals may be prepared using well known methods such as those described in U.S. Patent No 5,489,743 and PCT application No. WO94/28122.

5 The present invention further includes non-human animals in which the promoter for one or more of the E3 α ubiquitin ligase polypeptides of the present invention is either activated or inactivated (*e.g.*, by using homologous recombination methods) to alter the level of expression of one or more of the native E3 α ubiquitin ligase polypeptides.

10 These non-human animals may be used for drug candidate screening. In such screening, the impact of a drug candidate on the animal may be measured. For example, drug candidates may decrease or increase the expression of the E3 α ubiquitin ligase polypeptide gene. In certain embodiments, the amount of E3 α ubiquitin ligase polypeptide, or a fragment(s), that is produced may be measured after the exposure of the animal to the drug candidate. Additionally, in certain embodiments, one may detect the actual impact of the drug candidate on the animal. For example, the overexpression of a particular gene may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate’s ability to decrease expression of the gene or its ability to prevent or inhibit a pathological condition. In other examples, the production of a particular metabolic product such as a fragment of a polypeptide, may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate’s ability to decrease the production of such a metabolic product or its ability to prevent or inhibit a pathological condition.

25 **Microarray**

It will be appreciated that DNA microarray technology can be utilized in accordance with the present invention. DNA microarrays are miniature, high density arrays of nucleic acids positioned on a solid support, such as glass. Each cell or element within the array has numerous copies of a single species of DNA which acts as a target for hybridization for its cognate mRNA. In expression profiling using DNA microarray technology, mRNA is first extracted from a cell or tissue sample and then converted enzymatically to fluorescently labeled cDNA. This material is hybridized to the microarray and unbound cDNA is removed by washing. The expression of discrete genes represented on the array is then visualized by quantitating the amount of labeled

cDNA which is specifically bound to each target DNA. In this way, the expression of thousands of genes can be quantitated in a high throughput, parallel manner from a single sample of biological material.

This high throughput expression profiling has a broad range of applications with respect to the h2520-109 molecules of the invention, including, but not limited to: the identification and validation of h2520-109 disease-related genes as targets for therapeutics; molecular toxicology of h2520-109 molecules and inhibitors thereof; stratification of populations and generation of surrogate markers for clinical trials; and the enhancement of an h2520-109-related small molecule drug discovery by aiding in the identification of selective compounds in high throughput screens (HTS).

Assaying for other modulators of huE3 α polypeptide activity

In some situations, it may be desirable to identify molecules that are modulators, *i.e.*, antagonists and agonists, of the activity of huE3 α polypeptide.

Natural or synthetic molecules that modulate huE3 α polypeptides can be identified using one or more screening assays, such as those described herein. Such molecules may be administered either in an *ex vivo* manner, or in an *in vivo* manner by injection, or by oral delivery, implantation device, or the like.

The following definition is used herein for describing the assays. "Test molecule(s)" refers to the molecule(s) that is/are under evaluation for the ability to modulate (*i.e.*, increase or decrease) the activity of a huE3 α polypeptide. Most commonly, a test molecule will interact directly with a huE3 α polypeptide. However, it is also contemplated that a test molecule may also modulate huE3 α polypeptide activity indirectly, such as by affecting huE3 α gene expression, or by binding to a huE3 α binding partner (*e.g.*, receptor, co-factor or ligand). In one embodiment, a test molecule will bind to a huE3 α polypeptide with an affinity constant of at least about 10^{-6} M, preferably about 10^{-8} M, more preferably about 10^{-9} M, and even more preferably about 10^{-10} M.

Methods for identifying compounds which interact with huE3 α polypeptides are encompassed by the present invention. In certain embodiments, a huE3 α polypeptide is incubated with a test molecule under conditions which permit the interaction of the test molecule with a huE3 α polypeptide, and the extent of the interaction can be measured. The test molecule(s) can be screened in a substantially purified form or in a crude mixture. Test molecule(s) can be nucleic acid molecules,

proteins, peptides, carbohydrates, lipids, or small molecular weight organic or inorganic compounds. Once a set of has been identified as interacting with a huE3 α polypeptide, the molecules may be further evaluated for their ability to increase or decrease huE3 α activity.

5 The measurement of the interaction of test molecules with huE3 α polypeptides may be carried out in several formats, including cell-based binding assays, membrane binding assays, solution-phase assays and immunoassays. In general, test molecules are incubated with a huE3 α polypeptide for a specified period of time, and huE3 α activity is determined by one or more assays described herein for measuring biological activity.

10 The interaction of test molecules with huE3 α polypeptides may also be assayed directly using polyclonal or monoclonal antibodies in an immunoassay. Alternatively, modified forms of huE3 α polypeptides containing epitope tags as described herein may be used in solution and immunoassays.

15 In certain embodiments, a huE3 α polypeptide agonist or antagonist may be a protein, peptide, carbohydrate, lipid, or small molecular weight molecule which interacts with huE3 α polypeptide to regulate its activity. Molecules which regulate huE3 α polypeptide expression include nucleic acids which are complementary to nucleic acids encoding a huE3 α polypeptide, or are complementary to nucleic acids sequences which direct or control the expression of huE3 α polypeptide, and which act as antisense regulators of expression.

20 Once a set of test molecules has been identified as interacting with a h2520-109 polypeptide, the molecules may be further evaluated for their ability to increase or decrease h2520-109 polypeptide activity. The measurement of the interaction of test molecules with h2520-109 polypeptides may be carried out in several formats, including cell-based binding assays, membrane binding assays, solution-phase assays and immunoassays. In general, test molecules are incubated with a h2520-109 polypeptide for a specified period of time, and h2520-109 polypeptide activity is determined by one or more assays for measuring biological activity.

25 The interaction of test molecules with h2520-109 polypeptides may also be assayed directly using polyclonal or monoclonal antibodies in an immunoassay. Alternatively, modified forms of h2520-109 polypeptides containing epitope tags as described herein may be used in immunoassays.

In the event that h2520-109 polypeptides display biological activity through an interaction with a binding partner (*e.g.*, a receptor, a ligand or a co-factor), a variety of *in vitro* assays may be used to measure the binding of a h2520-109 polypeptide to the corresponding binding partner (such as a selective binding agent, receptor, ligand, or co-factor). These assays may be used to screen test molecules for their ability to increase or decrease the rate and/or the extent of binding of a h2520-109 polypeptide to its binding partner. In one assay, a h2520-109 polypeptide is immobilized in the wells of a microtiter plate. Radiolabeled h2520-109 binding partner (for example, iodinated h2520-109 binding partner) and the test molecule(s) can then be added either one at a time (in either order) or simultaneously to the wells. After incubation, the wells can be washed and counted using a scintillation counter, for radioactivity to determine the extent to which the binding partner bound to h2520-109 polypeptide. Typically, the molecules will be tested over a range of concentrations, and a series of control wells lacking one or more elements of the test assays can be used for accuracy in the evaluation of the results. An alternative to this method involves reversing the "positions" of the proteins, *i.e.*, immobilizing h2520-109 binding partner to the microtiter plate wells, incubating with the test molecule and radiolabeled h2520-109 polypeptide, and determining the extent of h2520-109 polypeptide binding. *See*, for example, chapter 18, *Current Protocols in Molecular Biology*, Ausubel *et al.*, eds., John Wiley & Sons, New York, NY (1995).

As an alternative to radiolabelling, a h2520-109 polypeptide or its binding partner may be conjugated to biotin and the presence of biotinylated protein can then be detected using streptavidin linked to an enzyme, such as horseradish peroxidase (HRP) or alkaline phosphatase (AP), that can be detected colorimetrically, or by fluorescent tagging of streptavidin. An antibody directed to a h2520-109 polypeptide or to a h2520-109 binding partner and conjugated to biotin may also be used and can be detected after incubation with enzyme-linked streptavidin linked to AP or HRP.

A h2520-109 polypeptide or a h2520-109 like binding partner can also be immobilized by attachment to agarose beads, acrylic beads or other types of such inert solid phase substrates. The substrate-protein complex can be placed in a solution containing the complementary protein and the test compound. After incubation, the beads can be precipitated by centrifugation, and the amount of binding between a h2520-109 polypeptide and its binding partner can be assessed using the methods described herein. Alternatively, the substrate-protein complex can be immobilized in a column,

and the test molecule and complementary protein are passed through the column. The formation of a complex between a h2520-109 polypeptide and its binding partner can then be assessed using any of the techniques set forth herein, *i.e.*, radiolabelling, antibody binding or the like.

5 Another *in vitro* assay that is useful for identifying a test molecule which increases or decreases the formation of a complex between a h2520-109 polypeptide and a h2520-109 binding partner is a surface plasmon resonance detector system such as the BIACore assay system (Pharmacia, Piscataway, NJ). The BIACore system may be carried out using the manufacturer's protocol. This assay essentially involves the 10 covalent binding of either h2520-109 polypeptide or a h2520-109 binding partner to a dextran-coated sensor chip which is located in a detector. The test compound and the other complementary protein can then be injected, either simultaneously or sequentially, into the chamber containing the sensor chip. The amount of complementary protein that binds can be assessed based on the change in molecular mass which is physically 15 associated with the dextran-coated side of the sensor chip; the change in molecular mass can be measured by the detector system.

In some cases, it may be desirable to evaluate two or more test compounds together for their ability to increase or decrease the formation of a complex between a h2520-109 polypeptide and a h2520-109 binding partner. In these cases, the assays set forth herein can be readily modified by adding such additional test compound(s) either simultaneous with, or subsequent to, the first test compound. The remainder of the steps 20 in the assay are set forth herein .

25 *In vitro* assays such as those described herein may be used advantageously to screen large numbers of compounds for effects on complex formation by h2520-109 polypeptide and h2520-109 binding partner. The assays may be automated to screen compounds generated in phage display, synthetic peptide, and chemical synthesis libraries.

Compounds which increase or decrease the formation of a complex between a 30 h2520-109 polypeptide and a h2520-109 binding partner may also be screened in cell culture using cells and cell lines expressing either h2520-109 polypeptide or h2520-109 binding partner. Cells and cell lines may be obtained from any mammal, but preferably will be from human or other primate, canine, or rodent sources. The binding of a h2520-109 polypeptide to cells expressing h2520-109 binding partner at the surface is evaluated in the presence or absence of test molecules, and the extent of binding may be

determined by, for example, flow cytometry using a biotinylated antibody to a h2520-109 binding partner. Cell culture assays can be used advantageously to further evaluate compounds that score positive in protein binding assays described herein

Cell cultures can be used to screen the impact of a drug candidate. For example, 5 drug candidates may decrease or increase the expression of the huE3 α polypeptide gene. In certain embodiments, the amount of huE3 α polypeptide or a fragment(s) that is produced may be measured after exposure of the cell culture to the drug candidate. In certain embodiments, one may detect the actual impact of the drug candidate on the cell culture. For example, the overexpression of a particular gene may have a particular 10 impact on the cell culture. In such cases, one may test a drug candidate's ability to increase or decrease the expression of the gene or its ability to prevent or inhibit a particular impact on the cell culture. In other examples, the production of a particular metabolic product such as a fragment of a polypeptide, may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's 15 ability to decrease the production of such a metabolic product in a cell culture.

A yeast two hybrid system (Chien *et al.*, *Proc. Natl. Acad. Sci. USA*, 88: 9578-9583, 1991) can be used to identify novel polypeptides that bind to a yeast-two hybrid bait construct can be generated in a vector(such as the pAS2-1 form Clontech) which encodes a yeast-two hybrid domain fused to the huE3 α polynucleotide. This bait 20 construct may be used to screen human cDNA libraries wherein the cDNA library sequences are fused to GAL4 activation domains. Positive interactions will result in the activation of a reporter gene such as β -gal. Positive clones emerging from the screening may be characterized further to identify interacting proteins.

25 **Internalizing Proteins**

The *TAT* protein sequence (from HIV) can be used to internalize proteins into a cell by targeting the lipid bi-layer component of the cell membrane. *See e.g.*, Falwell *et al.*, *Proc. Natl. Acad. Sci.*, 91: 664-668, 1994. For example, an 11 amino acid sequence (YGRKKRRQRRR; SEQ ID NO: 16) of the HIV TAT protein (termed the "protein transduction domain", or TAT PDT) has been shown to mediate delivery of 30 large bioactive proteins such as β -galactosidase and p27Kip across the cytoplasmic membrane and the nuclear membrane of a cell. *See* Schwarze *et al.*, *Science*, 285: 1569-1572, 1999; and Nagahara *et al.*, *Nature Medicine*, 4: 1449-1452, 1998. Schwartz *et al.* (*Science*, 285: 1569-72, 1999) demonstrated that cultured cells acquired β -gal

activity when exposed to a fusion of the TAT PDT and β -galactosidase. Injection of mice with the TAT- β -gal fusion proteins resulted in β -gal expression in a number of tissues, including liver, kidney, lung, heart, and brain tissue.

It will thus be appreciated that the TAT protein sequence may be used to internalize a desired protein or polypeptide into a cell. In the context of the present invention, the TAT protein sequence can be fused to another molecule such as a huE3 α antagonist (*i.e.*: anti-huE3 α selective binding agent or small molecule) and administered intracellularly to inhibit the activity of the huE3 α molecule. Where desired, the huE3 α protein itself, or a peptide fragment or modified form of huE3 α , may be fused to such a protein transducer for administrating to cells using the procedures, described above.

Therapeutic Uses

The huE3 α nucleic acid molecules, polypeptides, and antagonists thereof (including, but not limited to, anti-huE3 α selective binding agents) can be used to treat, diagnose, and/or prevent a number of diseases, conditions, and disorders, including but not limited to cachexia, muscle wasting diseases and other catabolic disorders such as cancer cachexia, renal cachexia, inflammatory cachexia, muscle wasting disorders associated with metabolic acidosis, uremia, burns, hyperthyroidism, Cushing's syndrome and fasting, and denervation atrophy, diabetes mellitus, sepsis and AIDS wasting syndrome.

Those skilled in the art will recognize that many combinations of deletions, insertions, and substitutions (individually or collectively "variant(s)" herein) can be made within the amino acid sequences of the huE3 α polypeptide, provided that the resulting molecule is biologically active (*e.g.*, possesses the ability to affect one or more of the diseases and disorders such as those recited herein).

As contemplated by the present invention, a polypeptide, or antagonist thereof (including, but not limited to, anti-huE3 α selective binding agents) may be administered as an adjunct to other therapy and also with other pharmaceutical compositions suitable for the indication being treated. A polypeptide and any of one or more additional therapies or pharmaceutical formulations may be administered separately, sequentially, or simultaneously.

In a specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) thereof in combination (pretreatment, post-treatment, or concurrent

treatment) with secreted or soluble human fas antigen or recombinant versions thereof (WO96/20206 and Mountz *et al.*, *J. Immunology*, 155: 4829-4837; and EP 510 691. WO96/20206 discloses secreted human fas antigen (native and recombinant, including an Ig fusion protein), methods for isolating the genes responsible for coding the soluble recombinant human fas antigen, methods for cloning the gene in suitable vectors and cell types, and methods for expressing the gene to produce the inhibitors. EP 510 691 teaches DNAs coding for human fas antigen, including soluble fas antigen, vectors expressing for said DNAs and transformants transfected with the vector. When administered parenterally, doses of a secreted or soluble fas antigen fusion protein each are generally from about 1 microgram/kg to about 100 micrograms/kg.

Treatment of the diseases and disorders recited herein can include the use of first line drugs for control of pain and inflammation; these drugs are classified as non-steroidal, anti-inflammatory drugs (NSAIDs). Secondary treatments include corticosteroids, slow acting antirheumatic drugs (SAARDs), or disease modifying (DM) drugs. Information regarding the following compounds can be found in The Merck Manual of Diagnosis and Therapy, Sixteenth Edition, Merck, Sharp & Dohme Research Laboratories, Merck & Co., Rahway, NJ (1992) and in Pharmaprojects, PJB Publications Ltd.

In a specific embodiment, the present invention is directed to the use of a huE3 α , or antagonist (including, but not limited to, anti-huE3 α selective binding agents) and any of one or more NSAIDs for the treatment of the diseases and disorders recited herein. NSAIDs owe their anti-inflammatory action, at least in part, to the inhibition of prostaglandin synthesis (Goodman and Gilman in "The Pharmacological Basis of Therapeutics," MacMillan 7th Edition (1985)). NSAIDs can be characterized into at least nine groups: (1) salicylic acid derivatives; (2) propionic acid derivatives; (3) acetic acid derivatives; (4) fenamic acid derivatives; (5) carboxylic acid derivatives; (6) butyric acid derivatives; (7) oxicams; (8) pyrazoles and (9) pyrazolones.

In another specific embodiment, the present invention is directed to the use of an huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more salicylic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. Such salicylic acid derivatives, prodrug esters and pharmaceutically acceptable salts thereof comprise: acetaminosalol, aloxiprin, aspirin, benorylate, bromosaligenin, calcium acetylsalicylate, choline magnesium

trisalicylate, magnesium salicylate, choline salicylate, diflusinal, etersalate, fendosal, gentisic acid, glycol salicylate, imidazole salicylate, lysine acetylsalicylate, mesalamine, morpholine salicylate, 1-naphthyl salicylate, olsalazine, parsalmide, phenyl acetylsalicylate, phenyl salicylate, salacetamide, salicylamide O-acetic acid, salsalate, sodium salicylate and sulfasalazine. Structurally related salicylic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In an additional specific embodiment, the present invention is directed to the use of an huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more propionic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The propionic acid derivatives, prodrug esters, and pharmaceutically acceptable salts thereof comprise: alminoprofen, benoxaprofen, bucloxic acid, carprofen, dexindoprofen, fenoprofen, flunoxaprofen, fluprofen, flurbiprofen, furcloprofen, ibuprofen, ibuprofen aluminum, ibuproxam, indoprofen, isoprofen, ketoprofen, loxoprofen, mioprofen, naproxen, naproxen sodium, oxaprozin, piketoprofen, pimeprofen, pirprofen, pranoprofen, protizinic acid, pyridoxiprofen, suprofen, tiaprofenic acid and tioxaprofen. Structurally related propionic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In yet another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more acetic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The acetic acid derivatives, prodrug esters, and pharmaceutically acceptable salts thereof comprise: acemetacin, alclofenac, amfenac, bufexamac, cinmetacin, clopirac, delmetacin, diclofenac potassium, diclofenac sodium, etodolac, felbinac, fenclofenac, fenclorac, fenclozic acid, fentiazac, furofenac, glucametacin, ibufenac, indometacin, isofezolac, isoxepac, lonazolac, metiazinic acid, oxametacin, oxpinac, pimetacin, proglumetacin, sulindac, talmetacin, tiaramide, tiopinac, tolmetin, tolmetin sodium, zidometacin and zomepirac. Structurally related acetic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more fenamic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The fenamic acid derivatives, prodrug esters and pharmaceutically acceptable salts thereof comprise: enfenamic acid, etofenamate, flufenamic acid, isonixin, meclofenamic acid, meclofenamate sodium, medofenamic acid, mefenamic acid, niflumic acid, talniflumate, terofenamate, tolafenamic acid and ufenamate. Structurally related fenamic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In an additional specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more carboxylic acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The carboxylic acid derivatives, prodrug esters, and pharmaceutically acceptable salts thereof which can be used comprise: clidanac, disflunisal, flufenisal, inoridine, ketorolac and tinoridine. Structurally related carboxylic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In yet another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more butyric acid derivatives, prodrug esters or pharmaceutically acceptable salts thereof. The butyric acid derivatives, prodrug esters, and pharmaceutically acceptable salts thereof comprise: bumadizon, butibufen, fenbufen and xenbucin. Structurally related butyric acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more oxicams, prodrug esters, or pharmaceutically acceptable salts thereof. The oxicams, prodrug esters, and pharmaceutically acceptable salts thereof comprise: droxicam, enolicam, isoxicam, piroxicam, sudoxicam, tenoxicam and 4-hydroxyl-1,2-benzothiazine 1,1-dioxide 4-(N-phenyl)-carboxamide. Structurally

related oxicams having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In still another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more pyrazoles, prodrug esters, or pharmaceutically acceptable salts thereof. The pyrazoles, prodrug esters, and pharmaceutically acceptable salts thereof which may be used comprise: difenamizole and epirizole. Structurally related pyrazoles having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In an additional specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment or, concurrent treatment) with any of one or more pyrazolones, prodrug esters, or pharmaceutically acceptable salts thereof. The pyrazolones, prodrug esters and pharmaceutically acceptable salts thereof which may be used comprise: apazone, azapropazone, benzpiperylon, feprazone, mofebutazone, morazone, oxyphenbutazone, phenylbutazone, pipebuzone, propylphenazone, ramifenazone, suxibuzone and thiazolinobutazone. Structurally related pyrazolones having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more of the following NSAIDs: e-acetamidocaproic acid, S-adenosyl-methionine, 3-amino-4-hydroxybutyric acid, amixetrine, anitrazafen, antrafenine, bendazac, bendazac lysinate, benzydamine, beprozin, broperamole, bucolome, bufeziolac, ciproquazone, cloximate, dazidamine, deboxamet, detomidine, difenpiramide, difenpyramide, difisalamine, ditazol, emorfazone, fanetizole mesylate, fenflumizole, floctafenine, flumizole, flunixin, fluproquazone, fopirtoline, fosfosal, guaimesal, guaiazolene, isonixirn, lefetamine HCl, leflunomide, lofemizole, lotifazole, lysin clonixinate, meseclazole, nabumetone, nictindole, nimesulide, orgotein, orpanoxin, oxaceprol, oxapadol, paranyline, perisoxal, perisoxal citrate, pifoxime, piproxen, pirazolac, pifendidine, proquazone, proxazole, thielavin B, tiflamizole, timegadine, tolectin, tolpadol, tryptamid and those designated by company code number such as

480156S, AA861, AD1590, AFP802, AFP860, AI77B, AP504, AU8001, BPPC, BW540C, CHINOIN 127, CN100, EB382, EL508, F1044, FK-506, GV3658, ITF182, KCNTEI6090, KME4, LA2851, MR714, MR897, MY309, ONO3144, PR823, PV102, PV108, R830, RS2131, SCR152, SH440, SIR133, SPAS510, SQ27239, ST281, SY6001, TA60, TAI-901 (4-benzoyl-1-indancarboxylic acid), TVX2706, U60257, UR2301 and WY41770. Structurally related NSAIDs having similar analgesic and anti-inflammatory properties to the NSAIDs are also intended to be encompassed by this group.

In still another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment or concurrent treatment) with any of one or more corticosteroids, prodrug esters or pharmaceutically acceptable salts thereof for the treatment of the diseases and disorders recited herein, including acute and chronic inflammation such as rheumatic diseases, graft versus host disease and multiple sclerosis. Corticosteroids, prodrug esters and pharmaceutically acceptable salts thereof include hydrocortisone and compounds which are derived from hydrocortisone, such as 21-acetoxypregnolone, aclomerasone, algestone, amcinonide, beclomethasone, betamethasone, betamethasone valerate, budesonide, chloroprednisone, clobetasol, clobetasol propionate, clobetasone, clobetasone butyrate, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacon, desonide, desoximerasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucetonide, flumethasone, flumethasone pivalate, flucinolone acetonide, flunisolide, fluocinonide, fluorocinolone acetonide, fluocortin butyl, fluocortolone, fluocortolone hexanoate, diflucortolone valerate, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, formocortal, halcinonide, halometasone, halopredone acetate, hydro-cortamate, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone phosphate, hydrocortisone 21-sodium succinate, hydrocortisone tebutate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 21-driedryaminoacetate, prednisolone sodium phosphate, prednisolone sodium succinate, prednisolone sodium 21-m-sulfobenzoate, prednisolone sodium 21-stearoglycolate, prednisolone tebutate, prednisolone 21-trimethylacetate, prednisone, prednival, prednylidene, prednylidene 21-diethylaminoacetate, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide and triamcinolone hexacetonide.

Structurally related corticosteroids having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of an huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more slow-acting antirheumatic drugs (SAARDs) or disease modifying antirheumatic drugs (DMARDs), prodrug esters, or pharmaceutically acceptable salts thereof for the treatment of the diseases and disorders recited herein, including acute and chronic inflammation such as rheumatic diseases, graft versus host disease and multiple sclerosis. SAARDs or DMARDs, prodrug esters and pharmaceutically acceptable salts thereof comprise: allocupreide sodium, auranofin, aurothioglucose, aurothioglycanide, azathioprine, brequinar sodium, bucillamine, calcium 3-aurothio-2-propanol-1-sulfonate, chlorambucil, chloroquine, clobuzarit, cuproxoline, cyclo-phosphamide, cyclosporin, dapsone, 15-deoxyspergualin, diacerein, glucosamine, gold salts (*e.g.*, cycloquine gold salt, gold sodium thiomalate, gold sodium thiosulfate), hydroxychloroquine, hydroxychloroquine sulfate, hydroxyurea, kebuzone, levamisole, lobenzarit, melittin, 6-mercaptopurine, methotrexate, mizoribine, mycophenolate mofetil, myoral, nitrogen mustard, D-penicillamine, pyridinol imidazoles such as SKNF86002 and SB203580, rapamycin, thiols, thymopoietin and vincristine. Structurally related SAARDs or DMARDs having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more COX2 inhibitors, prodrug esters or pharmaceutically acceptable salts thereof for the treatment of the diseases and disorders recited herein, including acute and chronic inflammation. Examples of COX2 inhibitors, prodrug esters or pharmaceutically acceptable salts thereof include, for example, celecoxib. Structurally related COX2 inhibitors having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

In still another specific embodiment, the present invention is directed to the use of a huE3 α polypeptide, or antagonist (including, but not limited to, anti-huE3 α selective binding agents) in combination (pretreatment, post-treatment, or concurrent treatment) with any of one or more antimicrobials, prodrug esters or pharmaceutically

acceptable salts thereof for the treatment of the diseases and disorders recited herein, including cachexia, muscle wasting diseases and other catabolic disorders. Antimicrobials include, for example, the broad classes of penicillins, cephalosporins and other beta-lactams, aminoglycosides, azoles, quinolones, macrolides, rifamycins, tetracyclines, sulfonamides, lincosamides and polymyxins. The penicillins include, but are not limited to penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, floxacillin, ampicillin, ampicillin/sulbactam, amoxicillin, amoxicillin/clavulanate, hetacillin, cyclacillin, bacampicillin, carbenicillin, carbenicillin indanyl, ticarcillin, ticarcillin/clavulanate, azlocillin, mezlocillin, peperacillin, and mecillinam. The cephalosporins and other beta-lactams include, but are not limited to cephalothin, cephapirin, cephalexin, cephadrine, cefazolin, cefadroxil, cefaclor, cefamandole, cefotetan, cefoxitin, ceruroxime, cefonicid, ceforadine, cefixime, cefotaxime, moxalactam, ceftizoxime, ceftriaxone, cephoperazone, ceftazidime, imipenem and aztreonam. The aminoglycosides include, but are not limited to streptomycin, gentamicin, tobramycin, amikacin, netilmicin, kanamycin and neomycin. The azoles include, but are not limited to fluconazole. The quinolones include, but are not limited to nalidixic acid, norfloxacin, enoxacin, ciprofloxacin, ofloxacin, sparfloxacin and temafloxacin. The macrolides include, but are not limited to erythromycin, spiramycin and azithromycin. The rifamycins include, but are not limited to rifampin. The tetracyclines include, but are not limited to spicycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, guamecycline, lymecycline, mecloxycline, methacycline, minocycline, oxytetracycline, penimepicycline, pipacycline, rolitetracycline, sancycline, senociclin and tetracycline. The sulfonamides include, but are not limited to sulfanilamide, sulfamethoxazole, sulfacetamide, sulfadiazine, sulfisoxazole and co-trimoxazole (trimethoprim/sulfamethoxazole). The lincosamides include, but are not limited to clindamycin and lincomycin. The polymyxins (polypeptides) include, but are not limited to polymyxin B and colistin.

30 **Human E3 α Compositions and Administration**

Therapeutic compositions are within the scope of the present invention. Such compositions may comprise a therapeutically effective amount of a huE3 α polypeptide, including a fragment, variant, derivative, or one or more selective binding agents which either inhibit or stimulate an activity of huE3 α in admixture with a

pharmaceutically acceptable agent such as a pharmaceutically acceptable formulation agent; wherein huE3 α refers to the polypeptide sequence of huE3 α I or huE3 α II.

Human E3 α pharmaceutical compositions typically include a therapeutically or prophylactically effective amount of huE3 α polypeptide, (an inhibitor of huE3 α action) nucleic acid molecule or selective binding agent in a mixture with one or more pharmaceutically and physiologically acceptable formulation agents selected for suitability with the mode of administration. Suitable formulation materials or pharmaceutically acceptable agents include, but are not limited to, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants. For example, a suitable vehicle or carrier may be water for injection, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or more formulation agents suitable for accomplishing or enhancing the delivery of the huE3 α polypeptide, nucleic acid molecule or selective binding agent as a pharmaceutical composition.

Acceptable formulation materials preferably are nontoxic to recipients and are preferably inert at the dosages and concentrations employed. The materials may include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as ethylenediamine tetraacetic acid (EDTA); sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as tween, pluronics, or polyethylene glycol (PEG).

Typically, a huE3 α molecule pharmaceutical composition will be administered in the form of a composition comprising a purified polypeptide, in conjunction with one or more physiologically acceptable agents. It will be appreciated that when used herein, the term "huE3 α molecule pharmaceutical composition" also encompasses compositions containing a nucleic acid molecule or selective binding agent of the present invention.

Neutral buffered saline or saline mixed with serum albumin are exemplary appropriate carriers. Other standard pharmaceutically acceptable agents such as diluents and excipients may be included as desired. For example, the huE3 α polypeptide product may be formulated as a lyophilizate using appropriate excipients such as sucrose. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which may further include sorbitol or a suitable substitute therefor.

The primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. In addition, the composition may contain other formulation materials for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the composition may contain additional formulation materials for modifying or maintaining the rate of release of huE3 α polypeptide, nucleic acid molecule or selective binding agent, or for promoting the absorption or penetration of huE3 α such molecules.

The huE3 α molecule pharmaceutical compositions can be administered parenterally. Alternatively, the compositions may be administered through the digestive tract, such as orally, or by inhalation. When parenterally administered, the therapeutic compositions for use in this invention may be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such pharmaceutically acceptable compositions, with due regard to pH, isotonicity, stability and the like, is within the skill of the art.

A particularly suitable vehicle for parenteral injection is sterile distilled water in which a huE3 α polypeptide is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles or beads, or liposomes, that provides for the controlled or sustained release of the product which may then be delivered as a depot injection. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

The pharmaceutical compositions of the present invention may include other components, for example parenterally acceptable preservatives, tonicity agents, cosolvents, wetting agents, complexing agents, buffering agents, antimicrobials, antioxidants and surfactants, as are well known in the art. For example, suitable tonicity enhancing agents include alkali metal halides (preferably sodium or potassium chloride),

mannitol, sorbitol, and the like. Suitable preservatives include, but are not limited to, benzalkonium chloride, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, and the like. Hydrogen peroxide may also be used as preservative. Suitable cosolvents are for example glycerin, propylene glycol and polyethylene glycol. Suitable complexing agents are for example caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin. Suitable surfactants or wetting agents include sorbitan esters, polysorbates such as polysorbate 80, tromethamine, lecithin, cholesterol, tyloxapal, and the like. The buffers can be conventional buffers such as borate, citrate, phosphate, bicarbonate, or Tris-HCl.

The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at slightly lower pH, typically within a pH range of from about 5 to about 8.

In one embodiment of the present invention, huE3 α polypeptide compositions may be prepared for storage by mixing the selected composition having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (*Remington's pharmaceutical sciences*, 18th edition, A.R. Gennaro, ed., Mack Publishing Company (1990)) in the form of a lyophilized cake or an aqueous solution.

The optimal pharmaceutical formulation will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format, and desired dosage. See for example, *Remington's Pharmaceutical Sciences*, pp. 1435-1712. Such compositions may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the present huE3 α polypeptides.

An effective amount of a huE3 α polypeptide composition to be employed therapeutically will depend, for example, upon the therapeutic objectives such as the indication for which the huE3 α polypeptide is being used, the route of administration, and the condition of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. A typical dosage may range from about 0.1 μ g/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 1 μ g/kg up to about 100 mg/kg; or 5 μ g/kg up to about 100 mg/kg; or 0.1 μ g/kg up to about 100 mg/kg; or 1 μ g/kg up to about 100 mg/kg.

Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter.

One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the therapeutic context, type of disorder under treatment, the age, and general health of the recipient.

The huE3 α molecule pharmaceutical composition to be used for *in vivo* administration typically must be sterile. This may be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using these methods may be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration may be stored in lyophilized form or in solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Once the pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or a dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form or in a form (*e.g.*, lyophilized) requiring reconstitution prior to administration.

In a specific embodiment, the present invention is directed to kits for producing a single-dose administration unit. The kits may each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this invention are kits containing single and multi-chambered pre-filled syringes (*e.g.*, liquid syringes and lyosyringes).

An effective amount of a h2520-109 pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the h2520-109 molecule is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. A typical dosage may range

from about 0.1 mg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1 mg/kg up to about 100 mg/kg; or 1 mg/kg up to about 100 mg/kg; or 5 mg/kg up to about 100 mg/kg.

The frequency of dosing will depend upon the pharmacokinetic parameters of the h2520-109 molecule in the formulation used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter.

Pharmaceutical compositions such as (1) slow-release formulations, (2) inhalant mists, or (3) orally active formulations are also envisioned. The huE3 α molecule pharmaceutical composition generally is formulated for parenteral administration. Such parenterally administered therapeutic compositions are typically in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising the desired huE3 α molecule in a pharmaceutically acceptable vehicle. The huE3 α molecule pharmaceutical compositions also may include particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or the introduction of the molecule into liposomes. Hyaluronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation.

In one embodiment, a pharmaceutical composition may be formulated for inhalation. For example, huE3 α polypeptide may be formulated as a dry powder for inhalation. Human E3 α polypeptide or nucleic acid molecule inhalation solutions may also be formulated in a liquefied propellant for aerosol delivery, with or without a liquified propellant. In yet another embodiment, solutions may be nebulized. Pulmonary administration is further described in PCT WO94/20069, which describes pulmonary delivery of chemically modified proteins.

It is also contemplated that certain formulations may be administered orally. In one embodiment of the present invention, huE3 α polypeptides which are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the huE3 α polypeptide. Diluents, flavorings, low melting point waxes, vegetable oils,

lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.

Another pharmaceutical composition may involve an effective quantity of huE3 α polypeptides in a mixture with non-toxic excipients which are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or other appropriate vehicle, solutions can be prepared in unit dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

Additional huE3 α molecule formulations will be evident to those skilled in the art, including formulations involving huE3 α molecules in combination with one or more other therapeutic agents. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. See for example, PCT/US93/00829 which describes controlled release of porous polymeric microparticles for the delivery of pharmaceutical compositions.

Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices may include polyesters, hydrogels, polylactides (U.S. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*, *Biopolymers*, 22: 547-556, 1983), poly (2-hydroxyethyl-methacrylate) (Langer *et al.*, *J. Biomed. Mater. Res.*, 15: 167-27, 1981; and Langer, *Chem. Tech.*, 12: 98-105, 1982), ethylene vinyl acetate (Langer *et al.*, *supra*) or poly-D(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also may include liposomes, which can be prepared by any of several methods known in the art. (See e.g., Eppstein *et al.*, *Proc. Natl. Acad. Sci. USA*, 82: 3688-3692, 1985; EP 36,676; EP 88,046; EP 143,949.)

Regardless of the manner of administration, the specific dose may be calculated according to body weight, body surface area or organ size. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose-response data.

The route of administration of the pharmaceutical composition is in accord with known methods, e.g. oral, inhalation, injection or infusion by intravenous,

intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial, intraportal, or intralesional routes, or by sustained release systems or implantation device. Where desired, the compositions may be administered continuously by infusion, by bolus injection devices or by implantation device.

5 Alternatively or additionally, the composition may be administered locally via implantation into the affected area of a membrane, sponge, or other appropriate material on to which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be directly 10 through the device via diffusion, time-released bolus, or via continuous administration, or via catheter using continuous infusion.

15 It will further be appreciated that the huE3 α polypeptides, including fragments, variants, and derivatives, may be employed alone, together, or in combination with other polypeptides and pharmaceutical compositions. For example, the huE3 α polypeptides may be used in combination with cytokines, growth factors, antibiotics, anti-inflammatories, and/or chemotherapeutic agents as is appropriate for the indication being treated.

20 In some cases, it may be desirable to use huE3 α pharmaceutical compositions in an *ex vivo* manner. In such instances, cells, tissues, or organs that have been removed from the patient are exposed to huE3 α pharmaceutical compositions after which the cells, tissues and/or organs are subsequently implanted back into the patient.

25 In other cases, a huE3 α polypeptide can be delivered by implanting certain cells that have been genetically engineered, using methods such as those described herein, to express and secrete the polypeptides. Such cells may be animal or human cells, and may be autologous, heterologous, or xenogeneic. Optionally, the cells may be immortalized. However, in order to decrease the chance of an immunological response, the cells may be encapsulated to avoid infiltration of surrounding tissues. The encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the cells by the patient's immune system or by other detrimental factors 30 from the surrounding tissues.

Additional embodiments of the present invention relate to cells and methods (*e.g.*, homologous recombination and /or other recombinant production methods) for both the *in vitro* production of therapeutic polypeptides by means of

homologous recombination and for the production and delivery of therapeutic polypeptides by gene therapy or cell therapy.

It is further envisioned that huE3 α polypeptides can be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding huE3 α polypeptides. For example, homologous recombination methods may be used to modify a cell that contains a normally transcriptionally silent huE3 α gene, or an under expressed gene, and thereby produce a cell which expresses therapeutically efficacious amounts of huE3 α polypeptides. Homologous recombination is a technique originally developed for targeting genes to induce or correct mutations in transcriptionally active genes. Kucherlapati, *Prog. in Nucl. Acid Res. & Mol. Biol.*, 36:301, 1989. The basic technique was developed as a method for introducing specific mutations into specific regions of the mammalian genome (Thomas *et al.*, *Cell*, 44: 419-428, 1986; Thomas and Capecchi, *Cell*, 51:503-512, 1987; Doetschman *et al.*, *Proc. Natl. Acad. Sci.*, 85: 8583-8587, 1988) or to correct specific mutations within defective genes (Doetschman *et al.*, *Nature*, 330: 576-578, 1987). Exemplary homologous recombination techniques are described in U.S. Patent No. 5,272,071 (EP 9193051, EP Publication No. 505500; PCT/US90/07642, International Publication No. WO 91/09955).

Through homologous recombination, the DNA sequence to be inserted into the genome can be directed to a specific region of the gene of interest by attaching it to targeting DNA. The targeting DNA is a nucleotide sequence that is complementary (homologous) to a region of the genomic DNA. Small pieces of targeting DNA that are complementary to a specific region of the genome are put in contact with the parental strand during the DNA replication process. It is a general property of DNA that has been inserted into a cell to hybridize, and therefore, recombine with other pieces of endogenous DNA through shared homologous regions. If this complementary strand is attached to an oligonucleotide that contains a mutation or a different sequence or an additional nucleotide, it too is incorporated into the newly synthesized strand as a result of the recombination. As a result of the proofreading function, it is possible for the new sequence of DNA to serve as the template. Thus, the transferred DNA is incorporated into the genome.

Attached to these pieces of targeting DNA are regions of DNA which may interact with or control the expression of a huE3 α polypeptide, *e.g.*, flanking sequences. For example, a promoter/enhancer element, a suppressor, or an exogenous

transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired huE3 α polypeptide. The control element controls a portion of the DNA present in the host cell genome. Thus, the expression of huE3 α polypeptide may be achieved
5 not by transfection of DNA that encodes the huE3 α gene itself, but rather by the use of targeting DNA (containing regions of homology with the endogenous gene of interest) coupled with DNA regulatory segments that provide the endogenous gene sequence with recognizable signals for transcription of a huE3 α polypeptide.

In an exemplary method, the expression of a desired targeted gene in a
10 cell (*i.e.*, a desired endogenous cellular gene) is altered by the introduction, by homologous recombination into the cellular genome at a preselected site, by the introduction of DNA which includes at least a regulatory sequence, an exon and a splice donor site. These components are introduced into the chromosomal (genomic) DNA in such a manner that this, in effect, results in the production of a new transcription unit (in
15 which the regulatory sequence, the exon and the splice donor site present in the DNA construct are operatively linked to the endogenous gene). As a result of the introduction of these components into the chromosomal DNA, the expression of the desired endogenous gene is altered.

Altered gene expression, as described herein, encompasses activating (or
20 causing to be expressed) a gene which is normally silent (unexpressed) in the cell as obtained, as well as increasing the expression of a gene which is not expressed at physiologically significant levels in the cell as obtained. The embodiments further encompass changing the pattern of regulation or induction such that it is different from the pattern of regulation or induction that occurs in the cell as obtained, and reducing
25 (including eliminating) the expression of a gene which is expressed in the cell as obtained.

One method by which homologous recombination can be used to increase, or cause, huE3 α polypeptide production from a cell's endogenous huE3 α gene involves first using homologous recombination to place a recombination sequence from a site-specific recombination system (*e.g.*, Cre/loxP, FLP/FRT) (Sauer, *Current Opinion In Biotechnology*, 5: 521-527, 1994; Sauer, *Methods In Enzymology*, 225: 890-900, 1993) upstream (that is, 5' to) of the cell's endogenous genomic huE3 α coding region. A plasmid containing a recombination site homologous to the site that was placed just upstream of the genomic huE3 α coding region is introduced into the modified cell line
30

along with the appropriate recombinase enzyme. This recombinase causes the plasmid to integrate, via the plasmid's recombination site, into the recombination site located just upstream of the genomic huE3 α coding region in the cell line (Baubonis and Sauer, *Nucleic Acids Res.*, 21: 2025-2029, 1993; O'Gorman *et al.*, *Science*, 251: 1351-1355, 1991). Any flanking sequences known to increase transcription (e.g., enhancer/promoter, intron, translational enhancer), if properly positioned in this plasmid, would integrate in such a manner as to create a new or modified transcriptional unit resulting in *de novo* or increased huE3 α polypeptide production from the cell's endogenous huE3 α gene.

A further method to use the cell line in which the site specific recombination sequence had been placed just upstream of the cell's endogenous genomic huE3 α coding region is to use homologous recombination to introduce a second recombination site elsewhere in the cell line's genome. The appropriate recombinase enzyme is then introduced into the two-recombination-site cell line, causing a recombination event (deletion, inversion, translocation) (Sauer, *Current Opinion In Biotechnology*, 5: 521-527, 1994; Sauer, *Methods In Enzymology*, 225: 890-900, 1993) that would create a new or modified transcriptional unit resulting in *de novo* or increased huE3 α polypeptide production from the cell's endogenous huE3 α gene.

An additional approach for increasing, or causing, the expression of huE3 α polypeptide from a cell's endogenous huE3 α gene involves increasing, or causing, the expression of a gene or genes (e.g., transcription factors) and/or decreasing the expression of a gene or genes (e.g., transcriptional repressors) in a manner which results in *de novo* or increased huE3 α polypeptide production from the cell's endogenous huE3 α gene. This method includes the introduction of a non-naturally occurring polypeptide (e.g., a polypeptide comprising a site specific DNA binding domain fused to a transcriptional factor domain) into the cell such that *de novo* or increased huE3 α polypeptide production from the cell's endogenous huE3 α gene results.

The present invention further relates to DNA constructs useful in the method of altering expression of a target gene. In certain embodiments, the exemplary DNA constructs comprise: (a) one or more targeting sequences; (b) a regulatory sequence; (c) an exon; and (d) an unpaired splice-donor site. The targeting sequence in the DNA construct directs the integration of elements (a)-(d) into a target gene in a cell such that the elements (b)-(d) are operatively linked to sequences of the endogenous target gene. In another embodiment, the DNA constructs comprise: (a) one or more

targeting sequences, (b) a regulatory sequence, (c) an exon, (d) a splice-donor site, (e) an intron, and (f) a splice-acceptor site, wherein the targeting sequence directs the integration of elements (a)-(f) such that the elements of (b)-(f) are operatively linked to the endogenous gene. The targeting sequence is homologous to the preselected site in the cellular chromosomal DNA with which homologous recombination is to occur. In the construct, the exon is generally 3' of the regulatory sequence and the splice-donor site is 3' of the exon.

If the sequence of a particular gene is known, such as the nucleic acid sequence encoding a huE3 α polypeptide presented herein, a piece of DNA that is complementary to a selected region of the gene can be synthesized or otherwise obtained, such as by appropriate restriction of the native DNA at specific recognition sites bounding the region of interest. This piece serves as a targeting sequence upon insertion into the cell and will hybridize to its homologous region within the genome. If this hybridization occurs during DNA replication, this piece of DNA, and any additional sequence attached thereto, will act as an Okazaki fragment and will be incorporated into the newly synthesized daughter strand of DNA. The present invention, therefore, includes nucleotides encoding a huE3 α polypeptide, which nucleotides may be used as targeting sequences.

Human E3 α polypeptide cell therapy, *e.g.*, the implantation of cells producing huE3 α polypeptides, is also contemplated. This embodiment involves implanting cells capable of synthesizing and secreting a biologically active form of huE3 α polypeptide. Such huE3 α polypeptide-producing cells can be cells that are natural producers of huE3 α polypeptides or may be recombinant cells whose ability to produce huE3 α polypeptides has been augmented by transformation with a gene encoding the desired huE3 α polypeptide or with a gene augmenting the expression of huE3 α polypeptide. Such a modification may be accomplished by means of a vector suitable for delivering the gene as well as promoting its expression and secretion. In order to minimize a potential immunological reaction in patients being administered a huE3 α polypeptide, as may occur with the administration of a polypeptide of a foreign species, it is preferred that the natural cells producing huE3 α polypeptide be of human origin and produce huE3 α polypeptide. Likewise, it is preferred that the recombinant cells producing huE3 α polypeptide be transformed with an expression vector containing a gene encoding a human huE3 α polypeptide.

Implanted cells may be encapsulated to avoid the infiltration of surrounding tissue. Human or non-human animal cells may be implanted in patients in biocompatible, semipermeable polymeric enclosures or membranes that allow the release of huE3 α polypeptide, but that prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissue. Alternatively, the patient's own cells, transformed to produce huE3 α polypeptides *ex vivo*, may be implanted directly into the patient without such encapsulation.

Techniques for the encapsulation of living cells are known in the art, and the preparation of the encapsulated cells and their implantation in patients may be routinely accomplished. For example, Baetge *et al.* (WO95/05452; PCT/US94/09299) describe membrane capsules containing genetically engineered cells for the effective delivery of biologically active molecules. The capsules are biocompatible and are easily retrievable. The capsules encapsulate cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation *in vivo* upon implantation into a mammalian host. The devices provide for the delivery of the molecules from living cells to specific sites within a recipient. In addition, see U.S. Patent Nos. 4,892,538, 5,011,472, and 5,106,627. A system for encapsulating living cells is described in PCT Application WO91/10425 of Aebischer *et al.* See also, PCT Application WO91/10470 of Aebischer *et al.*, Winn *et al.*, *Exper. Neurol.*, 113: 322-329, 1991, Aebischer *et al.*, *Exper. Neurol.*, 111: 269-275, 1991; and Tresco *et al.*, *ASAIO*, 38: 17-23, 1992.

In vivo and *in vitro* gene therapy delivery of huE3 α polypeptides is also envisioned. *In vivo* gene therapy may be accomplished by introducing the gene encoding huE3 α polypeptide into cells via local injection of a huE3 α nucleic acid molecule or by other appropriate viral or non-viral delivery vectors (Hefti, *Neurobiology*, 25: 1418-1435, 1994). For example, a nucleic acid molecule encoding a huE3 α polypeptide may be contained in an adeno-associated virus vector for delivery to the targeted cells (*e.g.*, Johnson, International Publication No. WO95/34670; International Application No. PCT/US95/07178). The recombinant adeno-associated virus (AAV) genome typically contains AAV inverted terminal repeats flanking a DNA sequence encoding a huE3 α polypeptide operably linked to functional promoter and polyadenylation sequences.

Alternative suitable viral vectors include, but are not limited to, retrovirus, adenovirus, herpes simplex virus, lentivirus, hepatitis virus, parvovirus, papovavirus, poxvirus, alphavirus, coronavirus, rhabdovirus, paramyxovirus, and papilloma virus vectors. U.S. Patent No. 5,672,344 describes an *in vivo* viral-mediated gene transfer system involving a recombinant neurotrophic HSV-1 vector. U.S. Patent No. 5,399,346 provides examples of a process for providing a patient with a therapeutic protein by the delivery of human cells which have been treated *in vitro* to insert a DNA segment encoding a therapeutic protein. Additional methods and materials for the practice of gene therapy techniques are described in U.S. Patent No. 5,631,236 involving adenoviral vectors; U.S. Patent No. 5,672,510 involving retroviral vectors; and U.S. 5,635,399 involving retroviral vectors expressing cytokines.

Nonviral delivery methods include, but are not limited to, liposome-mediated transfer, naked DNA delivery (direct injection), receptor-mediated transfer (ligand-DNA complex), electroporation, calcium phosphate precipitation, and microparticle bombardment (*e.g.*, gene gun). Gene therapy materials and methods may also include the use of inducible promoters, tissue-specific enhancer-promoters, DNA sequences designed for site-specific integration, DNA sequences capable of providing a selective advantage over the parent cell, labels to identify transformed cells, negative selection systems and expression control systems (safety measures), cell-specific binding agents (for cell targeting), cell-specific internalization factors, and transcription factors to enhance expression by a vector as well as methods of vector manufacture. Such additional methods and materials for the practice of gene therapy techniques are described in U.S. Patent No. 4,970,154 involving electroporation techniques; WO96/40958 involving nuclear ligands; U.S. Patent No. 5,679,559 describing a lipoprotein-containing system for gene delivery; U.S. Patent No. 5,676,954 involving liposome carriers; U.S. Patent No. 5,593,875 concerning methods for calcium phosphate transfection; and U.S. Patent No. 4,945,050 wherein biologically active particles are propelled at cells at a speed whereby the particles penetrate the surface of the cells and become incorporated into the interior of the cells.

In yet other embodiments, regulatory elements can be included for the controlled expression of the huE3 α gene in the target cell. Such elements are turned on in response to an appropriate effector. In this way, a therapeutic polypeptide can be expressed when desired. One conventional control means involves the use of small molecule dimerizers or rapalogs (as described in WO9641865 (PCT/US96/099486);

WO9731898 (PCT/US97/03137) and WO9731899 (PCT/US95/03157)) used to dimerize chimeric proteins which contain a small molecule-binding domain and a domain capable of initiating biological process, such as a DNA-binding protein or transcriptional activation protein. The dimerization of the proteins can be used to initiate transcription of the huE3 α gene.

Other suitable control means or gene switches include, but are not limited to, the following systems. Mifepristone (RU486) is used as a progesterone antagonist. The binding of a modified progesterone receptor ligand-binding domain to the progesterone antagonist activates transcription by forming a dimer of two transcription factors which then pass into the nucleus to bind DNA. The ligand binding domain is modified to eliminate the ability of the receptor to bind to the natural ligand. The modified steroid hormone receptor system is further described in U.S. 5,364,791; WO9640911, and WO9710337.

Yet another control system uses ecdysone (a fruit fly steroid hormone) which binds to and activates an ecdysone receptor (cytoplasmic receptor). The receptor then translocates to the nucleus to bind a specific DNA response element (promoter from ecdysone-responsive gene). The ecdysone receptor includes a transactivation domain/DNA-binding domain/ligand-binding domain to initiate transcription. The ecdysone system is further described in U.S. 5,514,578; WO9738117; WO9637609; and WO9303162.

Another control means uses a positive tetracycline-controllable transactivator. This system involves a mutated tet repressor protein DNA-binding domain (mutated tet R-4 amino acid changes which resulted in a reverse tetracycline-regulated transactivator protein, *i.e.*, it binds to a tet operator in the presence of tetracycline) linked to a polypeptide which activates transcription. Such systems are described in U.S. Patent Nos. 5,464,758; 5,650,298 and 5,654,168.

Additional expression control systems and nucleic acid constructs are described in U.S. Patent Nos. 5,741,679 and 5,834,186 to Innovir Laboratories Inc.

One example of a gene therapy technique is to use the huE3 α gene (either genomic DNA, cDNA, and/or synthetic DNA encoding a huE3 α polypeptide which may be operably linked to a constitutive or inducible promoter to form a “gene therapy DNA construct”. The promoter may be homologous or heterologous to the endogenous huE3 α gene, provided that it is active in the cell or tissue type into which the construct will be inserted. Other components of the gene therapy DNA construct may optionally include,

DNA molecules designed for site-specific integration (*e.g.*, endogenous sequences useful for homologous recombination), tissue-specific promoter, enhancer(s) or silencer(s), DNA molecules capable of providing a selective advantage over the parent cell, DNA molecules useful as labels to identify transformed cells, negative selection systems, cell specific binding agents (as, for example, for cell targeting), cell-specific internalization factors, and transcription factors to enhance expression by a vector as well as factors to enable vector manufacture.

This gene therapy DNA construct can then be introduced into cells (either *ex vivo* or *in vivo*). One means for introducing the gene therapy DNA construct is by means of viral vectors as described herein. Certain vectors, such as retroviral vectors, will deliver the gene therapy DNA construct to the chromosomal DNA of the cells, and the gene therapy DNA construct can integrate into the chromosomal DNA. Other vectors will function as episomes, and the gene therapy DNA construct will remain in the cytoplasm.

Another means to increase endogenous huE3 α polypeptide expression in a cell via gene therapy is to insert one or more enhancer elements into the huE3 α polypeptide promoter, where the enhancer element(s) can serve to increase transcriptional activity of the huE3 α gene. The enhancer element(s) used will be selected based on the tissue in which one desires to activate the gene(s); enhancer elements known to confer promoter activation in that tissue will be selected. For example, if a gene encoding a huE3 α polypeptide is to be “turned on” in T-cells, the *lck* promoter enhancer element may be used. Here, the functional portion of the transcriptional element to be added may be inserted into a fragment of DNA containing the huE3 α polypeptide promoter (and optionally, inserted into a vector and/or 5' and/or 3' flanking sequence(s), etc.) using standard cloning techniques. This construct, known as a “homologous recombination construct”, can then be introduced into the desired cells either *ex vivo* or *in vivo*.

Gene therapy can be used to decrease huE3 α polypeptide expression by modifying the nucleotide sequence of the endogenous promoter(s). Such modification is typically accomplished via homologous recombination methods. For example, a DNA molecule containing all or a portion of the promoter of the huE3 α gene(s) selected for inactivation can be engineered to remove and/or replace pieces of the promoter that regulate transcription. For example the TATA box and/or the binding site of a transcriptional activator of the promoter may be deleted using standard molecular

biology techniques; such deletion can inhibit promoter activity thereby repressing the transcription of the corresponding huE3 α gene. The deletion of the TATA box or the transcription activator binding site in the promoter may be accomplished by generating a DNA construct comprising all or the relevant portion of the huE3 α polypeptide promoter(s) (from the same or a related species as the huE3 α gene(s) to be regulated) in which one or more of the TATA box and/or transcriptional activator binding site nucleotides are mutated via substitution, deletion and/or insertion of one or more nucleotides. As a result, the TATA box and/or activator binding site has decreased activity or is rendered completely inactive. This construct, which also will typically contain at least about 500 bases of DNA that correspond to the native (endogenous) 5' and 3' DNA sequences adjacent to the promoter segment that has been modified, may be introduced into the appropriate cells (either *ex vivo* or *in vivo*) either directly or via a viral vector as described herein. Typically, the integration of the construct into the genomic DNA of the cells will be via homologous recombination, where the 5' and 3' DNA sequences in the promoter construct can serve to help integrate the modified promoter region via hybridization to the endogenous chromosomal DNA.

Other gene therapy methods may also be employed where it is desirable to inhibit the activity of one or more huE3 α polypeptides. For example, antisense DNA or RNA molecules, which have a sequence that is complementary to at least a portion of the selected huE3 α gene(s) can be introduced into the cell. Typically, each such antisense molecule will be complementary to the start site (5' end) of each selected huE3 α gene. When the antisense molecule then hybridizes to the corresponding huE3 α mRNA, translation of this mRNA is prevented or reduced. It will also be appreciated by those skilled in the art that antisense and ribozyme molecules may also be administered directly.

Alternatively, gene therapy may be employed to create a dominant-negative inhibitor of one or more huE3 α polypeptides. In this situation, the DNA encoding a mutant full length or truncated polypeptide of each selected huE3 α polypeptide can be prepared and introduced into the cells of a patient using either viral or non-viral methods as described herein. Each such mutant is typically designed to compete with endogenous polypeptide in its biological role.

Additional Uses of huE3 α Nucleic Acids and Polypeptides

Nucleic acid molecules of the present invention may be used to map the locations of the huE3 α gene and related genes on chromosomes. Mapping may be done by techniques known in the art, such as PCR amplification and *in situ* hybridization.

5 The nucleic acid molecules are also used as antisense inhibitors of huE3 α polypeptide expression. Such inhibition may be effected by nucleic acid molecules which are complementary to and hybridize to expression control sequences (triple helix formation) or to huE3 α mRNA. Antisense probes may be designed by available techniques using the sequence of huE3 α nucleic acid molecules disclosed herein.
10 Antisense inhibitors provide information relating to the decrease or absence of a huE3 α polypeptide in a cell or organism.

15 Hybridization probes may be prepared using the huE3 α nucleic acid sequences provided herein to screen cDNA, genomic or synthetic DNA libraries for related sequences. Regions of the DNA and/or amino acid sequence of huE3 α polypeptide that exhibit significant identity to known sequences are readily determined using sequence alignment algorithms as described herein and those regions may be used to design probes for screening.

20 Human E3 α nucleic acid molecules, as well as fragments, variants, and/or derivatives that do not themselves encode biologically active polypeptides, may be useful as hybridization probes in diagnostic assays to test, either qualitatively or quantitatively, for the presence of huE3 α DNA or corresponding RNA in mammalian tissue or bodily fluid samples.

25 Human E3 α polypeptide fragments, variants, and/or derivatives, whether biologically active or not, are also useful for preparing antibodies that bind to a huE3 α polypeptide. The antibodies may be used for *in vitro* diagnostic purposes, including, but not limited to, use in labeled form to detect the presence of huE3 α polypeptide in a body fluid or cell sample.

30 The full length cDNAs encoding huE3 α I was subcloned into pCR 2.1 vector (Invitrogen, Cat.# K2030-40). The full length cDNA encoding huE3 α II was subcloned into pcDNA 3.1/His A vector (Invitrogen Cat.#V38-20). The full length cDNA encoding muE3 α II was subcloned into pCR 2.1 vector (Invitrogen). The above plasmids were deposited on March 15, 2000 to the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 . The plasmid containing

huE3 α 1 is designated PTA-1489, the plasmid containing huE3 α II is designated PTA-1490 and the plasmid containing muE3 α II is designated PTA-1488.

The following examples are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.

5

EXAMPLE 1

Cloning of cDNA Encoding Human E3 α I

Materials and methods for cDNA cloning and analysis are described in Sambrook *et al.*, *supra*. which is incorporated herein by reference.

10 BLAST analysis of the Genebank dbEST database with the full length murine E3 α ubiquitin ligase nucleotide sequence (muE3I; Genebank Accession No.: AF061555; SEQ ID NO: 15), revealed 4 human EST sequences (Genebank accession numbers AI187306, AI92195, AI87306, and AI400279) which potentially encode different regions of a novel human E3 α ubiquitin ligase ortholog (huE3 α I) gene.

15 Based on these EST sequences, two sets of PCR primers (#2282-91/2282-93 and #2282-94/2282-97) were designed. These sequences are set out below in Table III.

Table III

Primer	Sequence	SEQ ID NO:
2282-91	CTC CTC GAG TCT GCG TCA AAC	7
2385-35	TCT GCA TAT GTT CAG CCT TGC TA	8
2282-94	GTA TGA ACT TGC CGA GGC TTT TA	9
2294-37	CAA TAC TTT CCC AGC CCT CAG AA	10

25 The primer sets #2282-91/2282-93 (SEQ ID NOS: 7 and 8) and #2282-94/2294-37 (SEQ ID NOS: 9 and 10) were used to generate two PCR products which span the whole huE3 α I gene including the 5' and 3' untranslated regions. Polymerase chain reactions (PCR) were performed using a Perkin-Elmer 9600 thermocycler. In general, 50 μ l PCR reactions contained 24 μ l of H₂O, 5 μ l of 10x cDNA PCR Reaction Buffer (Clontech), 2 μ l of 10 mM dNTP mix (dATP, dCTP, dGTP, dTTP), 1 μ l of Primer 2282-91 or 2282-94 (20 μ l), 1 μ l of Primer 2285-35 or 2294-37 (20 μ l), 2 μ l of 50x Advantage 2 Polymerase Mix (Clontech) and 15 μ l of Marathon Ready cDNA from a human heart library (Clontech cat.# 7404-1) or a human muscle library (Clontech cat. # 7413-1). The reaction mixture was incubated at 94°C for 30 seconds, followed by 40 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 5 minutes.

The PCR products were electrophoresed on a 1% agarose gel as described by Sambrook *et al.*, *supra*. The appropriate sized bands (14 kB and 3 kB) were excised from the agarose gel and purified with the QIAquick Gel Extraction kit (Qiagen, cat# 28704). The two purified DNA fragments were subcloned into pCR2.1 vectors and transformed into *E. coli* (Strain INVαF) utilizing the Invitrogen Original TA Cloning kit (cat.# K2000-40).

After subcloning, DNA plasmids were purified with the QIAprep Spin Miniprep kit (cat# 27104). The sequence of the PCR products were verified by automated sequencing with the Prism 377 Sequencer and the BIg Dye Terminator Ready Reaction mix with AmpliTaq DNA polymerase (Perkin Elmer Applied Biosystems). Each sequencing reaction was performed in a Perkin Elmer 9600 thermocycler with 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 2 minutes. The samples were purified using Centriflex Gel Filtration cartridges (Edge Biosystems). The samples were heated to 85oC for 2 minutes and inserted into the Prism 377 Sequencer. The sequences were analyzed using the Seqnecher™ Sequence Analysis software (Gene Codes Corp.). The sequences of the PCR product generated from human heart and human muscle were identical. The full length huE3αI clone was obtained by ligating the two PCR products together at their XbaI site.

The nucleic acid sequence of huE3αI (SEQ ID NO: 1), consists of an open reading frame of 5247 nucleotides which encodes a 1749 amino acid polypeptide, in addition to 695 bp in the 5' untranslated region and 362 bp in the 3' untranslated region. Alignment of the human and mouse amino acid sequence, as shown in Figure 1 (SEQ ID NOS: 2 and 15, respectively), exhibited 92.5% overall sequence identity.

In the present invention, a novel full length human E3α cDNA (huE3αI; SEQ ID NO: 1) was isolated and cloned and the full length polypeptide sequence (SEQ ID NO: 2) was disclosed. A partial sequence of the human E3α gene had been previously reported. (*See U.S. Patent 5,861,312; Kwon et al., Proc. Natl. Acad. of Sci. USA, 95: 7898-7903, 1998.*) The reported partial sequence is encompassed in SEQ ID NO: 1; but only represents a small portion of the entire full length gene (nucleotides 702 to 1066).

EXAMPLE 2

Cloning of cDNA Encoding Human E3 α Ortholog, huE3 α II

BLAST analysis of the Amgenesis database (Amgen internal EST database) with the human E3 α I amino acid sequences revealed 4 Amgenesis EST sequences (amgi-039645, smop2-0079f12 and zhgb-aa693825 and Genebank accession no.: AA002347) which encode potential regions of the human and mouse E3 α ubiquitin ligase ortholog nucleotide sequences which are denoted as E3 α II. Based on the zhgb-aa693825 and AA002347 sequences, two PCR primer sets (#2380-88/2378-32 and #2381-48/2385-94) were designed. These sequences are set out below in Table IV.

10

Table IV

Primer	Sequence	SEQ ID NO:
2380-88	ATG GCG TCG CTA GAG CCA	11
2378-32	CAA AGC GGC TGA GCA TGA TCA TC	12
2381-48	TGA ACA GCC AAT CAC ACT AAG CA	13
2385-94	TTA TAA ATG CCA GTC AAT GCC AA	14

The primer sets #2380-88/2378-32 (SEQ ID NOS: 11 and 12) and #2381-48/2385-94 (SEQ ID NOS: 13 and 14) were used to generate two PCR products which encode the coding region of a novel ortholog of human E3 α ligase (huE3 α II). The 5' and 3' untranslated regions of huE3 α II were determined based on the EST sequences amgi-03645 and smop2-0079f12 in order to obtain the full length huE3 α II cDNA. PCR was performed as described above utilizing Marathon-Ready cDNA from human heart and human muscle libraries. The two PCR products were electrophoresed on a 1% gel as described by Sambrook *et al.*, *supra*. The appropriate sized bands (2.2 kB and 3.5 kB) were excised from the agarose and purified by QIAquick Gel Extraction kit (cat.# 28704). The PCR products were subcloned into the pcDNA3.1-HisA vector (Invitrogen cat.# V385-20) and transformed into *E.coli* (Strain INV α F) using the Invitrogen Original TA Cloning kit. The insert DNA was purified with the QIAprep Spin Miniprep kit (QIAGEN cat.# 27104) and subsequently digested with NotI/SacI for the 2 kB product and SacI/XhoI for the 3.3 kB product. The PCR products were sequenced as described in Example 1 and the products generated from human heart and human muscle cDNA libraries were identical. The full length huE3 α II gene was generated by ligating these two PCR products at their SacI sites.

The nucleic acid sequence of huE3 α II (SEQ ID NO: 3), consists of an open reading frame of 5265 nucleotides which encodes a 1755 amino acid polypeptide, in addition to 294 bp in the 5' untranslated region and 740 bp in the 3' untranslated region. Alignment of the human and mouse amino acid E3 α II sequences, as shown in Figure 1 (SEQ ID NOS: 4 and 6, respectively), exhibited 90.4% overall sequence identity. There is a 48.1% overall amino acid sequence identity between human E3 α I and human E3 α II (SEQ ID NOS:2 and 4, respectively).

In the present invention, a novel full length cDNA sequence encoding huE3 α II (SEQ ID NO: 3) was cloned and isolated, and the full length polypeptide sequence was disclosed (SEQ ID NO: 4). A partial sequence of huE3 α II was identified in WO9904265 as one of many partial sequences with unknown identities that were speculated to be cancer markers.

EXAMPLE 3

Cloning of the Murine E3 α II Ortholog

BLAST analysis of the Amgen internal database, Amgensis, with human E3 α II amino acid sequences identified the mouse cDNA clone (Smop2-00079-fl2) as a potential mouse ortholog of E3 α II ubiquitin ligase. The Amgenesis database contained the entire coding region of the mouse E3 α II ubiquitin ligase (muE3 α II) gene. The cDNA clone of was obtained from the Amgen sequencing group. The sequence of the clone was confirmed to be the full cDNA of muE3 α II as described in Example 1. The nucleic acid sequence of muE3 α II (SEQ ID NO: 5), consists of an open reading frame of 5265 nucleotides which encodes a 1755 amino acid polypeptide, in addition to 765 bp in the 5' untranslated region and 56 bp in the 3' untranslated region.

EXAMPLE 4

Human E3 α II Tissue Expression

Tissue expression patterns of huE3 α I and huE3 α II mRNA were analyzed by Northern blot analysis. To detect the presence of huE3 α II transcript in various tissues, a 32 P-labeled fragment of huE3 α II, which was 452 bp and corresponded to nucleotides 3557-4009 of SEQ ID NO: 3, was used as a probe. For detection of huE3 α I transcript in various tissues, a 32 P-labeled fragment of huE3 α I, which was 696 bp and corresponded to nucleotides 3468 -4164 of SEQ ID NO: 1, was used as a probe.

The probes were labeled by random priming method using Prime-it RMT labeling kit (Stratagene, Cat# 300392). The specific activities was 1.436×10^6 cpm/ μ l for the huE3 α II probe and 1.207×10^6 cpm/ μ l for the huE3 α I probe. Human multiple tissue poly A+ RNA blots (Clontech cat.# 7780-1) were prehybridized in Church hybridization solution (1% BSA, 7% SDS, 0.5 M sodium phosphate, pH 7.0, 1 mM EDTA) for 4 hour at 65°C. The blots are then hybridized in Church hybridization solution with 3.0×10^6 cpm/ml 32 P labeled probe for overnight at 65°C. The blots are then washed 3 times in Wash B buffer (1% SDS, 0.04 M sodium phosphate, 1 mM EDTA) for 5 minutes each at room temperature, followed by two times at 65°C. The blots were exposed to X-ray film at room temperature overnight (for huE3 α II detection) or one week (for huE3 α I detection).

The Northern blot analysis revealed that huE3 α II (Figure 2) is predominantly expressed in skeletal muscle, with moderate expression in heart and kidney tissue and minimal or no expression in other tissues examined including brain, colon, thymus, spleen, liver, small intestines, placenta, lung and peripheral white blood cells. In contrast, the expression of huE3 α I (Figure 3) is less muscle-specific. Although heart and skeletal muscle had relative high levels of huE3 α I transcripts, moderate levels of huE3 α I was found to spread through the various tissues examined. The results indicate that huE3 α II is the more muscle-specific form of huE3 α which is predominantly expressed in skeletal muscle tissue.

EXAMPLE 5

Production of huE3 α Polypeptides

A. Bacterial Expression of huE3 α Polypeptides

PCR is used to amplify template DNA sequences encoding a huE3 α polypeptide using primers corresponding to the 5' and 3' ends of the sequence. The amplified DNA products may be modified to contain restriction enzyme sites to allow for insertion into expression vectors. PCR products are gel purified and inserted into expression vectors using standard recombinant DNA methodology. An exemplary vector, such as pAMG21 (ATCC No. 98113) containing the *lux* promoter and a gene encoding kanamycin resistance is digested with BamHI and NdeI for directional cloning of inserted DNA. The ligated mixture is transformed into an *E. coli* host strain by electroporation and transformants are selected for kanamycin resistance. Plasmid DNA

from selected colonies is isolated and subjected to DNA sequencing to confirm the presence of the insert.

Transformed host cells are incubated in 2x YT medium containing 30 µg/ml kanamycin at 30°C prior to induction. Gene expression is induced by the addition of N-(3-oxohexanoyl)-dl-homoserine lactone to a final concentration of 30 ng/ml followed by incubation at either 30°C or 37°C for six hours. The expression of huE3 α polypeptide is evaluated by centrifugation of the culture, resuspension and lysis of the bacterial pellets, and analysis of host cell proteins by SDS-polyacrylamide gel electrophoresis.

Inclusion bodies containing huE3 α polypeptide are purified as follows. Bacterial cells are pelleted by centrifugation and resuspended in water. The cell suspension is lysed by sonication and pelleted by centrifugation at 195,000 x g for 5 to 10 minutes. The supernatant is discarded, and the pellet is washed and transferred to a homogenizer. The pellet is homogenized in 5 ml of a Percoll solution (75% liquid Percoll/0.15 M NaCl) until uniformly suspended and then diluted and centrifuged at 21,600 x g for 30 minutes. Gradient fractions containing the inclusion bodies are recovered and pooled. The isolated inclusion bodies are analyzed by SDS-PAGE. A single band on an SDS polyacrylamide gel corresponding to *E. coli*-produced huE3 α polypeptide is excised from the gel, and the N-terminal amino acid sequence is determined essentially as described by Matsudaira *et al.*, *J. Biol. Chem.*, 262: 10-35 (1987).

B. Mammalian Cell Production of huE3 α Polypeptides

The huE3 α DNA was subcloned into a mammalian expression vector as described above using standard DNA technology. An exemplary expression vector, pCEP4 (Invitrogen, Carlsbad, CA), which contains an Epstein-Barr virus origin of replication, may be used for the expression of huE3 α in 293-EBNA-1 cells. Amplified and gel purified PCR products are ligated into pCEP4 vector and lipofected into 293-EBNA cells. The transfected cells are selected in 100 µg/ml hygromycin and the resulting drug-resistant cultures are grown to confluence. The cells are then cultured in serum-free media for 72 hours. The conditioned media is removed and, huE3 α protein polypeptide expression is analyzed by SDS-PAGE. Human E3 α polypeptide expression may be detected by silver staining. Alternatively, huE3 α polypeptide is produced as a

fusion protein with an epitope tag, such as an IgG constant domain or a FLAG epitope, which may be detected by Western blot analysis using antibodies to the tag peptide.

Human E3 α polypeptides may be excised from an SDS-polyacrylamide gel, or huE3 α fusion proteins are purified by affinity chromatography to the epitope tag, and subjected to N-terminal amino acid sequence analysis as described herein.

EXAMPLE 6

Production of Anti-huE3 α Polypeptide Antibodies

Antibodies to huE3 α polypeptides may be obtained by immunization with purified protein or with huE3 α peptides produced by biological or chemical synthesis. Suitable procedures for generating antibodies include those described in Hudson and Bay, *Practical Immunology, Second Edition*, Edition, Blackwell Scientific Publications.

In one procedure for the production of antibodies, animals (typically mice or rabbits) are injected with a huE3 α antigen (such as an recombinant truncated forms of huE3 α polypeptide), and those with sufficient serum titer levels as determined by ELISA are selected for hybridoma production. Spleens of immunized animals are collected and prepared as single cell suspensions from which splenocytes are recovered. The splenocytes are fused to mouse myeloma cells (such as Sp2/0-Ag14 cells), allowed to incubate in DMEM with 200 U/ml penicillin, 200 μ g/ml streptomycin sulfate, and 4 mM glutamine, then incubated in HAT selection medium (Hypoxanthine; Aminopterin; Thymidine). After selection, the tissue culture supernatants are taken from each fusion well and tested for anti-huE3 α antibody production by ELISA.

Alternative procedures for obtaining anti-huE3 α antibodies may also be employed, such as the immunization of transgenic mice harboring human Ig loci for production of human antibodies, and the screening of synthetic antibody libraries, such as those generated by mutagenesis of an antibody variable domain.

EXAMPLE 7

Biological Activity of huE3 α polypeptides

Human E3 α family members are known to catalyze the ubiquitin conjugation reaction which ultimately results in protein degradation. To determine the biological activity of huE3 α polypeptide, the rate of ubiquitin conjugation and the

rate of protein degradation are measured. The following are examples of assays to measure these biological activities.

A. Ubiquitin Conjugation Assay:

The enzymatic activity of E3 α family members is thought to be the rate limiting step in ubiquitin conjugation. Rat skeletal muscles are dissected, homogenized, and centrifuged at 100,000 x g to remove proteosomes. The soluble extract is incubated with 125 I-ubiquitin (Amersham, Arlington Heights, IL) (0.15 mg/ml) in 20 mM Tris (pH 7.4), 1 mM DTT, 5 mM MgCl₂, and 2 mM ATP γ S at 37°C in the presence and absence of huE3 α polypeptide. At various time points, the reactions are terminated by the addition of sample buffer and SDS-PAGE is performed on a 12% gel. The gel is then dried and autoradiographed. If huE3 α acts as an E3 α family member, the level of ubiquitination should increase in extracts treated with the huE3 α polypeptide (Solomon *et al.*, *Proc. Natl. Acad. of Sci. U.S.A.*, 95: 12602-07, 1998).

B. Protein Degradation Assays:

Measurement of tyrosine release is a preferred method for determining the rate of protein turnover in skeletal muscles. Rat skeletal muscles are dissected and homogenized. The extracts are incubated at 37°C for 2 hours in 20 mM Tris (pH 7.6), 5 mM MgCl₂, 2 mM DTT, ATP-regenerating system (10 μ g creatine phosphokinase and 10 mM creatine phosphate), 1 mM ATP, and 25 mg of ubiquitin in the presence and absence of huE3 α polypeptide. Subsequently, the reactions are terminated with 20% TCA. After centrifugation, the concentrations of tyrosine in the supernatant is measured by fluorescence spectroscopy according to the method of Waakkes and Udenfriend (*J. Lab. Clin. Med.*, 50: 733-736, 1957).

Measurement of radiolabeled proteins will also indicate if huE3 α polypeptide exhibits E3 α family biological activity. Rat skeletal muscle homogenates are incubated at 37°C for 2 hours with 125 I-labeled N-end pathway substrates, such as 125 I-lyzozyme and 125 I-lactalbumin, in the presence and absence of huE3 α polypeptide.

Following the incubation, 20% TCA is added to precipitate the radioactivity. The release of TCA-soluble radioactivity is measured using a gamma counter and correlates the rate of protein degradation. The addition of huE3 α polypeptide should increase the rate of protein degradation in both of these assays.

EXAMPLE 8

Identification of Modulators of the Biological Activity of huE3 α Polypeptides

The assays described in Example 7 demonstrate preferred methods to measure the biological activity of huE3 α as an ubiquitin ligase. These methods are also useful for identifying modulators of huE3 α ubiquitin ligase activity.

The rate limiting step of ubiquitin conjugation consists of E3 α catalyzing the transfer of the activated ubiquitin molecule to the target protein. The rate of ubiquitination modulated by huE3 α can be measured in dissected rat skeletal muscles as described in Example 7. The addition of potential huE3 α modulators (inhibitors or stimulators) to this system will allow for the identification of E3 α stimulators and inhibitors by virtue of their ability to modulate the level or rate of ubiquitin conjugation to the target protein. If the addition of the modulator decreases the rate of huE3 α -modulated ubiquitin conjugation, it is considered a huE3 α inhibitor. If the modulator increases the rate of ubiquitin conjugation it is considered a stimulator.

The effect of huE3 α modulators can also be determined by measuring their effect on the rate of protein turnover as described in Example 7. If huE3 α exhibits the biological activity of an ubiquitin ligase, it will induce protein degradation. Protein turnover is measured by quantitating tyrosine release or the degradation of radioactively labeled N-end pathway substrates in the presence of E3 α modulators. The addition of effective huE3 α modulators will either increase or decrease the rate of protein degradation.

EXAMPLE 9

Identification of huE3 α I Single Nucleotide Polymorphisms (SNP)

A BLAST search of the Celera Human Genome database was conducted using the huE3 α I cDNA sequence (SEQ ID NO: 1) as a probe. The sequences identified in the search were used to manually assemble a polynucleotide sequence (SEQ ID NO: 18) which was discovered to have a single nucleotide mismatch at nucleotide 5397 of the huE3 α I cDNA sequence (SEQ ID NO: 1). The polynucleotide sequence of SEQ ID NO: 18 contains a huE3 α I SNP with a change of a cytosine to a thymidine at position 4702, which caused the predicted amino acid sequence of SEQ ID NO: 2 to change from an Arg residue to a W (Trp) residue at position 1508.

PCR was carried out to confirm the polynucleotide sequence of huE3 α I cDNA. Primers were designed to flank the mismatch as follows: 5' AGAAGGAGAGTACAGTGCACTC3' (SEQ ID NO: 20) and 5'CGAAAGCATCCTGTCCTCTG (SEQ ID NO: 21). PCR was carried out as described in Example 1 with the Marathon-Ready cDNA library (Clontech cat no. 7413-1) from which huE3 α I cDNA was cloned. The PCR reactions resulted in 5 individual PCR products which had identical sequences to the huE3 α I SNP (SEQ ID NO: 18).

These experiments have confirmed the sequence of a huE3 α I SNP set out in SEQ ID NO: 17 wherein the nucleotide at position 4702 is a thymidine. 10 Accordingly, the correct predicted amino acid sequence is set out as SEQ ID NO: 19, wherein the residue at position 1568 is W (Trp).

EXAMPLE 10

Human E3 α I and E3 α II Stimulate Ubiquitination

To confirm that huE3 α I and huE3 α II have the predicted enzymatic activity of stimulating ubiquitin conjugation, ubiquitination reactions were carried out in 293 cells. Cultures of 293T cells (ATCC accession no. CRL1573) were transfected with huE3 α I or huE3 α II full length cDNA (SEQ ID NOS: 1 or 3, respectively) that had been subcloned into pcDNA3.1 vector (Invitrogen) under the control of the CMV promoter using Lipofectamine reagent 2000 (Gibco, cat no. 11668-027) according to the manufacturer's instructions. As a control, 293T cultures were transfected with pcDNA3.1 vector without the cDNA insert. The transfected cells were lysed in ice-cold lysis buffer (50mM Tris-HCl (pH 8.0), 2mM DTT, 5 mM MgCl₂) in the presence of Sigma P8340 protease inhibitor cocktail (containing 4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin and aprotinin) at 100 μ l/10⁷ cells. The crude lysates were then centrifuged at 10,000 g for 20 minutes.

The supernatants prepared from vector- (Control), human E3 α -I- (hu-E3 α -I) or human E3 α -II- (hu-E3 α -II) transfected cells were subjected to ubiquitination reactions. To measure ubiquitination of endogenous proteins, 30 μ g of cell lysate was incubated with ¹²⁵I-ubiquitin (0.15 mg/ml, approximately 10⁷ cpm) in a total volume of 40 μ l in a buffer containing 50 mM Tris, pH 8.0, 2 mM DTT, 5 mM MgCl₂, 2 mM adenosine 5'-[-thio]triphosphate (ATP S), 50 μ g/ml ubiquitin

aldehyde, MG132 20 µg/ml and protease inhibitor cocktail (Sigma P8340) at 37°C for 30 minutes. Reactions were stopped by adding sample buffer and were subjected to 12% SDS PAGE. The gels were then dried and autoradiographed.

The ubiquitination of α -lactalbumin, a known substrate for N-end Rule Ubiquitination was also measured with the 239T transfected cells. For these reactions, 30 µg of cell lysate proteins was incubated with 0.15 mg/ml 125 I- α -Lactalbumin and 0.25 mg/ml unlabeled ubiquitin in a total volume of 40 µl in a buffer containing 50 mM Tris (pH 8.0) 2 mM DTT, 5 mM MgCl₂, 2 mM adenosine 5'-[thio]triphosphate (ATP S), ubiquitin aldehyde 50 ug/ml, 20 µg/ml MG132 and protease inhibitor cocktail (Sigma P8340) at 37°C for 30 minutes. Reactions were stopped by adding sample buffer and each reaction was run of a 8% SDS PAGE was performed. The gels were then dried and autoradiographed

The amount of radioactivity incorporated into high molecular weight bands denoted as “ubiquitin-protein conjugates” in Figure 4 (above 18 kDa for endogenous proteins and above 35 kDa for α -Lactalbumin) were quantitated by using PhosphaImager and plotted (right panel). These reactions indicated that recombinant expression of huE3 α I or huE3 α II in 293 cells lead to accelerated ubiquination of endogenous cellular proteins and ubiquitin conjugation to α -lactobumin, a bona fide N-end rule substrate.

To further substantiate the enzymatic activity of huE3 α I and huE3 α II, ubiquitin conjugation to endogenous cellular proteins were measured in cultured muscle cell lines. Cultures of murine C₂C₁₂ or rat L6 myotube cells (ATCC accession nos. CRL-1772 and CRL-1458, respectively) were transfected with huE3 α I or huE3 α II full length cDNA under control of the CMV promoter using Lipofectamine 2000 Reagent (Gibco). Mock transfection with the pcDNA3.1 vector without a cDNA insert was performed as a control. Cell lysates were prepared as described above for the 293T cells and the resulting supernatants were used in ubiquitin conjugation reactions. For each reaction, 30 µg of C₂C₁₂ or L6 myotube cell lysate was incubated with 125 I-ubiquitin (0.15 mg/ml, approximately x10⁷cpm) in a total volume of 25-30 µl in a buffer containing 50 mM Tris, pH 8.0, 2 mM DTT, 5 mM MgCl₂, 2 mM adenosine 5'-[thio]triphosphate (ATP S), 50 µg/ml ubiquitin aldehyde, 20 µg/ml MG132 and protease inhibitor cocktail (Sigma P8340) at 37°C for 30 minutes. Reactions were stopped by adding sample buffer and were subjected to 12% SDS PAGE. The gels were then dried and autoradiographed.

The amount of ubiquitinated muscle proteins (¹²⁵I-Ubiquitin protein conjugates) were quantitated as the total radioactivity incorporated into high molecular weight bands (above 18 kDa) using a Phosphoimager as shown in Figure 5 (left panel). These reactions indicated that transfection of huE3 α I and huE3 α II increased ubiquitination of cellular proteins 2-3 fold (see Figure 5, right panel) in murine C₂C₁₂ and rat myotube cultures.

EXAMPLE 11

Expression of Human E3 α I and Human E3 α II is Unregulated During Cachexia Disease States

The Yoshida Hepatoma-130 (YAH) cachexia rat model as described in Baracos *et al.* (*Am. J. Physiol.*, 268(5 Pt 1): E996-1006, 1995) was used to determine if huE3 α I and huE3 α II are upregulated in cachexia disease states. For tumor implantation, female Sprague-Dawley rats of the Buffalo strain from a colony maintained at the University of Alberta were used as the host for the YAH tumor cells. Tumor cell stocks were maintained in liquid nitrogen and used after two passages in recipient female animals of the same strain. Rats were housed in individual wire mesh cages in a temperature (24°C)- and humidity (80%)-controlled room on a 12:12-h light-dark cycle. Rats were fed ground laboratory chow (Continental Grain, Chicago, IL) containing 24% crude protein.

Rats were allocated by initial body weight to three groups such that the sizes (mean \pm SE) of the animals receiving each treatment were similar (~ 200g). Two different treatments were compared: YAH-bearing and pair-fed control rats. The pair-fed rats, which received one meal per every day at 9.00am, were fed on the basis of their body weights, the same amount of food consumed by the tumor-bearing rats. On days 1,2,3,4 and 5 after tumor-implantation, food intake was determined in preliminary experiments to be 9, 7.5, 5.3, 1.5, and 0.9% respectively, of initial body weight per day. Rats were implanted with 100 ml of ascites fluid containing YAH cells from a single donor animal. The control rats were implanted with an equal volume of saline buffer. Rats were sacrificed by CO₂ asphyxiation after 3 and 5 days, and epitrochelaris, EDL, soleus, medial gastrocnemius muscles were rapidly dissected and the gastrocnemius muscles were weighed. Tissues were frozen immediately in liquid nitrogen and stored at -70°C until use.

The gastrocnemius skeletal muscle weights in YAH-130 tumor bearing rats were significantly lower than those measured from the pair-fed control rats. As indicated in the Table V below, the YAH-130 tumor bearing rats underwent muscle wasting by day 3 after tumor implantation which was more apparent at day 5 after implantation. The muscle weights are calculated (in grams) as the mean \pm standard error.

Days after Tumor Implantation	n	Pair Fed Control (in grams)	Tumor-Bearing (in grams)	Percent Change
3 days	8	530 \pm 14.6	508 \pm 7.3	-4.3%
5 days	8	593 \pm 8.1	443 \pm 9.4	-25.3%

n = number of animals

The rate of ubiquitin conjugation of the endogenous muscle proteins were carried out as described in Example 10 using the skeletal muscles from the YAH tumor-bearing rats. The frozen gastrocnemius muscles collected (via dissection at sacrifice) from 6 tumor-bearing rats were combined. The muscle extracts (20% weight/volume) were prepared by homogenizing the muscles in a buffer containing 50 mM Tris HCl (pH 8.00), 5 mM MgCl₂, 2 mM DTT, protease inhibitor cocktail (Sigma P8340) and 10% glycerol. The homogenates were then centrifuged at 40,000g for 1 hr and the resulting supernatants were used as crude muscle extracts.

For some assays, the crude muscle extracts were fractionated further by chromatography on DEAE-cellulose (Whatman, Clifton, New Jersey) to remove endogenous ubiquitin as described by Solomon *et al.* (*Proc. natl. Acad. Sci. U.S.A.*, 95: 12602-7, 1998). The bound material Fraction II, which contained most of the ubiquitin conjugating enzymes were eluted with 50 mM Tris, pH 8.0 containing 0.5M NaCl and 1 mM DTT. Both crude extracts and Fraction II were dialyzed prior to use for ubiquitination assay against buffer containing 20 mM Tris, pH 8.0, 2 mM DTT, 5 mM MgCl₂, and 10% glycerol and stored at 70 °C until use. Crude muscle extracts were used for ubiquitin conjugation to ¹²⁵I- α -lactalbumin. Fraction II was used when rates of endogenous skeletal muscles proteins were compared and also when effects of E3 α inhibitors on skeletal muscle protein ubiquitination were tested.

The Fraction II from both tumor-bearing and pair-fed control rats were subjected to ubiquitination reactions of the endogenous muscle proteins as described in

Example 10 in the presence of 20 µg/ml of bestatin and 10 mM of either the E3 α selective inhibitor arginine methyl ester (Arg-ME) or the control alanine methyl ester (Ala-ME) (Sigma Chemicals, St. Louis MO). The reactions were incubated at 37°C for 20 minutes and the 125 I-Ubiquitin conjugates were resolved by 12% SDS PAGE as described in Example 10.

As shown in Figure 6, the tumor-bearing rats exhibited accelerated muscle protein ubiquitination. The increase in ubiquitination within the rat skeletal muscles of the tumor-bearing rats was attributable to the activation of the E3 α /N-end rule pathway, since the addition of E3 α specific inhibitor arginine methylester virtually abolished the accelerated ubiquitination activity (see lanes 9 and 10 on Figure 6).

To further establish the role of huE3 α I and huE3 α II in the N-end rule pathway in muscle wasting in the rat cachexia model, the rates of ubiquitination of N-end rule substrate α -lactalbumin was measured in skeletal muscle extracts from control and tumor-bearing mice. 125 I- α -lactalbumin (0.15 mg/ml) was incubated with crude skeletal muscle extracts (2 mg/ml) in the presence of 0.25 mg/ml of ubiquitin at 37°C for 0 or 20 minutes as described in Example 10. As shown in Figure 7, the atrophying muscles dissected from the tumor-bearing rats exhibited increased ubiquitin conjugation to 125 I- α -lactalbumin.

Northern blot analysis was carried out to measure the huE3 α I and huE3 α II mRNA expression in the gastrocnemius muscles of YAH-130 tumor-bearing mice. RNA from the dissected muscles was isolated with Trizol Reagent (Gibco, cat: 15596-018). The final RNA pellets were resuspended in DEPC-H₂O and 20 µg of total RNA per lane were separated by electrophoresis through 1% agarose gels. The separated RNA was transferred to nylon membranes and cross-linked to the filter by exposure to ultraviolet light.

The cDNA probes were generated by PCR with the following primers: for Hu-E3 α -I probe: 5' primer, AGG AAG CTG TGG TCA TGT (SEQ ID NO: 22) ; 3' primer, GTT AGG AAG AAC AAC TG (SEQ ID NO: 23); for Hu-E3 α -II probe: CTA AAG AAC AGC GAA GGC AAC AG (SEQ ID NO: 24); 3' primer, CGC AGC TAC CCC AAC ACA TTA T (SEQ ID NO: 25). PCR was carried out for 30 cycles at 94°C for 45 seconds, 50-58 °C for 45 seconds, and 72°C for 1 minutes using a commercially avaiblae kit (Boehringer Mannheim, cat: 1578553,). The PCR product was cloned into the pCR2.1 vector using the Original TA Cloning kit (Invitrogen). After digestion with EcoRI, the cloned PCR product was sequenced and confirmed.

The resulting cDNA probes were radiolabeled with [³²P]dCTP using the Prime-it RMT labeling kit (Stratagene, cat: 300392). Membranes were prehybridized and hybridized (with the cDNA probes) in buffer containing 1% BSA, 7% SDS, 0.5 M Sodium Phosphate (pH 7.0), 1mM EDTA. Subsequently, the blots were washed in buffer containing 1% SDS, 0.04 M Sodium Phosphate, 1 M EDTA, by the method of Church and Gilbert (*Proc. Natl. Acad. Sci. U.S.A.* 81:1991-1995, 1984) and exposed to radiographic film at -70°C overnight.

As shown in Figure 8, the expression of huE3 α II mRNA was increased at day 3 post-tumor implantation (see left panel) but the level of huE3 α I had not changed significantly at day 3 (see right panel). This coincides with the time point when the significant decrease in muscle mass was detectable in the C26 tumor-bearing mice (See Table VI in Example 12). The expression of both huE3 α I and huE3 α II was elevated at day 5 post-tumor implantation in the tumor bearing rats. This corresponds to a cachexia state with severe muscle wasting.

EXAMPLE 12
Expression of Human E3 α I and Human E3 α II in a Murine Cancer Cachexia Model of C26 Tumor Bearing Mice

The Colon-26 (C-26) tumor model of cachexia was used to demonstrate the role of huE3 α I and huE3 α II as described in Matsumoto *et al.*, *Brit. J. Can.* 79: 764-9 (1999) and Tanaka *et al.*, *Can. Res.*, 50: 2290-5 (1990). Seventy-two week old male CDF1 mice were injected in the left flank with 0.2 ml containing either 0.5 x 10⁶ C26 cells or PBS. Following injection, body weight and food intake was observed daily. The pair fed control mice (generated as described in Example 11) were fed the daily average food intake of the tumor bearing group. On the day 12 or 17 post-injection, tumor bearing mice and pair fed control mice were sacrificed by CO₂ asphyxiation. Subsequently, a terminal serum sample was collected and the kidney, heart and gastrocnemius muscles were rapidly dissected and weighed. The resulting C26 tumors were also weighed. The tissues were frozen on dry ice and stored at -70°C .

The wet weight of the skeletal muscles from the tumor-bearing mice were significantly less than the weight of those from the pair-fed control mice as shown below in Table VI:

	Days after Tumor Implantation	n	Pair Fed Control (in grams)	Tumor-Bearing (in grams)	Percent Change
5	12 days	12	0.127 ± 0.007	0.116 ± 0.0072	-8.6%
	17 days	12	0.117 ± 0.009	0.087 ± 0.001	-26%

n = number of animals

RNA was isolated at day 12 and day 17 from the gastrocnemius muscle and cardiac muscle from the C26 tumor-bearing and pair-fed control mice as described in Example 11. Northern blot analysis was carried out by loading 20 µg of total RNA per lane and separating by electrophoresis through 1% agarose gels. The separated RNA was transferred to nylon membranes and cross-linked to the filter by exposure to ultraviolet light.

The cDNA probes were generated by PCR with the following primers: for mouse E3α-I probe: 5' primer, TTT CTT CCA TTC CCT GCA TAC A (SEQ ID NO: 26), 3' primer, CAA AAC TTT ATA AAG GTG CCC GTA A (SEQ ID NO: 27), and for Mouse E3α-II probe: 5' primer, ATT CCC TGC ATG CAC TTC AGT AA (SEQ ID NO: 28), 3' primer, CAT TCC CTG CAT GCA CTT CAG SEQ ID NO: 29). PCR was carried out for 30 cycles at 94°C for 45 seconds, 50-58 °C for 45 seconds, and 72°C for 1 minutes using a commercially available kit (Boehringer Mannheim cat: 1578553,). The PCR product was cloned into the pCR2.1 vector using the Original TA Cloning kit (Invitrogen). After digestion with EcoRI, the cloned PCR product was sequenced and confirmed.

The resulting cDNA probes were radiolabeled with [³²P]dCTP using the Prime-it RMT labeling kit (Stratagene, cat: 300392). Membranes were prehybridized and hybridized (with the cDNA probes) in buffer containing 1% BSA, 7% SDS, 0.5 M Sodium Phosphate (pH 7.0), 1mM EDTA. Subsequently, the blots were washed in buffer containing 1% SDS, 0.04 M Sodium Phosphate, 1 M EDTA, by the method of Church and Gilbert (*Proc. Natl. Acad. Sci. U.S.A.* 81:1991-1995, 1984) and exposed to radiographic film at -70°C overnight.

As shown in Figure 9, at day 12 after tumor-implantation there was a clear increase in huE3αII mRNA expression in the skeletal muscles of tumor-bearing mice. Expression of both huE3αI and huE3αII was increased at day 17 post-implantation. Increased expression of huE3αII mRNA coincides with the time point

when the significant decrease in muscle mass became detectable in tumor-bearing mice (See Table VI above). The expression of huE3 α I and huE3 α II remained unchanged in the cardiac muscle of the tumor-bearing mice. This corresponds to a cachexia state with severe muscle wasting.

The data described in both Examples 11 and 12 show that in experimental cachexia models, there was a sharp rise in the rate of ubiquitination in skeletal muscle tissues. The accelerated ubiquitination is due largely to the activation of E3 α , since addition of the E3 α -selective inhibitor, arginine methylester, virtually abolished all the increased ubiquitination activities. In addition, the data demonstrated that in two widely used experimental models of cachexia (murine C26 tumor-bearing model and rat YAH-130 tumor-bearing model), the mRNA levels of E3 α -I and E3 α -II increase significantly and specifically within skeletal muscle during the course of cachexia and muscle wasting. In these disease models and during the course of cachexia, the induction of E3 α -II occurred earlier than that of E3 α -I and coincided with the early onset of muscle wasting. During the late stage of cachexia, both E3 α -I and E3 α -II were markedly induced when muscle wasting became pronounced. Therefore, the results suggest that E3 α -II may play a more critical role in cachexia, although both E3 α -I and E3 α -II are apparently involved in the disease process.

EXAMPLE 13

Treatment of Muscle Cells with TNF α and IL-6 leads to Increased Expression of Human E3 α II and Increased Ubiquitination

Treatment with the proinflammatory cytokines, TNF α and IL-6, caused the induction of huE3 α II in C₂C₁₂ myotube cultures. C₂C₁₂ myoblasts were cultured in 100-mm dishes in an atmosphere of 5% CO₂ at 37°C in DMEM supplemented with 10% FBS and L-glutamine to reach 100% confluence. Myoblast differentiation was induced with DMEM supplemented with 2% horse serum and L-glutamine for 96 hours. Differentiated myotubes were then treated with TNF α (10 ng/ml; R&D Systems cat no. 210-TA) or IL-6 (10 ng/ml; R&D Systems cat no. 206-IL) for 3 days and 5 days.

After the 3 or 5 day incubation, RNA from differentiated C₂C₁₂ cultures was isolated with Trizol Reagent and Northern blot analysis was carried out

as described in Example 11. Isolated RNA from untreated C₂C₁₂ cultures were used as a control. The blots were hybridized with a ³²P-labeled cDNA probes specific for muE3 α I (lower panels) and muE3 α II (upper panels). The probes were generated as described in Example 12.

As shown in Figure 10, the expression of muE3 α II was markedly increased in the cells treated with TNF α or IL-6 (See upper panels). Conversely, the expression of muE3 α I was not drastically induced in response to proinflammatory cytokine treatment. This data indicates a role for E3 α II in cytokine-mediated protein catabolism and muscle wasting.

Cytokine treatment also resulted in accelerated ubiquitination in differentiated C₂C₁₂ cells. C₂C₁₂ cells were differentiated for 5 days to allow formation of myotubes. The differentiated myotubes were treated with 2 ng/ml of IL-6 for 5, 24 or 48 hours. After the incubation, the cells were lysed and ¹²⁵I-Ubiquitin conjugation was carried out as described in Example 10. As shown in Figure 11, IL-6 treatment resulted in a marked increase in ubiquitination of cellular proteins (left panel) which was detectable 5 hours post-treatment. The increase in ubiquitination was time dependent (see right panel).

Differentiated C₂C₁₂ myotubes were also treated with increasing concentrations of TNF α (0, 3, 6, 10, 20 ng/ml) for one hour. This treatment resulted in a dose dependent increase in ¹²⁵I- ubiquitin conjugation of cellular proteins as shown in Figure 12.

TNF α and IL-6 are major proinflammatory cytokines known to be involved in cachexia and tissue wasting. The data reveals that these cytokines significantly upregulate the mRNA expression of E3 α II in muscle cells and stimulate muscle protein ubiquitination. Proinflammatory cytokines, such as TNF α , IL-6, IL-1, interferon-gamma, CNTF and leptin, have been shown to be involved in disease states of cachexia and protein/tissue wasting, including cancer cachexia, renal cachexia (energy-protein malnutrition), burn cachexia and AIDS wasting. These findings that TNF α and IL-6 induce the expression of E3 α II (Figure 9) and stimulate protein ubiquitination in muscle cells (Figures 10 and 11) strongly suggest that E3 α II is critical target via which various cachectic factors induce protein catabolism and cachexia/muscle wasting. This argument is further supported by our finding that

recombinant expression of E3 α II by cDNA transfection leads to marked protein ubiquitination in myotube cultures (Figure 5).

While the present invention has been described in terms of the preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations which come within the scope of the invention as claimed.

10

15

20

25

30

CLAIMS

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- 5 (a) the nucleotide sequence as set forth in SEQ ID NOS: 1 or 3;
- (b) a nucleotide sequence encoding the polypeptide set forth in SEQ ID NOS: 2 or 4;
- 10 (c) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of (a) or (b); and
- (e) a nucleotide sequence complementary to any of (a)-(c).

2. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- 15 (a) a nucleotide sequence encoding a polypeptide that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the polypeptide set forth in SEQ ID NOS: 2 or 4, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- 20 (b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence as set forth in SEQ ID NOS: 1 or 3;
- (c) a nucleotide sequence of SEQ ID NOS: 1; 3; (a); or (b) encoding a polypeptide fragment of at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;
- 25 (d) a nucleotide sequence of SEQ ID NOS: 1, 3, or (a)-(c) comprising a fragment of at least about 16 nucleotides;
- (e) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(d); and
- (f) a nucleotide sequence complementary to any of (a)-(c).

3. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a polypeptide set forth in SEQ

ID NOS: 2 or 4 with at least one conservative amino acid substitution, wherein the 5 polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

(b) a nucleotide sequence encoding a polypeptide set forth in SEQ

ID NOS: 2 or 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

(c) a nucleotide sequence encoding a polypeptide set forth in SEQ

10 ID NOS: 2 or 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

(d) a nucleotide sequence encoding a polypeptide set forth in SEQ

ID NOS: 2 or 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

(e) a nucleotide sequence encoding a polypeptide set forth in SEQ

15 ID NOS: 2 or 4 with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

(f) a nucleotide sequence of (a)-(e) comprising a fragment of at

20 least about 16 nucleotides;

(g) a nucleotide sequence which hybridizes under moderately or

highly stringent conditions to the complement of any of (a)-(f); and

(h) a nucleotide sequence complementary to any of (a)-(e).

25

4. A vector comprising the nucleic acid molecule of claims 1, 2, or 3.

30 5. A host cell comprising the vector of claim 4.

6. The host cell of claim 5 that is a eukaryotic cell.

7. The host cell of claim 5 that is a prokaryotic cell.

8. A process of producing a huE3 α polypeptide comprising culturing the host cell of claim 5 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

5 9. A polypeptide produced by the process of claim 8.

10 10. The process of claim 8, wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native huE3 α polypeptide operatively linked to the DNA encoding the huE3 α polypeptide.

10 11. The isolated nucleic acid molecule according to claim 2 wherein the percent identity is determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm.

15 12. A process for determining whether a compound inhibits huE3 α polypeptide activity or production comprising exposing a cell according to claims 5, 6, or 7 to the compound, and measuring huE3 α polypeptide activity or production in said cell.

20 13. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NOS: 2 or 4.

25 14. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:

(a) the mature amino acid sequence as set forth in SEQ ID NOS: 2 or 4 comprising a mature amino terminus at residue 1, optionally further comprising an amino-terminal methionine;

(b) an amino acid sequence for an ortholog of SEQ ID NOS: 2 or 4;

30 (c) an amino acid sequence that is at least about 70, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the amino acid sequence of SEQ ID NOS: 2 or 4, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

(d) a fragment of the amino acid sequence set forth in SEQ ID NOS: 2 or 4 comprising at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

5 (e) an amino acid sequence for an allelic variant or splice variant of either the amino acid sequence as set forth in SEQ ID NOS: 2 or 4, or at least one of (a)-(c).

15. An isolated polypeptide of claim 14 wherein the amino acid sequence is a mouse ortholog set out in SEQ ID NO: 6.

10 16. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:

(a) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

15 (b) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

20 (c) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4;

(d) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4; and

25 (e) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4, with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in SEQ ID NOS: 2 or 4.

30 17. An isolated polypeptide encoded by the nucleic acid molecule of claims 1, 2, or 3.

18. The isolated polypeptide according to claim 14 wherein the percent identity is determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm.

5

19. An antibody produced by immunizing an animal with a peptide comprising an amino acid sequence of SEQ ID NOS: 2 or 4.

10 20. An antibody or fragment thereof that specifically binds the polypeptide of claims 13, 14, 15 or 16.

21. The antibody of claim 20 that is a monoclonal antibody.

15 22. A hybridoma that produces a monoclonal antibody that binds to a peptide comprising an amino acid sequence of SEQ ID NOS: 2 or 4.

23. A method of detecting or quantitating the amount of huE3 α polypeptide using the anti-huE3 α antibody or fragment of claims 18, 19, or 20.

20 24. A method for determining the presence and/or concentration of huE3 α polypeptide in a biological sample comprising the steps of:

(a) obtaining a biological sample;

25 (b) contacting the biological sample with an antibody according to claim 22 under conditions which allow for the antibody to bind to the huE3 α polypeptide;

(c) detecting antibody binding to huE3 α polypeptide in the biological sample, wherein the detection of antibody binding is indicative of the presence of huE3 α polypeptide in said biological sample; and

30 (d) comparing the level of antibody binding to huE3 α polypeptide within said biological sample and the level of the antibody binding to a known concentration of huE3 α polypeptide.

25. A selective binding agent or fragment thereof that specifically binds at least one polypeptide wherein said polypeptide comprises the amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence as set forth in SEQ ID NOS: 2 or 4; and
- 5 (b) fragment of the amino acid sequence set forth in at least one of SEQ ID NOS: 2 or 4; or a naturally occurring variant thereof.

26. The selective binding agent of claim 25 that is an antibody or fragment thereof.

10

27. The selective binding agent of claim 25 that is a humanized antibody.

28. The selective binding agent of claim 25 that is a human antibody or fragment thereof.

15

29. The selective binding agent of claim 25 that is a polyclonal antibody or fragment thereof.

20

30. The selective binding agent of claim 25 that is a monoclonal antibody or fragment thereof.

31. The selective binding agent of claim 25 that is a chimeric antibody or fragment thereof.

25

32. The selective binding agent of claim 25 that is a CDR-grafted antibody or fragment thereof.

33. The selective binding agent of claim 25 that is an antiidiotypic antibody or fragment thereof.

30

34. The selective binding agent of claim 25 which is a variable region fragment.

35. The variable region fragment of claim 25 which is a Fab or a Fab' fragment.

5 36. A selective binding agent or fragment thereof comprising at least one complementarity determining region with specificity for a polypeptide having the amino acid sequence of SEQ ID NOS: 2 or 4.

10 37. The selective binding agent of claim 25 which is bound to a detectable label.

15 38. A selective binding agent produced by immunizing an animal with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2 or 4.

20 39. A hybridoma that produces a selective binding agent capable of binding a polypeptide according to claims 1, 2, or 3.

25 40. A composition comprising the polypeptide of claims 13, 14, or 16 and a pharmaceutically acceptable formulation agent.

30 41. The composition of claim 40 wherein the pharmaceutically acceptable formulation agent is a carrier, adjuvant, solubilizer, stabilizer, or anti-oxidant.

35 42. The composition of claim 40 wherein the polypeptide comprises the mature amino acid sequence as set forth in SEQ ID NOS: 2 or 4.

40 43. A polypeptide comprising a derivative of the polypeptide of claims 13, 14, or 16.

45 44. The polypeptide of claim 43 which is covalently modified with a water-soluble polymer.

45. The polypeptide of claim 44 wherein the water-soluble polymer is selected from the group consisting of polyethylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide copolymers, polyoxyethylated polyols, and polyvinyl alcohol.

5
46. A composition comprising a nucleic acid molecule of claims 1, 2, or 3 and a pharmaceutically acceptable formulation agent.

10
47. A composition of claim 46 wherein said nucleic acid molecule is contained in a viral vector.

48. A viral vector comprising a nucleic acid molecule of claims 1, 2, or 3.

15
49. A fusion polypeptide comprising the polypeptide of claims 13, 14, or 16 fused to a heterologous amino acid sequence.

50. The fusion polypeptide of claim 49 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.

20
51. A method for treating, preventing or ameliorating a medical condition in a mammal resulting from decreased levels of huE3 α polypeptide comprising administering a huE3 α polypeptide to said mammal.

25
52. The method of claim 51 wherein the huE3 α polypeptide administered is the amino acid sequence set forth in SEQ ID NOS: 2 or 4 or a fragment thereof at least 25 amino acids or a homolog, analog or variant of said huE3 α polypeptide or fragment thereof.

30
53. The method of claim 51 wherein the huE3 α polypeptide administered has the amino acid set forth in SEQ ID NOS: 2 or 4 with at least one amino acid substitution.

54. The method of claim 51 wherein the huE3 α polypeptide administered has the amino acid sequence set forth in SEQ ID NOS: 2 or 4 with at least one amino acid deleted.

5 55. A method of diagnosing the existence or a susceptibility to a pathological condition in a subject caused by or resulting from abnormal levels of huE3 α in a mammalian subject comprising:

10 (a) determining the level of huE3 α in a biological, tissue or cellular sample; and

(b) comparing the level of huE3 α polypeptide in biological, tissue or cellular samples from normal subjects or the subject at an earlier time; wherein a susceptibility of an existence of a pathological condition is based on the presence or amount of expression of huE3 α polypeptide.

15 56. A device, comprising:

(a) a membrane suitable for implantation; and
(b) cells encapsulated within said membrane, wherein said cells secrete a protein of claims 13, 14, or 16; said membrane being permeable to said protein product and impermeable to materials detrimental to said cells.

20 57. A device, comprising:

(a) a membrane suitable for implantation; and
(b) The huE3 α polypeptide encapsulated within said membrane, wherein said membrane is permeable to the polypeptide.

25 58. A method of identifying a compound which binds to a polypeptide comprising:

(a) contacting the polypeptide of claims 13, 14, or 16 with a compound; and
(b) determining the extent of binding of the polypeptide to the compound.

59. A diagnostic reagent comprising a detectably labeled polynucleotide encoding the amino acid sequence set out in SEQ ID NOS: 2 or 4; or a fragment, variant or homolog thereof including allelic variants and spliced variants thereof.

5 60. The diagnostic reagent of claim 58, wherein said labeled polynucleotide is a first-strand cDNA.

61. A method for determine the presence of huE3 α nucleic acids in a biological sample comprising the steps of:

10 (a) providing a biological sample suspected of containing huE3 α nucleic acids;

(b) contacting the biological sample with a diagnostic reagent according to claim 59 under conditions wherein the diagnostic reagent will hybridize with huE3 α nucleic acids contained in said biological sample;

15 (c) detecting hybridization between huE3 α nucleic acid in the biological sample and the diagnostic reagent; and

(d) comparing the level of hybridization between the biological sample and diagnostic reagent with the level of hybridization between a known concentration of huE3 α nucleic acid and the diagnostic reagent.

20 62. A method for detecting the presence of huE3 α nucleic acids in a tissue or cellular sample comprising the steps of:

25 (a) providing a tissue or cellular sample suspected of containing huE3 α nucleic acids;

(b) contacting the tissue or cellular sample with a diagnostic reagent according to claim 59 under conditions wherein the diagnostic reagent will hybridize with huE3 α nucleic acids;

(c) detecting hybridization between huE3 α nucleic acid in the tissue or cellular sample and the diagnostic reagent; and

30 (d) comparing the level of hybridization between the tissue or cellular sample and diagnostic reagent with the level of hybridization between a known concentration of huE3 α nucleic acid and the diagnostic reagent.

63. The method of claim 59 wherein said polynucleotide molecule is
DNA.

5 64. The method of claim 59 wherein said polynucleotide molecule is
RNA.

65. A method of modulating levels of a polypeptide in an animal
comprising administering to the animal the nucleic acid molecule of claims 1, 2, or 3.

10 66. A transgenic non-human mammal comprising the nucleic acid
molecule of claims 1, 2, or 3.

SEARCHED
INDEXED
MAILED
FILED
RECEIVED
JULY 11 1991
U.S. PATENT AND TRADEMARK OFFICE

ABSTRACT OF THE DISCLOSURE

The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3 α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.

Figure 1

SEQ ID NO:

6	mouse_E3 α II	MASEMEPEVQ AID-RSLLEC SAEEIAGRWL QATDLNREVY QHLAHCVPKI	49
4	human_E3 α II	MASELEPEVQ AID-RSLLEC SAEEIAGKWL QATDLTREVY QHLAHYVPKI	49
15	mouse_E3 α I	MADEEMDGAE RMDVSPEPL APQRTPASWWD QQVDFYTAFL HHLAQLVPEI	50
2	human_E3 α I	MADEEAGGTE RMEISAEQP TPQRLASWWD QQVDFYTAFL HHLAQLVPEI	50
	Consensus	MA.E..... .D....L..A..W. Q..D..... .HLA..VP.I	50
6	mouse_E3 α II	YCRGPNPFPQ KEDTLAQHIL LGPMEWYICA EDPALGFPKL EQANKPSHLC	99
4	human_E3 α II	YCRGPNPFPQ KEDMLAQHVL LGPMEWYLCG EDPAFGFPKL EQANKPSHLC	99
15	mouse_E3 α I	YFAEMDPDLE KQEESVQMSI LTPLEWYLFQ EDPDICLKEKL KHSG-AFQLC	99
2	human_E3 α I	YFAEMDPDLE KQEESVQMSI FTPLEWYLFQ EDPDICLKEKL KHSG-AFQLC	99
	Consensus	Y.....P... K.....Q... L.P.EWYL.G EDP.....KLLC	100
6	mouse_E3 α II	GRVFKVGEPT YSCRDCAVDP TCVLCMECFL GSIHRDHRYR MTTSGGGFC	149
4	human_E3 α II	GRVFKVGEPT YSCRDCAVDP TCVLCMECFL GSIHRDHRYR MTTSGGGFC	149
15	mouse_E3 α I	GKVFKSGETT YSCRDCAIDP TCVLCMDCFQ SSVHKNHRYK MHTSTGGFC	149
2	human_E3 α I	GRVFKSGETT YSCRDCAIDP TCVLCMDCFQ DSVHKNHRYK MHTSTGGFC	149
	Consensus	GRVFK.GE.T YSCRDCA.DP TCVLCM.CF. .S.H..HRY. M.TS.GGGFC	150
6	mouse_E3 α II	DCGDTEAWKE GPYCQKHKLS SSEVVEEEDP LVHLSEDVIA RTYNIFAIMF	199
4	human_E3 α II	DCGDTEAWKE GPYCQKHLEN TSEIEEEEEDP LVHLSEDVIA RTYNIFAITF	199
15	mouse_E3 α I	DCGDTEAWKT GPFCVDHEPG RAGTTKESLH -CPLNEEVIA QARRIFPSVI	198
2	human_E3 α I	DCGDTEAWKT GPFCVNHEPG RAGTIKENSR -CPLNEEVIV QARKIFPSVI	198
	Consensus	DCGDTEAWK. GP.C..HE.E... .L.E.VIAIF....	200
6	mouse_E3 α II	RYAVDILTWE KESELPEDLE VAEKSDTYYC MLFNDEVHTY EQVIYTLQKA	249
4	human_E3 α II	RYAVEILTWE KESELPADLE MVEKSDTYYC MLFNDEVHTY EQVIYTLQKA	249
15	mouse_E3 α I	KYIVEMTIWE EEKELPPPELO IREKNERYYC VLFNDEHHSY DHVIYSLQRA	248
2	human_E3 α I	KYVVEMTIWE EEKELPPPELO IREKNERYYC VLFNDEHHSY DHVIYSLQRA	248
	Consensus	.Y.VE...WE. .E.ELP..L. ..EK...YYC .LFNDE.H.Y ..VIY.LQ.A	250
6	mouse_E3 α II	VNCTQKEAIG FATTVDRDGR RPVRYGDFQY CDQAKTVIVR NTSRQTK-PL	298
4	human_E3 α II	VNCTQKEAIG FATTVDRDGR RSVRYGDFQY CEQAKSVIVR NTSRQTK-PL	298
15	mouse_E3 α I	LDCELAEAQL HTTAIDKEGR RAVKAGVYAT CQEAKEDIKS HSENVSQHFL	298
2	human_E3 α I	LDCELAEAQL HTTAIDKEGR RAVKAGAYAA CQEAKEDIKS HSENVSQHPL	298
	Consensus	..C...EA... .T..D..GR R.V..G.... C..AK..I..PL	300
6	mouse_E3 α II	KVQVMHSSVA AHQNFGLKAL SWLGSVIGYS DGLRRILCQV GLQEGPDGEN	348
4	human_E3 α II	KVQVMHSSIV AHQNFGLKLL SWLGSIIGYS DGLRRILCQV GLQEGPDGEN	348
15	mouse_E3 α I	HVEVLHSVVM AHQKFALRLG SWMNKIMSYS SDFRQIFCQA CLVEEPGSEN	348
2	human_E3 α I	HVEVLHSEIM AHQKFALRLG SWMNKIMSYS SDFRQIFCQA CLREEPDSEN	348
	Consensus	.V.V.HS... AHQ.F.L.L. SW...I..YS ...R.I.CQ. .L.E.PD.EN	350
6	mouse_E3 α II	SSLVDRLMLN DSKLWKGARS VYHQLFMSSL LMDLKYYKKLF ALRFAKNYRQ	398
4	human_E3 α II	SSLVDRLMLS DSKLWKGARS VYHQLFMSSL LMDLKYYKKLF AVRFAKNYQQ	398
15	mouse_E3 α I	PCLISRLMLW DAKLYKGARK ILHELIFSSF FMEMEYKKLF AMEFVKYYKQ	398
2	human_E3 α I	PCLISRLMLW DAKLYKGARK ILHELIFSSF FMEMEYKKLF AMEFVKYYKQ	398
	Consensus	..L..RLML. D.KL.KGAR. ..H.L..SS. .M...YKKLF A..F.K.Y.Q	400
6	mouse_E3 α II	LQRDFMEDDH ERAVSVTALS VQFFTAPTLA RMLLTENLM TVIIKAFMDH	448
4	human_E3 α II	LQRDFMEDDH ERAVSVTALS VQFFTAPTLA RMLITEENLM SIIIKTFMDH	448
15	mouse_E3 α I	LQKEYISDDH ERSISITALS VQMLTVPTLA RHLIEEQNVI SVITETLLEV	448
2	human_E3 α I	LQKEYISDDH DRSISITALS VQMFTVPTLA RHLIEEQNVI SVITETLLEV	448
	Consensus	LQ.....DDH ER..S.TALS VQ.FT.PTLA R.LI.E.N.. SVI..T...	450

Figure 1 (continued)

SEQ	ID NO:								
6	mouse_E3αII	LKHRDAQGRF	QFERYTALQA	FKFRRVQSLI	LDLKYLISK	PTEWSDELRO			498
4	human_E3αII	LRHRDAQGRF	QFERYTALQA	FKFRRVQSLI	LDLKYLISK	PTEWSDELRO			498
15	mouse_E3αI	LPEYLDRNN-	KFN-FQGYSQ	DKLGRVYAVI	CDLKYILISK	PVIWTERLRA			496
2	human_E3αI	LPEYLDRNN-	KFN-FQGYSQ	DKLGRVYAVI	CDLKYILISK	PTIWTERLRM			496
	Consensus	L.....	.F.....	.K..RV...I	.DLKY.LISK	PT.W...LR.			500
6	mouse_E3αII	KFLQGFDAL	ELLKCMQGMD	PITRQVGQHI	EMEPEWEAAF	TLQMKLTHVI			548
4	human_E3αII	KFLEGFDAFL	ELLKCMQGMD	PITRQVGQHI	EMEPEWEAAF	TLQMKLTHVI			548
15	mouse_E3αI	QFLEGFRSFL	KILTCMQGME	EIRRQVGQHI	EVDPDWEAAI	AIQMQLKNIL			546
2	human_E3αI	QFLEGFRSFL	KILTCMQGME	EIRRQVGQHI	EVDPDWEAAI	AIQMQLKNIL			546
	Consensus	.FLEGF..FL	..L.CMQGM.	.I.RQVGQHI	E..P.WEAA.	..QM.L....			550
6	mouse_E3αII	SMVQDWCA	L EKV LIEAYKK	CLAVLTQCHG	GFTDGEQPIT	LSICGHHSVET			598
4	human_E3αII	SMMQDWCA	S EKV LIEAYKK	CLAVLMQCHG	GYTDGEQPIT	LSICGHHSVET			598
15	mouse_E3αI	LMFQEWCACD	EDLLL VAYKE	CHKAVMRCST	NFMSSTKTV-	VQLCGHSLET			595
2	human_E3αI	LMFQEWCACD	EELL VAYKE	CHKAVMRCST	SFISSSKTV-	VQSCGHSLET			595
	Consensus	:M.Q.WCA.D	E...L..AYK.	C....M.C...	.F.....	...CGHS.E.T			600
6	mouse_E3αII	I RYCVSQEKV	SIHLPISRLL	AGLHVLLSKS	EVAYKFPELL	PLSELSPPML			648
4	human_E3αII	I YCVSQEKV	SIHLPVSRL	AGLHVLLSKS	EVAYKFPELL	PLSELSPPML			648
15	mouse_E3αI	KSYKVSEDLV	SIHLPLSRTL	AGLHVRLSRL	GAISRLHEFV	PFDSFQVEVL			645
2	human_E3αI	KSYRVSEDLV	SIHLPLSRTL	AGLHVRLSRL	GAVSLRHEFV	SFEDFQVEVL			645
	Consensus	..Y.VS....V	SIHLP.SR.L	AGLHV.LS...E..	P.....L			650
6	mouse_E3αII	I EHPLRCLVL	CAQVHAGMWR	RNGFSLVNQI	YYYHNVKCRR	EMFDKDIVML			698
4	human_E3αII	I EHPLRCLVL	CAQVHAGMWR	RNGFSLVNQI	YYYHNVKCRR	EMFDKDVVML			698
15	mouse_E3αI	VEYPLRCLVL	VAQVVAEMWR	RNGLSSLISQV	FYYQDVKCRE	EMYDKDIIML			695
2	human_E3αI	VEYPLRCLVL	VAQVVAEMWR	RNGLSSLISQV	FYYQDVKCRE	EMYDKDIIML			695
	Consensus	.E.PLRCLVL	.AQV.A.MWR	RNG.SL..Q.	.YY..VKCR.	EM.DKDI.ML			700
6	mouse_E3αII	QTGVSMMDPN	HFLMIMLSRF	ELYQLFSTPD	YGKRFSSSEVT	HKDVVQQNNT			748
4	human_E3αII	QTGVSMMDPN	HFLMIMLSRF	ELYQIFSTPD	YGKRFSSSEIT	HKDVVQQNNT			748
15	mouse_E3αI	QIGASIMDPN	KFLLLVLQRY	EL----TDA	FNKTIST--K	DQDLIKQYNT			738
2	human_E3αI	QIGASLMDPN	KFLLLVLQRY	EL----AEA	FNKTIST--K	DQDLIKQYNT			738
	Consensus	Q.G.S.MDPN	.FL...L.R.	EL....T..	..K..S....	..D...Q.NT			750
6	mouse_E3αII	LIEEMLYLI	MLVGERFNPG	VGQVAATDEI	KREIIHQLSI	KPMAHSELVK			798
4	human_E3αII	LIEEMLYLI	MLVGERFSPG	VGQVNATDEI	KREIIHQLSI	KPMAHSELVK			798
15	mouse_E3αI	LIEEMLQVLI	YIVGERYVPG	VGTVTREEVI	MREITHLLCI	EPMPHSAIAR			788
2	human_E3αI	LIEEMLQVLI	YIVGERYVPG	VGTVTKEEV	MREIIHLLCI	EPMPHSIAAK			788
	Consensus	LIEEML...I	..VGER..PG	VG.V....I	.REIIH.L.I	.PM.HS...K			800
6	mouse_E3αII	SLPEDENKET	GMESVIESVA	HFKKPGLTGR	GMYELKPECA	KEFNLYFYHF			848
4	human_E3αII	SLPEDENKET	GMESVIEAVA	HFKKPGLTGR	GMYELKPECA	KEFNLYFYHF			848
15	mouse_E3αI	NLPENENNET	GLENVINKVA	TFKKPGVSGH	GVYELKDESL	KDFNMYFYHY			838
2	human_E3αI	NLPENENNET	GLENVINKVA	TFKKPGVSGH	GVYELKDESL	KDFNMYFYHY			838
	Consensus	.LPE.EN.ET	G.E.VI..VA	.FKKPG..G.	G.YELK.E..	K.FN.YFYH.			850
6	mouse_E3αII	SRAEQSKAEE	AQRKLKRENK	EDTALPPP	PPFCPLFASL	VNILQCDVML			898
4	human_E3αII	SRAEQSKAEE	AQRKLKRQNR	EDTALPPP	PPFCPLFASL	VNILQSDVML			898
15	mouse_E3αI	SKTQHSKAEH	MQKKRRKQEN	KDEALPPP	PEFCPAFSKV	VNLNCDIMM			888
2	human_E3αI	SKTQHSKAEH	MQKKRRKQEN	KDEALPPP	PEFCPAFSKV	INLLNCDIMM			888
	Consensus	S....SKAE.	.Q.K....Q...	.D.ALPPP..	P.FCP.F...	VN.L.CDVM.			900

Figure 1 (continued)

SEQ ID NO:

6	mouse_E3 α II	YIMGTLQWA VEHHGSAWSE SMLQRVLHLI GMALQEEKHH LENAVEGHVQ	948
4	human_E3 α II	CIMGTLQWA VEHNGYAWSE SMLQRVLHLI GMALQEEKQH LENVTEEEHVV	948
15	mouse_E3 α I	YILRTIFERA VDTESNLWTE GMLQMAFHIL ALGLLEEKQQ LQKAPEEEV-	937
2	human_E3 α I	YILRTVFERA IDTDSNLWTE GMLQMAFHIL ALGLLEEKQQ LQKAPEEEV-	937
	Consensus	YI..TI...A V.....W.E .MLQ...H... .L.EEKQ. L..A.EE.V.	950
6	mouse_E3 α II	TFTFTQKISK PGDAPHNSPS ILAMLETLQN APSLEAHKDM IRWLLKMFNA	998
4	human_E3 α II	TFTFTQKISK PGEAPKNSPS ILAMLETLQN APYLEVKDM IRWILKTFNA	998
15	mouse_E3 α I	AFDFYHKASR LGSSAMNAQN IQMLLERLKG IPQLEGQKDM ITWILQMFDT	987
2	human_E3 α I	TFDFYHKASR LGSSAMNIQM L---LEKLKG IPQLEGQKDM ITWILQMFDT	984
	Consensus	TF.F..K.S. .G....N... I...LE.L.. .P.LE..KDM I.WIL.MF..	1000
6	mouse_E3 α II	IKKIRE--CS SSSPVAAEAEG TIMEESSRDK DKAERKRKAE IARLRREKIM	1046
4	human_E3 α I	VKKMRE--SS PTSPVAETEG TIMEESSRDK DKAERKRKAE IARLRREKIM	1046
15	mouse_E3 α I	VKRLREKSCL VVATTSGLEC IKSEEITHDK EKAERKRKAE AARLHRQKIM	1037
2	human_E3 α I	VKRLREKSCL IVATTSGSES IKNDEITHDK EKAERKRKAE AARLHRQKIM	1034
	Consensus	VK..RE..C.E.EE...DK .KAERKRKAE .ARL.R.KIM	1050
6	mouse_E3 α II	AQMSEMQRHF IDENKELFQQ TLELDTSASA TL--DSSPPV SDAALTALGP	1094
4	human_E3 α II	AQMSEMQRHF IDENKELFQQ TLELDASTSA VL--DHSPVA SDMTLTALGP	1094
15	mouse_E3 α I	AQMSALQKNF IETHKLMYDN TSEVTGKEDS IMEEEESTSAV SEASRIALGP	1087
2	human_E3 α I	AQMSALQKNF IETHKLMYDN TSEMPGKEDS IMEEEESTPAV SDYSRIALGP	1084
	Consensus	AQMS..Q..F I...K.... T.E.....S.P.V SD....ALGP	1100
6	mouse_E3 α II	AQTQVPEPRQ FVTCILCQEE QEVTVGSRAM VLAAFVQRST VLSKDRTKTI	1144
4	human_E3 α II	TQTQVPEQRQ FVTCILCQEE QEVKVESRAM VLAAFVQRST VLSKNRSKFI	1144
15	mouse_E3 α I	KRGPAVTEKE VLTCILCQEE QEVKLENNAM VLSACVQKST ALTQHRGKPV	1137
2	human_E3 α I	KRGPSVTEKE VLTCILCQEE QEVKIENNAM VLSACVQKST ALTQHRGKPI	1134
	ConsensusTCILCQEE QEVK.E..AM VL.A.VQ.ST .L...R.K.I	1150
6	mouse_E3 α II	AD-PEKYDPL FMHPDLSCGT HTGSCGHVMH AHCWQRYFDS VQAKEQRRQQ	1193
4	human_E3 α II	QD-PEKYDPL FMHPDLSCGT HTSSCGHIMH AHCWQRYFDS VQAKEQRRQQ	1193
15	mouse_E3 α I	DHLGETLDP FMDPDLAHGT YTGSCGHVMH AVCWQKYFEA VQ---LSSQQ	1184
2	human_E3 α I	ELSGEALDPL FMDPDLAYGT YTGSCGHVMH AVCWQKYFEA VQ---LSSQQ	1181
	ConsensusE..DPL FM.PDL..GT .TGSCGHVMH A.CWQ.YF.. VQ.....QQ	1200
6	mouse_E3 α II	RRLRHTSYDV ENGEFLCPLC ECLSNTVIPL L-LPPRSILS RRLN-FSDQP	1241
4	human_E3 α II	RRLRHTSYDV ENGEFLCPLC ECLSNTVIPL L-LPPRNIFN NRLN-FSDQP	1241
15	mouse_E3 α I	RIHVDL-FDL ESGEYLCPLC KSLCNTVIPI IPLQPQKINS ENAEALAQLL	1233
2	human_E3 α I	RIHVDL-FDL ESGEYLCPLC KSLCNTVIPI IPLQPQKINS ENADALAQLL	1230
	Consensus	R.....D. E.GE.LCPLC ..L.NTVIP. ..L.P..I.S	1250
6	mouse_E3 α II	DLAQWTRAVT QQIKVVQMLR RKHNAADTS SSEDETEAMNI IPIPEGFRPD	1290
4	human_E3 α II	NLTQWIRTIS QQIKALQFLR KEESTP-NNA STKNSENVDE LQLPEGFRPD	1290
15	mouse_E3 α I	TLARWIQTVL ARISGYNIKH AKGEAPAVPV LFNQGMGDST FEFHSILSFG	1283
2	human_E3 α I	TLARWIQTVL ARISGYNIRH AKGENP-IPI FFNQGMGDST LEFHSILSFG	1279
	Consensus	.LA.WI.TV. .I..... K...P-----	1300
6	mouse_E3 α II	FYPRNPYSDS IKEMLTTFGT AAYKVGLKVH PNEGDPRVPI LCWGTCAVTI	1340
4	human_E3 α II	FRPKIPYSES IKEMLTTFGT ATYKVGLKVH PNEEDPRVPI MCWGSCAYTI	1340
15	mouse_E3 α I	VQSSVKYSNS IKEMVILFAT TIYRIGLKVP PDELDPRVPM MTWSTCAFTI	1333
2	human_E3 α I	VESSIKYSNS IKEMVILFAT TIYRIGLKVP PDERDPRVPM LTWSTCAFTI	1329
	ConsensusYS.S IKEM...F.T ..Y..GLKV. P.E.DPRVP. ...W.TCA.TI	1350

Figure 1 (continued)

SEQ	ID NO:					
6	mouse_E3αII	QSIERILSDE	EKPVFGPLPC	RLDDCLRSLT	RFAAAHWTVA	LLPVVQGHFC 1390
4	human_E3αII	QSIERILSDE	DKPLFGPLPC	RLDDCLRSLT	RFAAAHWTVA	SVSVVQGHFC 1390
15	mouse_E3αI	QAIENLLGDE	GKPLFGALQN	RQHSGLKALM	QFAVAQRATC	PQVLIHKHLA 1383
2	human_E3αI	QAIENLLGDE	GKPLFGALQN	RQHNGLKALM	QFAVAQRITC	PQVLIQKHLV 1379
	Consensus	Q.IE..L.DE	.KPLFG.L..	R....L..L.	.FA.A.....	Q.H.. 1400
6	mouse_E3αII	KLFASLVPSD	SYEDLPCILD	IDMFHLLVGL	VLAFFPALQCQ	D---FSGSSL 1437
4	human_E3αII	KLFASLVPND	SHEELPCILD	IDMFHLLVGL	VLAFFPALQCQ	D---FSGISL 1437
15	mouse_E3αI	RLLSVILPNL	QSENTPGLLS	VDLFHVLVGA	VLAFFPSLYWD	DTVDLQPSPL 1433
2	human_E3αI	RLLSVVLPNI	KSEDTPCQLLS	IDLFHVLVGA	VLAFFPSLYWD	DPVDLQPSSV 1429
	Consensus	.L.....PN.	..E..PC.L.	ID.FH.LVG.	VLAFF.P.L...	D.....SSL 1450
6	mouse_E3αII	ATG--DLHIF	HLVTMAHIVQ	ILLTSCTEEN	---GMDQENP	TGEEELAILS 1482
4	human_E3αII	GTG--DLHIF	HLVTMAHIIQ	ILLTSCTEEN	---GMDQENP	PCEEESAVLA 1482
15	mouse_E3αI	SSSYNHLYLF	HLITMAHMLQ	ILLTTDTDLS	PGPPLAECEE	DSEEARCASA 1483
2	human_E3αI	SSSYNHLYLF	HLITMAHMLQ	ILLTVDTGL-	---PLAQVQE	DSEEAHSASS 1475
	ConsensusL..F	HL.TMAH..Q	ILLT..T...Q....	EE..... 1500
6	mouse_E3αII	LHKTLHQYTG	SALKEAPSGW	HLWRSPVRAAI	MPFLKCSALF	FHYLNGVPAP 1532
4	human_E3αII	LYKTLHQYTG	SALKEIPSGW	HLWRSPVRAGI	MPFLKCSALF	FHYLNGVPSP 1532
15	mouse_E3αI	FFVEVSQHTD	GLTGCGAPGW	YLWLSLRNGI	TPYLRCAALL	FHYLLGVAPP 1533
2	human_E3αI	FFAEISQYTS	GSIGCDIPGW	YLWVSLKNGI	TPYLRCAALF	FHYLLGVTPP 1525
	ConsensusQYT.GW	.LW.S.R.GI	.P.L.C.ALF	FHYL.GV..P 1550
6	mouse_E3αII	PDLQV-SGTS	HFEHLCNYLS	LPTNLIHLFQ	ENSDIMNSLI	ESWCQNSEVK 1581
4	human_E3αII	PDIQV-PGTS	HFEHLCSYLS	LPNNLICLFO	ENSEIMNSLI	ESWCRNSEVK 1581
15	mouse_E3αI	EELFANSAAEG	EFSALCSYLS	LPTNLFLLFQ	EYWDTIRPLL	QRWCGDPALL 1583
2	human_E3αI	EELHTNSAAEG	EYSALCSYLS	LPTNLFLLFQ	EYWDTVRPLL	QRWCADPALL 1575
	Consensus	..L...S...	.F..LCSYLS	LPTNL..LFQ	E..D....L.	..WC..... 1600
6	mouse_E3αII	RYLNGERGAI	SYPRGANKLI	DLPEDYSSLI	NQASFNSCPK	SGGDKSRAPT 1631
4	human_E3αII	RYLEGERDAI	RYPRESNKLI	NLPEDYSSLI	NQASFNSCPK	SGGDKSRAPT 1631
15	mouse_E3αI	KSLKQKSAVV	RYPRKRNSLI	ELPEDYSCLL	NQASHFRCPR	SADDERKHPV 1633
2	human_E3αI	NCLKQKNTVV	RYPRKRNSLI	ELPDDYSCLL	NQASHFRCPR	SADDERKHPV 1625
	Consensus	..L.....	RYPR..N.LI	.LPEDYS.L.	NQAS.F.CP.	S..D....P. 1650
6	mouse_E3αII	LCLVCGSLLC	SQSYCCQAEL	EDEDVGACTA	HTYSCGSGAG	IFLRVRECQV 1681
4	human_E3αII	LCLVCGSLLC	SQSYCCQTEL	EDEDVGACTA	HTYSCGSGVG	IFLRVRECQV 1681
15	mouse_E3αI	LCLFCGAILC	SQNICCQEIV	NGEEVGACVF	HALHCGAGVC	IFLKIRECRV 1683
2	human_E3αI	LCLFCGAILC	SQNICCQEIV	NGEEVGACIF	HALHCGAGVC	IFLKIRECRV 1675
	Consensus	LCL.CG..LC	SQ..CCQ....GE.VGAC..	H...CG.GV.	IFL..REC.V	1700
6	mouse_E3αII	LFLAGTKGC	FYSPPYLDDY	GETDQGLRRG	NPLHLCQERF	RKIQKLWQQH 1731
4	human_E3αII	LFLAGTKGC	FYSPPYLDDY	GETDQGLRRG	NPLHLCERF	KKIQKLWHQQH 1731
15	mouse_E3αI	VLVEGKARGC	AYPAPYLDEY	GETDPGLKRG	NPLHLSRERY	RKLHLVWQQH 1733
2	human_E3αI	VLVEGKARGC	AYPAPYLDEY	GETDPGLKRG	NPLHLSRERY	RKLHLVWQQH 1725
	ConsensusGK..GC	Y..PYLD.Y	GETD.GL.RG	NPLHL..ER.	RK....WQQH 1750
6	mouse_E3αII	SITEEIGHAQ	EANQTLVGID	WQHL		1755
4	human_E3αII	SVTEEIGHAQ	EANQTLVGID	WQHL		1755
15	mouse_E3αI	CIIIEEIARSQ	ETNQMLFGFN	WQLL		1757
2	human_E3αI	CIIIEEIARSQ	ETNQMLFGFN	WQLL		1749
	Consensus	.I.EEI...Q	E.NQ.L.G..	WQ.L		1774

Figure 2
The Expression Profile of huE3 α -II in Human Tissues




Figure 3
The Expression Profile of huE3 α -I in Human Tissues




Figure 4- Ubiquitination of Endogenous Proteins




Figure 4- Ubiquitination of Endogenous Proteins




Figure 5

**Transfection of Human E3a-I or E3a-II cDNA Stimulates
Ubiquitin Conjugation in Cultured Muscle Cell Lines**




Figure 6 ^{125}I -Ubiquitin Conjugation to Muscle Proteins and Its Sensitivity to E3 α Inhibitor in Skeletal Muscle Extracts




Figure 7

Rates of Ubiquitination of N-end Rule Substrate α -Lactalbumin in Skeletal Muscle Extracts

Control v.s. 3 Day-Tumor-Bearing

Control v.s. 5 Day-Tumor-Bearing

^{125}I -Lactalbumin-Ub Conjugates

^{125}I -Lactalbumin-Ub Conjugates




Figure 8

**Northern blot analysis of E3 α -I & E3 α -II expression
in gastrocnemius muscles in YAH-130 experimental cachexia model**




Figure 9

Northern blot analysis of E3 α -I and E3 α -II expression in gastrocnemius muscle and cardiac muscle in C26 experimental cachexia model




Figure 10

Proinflammatory cytokines TNF- α and IL-6 induce E3 α -II Expression in C2C12 myotube culture




Figure 11

IL-6 Elicits Accelerated Ubiquitination in C2C12 Myotube Cultures





Figure 12

TNF α Elicits Accelerated Ubiquitination in C2C12 Myotube Cultures



SEQUENCE LISTING

<110> Han, Hui-Quan
Kwak, Keith

<120> Human E3 Alpha Ubiquitin Ligase

<130> 01017/35966

<140>
<141>

<150> US 60/187,911
<151> 1999-03-08

<160> 29

<170> PatentIn Ver. 2.0

<210> 1
<211> 6308
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (696)..(5942)

<400> 1
gccaagaatt cggcacgagg ggaaaagctg agcccaggaa ccaaatttact tgctttaccc 60
cattgtgtaa gacaaggcgtc aaaaacagct tcaacctatc ttgaacaaga gaacttaccc 120
ccaaaggctt atcatctgtc ttccacttat ccaacaagct gctatggcca ctgcctgtgc 180
cgcacctgga accaccgcca gccccactac tgcctccact accactgggtt ctcccaccct 240
gatcagctgc ttgctgctgc catcttatcc gtttctgcct gttctgagta aatgtataca 300
caccctggaa accaccattc tactttctgt gtctatgaat ttgactactc tagctggatc 360
ccgagctttt ttgtacacat gtgcaagtgc ccacgggta gaatcctaaa aatagaagat 420
gtatgcaaca gttcccagca ccaaaccagg atatacaacc attcagctac caagagctac 480
gcctgataaa tttagagggaa aaaaaaaaaat ctccagtcctc ttcacgtcgt gacgcttgct 540
tccgggaagc gggccggaaag ccactcctcg agtctgcgtc aaacccgact tcagggccg 600
tcgtaaaagt gtcgtccctg tctctccgac cggccacagg tttccgcttg cctctggccg 660
gggtcggca actgcaggcg tcagttccc tcaag atg gcg gac gag gag gct 713
Met Ala Asp Glu Glu Ala
1 5

gga ggt act gag agg atg gaa atc agc gcg gag tta ccc cag acc cct 761
Gly Gly Thr Glu Arg Met Glu Ile Ser Ala Glu Leu Pro Gln Thr Pro
10 15 20

cag cgt ctg gca tct tgg tgg gat cag caa gtt gat ttt tat act gct 809
Gln Arg Leu Ala Ser Trp Trp Asp Gln Gln Val Asp Phe Tyr Thr Ala
25 30 35

ttc ttg cat cat ttg gca caa ttg gtg cca gaa att tac ttt gct gaa Phe Leu His His Leu Ala Gln Leu Val Pro Glu Ile Tyr Phe Ala Glu	857
40 45 50	
atg gac cca gac ttg gaa aag cag gag gaa agt gta caa atg tca ata Met Asp Pro Asp Leu Glu Lys Gln Glu Glu Ser Val Gln Met Ser Ile	905
55 60 65 70	
ttc act cca ctg gaa tgg tac tta ttt gga gaa gat cca gat att tgc Phe Thr Pro Leu Glu Trp Tyr Leu Phe Gly Glu Asp Pro Asp Ile Cys	953
75 80 85	
tta gag aaa ttg aag cac agt gga gca ttt cag ctt tgt ggg agg gtt Leu Glu Lys Leu Lys His Ser Gly Ala Phe Gln Leu Cys Gly Arg Val	1001
90 95 100	
ttc aaa agt gga gag aca acc tat tct tgc agg gat tgt gca att gat Phe Lys Ser Gly Glu Thr Thr Tyr Ser Cys Arg Asp Cys Ala Ile Asp	1049
105 110 115	
cca aca tgt gta ctc tgt atg gac tgc ttc cag gac agt gtt cat aaa Pro Thr Cys Val Leu Cys Met Asp Cys Phe Gln Asp Ser Val His Lys	1097
120 125 130	
aat cat cgt tac aag atg cat act tct act gga gga ggg ttc tgt gac Asn His Arg Tyr Lys Met His Thr Ser Thr Gly Gly Gly Phe Cys Asp	1145
135 140 145 150	
tgt gga gac aca gag gca tgg aaa act ggc cct ttt tgt gta aat cat Cys Gly Asp Thr Glu Ala Trp Lys Thr Gly Pro Phe Cys Val Asn His	1193
155 160 165	
gaa cct gga aga gca ggt act ata aaa gag aat tca cgc tgt ccg ttg Glu Pro Gly Ala Gly Thr Ile Lys Glu Asn Ser Arg Cys Pro Leu	1241
170 175 180	
aat gaa gag gta att gtc caa gcc agg aaa ata ttt cct tca gtg ata Asn Glu Glu Val Ile Val Gln Ala Arg Lys Ile Phe Pro Ser Val Ile	1289
185 190 195	
aaa tat gtc gta gaa atg act ata tgg gaa gag gaa aaa gaa ctg cct Lys Tyr Val Val Glu Met Thr Ile Trp Glu Glu Glu Lys Glu Leu Pro	1337
200 205 210	
cct gaa ctc cag ata agg gag aaa aat gaa aga tac tat tgt gtc ctt Pro Glu Leu Gln Ile Arg Glu Lys Asn Glu Arg Tyr Tyr Cys Val Leu	1385
215 220 225 230	
ttc aat gat gaa cac cat tca tat gac cac gtc ata tac agc cta caa Phe Asn Asp Glu His His Ser Tyr Asp His Val Ile Tyr Ser Leu Gln	1433
235 240 245	
aga gct ctt gac tgt gag ctc gca gag gcc cag ttg cat acc act gcc Arg Ala Leu Asp Cys Glu Leu Ala Glu Ala Gln Leu His Thr Thr Ala	1481
250 255 260	
att gac aaa gag ggt cgt cggt gct gtt aaa gcg gga gct tat gct gct Ile Asp Lys Glu Gly Arg Arg Ala Val Lys Ala Gly Ala Tyr Ala Ala	1529
265 270 275	
tgc cag gaa gca aag gaa gat ata aag agt cat tca gaa aat gtc tct Cys Gln Glu Ala Lys Glu Asp Ile Lys Ser His Ser Glu Asn Val Ser	1577
280 285 290	

caa cat cca ctt cat gta gaa gta tta cac tca gag att atg gct cat		1625
Gln His Pro Leu His Val Glu Val Leu His Ser Glu Ile Met Ala His		
295 300 305 310		
cag aaa ttt gct ttg cgt ctt ggt tcc tgg atg aac aaa att atg agc		1673
Gln Lys Phe Ala Leu Arg Leu Gly Ser Trp Met Asn Lys Ile Met Ser		
315 320 325		
tat tca agt gac ttt agg cag atc ttt tgc caa gca tgc ctt aga gaa		1721
Tyr Ser Ser Asp Phe Arg Gln Ile Phe Cys Gln Ala Cys Leu Arg Glu		
330 335 340		
gaa cct gac tcg gag aat ccc tgt ctc ata agc agg tta atg ctt tgg		1769
Glu Pro Asp Ser Glu Asn Pro Cys Leu Ile Ser Arg Leu Met Leu Trp		
345 350 355		
gat gca aag ctt tat aaa ggt gcc cgt aag atc ctt cat gaa ttg atc		1817
Asp Ala Lys Leu Tyr Lys Gly Ala Arg Lys Ile Leu His Glu Leu Ile		
360 365 370		
ttc agc agt ttt ttt atg gag atg gaa tac aaa aca ctc ttt gct atg		1865
Phe Ser Ser Phe Phe Met Glu Met Glu Tyr Lys Lys Leu Phe Ala Met		
375 380 385 390		
gaa ttt gtg aag tat tat aaa caa ctg cag aaa gaa tat atc agt gat		1913
Glu Phe Val Lys Tyr Tyr Lys Gln Leu Gln Lys Glu Tyr Ile Ser Asp		
395 400 405		
gat cat gac aga agt atc tct ata act gca ctt tca gtt cag atg ttt		1961
Asp His Asp Arg Ser Ile Ser Ile Thr Ala Leu Ser Val Gln Met Phe		
410 415 420		
act gtt cct act ctg gct cga cat ctt att gaa gag cag aat gtt atc		2009
Thr Val Pro Thr Leu Ala Arg His Leu Ile Glu Glu Gln Asn Val Ile		
425 430 435		
tct gtc att act gaa act ctg cta gaa gtt tta cct gag tac ttg gac		2057
Ser Val Ile Thr Glu Thr Leu Leu Glu Val Leu Pro Glu Tyr Leu Asp		
440 445 450		
agg aac aat aaa ttc aac ttc cag ggt tat agc cag gac aaa ttg gga		2105
Arg Asn Asn Lys Phe Asn Phe Gln Gly Tyr Ser Gln Asp Lys Leu Gly		
455 460 465 470		
aga gta tat gca gta ata tgt gac cta aag tat atc ctg atc agc aaa		2153
Arg Val Tyr Ala Val Ile Cys Asp Leu Lys Tyr Ile Leu Ile Ser Lys		
475 480 485		
ccc aca ata tgg aca gaa aga tta aga atg cag ttc ctt gaa ggt ttt		2201
Pro Thr Ile Trp Thr Glu Arg Leu Arg Met Gln Phe Leu Glu Gly Phe		
490 495 500		
cga tct ttt ttg aag att ctt acc tgt atg cag gga atg gaa gaa atc		2249
Arg Ser Phe Leu Lys Ile Leu Thr Cys Met Gln Gly Met Glu Glu Ile		
505 510 515		
cga aga cag gtt ggg caa cac att gaa gtg gat cct gat tgg gag gct		2297
Arg Arg Gln Val Gly Gln His Ile Glu Val Asp Pro Asp Trp Glu Ala		
520 525 530		
gcc att gct ata cag atg caa ttg aag aat att tta ctc atg ttc caa		2345
Ala Ile Ala Ile Gln Met Gln Leu Lys Asn Ile Leu Leu Met Phe Gln		
535 540 545 550		

gag tgg tgt gct tgt gat gaa gaa ctc tta ctt gtg gct tat aaa gaa Glu Trp Cys Ala Cys Asp Glu Glu Leu Leu Leu Val Ala Tyr Lys Glu 555 560 565	2393
tgt cac aaa gct gtg atg agg tgc agt acc agt ttc ata tct agt agc Cys His Lys Ala Val Met Arg Cys Ser Thr Ser Phe Ile Ser Ser Ser 570 575 580	2441
aag aca gta gta caa tcg tgt gga cat agt ttg gaa aca aag tcc tac Lys Thr Val Val Gln Ser Cys Gly His Ser Leu Glu Thr Lys Ser Tyr 585 590 595	2489
aga gta tct gag gat ctt gta agc ata cat ctg cca ctc tct agg acc Arg Val Ser Glu Asp Leu Val Ser Ile His Leu Pro Leu Ser Arg Thr 600 605 610	2537
ctt gct ggt ctt cat gta cgt tta agc agg ctg ggt gct gtt tca aga Leu Ala Gly Leu His Val Arg Leu Ser Arg Leu Gly Ala Val Ser Arg 615 620 625 630	2585
ctg cat gaa ttt gtg tct ttt gag gac ttt caa gta gag gta cta gtg Leu His Glu Phe Val Ser Phe Glu Asp Phe Gln Val Glu Val Leu Val 635 640 645	2633
gaa tat cct tta cgt tgt ctg gtg ttg gtt gcc cag gtt gtt gct gag Glu Tyr Pro Leu Arg Cys Leu Val Leu Val Ala Gln Val Val Ala Glu 650 655 660	2681
atg tgg cga aga aat gga ctg tct ctt att agc cag gtg ttt tat tac Met Trp Arg Arg Asn Gly Leu Ser Leu Ile Ser Gln Val Phe Tyr Tyr 665 670 675	2729
caa gat gtt aag tgc aga gaa gaa atg tat gat aaa gat atc atc atg Gln Asp Val Lys Cys Arg Glu Met Tyr Asp Lys Asp Ile Ile Met 680 685 690	2777
ctt cag att ggt gca tct tta atg gat ccc aat aag ttc ttg tta ctg Leu Gln Ile Gly Ala Ser Leu Met Asp Pro Asn Lys Phe Leu Leu Leu 695 700 705 710	2825
gta ctt cag agg tat gaa ctt gcc gag gct ttt aac aag acc ata tct Val Leu Gln Arg Tyr Glu Leu Ala Glu Ala Phe Asn Lys Thr Ile Ser 715 720 725	2873
aca aaa gac cag gat ttg att aaa caa tat aat aca cta ata gaa gaa Thr Lys Asp Gln Asp Leu Ile Lys Gln Tyr Asn Thr Leu Ile Glu Glu 730 735 740	2921
atg ctt cag gtc ctc atc tat att gtg ggt gag cgt tat gta cct gga Met Leu Gln Val Leu Ile Tyr Ile Val Gly Glu Arg Tyr Val Pro Gly 745 750 755	2969
gtg gga aat gtg acc aaa gaa gag gtc aca atg aga gaa atc att cac Val Gly Asn Val Thr Lys Glu Glu Val Thr Met Arg Glu Ile Ile His 760 765 770	3017
ttg ctt tgc att gaa ccc atg cca cac agt gcc att gcc aaa aat tta Leu Leu Cys Ile Glu Pro Met Pro His Ser Ala Ile Ala Lys Asn Leu 775 780 785 790	3065
cct gag aat gaa aat aat gaa act ggc tta gag aat gtc ata aac aaa Pro Glu Asn Glu Asn Asn Glu Thr Gly Leu Glu Asn Val Ile Asn Lys 795 800 805	3113

gtg gcc aca ttt aag aaa cca ggt gta tca ggc cat gga gtt tat gaa		3161	
Val Ala Thr Phe Lys Lys Pro Gly Val Ser Gly His Gly Val Tyr Glu			
810	815	820	
cta aaa gat gaa tca ctg aaa gac ttc aat atg tac ttt tat cat tac		3209	
Leu Lys Asp Glu Ser Leu Lys Asp Phe Asn Met Tyr Phe Tyr His Tyr			
825	830	835	
tcc aaa acc cag cat agc aag gct gaa cat atg cag aag aaa agg aga		3257	
Ser Lys Thr Gln His Ser Lys Ala Glu His Met Gln Lys Lys Arg Arg			
840	845	850	
aaa caa gaa aac aaa gat gaa gca ttg ccg cca cca cct cct gaa		3305	
Lys Gln Glu Asn Lys Asp Glu Ala Leu Pro Pro Pro Pro Pro Glu			
855	860	865	870
ttc tgc cct gct ttc agc aaa gtg att aac ctt ctc aac tgt gat atc		3353	
Phe Cys Pro Ala Phe Ser Lys Val Ile Asn Leu Leu Asn Cys Asp Ile			
875	880	885	
atg atg tac att ctc agg acc gta ttt gag cgg gca ata gac aca gat		3401	
Met Met Tyr Ile Leu Arg Thr Val Phe Glu Arg Ala Ile Asp Thr Asp			
890	895	900	
tct aac ttg tgg acc gaa ggg atg ctccaa atg gct ttt cat att ctg		3449	
Ser Asn Leu Trp Thr Glu Gly Met Leu Gln Met Ala Phe His Ile Leu			
905	910	915	
gca ttg ggt tta cta gaa gag aag caa cag ctt caa aaa gct cct gaa		3497	
Ala Leu Gly Leu Leu Glu Glu Lys Gln Gln Leu Gln Lys Ala Pro Glu			
920	925	930	
gaa gaa gta aca ttt gac ttt tat cat aag gct tca aga ttg gga agt		3545	
Glu Glu Val Thr Phe Asp Phe Tyr His Lys Ala Ser Arg Leu Gly Ser			
935	940	945	950
tca gcc atg aat ata caa atg ctt ttg gaa aaa ctc aaa gga att ccc		3593	
Ser Ala Met Asn Ile Gln Met Leu Leu Glu Lys Leu Lys Gly Ile Pro			
955	960	965	
cag tta gaa ggc cag aag gac atg ata acg tgg ata ctt cag atg ttt		3641	
Gln Leu Glu Gly Gln Lys Asp Met Ile Thr Trp Ile Leu Gln Met Phe			
970	975	980	
gac aca gtg aag cga tta aga gaa aaa tct tgt tta att gta gca acc		3689	
Asp Thr Val Lys Arg Leu Arg Glu Lys Ser Cys Leu Ile Val Ala Thr			
985	990	995	
aca tca gga tcg gaa tct att aag aat gat gag att act cat gat aaa		3737	
Thr Ser Gly Ser Glu Ser Ile Lys Asn Asp Glu Ile Thr His Asp Lys			
1000	1005	1010	
gaa aaa gca gaa cga aaa aga aaa gct gaa gct gct agg cta cat cgc		3785	
Glu Lys Ala Glu Arg Lys Arg Lys Ala Glu Ala Ala Arg Leu His Arg			
1015	1020	1025	1030
cag aag atc atg gct cag atg tct gcc tta cag aaa aac ttc att gaa		3833	
Gln Lys Ile Met Ala Gln Met Ser Ala Leu Gln Lys Asn Phe Ile Glu			
1035	1040	1045	
act cat aaa ctc atg tat gac aat aca tca gaa atg cct ggg aaa gaa		3881	
Thr His Lys Leu Met Tyr Asp Asn Thr Ser Glu Met Pro Gly Lys Glu			
1050	1055	1060	

gat tcc att atg gag gaa gag agc acc cca gca gtc agt gac tac tct Asp Ser Ile Met Glu Glu Ser Thr Pro Ala Val Ser Asp Tyr Ser 1065	1070	1075	3929
aga att gct ttg ggt cct aaa cgg ggt cca tct gtt act gaa aag gag Arg Ile Ala Leu Gly Pro Lys Arg Gly Pro Ser Val Thr Glu Lys Glu 1080	1085	1090	3977
gtg ctg acg tgc atc ctt tgc caa gaa cag gag gtg aaa ata gaa Val Leu Thr Cys Ile Leu Cys Gln Glu Gln Glu Val Lys Ile Glu 1095	1100	1105	1110
aat aat gcc atg gta tta tcg gcc tgt gtc cag aaa tct act gcc tta Asn Asn Ala Met Val Leu Ser Ala Cys Val Gln Lys Ser Thr Ala Leu 1115	1120	1125	4073
acc cag cac agg gga aaa ccc ata gaa ctc tca gga gaa gcc cta gac Thr Gln His Arg Gly Lys Pro Ile Glu Leu Ser Gly Glu Ala Leu Asp 1130	1135	1140	4121
cca ctt ttc atg gat cca gac ttg gca tat gga act tat aca gga agc Pro Leu Phe Met Asp Pro Asp Leu Ala Tyr Gly Thr Tyr Thr Gly Ser 1145	1150	1155	4169
tgt ggt cat gta atg cac gca gtg tgc tgg cag aag tat ttt gaa gct Cys Gly His Val Met His Ala Val Cys Trp Gln Lys Tyr Phe Glu Ala 1160	1165	1170	4217
gta cag ctg agc tct cag cag cgc att cat gtt gac ctt ttt gac ttg Val Gln Leu Ser Ser Gln Gln Arg Ile His Val Asp Leu Phe Asp Leu 1175	1180	1185	1190
gaa agt gga gaa tat ctt tgc cct ctt tgc aaa tct ctg tgc aat act Glu Ser Gly Glu Tyr Leu Cys Pro Leu Cys Lys Ser Leu Cys Asn Thr 1195	1200	1205	4313
gtg atc ccc att att cct ttg caa cct caa aag ata aac agt gag aat Val Ile Pro Ile Ile Pro Leu Gln Pro Gln Lys Ile Asn Ser Glu Asn 1210	1215	1220	4361
gca gat gct ctt gct caa ctt ttg acc ctg gca cgg tgg ata cag act Ala Asp Ala Leu Ala Gln Leu Leu Thr Leu Ala Arg Trp Ile Gln Thr 1225	1230	1235	4409
gtt ctg gcc aga ata tca ggt tat aat ata aga cat gct aaa gga gaa Val Leu Ala Arg Ile Ser Gly Tyr Asn Ile Arg His Ala Lys Gly Glu 1240	1245	1250	4457
aac cca att cct att ttc ttt aat caa gga atg gga gat tct act ttg Asn Pro Ile Pro Ile Phe Phe Asn Gln Gly Met Gly Asp Ser Thr Leu 1255	1260	1265	4505
gag ttc cat tcc atc ctg agt ttt ggc gtt gag tct tcg att aaa tat Glu Phe His Ser Ile Leu Ser Phe Gly Val Glu Ser Ser Ile Lys Tyr 1275	1280	1285	4553
tca aat agc atc aag gaa atg gtt att ctc ttt gcc aca aca att tat Ser Asn Ser Ile Lys Glu Met Val Ile Leu Phe Ala Thr Thr Ile Tyr 1290	1295	1300	4601
aga att gga ttg aaa gtg cca cct gat gaa agg gat cct cga gtc ccc Arg Ile Gly Leu Lys Val Pro Pro Asp Glu Arg Asp Pro Arg Val Pro 1305	1310	1315	4649

atg ctg acc tgg agc acc tgc gct ttc act atc cag gca att gaa aat Met Leu Thr Trp Ser Thr Cys Ala Phe Thr Ile Gln Ala Ile Glu Asn 1320 1325 1330	4697
cta ttg gga gat gaa gga aaa cct ctg ttt gga gca ctt caa aat agg Leu Leu Gly Asp Glu Gly Lys Pro Leu Phe Gly Ala Leu Gln Asn Arg 1335 1340 1345 1350	4745
cag cat aat ggt ctg aaa gca tta atg cag ttt gca gtt gca cag agg Gln His Asn Gly Leu Lys Ala Leu Met Gln Phe Ala Val Ala Gln Arg 1355 1360 1365	4793
att acc tgt cct cag gtc ctg ata cag aaa cat ctg gtt cgt ctt cta Ile Thr Cys Pro Gln Val Leu Ile Gln Lys His Leu Val Arg Leu Leu 1370 1375 1380	4841
tca gtt gtt ctt cct aac ata aaa tca gaa gat aca cca tgc ctt ctg Ser Val Val Leu Pro Asn Ile Lys Ser Glu Asp Thr Pro Cys Leu Leu 1385 1390 1395	4889
tct ata gat ctg ttt cat gtt ttg gtg ggt gct gtg tta gca ttc cca Ser Ile Asp Leu Phe His Val Leu Val Gly Ala Val Leu Ala Phe Pro 1400 1405 1410	4937
tcc ttg tat tgg gat gac cct gtt gat ctg cag cct tct tca gtt agt Ser Leu Tyr Trp Asp Asp Pro Val Asp Leu Gln Pro Ser Ser Val Ser 1415 1420 1425 1430	4985
tct tcc tat aac cac ctt tat ctc ttc cat ttg atc acc atg gca cac Ser Ser Tyr Asn His Leu Tyr Leu Phe His Leu Ile Thr Met Ala His 1435 1440 1445	5033
atg ctt cag ata cta ctt aca gta gac aca ggc cta ccc ctt gct cag Met Leu Gln Ile Leu Leu Thr Val Asp Thr Gly Leu Pro Leu Ala Gln 1450 1455 1460	5081
gtt caa gaa gac agt gaa gag gct cat tcc gca tct tct ttc ttt gca Val Gln Glu Asp Ser Glu Glu Ala His Ser Ala Ser Ser Phe Phe Ala 1465 1470 1475	5129
gaa att tct caa tat aca agt ggc tcc att ggg tgt gat att cct ggc Glu Ile Ser Gln Tyr Thr Ser Gly Ser Ile Gly Cys Asp Ile Pro Gly 1480 1485 1490	5177
tgg tat ttg tgg gtc tca ctg aag aat ggc atc acc cct tat ctt cgc Trp Tyr Leu Trp Val Ser Leu Lys Asn Gly Ile Thr Pro Tyr Leu Arg 1495 1500 1505 1510	5225
tgt gct gca ttg ttt ttc cac tat tta ctt ggg gta act ccg cct gag Cys Ala Ala Leu Phe Phe His Tyr Leu Leu Gly Val Thr Pro Pro Glu 1515 1520 1525	5273
gaa ctg cat acc aat tct gca gaa gga gag tac agt gca ctc tgt agc Glu Leu His Thr Asn Ser Ala Glu Gly Glu Tyr Ser Ala Leu Cys Ser 1530 1535 1540	5321
tat cta tct tta cct aca aat ttg ttc ctg ctc ttc cag gaa tat tgg Tyr Leu Ser Leu Pro Thr Asn Leu Phe Leu Leu Phe Gln Glu Tyr Trp 1545 1550 1555	5369
gat act gta agg ccc ttg ctc cag agg tgg tgt gca gat cct gcc tta Asp Thr Val Arg Pro Leu Leu Gln Arg Trp Cys Ala Asp Pro Ala Leu 1560 1565 1570	5417

cta aac tgt ttg aag caa aaa aac acc gtc agg tac cct aga aaa Leu Asn Cys Leu Lys Gln Lys Asn Thr Val Val Arg Tyr Pro Arg Lys 1575 1580 1585 1590	5465
aga aat agt ttg ata gag ctt cct gat gac tat agc tgc ctc ctg aat Arg Asn Ser Leu Ile Glu Leu Pro Asp Asp Tyr Ser Cys Leu Leu Asn 1595 1600 1605	5513
caa gct tct cat ttc agg tgc cca cggt tct gca gat gat gag cga aag Gln Ala Ser His Phe Arg Cys Pro Arg Ser Ala Asp Asp Glu Arg Lys 1610 1615 1620	5561
cat cct gtc ctc tgc ctt ttc tgt ggg gct ata cta tgt tct cag aac His Pro Val Leu Cys Leu Phe Cys Gly Ala Ile Leu Cys Ser Gln Asn 1625 1630 1635	5609
att tgc tgc cag gaa att gtg aac ggg gaa gag gtt gga gct tgc att Ile Cys Cys Gln Glu Ile Val Asn Gly Glu Val Gly Ala Cys Ile 1640 1645 1650	5657
ttt cac gca ctt cac tgt gga gcc gga gtc tgc att ttc cta aaa atc Phe His Ala Leu His Cys Gly Ala Gly Val Cys Ile Phe Leu Lys Ile 1655 1660 1665 1670	5705
aga gaa tgc cga gtg gtc ctg gtt gaa ggt aaa gcc aga ggc tgt gcc Arg Glu Cys Arg Val Val Leu Val Glu Gly Lys Ala Arg Gly Cys Ala 1675 1680 1685	5753
tat cca gct cct tac ttg gat gaa tat gga gaa aca gac cct ggc ctg Tyr Pro Ala Pro Tyr Leu Asp Glu Tyr Gly Glu Thr Asp Pro Gly Leu 1690 1695 1700	5801
aag agg ggc aac ccc ctt cat tta tct cgt gag cggt tat cgg aag ctc Lys Arg Gly Asn Pro Leu His Leu Ser Arg Glu Arg Tyr Arg Lys Leu 1705 1710 1715	5849
cat ttg gtc tgg caa caa cac tgc att ata gaa gag att gct agg agc His Leu Val Trp Gln Gln His Cys Ile Ile Glu Glu Ile Ala Arg Ser 1720 1725 1730	5897
caa gag act aat cag atg tta ttt gga ttc aac tgg cag tta ctg Gln Glu Thr Asn Gln Met Leu Phe Gly Phe Asn Trp Gln Leu Leu 1735 1740 1745	5942
tgagctccaa ctctgcctca agacaatcac aaatgacgac agtagtaaag gctgattcaa 6002	
aattatggaa aactttctga gggctggaa agtattggag ggtctttgc tccatgtcca 6062	
ggttcactta catcaataaa atatttctta atggagtatt gctttcaatt agcaaacata 6122	
tgcttcacag gaaaaaagga catagatcaa tctgtttat gtgcttagtat ttccaggaat 6182	
ttattccccct tcataatttg tctcatttca ttttatttca tccacttggt agatgaagtc 6242	
acgtcaaaca gttgttagaca ttttatgtgt tggtaactc ttctgcaatt ttgtatttgg 6302	
tgtttt	6308

<210> 2
<211> 1749
<212> PRT
<213> Homo sapiens

<400> 2
Met Ala Asp Glu Glu Ala Gly Gly Thr Glu Arg Met Glu Ile Ser Ala
1 5 10 15

Glu Leu Pro Gln Thr Pro Gln Arg Leu Ala Ser Trp Trp Asp Gln Gln
20 25 30

Val Asp Phe Tyr Thr Ala Phe Leu His His Leu Ala Gln Leu Val Pro
35 40 45

Glu Ile Tyr Phe Ala Glu Met Asp Pro Asp Leu Glu Lys Gln Glu Glu
50 55 60

Ser Val Gln Met Ser Ile Phe Thr Pro Leu Glu Trp Tyr Leu Phe Gly
65 70 75 80

Glu Asp Pro Asp Ile Cys Leu Glu Lys Leu Lys His Ser Gly Ala Phe
85 90 95

Gln Leu Cys Gly Arg Val Phe Lys Ser Gly Glu Thr Thr Tyr Ser Cys
100 105 110

Arg Asp Cys Ala Ile Asp Pro Thr Cys Val Leu Cys Met Asp Cys Phe
115 120 125

Gln Asp Ser Val His Lys Asn His Arg Tyr Lys Met His Thr Ser Thr
130 135 140

Gly Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Thr Gly
145 150 155 160

Pro Phe Cys Val Asn His Glu Pro Gly Arg Ala Gly Thr Ile Lys Glu
165 170 175

Asn Ser Arg Cys Pro Leu Asn Glu Val Ile Val Gln Ala Arg Lys
180 185 190

Ile Phe Pro Ser Val Ile Lys Tyr Val Val Glu Met Thr Ile Trp Glu
195 200 205

Glu Glu Lys Glu Leu Pro Pro Glu Leu Gln Ile Arg Glu Lys Asn Glu
210 215 220

Arg Tyr Tyr Cys Val Leu Phe Asn Asp Glu His His Ser Tyr Asp His
225 230 235 240

Val Ile Tyr Ser Leu Gln Arg Ala Leu Asp Cys Glu Leu Ala Glu Ala
245 250 255

Gln Leu His Thr Thr Ala Ile Asp Lys Glu Gly Arg Arg Ala Val Lys
260 265 270

Ala Gly Ala Tyr Ala Ala Cys Gln Glu Ala Lys Glu Asp Ile Lys Ser
275 280 285

His Ser Glu Asn Val Ser Gln His Pro Leu His Val Glu Val Leu His
290 295 300

Ser Glu Ile Met Ala His Gln Lys Phe Ala Leu Arg Leu Gly Ser Trp
305 310 315 320

Met Asn Lys Ile Met Ser Tyr Ser Ser Asp Phe Arg Gln Ile Phe Cys
325 330 335

Gln Ala Cys Leu Arg Glu Glu Pro Asp Ser Glu Asn Pro Cys Leu Ile
340 345 350

Ser Arg Leu Met Leu Trp Asp Ala Lys Leu Tyr Lys Gly Ala Arg Lys
355 360 365

Ile Leu His Glu Leu Ile Phe Ser Ser Phe Phe Met Glu Met Glu Tyr
370 375 380

Lys Lys Leu Phe Ala Met Glu Phe Val Lys Tyr Tyr Lys Gln Leu Gln
385 390 395 400

Lys Glu Tyr Ile Ser Asp Asp His Asp Arg Ser Ile Ser Ile Thr Ala
405 410 415

Leu Ser Val Gln Met Phe Thr Val Pro Thr Leu Ala Arg His Leu Ile
420 425 430

Glu Glu Gln Asn Val Ile Ser Val Ile Thr Glu Thr Leu Leu Glu Val
435 440 445

Leu Pro Glu Tyr Leu Asp Arg Asn Asn Lys Phe Asn Phe Gln Gly Tyr
450 455 460

Ser Gln Asp Lys Leu Gly Arg Val Tyr Ala Val Ile Cys Asp Leu Lys
465 470 475 480

Tyr Ile Leu Ile Ser Lys Pro Thr Ile Trp Thr Glu Arg Leu Arg Met
485 490 495

Gln Phe Leu Glu Gly Phe Arg Ser Phe Leu Lys Ile Leu Thr Cys Met
500 505 510

Gln Gly Met Glu Glu Ile Arg Arg Gln Val Gly Gln His Ile Glu Val
515 520 525

Asp Pro Asp Trp Glu Ala Ala Ile Ala Ile Gln Met Gln Leu Lys Asn
530 535 540

Ile Leu Leu Met Phe Gln Glu Trp Cys Ala Cys Asp Glu Glu Leu Leu
545 550 555 560

Leu Val Ala Tyr Lys Glu Cys His Lys Ala Val Met Arg Cys Ser Thr
565 570 575

Ser Phe Ile Ser Ser Ser Lys Thr Val Val Gln Ser Cys Gly His Ser
580 585 590

Leu Glu Thr Lys Ser Tyr Arg Val Ser Glu Asp Leu Val Ser Ile His
595 600 605

Leu Pro Leu Ser Arg Thr Leu Ala Gly Leu His Val Arg Leu Ser Arg
610 615 620

Leu Gly Ala Val Ser Arg Leu His Glu Phe Val Ser Phe Glu Asp Phe
625 630 635 640

Gln Val Glu Val Leu Val Glu Tyr Pro Leu Arg Cys Leu Val Leu Val
645 650 655

Ala Gln Val Val Ala Glu Met Trp Arg Arg Asn Gly Leu Ser Leu Ile
660 665 670

Ser Gln Val Phe Tyr Tyr Gln Asp Val Lys Cys Arg Glu Glu Met Tyr
675 680 685

Asp Lys Asp Ile Ile Met Leu Gln Ile Gly Ala Ser Leu Met Asp Pro
690 695 700

Asn Lys Phe Leu Leu Leu Val Leu Gln Arg Tyr Glu Leu Ala Glu Ala
705 710 715 720

Phe Asn Lys Thr Ile Ser Thr Lys Asp Gln Asp Leu Ile Lys Gln Tyr
725 730 735

Asn Thr Leu Ile Glu Glu Met Leu Gln Val Leu Ile Tyr Ile Val Gly
740 745 750

Glu Arg Tyr Val Pro Gly Val Gly Asn Val Thr Lys Glu Glu Val Thr
755 760 765

Met Arg Glu Ile Ile His Leu Leu Cys Ile Glu Pro Met Pro His Ser
770 775 780

Ala Ile Ala Lys Asn Leu Pro Glu Asn Glu Asn Asn Glu Thr Gly Leu
785 790 795 800

Glu Asn Val Ile Asn Lys Val Ala Thr Phe Lys Lys Pro Gly Val Ser
805 810 815

Gly His Gly Val Tyr Glu Leu Lys Asp Glu Ser Leu Lys Asp Phe Asn
820 825 830

Met Tyr Phe Tyr His Tyr Ser Lys Thr Gln His Ser Lys Ala Glu His
835 840 845

Met Gln Lys Lys Arg Arg Lys Gln Glu Asn Lys Asp Glu Ala Leu Pro
850 855 860

Pro Pro Pro Pro Pro Glu Phe Cys Pro Ala Phe Ser Lys Val Ile Asn
865 870 875 880

Leu Leu Asn Cys Asp Ile Met Met Tyr Ile Leu Arg Thr Val Phe Glu
885 890 895

Arg Ala Ile Asp Thr Asp Ser Asn Leu Trp Thr Glu Gly Met Leu Gln
900 905 910

Met Ala Phe His Ile Leu Ala Leu Gly Leu Leu Glu Glu Lys Gln Gln
915 920 925

Leu Gln Lys Ala Pro Glu Glu Val Thr Phe Asp Phe Tyr His Lys
930 935 940

Ala Ser Arg Leu Gly Ser Ser Ala Met Asn Ile Gln Met Leu Leu Glu
945 950 955 960

Lys Leu Lys Gly Ile Pro Gln Leu Glu Gly Gln Lys Asp Met Ile Thr
965 970 975

Trp Ile Leu Gln Met Phe Asp Thr Val Lys Arg Leu Arg Glu Lys Ser
980 985 990

Cys Leu Ile Val Ala Thr Thr Ser Gly Ser Glu Ser Ile Lys Asn Asp
995 1000 1005

Glu Ile Thr His Asp Lys Glu Lys Ala Glu Arg Lys Arg Lys Ala Glu
1010 1015 1020

Ala Ala Arg Leu His Arg Gln Lys Ile Met Ala Gln Met Ser Ala Leu
025 1030 1035 1040

Gln Lys Asn Phe Ile Glu Thr His Lys Leu Met Tyr Asp Asn Thr Ser
1045 1050 1055

Glu Met Pro Gly Lys Glu Asp Ser Ile Met Glu Glu Ser Thr Pro
1060 1065 1070

Ala Val Ser Asp Tyr Ser Arg Ile Ala Leu Gly Pro Lys Arg Gly Pro
1075 1080 1085

Ser Val Thr Glu Lys Glu Val Leu Thr Cys Ile Leu Cys Gln Glu Glu
1090 1095 1100

Gln Glu Val Lys Ile Glu Asn Asn Ala Met Val Leu Ser Ala Cys Val
105 1110 1115 1120

Gln Lys Ser Thr Ala Leu Thr Gln His Arg Gly Lys Pro Ile Glu Leu
1125 1130 1135

Ser Gly Glu Ala Leu Asp Pro Leu Phe Met Asp Pro Asp Leu Ala Tyr
1140 1145 1150

Gly Thr Tyr Thr Gly Ser Cys Gly His Val Met His Ala Val Cys Trp
1155 1160 1165

Gln Lys Tyr Phe Glu Ala Val Gln Leu Ser Ser Gln Gln Arg Ile His
1170 1175 1180

Val Asp Leu Phe Asp Leu Glu Ser Gly Glu Tyr Leu Cys Pro Leu Cys
185 1190 1195 1200

Lys Ser Leu Cys Asn Thr Val Ile Pro Ile Ile Pro Leu Gln Pro Gln
1205 1210 1215

Lys Ile Asn Ser Glu Asn Ala Asp Ala Leu Ala Gln Leu Leu Thr Leu
1220 1225 1230

Ala Arg Trp Ile Gln Thr Val Leu Ala Arg Ile Ser Gly Tyr Asn Ile
1235 1240 1245

Arg His Ala Lys Gly Glu Asn Pro Ile Pro Ile Phe Phe Asn Gln Gly
1250 1255 1260

Met Gly Asp Ser Thr Leu Glu Phe His Ser Ile Leu Ser Phe Gly Val
265 1270 1275 1280

Glu Ser Ser Ile Lys Tyr Ser Asn Ser Ile Lys Glu Met Val Ile Leu
1285 1290 1295

Phe Ala Thr Thr Ile Tyr Arg Ile Gly Leu Lys Val Pro Pro Asp Glu
1300 1305 1310

Arg Asp Pro Arg Val Pro Met Leu Thr Trp Ser Thr Cys Ala Phe Thr
1315 1320 1325

Ile Gln Ala Ile Glu Asn Leu Leu Gly Asp Glu Gly Lys Pro Leu Phe
1330 1335 1340

Gly Ala Leu Gln Asn Arg Gln His Asn Gly Leu Lys Ala Leu Met Gln
345 1350 1355 1360

Phe Ala Val Ala Gln Arg Ile Thr Cys Pro Gln Val Leu Ile Gln Lys
1365 1370 1375

His Leu Val Arg Leu Leu Ser Val Val Leu Pro Asn Ile Lys Ser Glu
1380 1385 1390

Asp Thr Pro Cys Leu Leu Ser Ile Asp Leu Phe His Val Leu Val Gly
1395 1400 1405

Ala Val Leu Ala Phe Pro Ser Leu Tyr Trp Asp Asp Pro Val Asp Leu
1410 1415 1420

Gln Pro Ser Ser Val Ser Ser Tyr Asn His Leu Tyr Leu Phe His
425 1430 1435 1440

Leu Ile Thr Met Ala His Met Leu Gln Ile Leu Leu Thr Val Asp Thr
1445 1450 1455

Gly Leu Pro Leu Ala Gln Val Gln Glu Asp Ser Glu Glu Ala His Ser
1460 1465 1470

Ala Ser Ser Phe Phe Ala Glu Ile Ser Gln Tyr Thr Ser Gly Ser Ile
1475 1480 1485

Gly Cys Asp Ile Pro Gly Trp Tyr Leu Trp Val Ser Leu Lys Asn Gly
1490 1495 1500

Ile Thr Pro Tyr Leu Arg Cys Ala Ala Leu Phe Phe His Tyr Leu Leu
505 1510 1515 1520

Gly Val Thr Pro Pro Glu Glu Leu His Thr Asn Ser Ala Glu Gly Glu
1525 1530 1535

Tyr Ser Ala Leu Cys Ser Tyr Leu Ser Leu Pro Thr Asn Leu Phe Leu
1540 1545 1550

Leu Phe Gln Glu Tyr Trp Asp Thr Val Arg Pro Leu Leu Gln Arg Trp
1555 1560 1565

Cys Ala Asp Pro Ala Leu Leu Asn Cys Leu Lys Gln Lys Asn Thr Val
1570 1575 1580

Val Arg Tyr Pro Arg Lys Arg Asn Ser Leu Ile Glu Leu Pro Asp Asp
585 1590 1595 1600

Tyr Ser Cys Leu Leu Asn Gln Ala Ser His Phe Arg Cys Pro Arg Ser
1605 1610 1615

Ala Asp Asp Glu Arg Lys His Pro Val Leu Cys Leu Phe Cys Gly Ala
1620 1625 1630

Ile Leu Cys Ser Gln Asn Ile Cys Cys Gln Glu Ile Val Asn Gly Glu
1635 1640 1645

Glu Val Gly Ala Cys Ile Phe His Ala Leu His Cys Gly Ala Gly Val
1650 1655 1660

Cys Ile Phe Leu Lys Ile Arg Glu Cys Arg Val Val Leu Val Glu Gly
665 1670 1675 1680

Lys Ala Arg Gly Cys Ala Tyr Pro Ala Pro Tyr Leu Asp Glu Tyr Gly
1685 1690 1695

Glu Thr Asp Pro Gly Leu Lys Arg Gly Asn Pro Leu His Leu Ser Arg
1700 1705 1710

Glu Arg Tyr Arg Lys Leu His Leu Val Trp Gln Gln His Cys Ile Ile
1715 1720 1725

Glu Glu Ile Ala Arg Ser Gln Glu Thr Asn Gln Met Leu Phe Gly Phe
1730 1735 1740

Asn Trp Gln Leu Leu
745

<210> 3
<211> 6300
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (295)..(5559)

<400> 3
gccaagaatt cggcacgagg tgtcaggcct ggggtttct gtgtccttcc ctgggtcagg 60
gacgagccag tgacttgact cttgggcgt aagcttggga gggagcgcag gaggccgctg 120
tccttccttt ccggttcacg tcacccttct ctccctctgt tgctccacct gcagccactt 180
ggacggctcc gggactgatt gcctggggca ggggtggcag tcgaggccgc cggggccgag 240
gtgaggctgc agctctccgg gcggcggtag cgctggggag gaggaggaga gaag atg 297
Met
1

gcg tcg gag cta gag cca gag gtg cag gcc atc gac cgg agt ttg ctg 345
Ala Ser Glu Leu Glu Pro Glu Val Gln Ala Ile Asp Arg Ser Leu Leu
5 10 15

gaa tgt tcg gcc gag gag att gcg ggg aaa tgg ctg caa gca act gac 393
Glu Cys Ser Ala Glu Glu Ile Ala Gly Lys Trp Leu Gln Ala Thr Asp
20 25 30

ctc act aga gaa gtg tac cag cat tta gcc cac tat gta ccc aaa atc 441
Leu Thr Arg Glu Val Tyr Gln His Leu Ala His Tyr Val Pro Lys Ile
35 40 45

tac tgc agg ggt ccc aac cct ttt cca cag aaa gaa gac atg ctg gca 489
Tyr Cys Arg Gly Pro Asn Pro Phe Pro Gln Lys Glu Asp Met Leu Ala
50 55 60 65

cag cat gtt ttg ttg gga cca atg gaa tgg tac ctt tgt ggt gaa gat 537
Gln His Val Leu Leu Gly Pro Met Glu Trp Tyr Leu Cys Gly Glu Asp
70 75 80

cct gca ttt gga ttt cca aaa ctt gag caa gca aac aaa cct tct cat 585
Pro Ala Phe Gly Phe Pro Lys Leu Glu Gln Ala Asn Lys Pro Ser His
85 90 95

ctt tgt ggt cgt gtt ttt aaa gta gga gag cct aca tat tct tgc aga Leu Cys Gly Arg Val Phe Lys Val Gly Glu Pro Thr Tyr Ser Cys Arg 100 105 110	633
gac tgt gca gtt gat cca act tgt gtt ttg tgc atg gag tgc ttt ttg Asp Cys Ala Val Asp Pro Thr Cys Val Leu Cys Met Glu Cys Phe Leu 115 120 125	681
gga agt att cac aga gat cat cga tat agg atg aca aca tca gga ggt Gly Ser Ile His Arg Asp His Arg Tyr Arg Met Thr Thr Ser Gly Gly 130 135 140 145	729
gga ggt ttc tgt gac tgt gat act gaa gcc tgg aaa gag ggt cct Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Glu Gly Pro 150 155 160	777
tac tgt caa aaa cat gaa ctt aac acc tct gaa att gag gaa gaa gag Tyr Cys Gln Lys His Glu Leu Asn Thr Ser Glu Ile Glu Glu Glu Glu 165 170 175	825
gat cct ctt gtt cat tta tca gaa gat gtg ata gca aga act tat aac Asp Pro Leu Val His Leu Ser Glu Asp Val Ile Ala Arg Thr Tyr Asn 180 185 190	873
att ttt gct att acg ttt cgg tat gca gta gaa ata tta acc tgg gaa Ile Phe Ala Ile Thr Phe Arg Tyr Ala Val Glu Ile Leu Thr Trp Glu 195 200 205	921
aaa gaa agt gaa ttg cca gca gat tta gag atg gta gag aag agt gac Lys Glu Ser Glu Leu Pro Ala Asp Leu Glu Met Val Glu Lys Ser Asp 210 215 220 225	969
acc tac tat tgc atg ctg ttt aat gat gag gtt cac acc tat gaa caa Thr Tyr Tyr Cys Met Leu Phe Asn Asp Glu Val His Thr Tyr Glu Gln 230 235 240	1017
gtt att tat act ctt cag aaa gct gtt aac tgt aca caa aaa gaa gct Val Ile Tyr Thr Leu Gln Lys Ala Val Asn Cys Thr Gln Lys Glu Ala 245 250 255	1065
att ggt ttt gca act aca gta gat cga gat ggg cgt agg tct gtt cga Ile Gly Phe Ala Thr Thr Val Asp Arg Asp Gly Arg Arg Ser Val Arg 260 265 270	1113
tat gga gat ttt cag tat tgt gag caa gca aaa tca gta att gtg aga Tyr Gly Asp Phe Gln Tyr Cys Glu Gln Ala Lys Ser Val Ile Val Arg 275 280 285	1161
aat acc agt aga cag aca aag cca ctc aaa gtt caa gtt atg cat tcg Asn Thr Ser Arg Gln Thr Lys Pro Leu Lys Val Gln Val Met His Ser 290 295 300 305	1209
tct att gtc gca cat cag aat ttt ggt ttg aaa ctt ttg tct tgg ctg Ser Ile Val Ala His Gln Asn Phe Gly Leu Lys Leu Leu Ser Trp Leu 310 315 320	1257
gga agt att att gga tat tca gat ggc ctt cgc cgg att tta tgt caa Gly Ser Ile Ile Gly Tyr Ser Asp Gly Leu Arg Arg Ile Leu Cys Gln 325 330 335	1305
gtt ggt tta caa gaa ggg cca gat ggt gaa aac tct tct cta gtg gac Val Gly Leu Gln Glu Gly Pro Asp Gly Glu Asn Ser Ser Leu Val Asp 340 345 350	1353

aga ctg atg ctt agt gat tcc aaa tta tgg aaa ggt gct agg agt gta Arg Leu Met Leu Ser Asp Ser Lys Leu Trp Lys Gly Ala Arg Ser Val 355 360 365	1401
	1449
tat cat cag ttg ttc atg agc agt ctg ctt atg gat ttg aaa tac aag Tyr His Gln Leu Phe Met Ser Ser Leu Leu Met Asp Leu Lys Tyr Lys 370 375 380 385	1449
	1497
aaa cta ttt gct gtt cga ttt gca aaa aat tac cag cag ttg cag aga Lys Leu Phe Ala Val Arg Phe Ala Lys Asn Tyr Gln Gln Leu Gln Arg 390 395 400	1497
	1545
gat ttt atg gag gat cac gag cga gca gtg tcg gtg act gct cta Asp Phe Met Glu Asp Asp His Glu Arg Ala Val Ser Val Thr Ala Leu 405 410 415	1545
	1593
tct gtc cag ttc acc gca cct act ctg gct cga atg ctc atc aca Ser Val Gln Phe Phe Thr Ala Pro Thr Leu Ala Arg Met Leu Ile Thr 420 425 430	1593
	1641
gaa gaa aac ttg atg agc att atc att aag act ttt atg gat cat ttg Glu Glu Asn Leu Met Ser Ile Ile Ile Lys Thr Phe Met Asp His Leu 435 440 445	1641
	1689
aga cat cga gat gcc cag ggc aga ttt cag ttt gaa cga tac act gct Arg His Arg Asp Ala Gln Gly Arg Phe Gln Phe Glu Arg Tyr Thr Ala 450 455 460 465	1689
	1737
tta caa gcc ttc aaa ttt agg aga gta cag agc ctt att tta gat ctc Leu Gln Ala Phe Lys Phe Arg Arg Val Gln Ser Leu Ile Leu Asp Leu 470 475 480	1737
	1785
aag tat gtg tta att agc aaa cca act gaa tgg tca gat gag ctg agg Lys Tyr Val Leu Ile Ser Lys Pro Thr Glu Trp Ser Asp Glu Leu Arg 485 490 495	1785
	1833
cag aag ttc cta gaa ggg ttt gat gcc ttt ttg gaa tta cta aaa tgt Gln Lys Phe Leu Glu Gly Phe Asp Ala Phe Leu Glu Leu Leu Lys Cys 500 505 510	1833
	1881
atg cag gga atg gat cca att aca cgtcaa gta gga caa cat att gaa Met Gln Gly Met Asp Pro Ile Thr Arg Gln Val Gly Gln His Ile Glu 515 520 525	1881
	1929
atg gaa cca gag tgg gaa gca gcc ttc aca cta caa atg aaa tta aca Met Glu Pro Glu Trp Glu Ala Ala Phe Thr Leu Gln Met Lys Leu Thr 530 535 540 545	1929
	1977
cat gtc att tca atg atg cag gac tgg tgt gct tca gat gaa aaa gtg His Val Ile Ser Met Met Gln Asp Trp Cys Ala Ser Asp Glu Lys Val 550 555 560	1977
	2025
tta atc gaa gct tac aag aaa tgt ctc gct gta ctg atg cag tgt cat Leu Ile Glu Ala Tyr Lys Lys Cys Leu Ala Val Leu Met Gln Cys His 565 570 575	2025
	2073
ggt ggt tat act gat ggt gaa cag cca atc aca cta agc att tgt gga Gly Gly Tyr Thr Asp Gly Glu Gln Pro Ile Thr Leu Ser Ile Cys Gly 580 585 590	2073
	2121
cat tca gtg gaa act atc aga tac tgt gtt tcc caa gaa aaa gtt agc His Ser Val Glu Thr Ile Arg Tyr Cys Val Ser Gln Glu Lys Val Ser 595 600 605	2121

att cac ctc cca gtt tct cgc tta ctt gca ggt tta cat gta tta tta Ile His Leu Pro Val Ser Arg Leu Leu Ala Gly Leu His Val Leu Leu 610 615 620 625	2169
agc aaa agt gaa gtg gca tat aaa ttt cca gag ctc cta cct cta agt Ser Lys Ser Glu Val Ala Tyr Lys Phe Pro Glu Leu Leu Pro Leu Ser 630 635 640	2217
gaa ctt agc cca ccc atg ttg ata gaa cac cct ctt aga tgt ctt gtt Glu Leu Ser Pro Pro Met Leu Ile Glu His Pro Leu Arg Cys Leu Val 645 650 655	2265
ctg tgt gcc caa gta cat gcc gga atg tgg aga aga aat ggg ttc tct Leu Cys Ala Gln Val His Ala Gly Met Trp Arg Arg Asn Gly Phe Ser 660 665 670	2313
cta gta aac cag att tat tac tac cat aat gtg aaa tgc aga cgt gag Leu Val Asn Gln Ile Tyr Tyr His Asn Val Lys Cys Arg Arg Glu 675 680 685	2361
atg ttt gac aag gat gta gta atg ctt cag aca ggt gtc tcc atg atg Met Phe Asp Lys Asp Val Val Met Leu Gln Thr Gly Val Ser Met Met 690 695 700 705	2409
gat cca aat cat ttc ctg atg atc atg ctc agc cgc ttt gaa ctt tat Asp Pro Asn His Phe Leu Met Ile Met Leu Ser Arg Phe Glu Leu Tyr 710 715 720	2457
cag att ttc agt act cca gac tat gga aaa aga ttt agt tct gag att Gln Ile Phe Ser Thr Pro Asp Tyr Gly Lys Arg Phe Ser Ser Glu Ile 725 730 735	2505
acc cat aag gat gtt gtt cag cag aac aat act cta ata gaa gaa atg Thr His Lys Asp Val Val Gln Gln Asn Asn Thr Leu Ile Glu Glu Met 740 745 750	2553
cta tac ctc att ata atg ctt gga gag aga ttt agt cct gga gtt Leu Tyr Leu Ile Ile Met Leu Val Gly Glu Arg Phe Ser Pro Gly Val 755 760 765	2601
gga cag gta aat gct aca gat gaa atc aag cga gag att atc cat cag Gly Gln Val Asn Ala Thr Asp Glu Ile Lys Arg Glu Ile Ile His Gln 770 775 780 785	2649
ttg agt atc aag cct atg gct cat agt gaa ttg gta aag tct tta cct Leu Ser Ile Lys Pro Met Ala His Ser Glu Leu Val Lys Ser Leu Pro 790 795 800	2697
gaa gat gag aac aag gag act ggc atg gag agt gta atc gaa gca gtt Glu Asp Glu Asn Lys Glu Thr Gly Met Glu Ser Val Ile Glu Ala Val 805 810 815	2745
gcc cat ttc aag aaa cct gga tta aca gga cga ggc atg tat gaa ctg Ala His Phe Lys Lys Pro Gly Leu Thr Gly Arg Gly Met Tyr Glu Leu 820 825 830	2793
aaa cca gaa tgt gcc aaa gag ttc aac ttg tat ttc tat cac ttt tca Lys Pro Glu Cys Ala Lys Glu Phe Asn Leu Tyr Phe Tyr His Phe Ser 835 840 845	2841
agg gca gaa cag tcc aag gca gaa gaa gcg caa cgg aaa ttg aaa aga Arg Ala Glu Gln Ser Lys Ala Glu Glu Ala Gln Arg Lys Leu Lys Arg 850 855 860 865	2889

caa aat aga gaa gat aca gca ctc cca cct ccg gtg ttg cct cca ttc Gln Asn Arg Glu Asp Thr Ala Leu Pro Pro Pro Val Leu Pro Pro Phe 870 875 880	2937
tgc cct ctg ttt gca agc ctg gtt aac att ttg cag tca gat gtc atg Cys Pro Leu Phe Ala Ser Leu Val Asn Ile Leu Gln Ser Asp Val Met 885 890 895	2985
ttg tgc atc atg gga aca att ctg caa tgg gct gtg gaa cat aat gga Leu Cys Ile Met Gly Thr Ile Leu Gln Trp Ala Val Glu His Asn Gly 900 905 910	3033
tat gcc tgg tca gag tcc atg ctg caa agg gtg tta cat tta att ggc Tyr Ala Trp Ser Glu Ser Met Leu Gln Arg Val Leu His Leu Ile Gly 915 920 925	3081
atg gca cta caa gaa aaa caa cat tta gag aat gtc acg gaa gag Met Ala Leu Gln Glu Lys Gln His Leu Glu Asn Val Thr Glu Glu 930 935 940 945	3129
cat gta gta aca ttt acc ttc act cag aag ata tca aaa cct ggt gaa His Val Val Thr Phe Thr Gln Lys Ile Ser Lys Pro Gly Glu 950 955 960	3177
gcg cca aaa aat tct cct agc ata cta gct atg ctg gaa aca cta caa Ala Pro Lys Asn Ser Pro Ser Ile Leu Ala Met Leu Glu Thr Leu Gln 965 970 975	3225
aat gct ccc tac cta gaa gtc cac aaa gac atg att cgg tgg ata ttg Asn Ala Pro Tyr Leu Glu Val His Lys Asp Met Ile Arg Trp Ile Leu 980 985 990	3273
aag act ttt aat gct gtt aaa aag atg agg gag agt tca cct acc agt Lys Thr Phe Asn Ala Val Lys Met Arg Glu Ser Ser Pro Thr Ser 995 1000 1005	3321
ccc gtg gca gag aca gaa gga acc ata atg gaa gag agt tca agg gac Pro Val Ala Glu Thr Glu Gly Thr Ile Met Glu Glu Ser Ser Arg Asp 1010 1015 1020 1025	3369
aaa gac aaa gct gag agg aag aga aaa gca gag att gcc aga ctg cgc Lys Asp Lys Ala Glu Arg Lys Arg Lys Ala Glu Ile Ala Arg Leu Arg 1030 1035 1040	3417
aga gaa aag atc atg gct cag atg tct gaa atg cag cgg cat ttt att Arg Glu Lys Ile Met Ala Gln Met Ser Glu Met Gln Arg His Phe Ile 1045 1050 1055	3465
gat gaa aac aaa gaa ctc ttt cag cag aca tta gaa ctg gat gcc tca Asp Glu Asn Lys Glu Leu Phe Gln Gln Thr Leu Glu Leu Asp Ala Ser 1060 1065 1070	3513
acc tct gct gtt ctt gat cat agc cct gtg gct tca gat atg aca ctt Thr Ser Ala Val Leu Asp His Ser Pro Val Ala Ser Asp Met Thr Leu 1075 1080 1085	3561
aca gca ctg ggt ccc aca caa act cag gtt cct gaa caa aga caa ttc Thr Ala Leu Gly Pro Thr Gln Thr Gln Val Pro Glu Gln Arg Gln Phe 1090 1095 1100 1105	3609
gtt aca tgt ata ttg tgt caa gag gag caa gaa gtt aaa gtg gaa agc Val Thr Cys Ile Leu Cys Gln Glu Glu Gln Glu Val Lys Val Glu Ser 1110 1115 1120	3657

agg gca atg gtc ttg gca gca ttt gtt cag aga tca act gta tta tca Arg Ala Met Val Leu Ala Ala Phe Val Gln Arg Ser Thr Val Leu Ser 1125 1130 1135	3705
aaa aac aga agt aaa ttt att caa gat cca gaa aaa tat gat cca tta Lys Asn Arg Ser Lys Phe Ile Gln Asp Pro Glu Lys Tyr Asp Pro Leu 1140 1145 1150	3753
ttc atg cac cct gat ctg tct tgt gga aca cac act agt agc tgt ggg Phe Met His Pro Asp Leu Ser Cys Gly Thr His Thr Ser Ser Cys Gly 1155 1160 1165	3801
cac att atg cat gcc cat tgt tgg caa agg tat ttt gat tcc gtt caa His Ile Met His Ala His Cys Trp Gln Arg Tyr Phe Asp Ser Val Gln 1170 1175 1180 1185	3849
gct aaa gaa cag cga agg caa cag aga tta cgc tta cat acg agc tat Ala Lys Glu Gln Arg Arg Gln Arg Leu Arg Leu His Thr Ser Tyr 1190 1195 1200	3897
gat gta gaa aac gga gaa ttc ctt tgc ccc ctt tgt gaa tgc ttg agt Asp Val Glu Asn Gly Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu Ser 1205 1210 1215	3945
aat act gtt att cct ctg ctg ctt cct cca aga aat att ttt aac aac Asn Thr Val Ile Pro Leu Leu Pro Pro Arg Asn Ile Phe Asn Asn 1220 1225 1230	3993
agg tta aat ttt tca gac caa cca aat ctg act cag tgg att aga aca Arg Leu Asn Phe Ser Asp Gln Pro Asn Leu Thr Gln Trp Ile Arg Thr 1235 1240 1245	4041
ata tct cag caa ata aaa gca tta cag ttt ctt agg aaa gaa gaa agt Ile Ser Gln Gln Ile Lys Ala Leu Gln Phe Leu Arg Lys Glu Glu Ser 1250 1255 1260 1265	4089
act cct aat aat gcc tct aca aag aat tca gaa aat gtg gat gaa tta Thr Pro Asn Asn Ala Ser Thr Lys Asn Ser Glu Asn Val Asp Glu Leu 1270 1275 1280	4137
cag ctc cct gaa ggg ttc agg cct gat ttt cgt cct aag atc cct tat Gln Leu Pro Glu Gly Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr 1285 1290 1295	4185
tct gag agc ata aaa gaa atg cta acg aca ttt gga act gct acc tac Ser Glu Ser Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Thr Tyr 1300 1305 1310	4233
aag gtg gga cta aag gtt cat ccc aat gaa gag gat cct cgt gtt ccc Lys Val Gly Leu Lys Val His Pro Asn Glu Asp Pro Arg Val Pro 1315 1320 1325	4281
ata atg tgt tgg ggt agc tgc gcg tac acc atc caa agc ata gaa aga Ile Met Cys Trp Gly Ser Cys Ala Tyr Thr Ile Gln Ser Ile Glu Arg 1330 1335 1340 1345	4329
att ttg agt gat gaa gat aaa cca ttg ttt ggt cct tta cct tgc aga Ile Leu Ser Asp Glu Asp Lys Pro Leu Phe Gly Pro Leu Pro Cys Arg 1350 1355 1360	4377
ctg gat gac tgt ctt agg tca ttg acg aga ttt gcc gca gca cac tgg Leu Asp Asp Cys Leu Arg Ser Leu Thr Arg Phe Ala Ala Ala His Trp 1365 1370 1375	4425

aca gtg gca tca gtt tca gtg gtg caa gga cat ttt tgt aaa ctt ttt Thr Val Ala Ser Val Ser Val Val Gln Gly His Phe Cys Lys Leu Phe 1380 1385 1390	4473
gca tca ctg gtg cct aat gac agc cat gag gaa ctt cca tgc ata tta Ala Ser Leu Val Pro Asn Asp Ser His Glu Glu Leu Pro Cys Ile Leu 1395 1400 1405	4521
gat att gac atg ttt cat tta ttg gtg ggc ttg gtg ctt gca ttt cct Asp Ile Asp Met Phe His Leu Leu Val Gly Leu Val Leu Ala Phe Pro 1410 1415 1420 1425	4569
gcg ttg cag tgt cag gat ttt tca ggg atc agc ctt ggc act gga gac Ala Leu Gln Cys Gln Asp Phe Ser Gly Ile Ser Leu Gly Thr Gly Asp 1430 1435 1440	4617
ctt cac att ttc cat ctg gtt act atg gca cac atc ata cag atc tta Leu His Ile Phe His Leu Val Thr Met Ala His Ile Ile Gln Ile Leu 1445 1450 1455	4665
ctt acc tca tgt aca gaa gag aat ggc atg gat caa gaa aat ccc cct Leu Thr Ser Cys Thr Glu Glu Asn Gly Met Asp Gln Glu Asn Pro Pro 1460 1465 1470	4713
tgt gaa gaa gaa tca gca gtt ctt gct ttg tat aaa aca ctt cac cag Cys Glu Glu Glu Ser Ala Val Leu Ala Leu Tyr Lys Thr Leu His Gln 1475 1480 1485	4761
tat acg gga agt gcc ttg aaa gaa ata cca tcc ggc tgg cat ctg tgg Tyr Thr Gly Ser Ala Leu Lys Glu Ile Pro Ser Gly Trp His Leu Trp 1490 1495 1500 1505	4809
agg agt gtc aga gct gga atc atg cct ttc ctg aag tgt tct gct tta Arg Ser Val Arg Ala Gly Ile Met Pro Phe Leu Lys Cys Ser Ala Leu 1510 1515 1520	4857
ttt ttt cat tac tta aat gga gtt cct tcc cca ccc gac att caa gtt Phe Phe His Tyr Leu Asn Gly Val Pro Ser Pro Pro Asp Ile Gln Val 1525 1530 1535	4905
cct gga aca agc cat ttt gaa cat tta tgt agc tat ctt tcc cta cca Pro Gly Thr Ser His Phe Glu His Leu Cys Ser Tyr Leu Ser Leu Pro 1540 1545 1550	4953
aac aac ctc att tgc ctt ttt caa gaa aat agt gag ata atg aat tca Asn Asn Leu Ile Cys Leu Phe Gln Glu Asn Ser Glu Ile Met Asn Ser 1555 1560 1565	5001
ctg att gaa agt tgg tgc cgt aac agt gaa gtt aaa aga tat cta gaa Leu Ile Glu Ser Trp Cys Arg Asn Ser Glu Val Lys Arg Tyr Leu Glu 1570 1575 1580 1585	5049
ggt gaa aga gat gct ata aga tat cca aga gaa tct aac aaa tta ata Gly Glu Arg Asp Ala Ile Arg Tyr Pro Arg Glu Ser Asn Lys Leu Ile 1590 1595 1600	5097
aac ctt cca gag gat tac agc agc ctc att aat caa gca tcc aat ttc Asn Leu Pro Glu Asp Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn Phe 1605 1610 1615	5145
tcg tgc ccg aaa tca ggt ggt gat aag agc aga gcc cca act ctg tgc Ser Cys Pro Lys Ser Gly Gly Asp Lys Ser Arg Ala Pro Thr Leu Cys 1620 1625 1630	5193

ctt gtg tgc gga tct ctg ctg tgc tcc cag agt tac tgc tgc cag act	5241
Leu Val Cys Gly Ser Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln Thr	
1635 1640 1645	
gaa ctg gaa ggg gag gat gta gga gcc tgc aca gct cac acc tac tcc	5289
Glu Leu Glu Gly Glu Asp Val Gly Ala Cys Thr Ala His Thr Tyr Ser	
1650 1655 1660 1665	
tgt ggc tct gga gtg ggc atc ttc ctg aga gta cggt gaa tgt cag gtg	5337
Cys Gly Ser Gly Val Gly Ile Phe Leu Arg Val Arg Glu Cys Gln Val	
1670 1675 1680	
cta ttt tta gct ggc aaa acc aaa ggc tgt ttt tat tct cct cct tac	5385
Leu Phe Leu Ala Gly Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro Tyr	
1685 1690 1695	
ctt gat gac tat ggg gag acc gac cag gga ctc aga cggt gga aat cct	5433
Leu Asp Asp Tyr Gly Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn Pro	
1700 1705 1710	
tta cat tta tgc aaa gag cga ttc aag aag att cag aag ctc tgg cac	5481
Leu His Leu Cys Lys Glu Arg Phe Lys Lys Ile Gln Lys Leu Trp His	
1715 1720 1725	
caa cac agt gtc aca gag gaa att gga cat gca cag gaa gcc aat cag	5529
Gln His Ser Val Thr Glu Glu Ile Gly His Ala Gln Glu Ala Asn Gln	
1730 1735 1740 1745	
aca ctg gtt ggc att gac tgg caa cat tta taattattgc accaccaaaa	5579
Thr Leu Val Gly Ile Asp Trp Gln His Leu	
1750 1755	
aacacaaaact tggattttt taacccagtt ggcttttaa gaaagaaaaga agttctgctg	5639
aatttggaaa taaattcttt atttaaactt tccttcccag tttatagtt tctgggtctg	5699
aggactgatg aaaatcatct tccatcagca gatttcttg cactgtttgc tgtgccctc	5759
aaatataatg tcttgggttt taagatcgag caaggagctt ctcttcctag attggatccc	5819
agcccctttg tgggggtctg actgcatagt cccagccatt atgtgatatt tcacgttatt	5879
gatgatagt aaccgtgggt ccgaagctga ctcaacggag gcagggaca aagtctctgt	5939
ggctctgtgg gtcatacttc ctgggtccac tgagtggccc aacactggga ctgggttggt	5999
gtccccctctg ctgacaggac cctactccta ggagcaaaagt ggttattttt gaaggcagtg	6059
ttcccttctc tccattgact atgagagagt tggggacac acatgcagaa gaagcccgtg	6119
gggagaaggt ggattctgg tggctggct ggttttcag ggctgttaga ggtttttttt	6179
ttctttttt ttttatggc aagacttttgc ttggagaa aactcactta gagggcttgc	6239
caaaaaactta ggatggctta aaaaattagg atattctttt agaatttagga agaaaaatta	6299
g	6300

<210> 4
<211> 1755
<212> PRT
<213> Homo sapiens

<400> 4
Met Ala Ser Glu Leu Glu Pro Glu Val Gln Ala Ile Asp Arg Ser Leu
1 5 10 15

Leu Glu Cys Ser Ala Glu Glu Ile Ala Gly Lys Trp Leu Gln Ala Thr
20 25 30

Asp Leu Thr Arg Glu Val Tyr Gln His Leu Ala His Tyr Val Pro Lys
35 40 45

Ile Tyr Cys Arg Gly Pro Asn Pro Phe Pro Gln Lys Glu Asp Met Leu
50 55 60

Ala Gln His Val Leu Leu Gly Pro Met Glu Trp Tyr Leu Cys Gly Glu
65 70 75 80

Asp Pro Ala Phe Gly Phe Pro Lys Leu Glu Gln Ala Asn Lys Pro Ser
85 90 95

His Leu Cys Gly Arg Val Phe Lys Val Gly Glu Pro Thr Tyr Ser Cys
100 105 110

Arg Asp Cys Ala Val Asp Pro Thr Cys Val Leu Cys Met Glu Cys Phe
115 120 125

Leu Gly Ser Ile His Arg Asp His Arg Tyr Arg Met Thr Thr Ser Gly
130 135 140

Gly Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Glu Gly
145 150 155 160

Pro Tyr Cys Gln Lys His Glu Leu Asn Thr Ser Glu Ile Glu Glu Glu
165 170 175

Glu Asp Pro Leu Val His Leu Ser Glu Asp Val Ile Ala Arg Thr Tyr
180 185 190

Asn Ile Phe Ala Ile Thr Phe Arg Tyr Ala Val Glu Ile Leu Thr Trp
195 200 205

Glu Lys Glu Ser Glu Leu Pro Ala Asp Leu Glu Met Val Glu Lys Ser
210 215 220

Asp Thr Tyr Tyr Cys Met Leu Phe Asn Asp Glu Val His Thr Tyr Glu
225 230 235 240

Gln Val Ile Tyr Thr Leu Gln Lys Ala Val Asn Cys Thr Gln Lys Glu
245 250 255

Ala Ile Gly Phe Ala Thr Thr Val Asp Arg Asp Gly Arg Arg Ser Val
260 265 270

Arg Tyr Gly Asp Phe Gln Tyr Cys Glu Gln Ala Lys Ser Val Ile Val
275 280 285

Arg Asn Thr Ser Arg Gln Thr Lys Pro Leu Lys Val Gln Val Met His
290 295 300

Ser Ser Ile Val Ala His Gln Asn Phe Gly Leu Lys Leu Leu Ser Trp
305 310 315 320

Leu Gly Ser Ile Ile Gly Tyr Ser Asp Gly Leu Arg Arg Ile Leu Cys
325 330 335

Gln Val Gly Leu Gln Glu Gly Pro Asp Gly Glu Asn Ser Ser Leu Val
340 345 350

Asp Arg Leu Met Leu Ser Asp Ser Lys Leu Trp Lys Gly Ala Arg Ser
355 360 365

Val Tyr His Gln Leu Phe Met Ser Ser Leu Leu Met Asp Leu Lys Tyr
370 375 380

Lys Lys Leu Phe Ala Val Arg Phe Ala Lys Asn Tyr Gln Gln Leu Gln
385 390 395 400

Arg Asp Phe Met Glu Asp Asp His Glu Arg Ala Val Ser Val Thr Ala
405 410 415

Leu Ser Val Gln Phe Phe Thr Ala Pro Thr Leu Ala Arg Met Leu Ile
420 425 430

Thr Glu Glu Asn Leu Met Ser Ile Ile Ile Lys Thr Phe Met Asp His
435 440 445

Leu Arg His Arg Asp Ala Gln Gly Arg Phe Gln Phe Glu Arg Tyr Thr
450 455 460

Ala Leu Gln Ala Phe Lys Phe Arg Arg Val Gln Ser Leu Ile Leu Asp
465 470 475 480

Leu Lys Tyr Val Leu Ile Ser Lys Pro Thr Glu Trp Ser Asp Glu Leu
485 490 495

Arg Gln Lys Phe Leu Glu Gly Phe Asp Ala Phe Leu Glu Leu Lys
500 505 510

Cys Met Gln Gly Met Asp Pro Ile Thr Arg Gln Val Gly Gln His Ile
515 520 525

Glu Met Glu Pro Glu Trp Glu Ala Ala Phe Thr Leu Gln Met Lys Leu
530 535 540

Thr His Val Ile Ser Met Met Gln Asp Trp Cys Ala Ser Asp Glu Lys
545 550 555 560

Val Leu Ile Glu Ala Tyr Lys Lys Cys Leu Ala Val Leu Met Gln Cys
565 570 575

His Gly Gly Tyr Thr Asp Gly Glu Gln Pro Ile Thr Leu Ser Ile Cys
580 585 590

Gly His Ser Val Glu Thr Ile Arg Tyr Cys Val Ser Gln Glu Lys Val
595 600 605

Ser Ile His Leu Pro Val Ser Arg Leu Leu Ala Gly Leu His Val Leu
610 615 620

Leu Ser Lys Ser Glu Val Ala Tyr Lys Phe Pro Glu Leu Leu Pro Leu
625 630 635 640

Ser Glu Leu Ser Pro Pro Met Leu Ile Glu His Pro Leu Arg Cys Leu
645 650 655

Val Leu Cys Ala Gln Val His Ala Gly Met Trp Arg Arg Asn Gly Phe
660 665 670

Ser Leu Val Asn Gln Ile Tyr Tyr Tyr His Asn Val Lys Cys Arg Arg
675 680 685

Glu Met Phe Asp Lys Asp Val Val Met Leu Gln Thr Gly Val Ser Met
690 695 700 720

Met Asp Pro Asn His Phe Leu Met Ile Met Leu Ser Arg Phe Glu Leu
705 710 715 720

Tyr Gln Ile Phe Ser Thr Pro Asp Tyr Gly Lys Arg Phe Ser Ser Glu
725 730 735

Ile Thr His Lys Asp Val Val Gln Gln Asn Asn Thr Leu Ile Glu Glu
740 745 750

Met Leu Tyr Leu Ile Ile Met Leu Val Gly Glu Arg Phe Ser Pro Gly
755 760 765

Val Gly Gln Val Asn Ala Thr Asp Glu Ile Lys Arg Glu Ile Ile His
770 775 780

Gln Leu Ser Ile Lys Pro Met Ala His Ser Glu Leu Val Lys Ser Leu
785 790 795 800

Pro Glu Asp Glu Asn Lys Glu Thr Gly Met Glu Ser Val Ile Glu Ala
805 810 815

Val Ala His Phe Lys Lys Pro Gly Leu Thr Gly Arg Gly Met Tyr Glu
820 825 830

Leu Lys Pro Glu Cys Ala Lys Glu Phe Asn Leu Tyr Phe Tyr His Phe
835 840 845

Ser Arg Ala Glu Gln Ser Lys Ala Glu Glu Ala Gln Arg Lys Leu Lys
850 855 860

Arg Gln Asn Arg Glu Asp Thr Ala Leu Prc Pro Pro Val Leu Pro Pro
865 870 875 880

Phe Cys Pro Leu Phe Ala Ser Leu Val Asn Ile Leu Gln Ser Asp Val
885 890 895

Met Leu Cys Ile Met Gly Thr Ile Leu Gln Trp Ala Val Glu His Asn
900 905 910

Gly Tyr Ala Trp Ser Glu Ser Met Leu Gln Arg Val Leu His Leu Ile
915 920 925

Gly Met Ala Leu Gln Glu Glu Lys Gln His Leu Glu Asn Val Thr Glu
930 935 940

Glu His Val Val Thr Phe Thr Phe Thr Gln Lys Ile Ser Lys Pro Gly
945 950 955 960

Glu Ala Pro Lys Asn Ser Pro Ser Ile Leu Ala Met Leu Glu Thr Leu
965 970 975

Gln Asn Ala Pro Tyr Leu Glu Val His Lys Asp Met Ile Arg Trp Ile
980 985 990

Lys Thr Phe Asn Ala Val Lys Lys Met Arg Glu Ser Ser Pro Thr
995 1000 1005

Ser Pro Val Ala Glu Thr Glu Gly Thr Ile Met Glu Glu Ser Ser Arg
1010 1015 1020

Asp Lys Asp Lys Ala Glu Arg Lys Arg Lys Ala Glu Ile Ala Arg Leu
025 1030 1035 1040

Arg Arg Glu Lys Ile Met Ala Gln Met Ser Glu Met Gln Arg His Phe
1045 1050 1055

Ile Asp Glu Asn Lys Glu Leu Phe Gln Gln Thr Leu Glu Leu Asp Ala
1060 1065 1070

Ser Thr Ser Ala Val Leu Asp His Ser Pro Val Ala Ser Asp Met Thr
1075 1080 1085

Leu Thr Ala Leu Gly Pro Thr Gln Thr Gln Val Pro Glu Gln Arg Gln
1090 1095 1100

Phe Val Thr Cys Ile Leu Cys Gln Glu Glu Gln Glu Val Lys Val Glu
105 1110 1115 1120

Ser Arg Ala Met Val Leu Ala Ala Phe Val Gln Arg Ser Thr Val Leu
1125 1130 1135

Ser Lys Asn Arg Ser Lys Phe Ile Gln Asp Pro Glu Lys Tyr Asp Pro
1140 1145 1150

Leu Phe Met His Pro Asp Leu Ser Cys Gly Thr His Thr Ser Ser Cys
1155 1160 1165

Gly His Ile Met His Ala His Cys Trp Gln Arg Tyr Phe Asp Ser Val
1170 1175 1180

Gln Ala Lys Glu Gln Arg Arg Gln Gln Arg Leu Arg Leu His Thr Ser
1185 1190 1195 1200

Tyr Asp Val Glu Asn Gly Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu
1205 1210 1215

Ser Asn Thr Val Ile Pro Leu Leu Pro Pro Arg Asn Ile Phe Asn
1220 1225 1230

Asn Arg Leu Asn Phe Ser Asp Gln Pro Asn Leu Thr Gln Trp Ile Arg
1235 1240 1245

Thr Ile Ser Gln Gln Ile Lys Ala Leu Gln Phe Leu Arg Lys Glu Glu
1250 1255 1260

Ser Thr Pro Asn Asn Ala Ser Thr Lys Asn Ser Glu Asn Val Asp Glu
1265 1270 1275 1280

Leu Gln Leu Pro Glu Gly Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro
1285 1290 1295

Tyr Ser Glu Ser Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Thr
1300 1305 1310

Tyr Lys Val Gly Leu Lys Val His Pro Asn Glu Glu Asp Pro Arg Val
1315 1320 1325

Pro Ile Met Cys Trp Gly Ser Cys Ala Tyr Thr Ile Gln Ser Ile Glu
1330 1335 1340

Arg Ile Leu Ser Asp Glu Asp Lys Pro Leu Phe Gly Pro Leu Pro Cys
345 1350 1355 1360

Arg Leu Asp Asp Cys Leu Arg Ser Leu Thr Arg Phe Ala Ala Ala His
1365 1370 1375

Trp Thr Val Ala Ser Val Ser Val Val Gln Gly His Phe Cys Lys Leu
1380 1385 1390

Phe Ala Ser Leu Val Pro Asn Asp Ser His Glu Glu Leu Pro Cys Ile
1395 1400 1405

Leu Asp Ile Asp Met Phe His Leu Leu Val Gly Leu Val Leu Ala Phe
1410 1415 1420

Pro Ala Leu Gln Cys Gln Asp Phe Ser Gly Ile Ser Leu Gly Thr Gly
425 1430 1435 1440

Asp Leu His Ile Phe His Leu Val Thr Met Ala His Ile Ile Gln Ile
1445 1450 1455

Leu Leu Thr Ser Cys Thr Glu Glu Asn Gly Met Asp Gln Glu Asn Pro
1460 1465 1470

Pro Cys Glu Glu Glu Ser Ala Val Leu Ala Leu Tyr Lys Thr Leu His
1475 1480 1485

Gln Tyr Thr Gly Ser Ala Leu Lys Glu Ile Pro Ser Gly Trp His Leu
1490 1495 1500

Trp Arg Ser Val Arg Ala Gly Ile Met Pro Phe Leu Lys Cys Ser Ala
505 1510 1515 1520

Leu Phe Phe His Tyr Leu Asn Gly Val Pro Ser Pro Pro Asp Ile Gln
1525 1530 1535

Val Pro Gly Thr Ser His Phe Glu His Leu Cys Ser Tyr Leu Ser Leu
1540 1545 1550

Pro Asn Asn Leu Ile Cys Leu Phe Gln Glu Asn Ser Glu Ile Met Asn
1555 1560 1565

Ser Leu Ile Glu Ser Trp Cys Arg Asn Ser Glu Val Lys Arg Tyr Leu
1570 1575 1580

Glu Gly Glu Arg Asp Ala Ile Arg Tyr Pro Arg Glu Ser Asn Lys Leu
585 1590 1595 1600

Ile Asn Leu Pro Glu Asp Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn
1605 1610 1615

Phe Ser Cys Pro Lys Ser Gly Gly Asp Lys Ser Arg Ala Pro Thr Leu
1620 1625 1630

Cys Leu Val Cys Gly Ser Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln
1635 1640 1645

Thr Glu Leu Glu Gly Glu Asp Val Gly Ala Cys Thr Ala His Thr Tyr
1650 1655 1660

Ser Cys Gly Ser Gly Val Gly Ile Phe Leu Arg Val Arg Glu Cys Gln
665 1670 1675 1680

Val Leu Phe Leu Ala Gly Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro
1685 1690 1695

Tyr Leu Asp Asp Tyr Gly Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn
1700 1705 1710

Pro Leu His Leu Cys Lys Glu Arg Phe Lys Lys Ile Gln Lys Leu Trp
1715 1720 1725

His Gln His Ser Val Thr Glu Glu Ile Gly His Ala Gln Glu Ala Asn
1730 1735 1740

Gln Thr Leu Val Gly Ile Asp Trp Gln His Leu
745 1750 1755

<210> 5

<211> 6089

<212> DNA

<213> Mouse

<220>

<221> CDS

<222> (766)..(6030)

<400> 5

caagtgtatc atatgccaag tacggccctt attgacgtca atgacggtaa atggcccgcc 60

tggcattatg cccagttacat gacccttatgg gactttccta cttggcagta catctacgta 120

ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag 180

cggtttgact cacggggatt tccaaatctc cacccattg acgtcaatgg gagtttgtt 240

tggcaccaaa atcaacggga ctttccaaaa tgtcgtaaca actccgcccc attgacgcaa 300

atggcggta ggcgtgtacg gtgggaggta tatataagca gagctctctg gctaactaga 360

gaacccactg cttactggct tatcgaaatt aatacgactc actataggga gacccaagct 420

tggtaccgag ctcggatcca ctactcgacc cacgcgtccg cggttagtggc tgtccggagt 480

gccaggcctg gggttctcgg tgccttccc ccggtaacgg gcgaggaggc gacttgactt 540

ctggcgccg agcccgccg cgcgcgaag cggctgccgt ccccgctgca ggttcgcgtc 600

ccgctttgtc ctcgcgcgt ctccggctcgg cggcagcccg gacggcccg gactgacggc 660

cccaggacag gggtaaccgt cgcggctgcg ggagcagagg cgaagctgag gcccgaaaa 720

aggcgacagc ggcgagagca cccggggaga ggaggaggag agaag atg gcg tcg gag 777
Met Ala Ser Glu

1

atg gag ccc gag gtg cag gcc atc gac cgc agt ttg ctg gaa tgt tct 825
Met Glu Pro Glu Val Gln Ala Ile Asp Arg Ser Leu Leu Glu Cys Ser
5 10 15 20

gcc gaa gag atc gca ggg aga tgg ctg caa gca acc gac ctc aac aga 873
Ala Glu Glu Ile Ala Gly Arg Trp Leu Gln Ala Thr Asp Leu Asn Arg
25 30 35

gaa gtg tac cag cat tta gcc cac tgt gtg ccc aaa atc tac tgc cg		921
Glu Val Tyr Gln His Leu Ala His Cys Val Pro Lys Ile Tyr Cys Arg		
40	45	50
ggc cct aac ccc ttc cct cag aag gaa gac acg ctg gca cag cac atc		969
Gly Pro Asn Pro Phe Pro Gln Lys Glu Asp Thr Leu Ala Gln His Ile		
55	60	65
ctg ctg gga ccg atg gag tgg tac atc tgc gct gaa gac cct gcg ctg		1017
Leu Leu Gly Pro Met Glu Trp Tyr Ile Cys Ala Glu Asp Pro Ala Leu		
70	75	80
gga ttt cca aag ctc gag cag gca aac aag cct tct cac ctc tgt ggc		1065
Gly Phe Pro Lys Leu Glu Gln Ala Asn Lys Pro Ser His Leu Cys Gly		
85	90	95
cga gtg ttt aaa gtg ggg gaa cct aca tac tcc tgc aga gac tgt gca		1113
Arg Val Phe Lys Val Gly Glu Pro Thr Tyr Ser Cys Arg Asp Cys Ala		
105	110	115
gtt gac ccc acc tgt gtt tta tgc atg gag tgc ttc ctg gga agt atc		1161
Val Asp Pro Thr Cys Val Leu Cys Met Glu Cys Phe Leu Gly Ser Ile		
120	125	130
cat aga gac cat cga tat agg atg acc aca tcg gga gga ggg ggc ttc		1209
His Arg Asp His Arg Tyr Arg Met Thr Thr Ser Gly Gly Gly Phe		
135	140	145
tgt gac tgt ggt gac act gag gcg tgg aaa gag gga cct tac tgc cag		1257
Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Glu Gly Pro Tyr Cys Gln		
150	155	160
aag cac aag ctc agc agc tct gaa gtt gtg gag gag gag gat cct ctt		1305
Lys His Lys Leu Ser Ser Glu Val Val Glu Glu Glu Asp Pro Leu		
165	170	175
gtg cat cta tca gaa gat gtg atc gcc aga act tac aac att ttt gct		1353
Val His Leu Ser Glu Asp Val Ile Ala Arg Thr Tyr Asn Ile Phe Ala		
185	190	195
att atg ttt cga tat gca gta gat ata ctg acc tgg gaa aaa gaa agt		1401
Ile Met Phe Arg Tyr Ala Val Asp Ile Leu Thr Trp Glu Lys Glu Ser		
200	205	210
gaa ttg cct gaa gac tta gaa gtg gca gag aag agt gac acc tac tac		1449
Glu Leu Pro Glu Asp Leu Glu Val Ala Glu Lys Ser Asp Thr Tyr Tyr		
215	220	225
tgc atg ctg ttt aat gat gag gtt cac acc tat gag caa gtc att tat		1497
Cys Met Leu Phe Asn Asp Glu Val His Thr Tyr Glu Gln Val Ile Tyr		
230	235	240
acc ctt cag aaa gct gtg aac tgt aca cag aag gaa gcc att ggc ttt		1545
Thr Leu Gln Lys Ala Val Asn Cys Thr Gln Lys Glu Ala Ile Gly Phe		
245	250	255
gca act aca gtt gat cga gat ggc cgt agg cct gtc cga tat gga gat		1593
Ala Thr Thr Val Asp Arg Asp Gly Arg Arg Pro Val Arg Tyr Gly Asp		
265	270	275
ttc cag tac tgt gat caa gca aag aca gtc att gtg agg aac acc agc		1641
Phe Gln Tyr Cys Asp Gln Ala Lys Thr Val Ile Val Arg Asn Thr Ser		
280	285	290

aga cag acc aag ccg ctc aaa gtt caa gtt atg cac tcc tcc gtg gct Arg Gln Thr Lys Pro Leu Lys Val Gln Val Met His Ser Ser Val Ala 295 300 305	1689
gct cat cag aat ttt ggt ttg aaa gct ctg tcg tgg ctg gga agt gtt Ala His Gln Asn Phe Gly Leu Lys Ala Leu Ser Trp Leu Gly Ser Val 310 315 320	1737
att gga tac tca gat ggc ctt cgc agg att ttg tgt caa gtt gga tta Ile Gly Tyr Ser Asp Gly Leu Arg Arg Ile Leu Cys Gln Val Gly Leu 325 330 335 340	1785
caa gaa ggt cca gat ggc gaa aac tct tct ctg gtc gac aga ctg atg Gln Glu Gly Pro Asp Gly Glu Asn Ser Ser Leu Val Asp Arg Leu Met 345 350 355	1833
ctt aat gat tcc aaa tta tgg aaa ggg gct agg agt gtg tat cac cag Leu Asn Asp Ser Lys Leu Trp Lys Gly Ala Arg Ser Val Tyr His Gln 360 365 370	1881
ttg ttc atg agc agc ctg ctc atg gac ctc aag tat aag aag ctg ttc Leu Phe Met Ser Ser Leu Leu Met Asp Leu Lys Tyr Lys Lys Leu Phe 375 380 385	1929
gcg ctt cga ttt gct aaa aat tac cgg cag ttg cag agg gat ttt atg Ala Leu Arg Phe Ala Lys Asn Tyr Arg Gln Leu Gln Arg Asp Phe Met 390 395 400	1977
gag gat gat cac gag cgg gca gtg tcg gtg act gct ctg tct gtc cag Glu Asp Asp His Glu Arg Ala Val Ser Val Thr Ala Leu Ser Val Gln 405 410 415 420	2025
ttc ttc acc gca ccg acg ctg gcg cga atg ctc ctc aca gaa gag aac Phe Phe Thr Ala Pro Thr Leu Ala Arg Met Leu Leu Thr Glu Glu Asn 425 430 435	2073
ctg atg acc gtt atc att aag gct ttc atg gac cat ttg aaa cac aga Leu Met Thr Val Ile Ile Lys Ala Phe Met Asp His Leu Lys His Arg 440 445 450	2121
gat gcc cag ggc aga ttc cag ttt gaa cgc tac act gcc ctc caa gcc Asp Ala Gln Gly Arg Phe Gln Phe Glu Arg Tyr Thr Ala Leu Gln Ala 455 460 465	2169
ttc aag ttc agg aga gtc cag agc ctc atc tta gat ctc aag tat gta Phe Lys Phe Arg Arg Val Gln Ser Leu Ile Leu Asp Leu Lys Tyr Val 470 475 480	2217
ttg att agc aaa cca acg gag tgg tca gat gag ctg agg cag aag ttc Leu Ile Ser Lys Pro Thr Glu Trp Ser Asp Glu Leu Arg Gln Lys Phe 485 490 495 500	2265
tta caa ggg ttc gat gcc ttc ttg gaa tta ctg aag tgc atg cag gga Leu Gln Gly Phe Asp Ala Phe Leu Glu Leu Leu Lys Cys Met Gln Gly 505 510 515	2313
atg gac ccg atc acg cgt cag gtg gga cag cac att gag atg gag cca Met Asp Pro Ile Thr Arg Gln Val Gly Gln His Ile Glu Met Glu Pro 520 525 530	2361
gag tgg gaa gca gcc ttc aca ctg cag atg aag ctg aca cac gtc atc Glu Trp Glu Ala Ala Phe Thr Leu Gln Met Lys Leu Thr His Val Ile 535 540 545	2409

tca atg gtg cag gac tgg tgt gct ctg gac gaa aaa gtg tta att gaa Ser Met Val Gln Asp Trp Cys Ala Leu Asp Glu Lys Val Leu Ile Glu 550 555 560	2457
gct tac aag aaa tgc ctg gct gtg ctg aca cag tgt cat ggc gga ttt Ala Tyr Lys Lys Cys Leu Ala Val Leu Thr Gln Cys His Gly Gly Phe 565 570 575 580	2505
act gat ggt gaa cag cca atc aca ctc agt att tgt gga cac tcg gtg Thr Asp Gly Glu Gln Pro Ile Thr Leu Ser Ile Cys Gly His Ser Val 585 590 595	2553
gaa acc atc aga tac tgt gtt tcc caa gaa aaa gtt agc att cac ctc Glu Thr Ile Arg Tyr Cys Val Ser Gln Glu Lys Val Ser Ile His Leu 600 605 610	2601
cca att tct cgc ttg ctt gca ggt ttg cat gta ttg tta agc aaa agt Pro Ile Ser Arg Leu Leu Ala Gly Leu His Val Leu Leu Ser Lys Ser 615 620 625	2649
gaa gtg gca tat aaa ttt cca gag ctc cta cct cta agt gaa ctg agc Glu Val Ala Tyr Lys Phe Pro Glu Leu Leu Pro Leu Ser Glu Leu Ser 630 635 640	2697
cca ccc atg ttg ata gaa cat cct ctt aga tgt ctt gtc tta tgt gct Pro Pro Met Leu Ile Glu His Pro Leu Arg Cys Leu Val Leu Cys Ala 645 650 655 660	2745
caa gtg cat gct ggg atg tgg aga aga aat ggc ttc tct cta gta aat Gln Val His Ala Gly Met Trp Arg Arg Asn Gly Phe Ser Leu Val Asn 665 670 675	2793
cag atc tat tac tac cat aat gtg aaa tgc agg cga gag atg ttc gac Gln Ile Tyr Tyr His Asn Val Lys Cys Arg Arg Glu Met Phe Asp 680 685 690	2841
aag gac ata gtg atg ctt cag aca ggt gtc tcc atg atg gac cca aac Lys Asp Ile Val Met Leu Gln Thr Gly Val Ser Met Met Asp Pro Asn 695 700 705	2889
cac ttc ctg atg atc atg ctc agc cgc ttt gaa ctc tat cag ctc ttc His Phe Leu Met Ile Met Leu Ser Arg Phe Glu Leu Tyr Gln Leu Phe 710 715 720	2937
agc acg cct gac tat ggg aag aga ttc agt tct gag gtt acc cat aag Ser Thr Pro Asp Tyr Gly Lys Arg Phe Ser Ser Glu Val Thr His Lys 725 730 735 740	2985
gac gtc gtt cag cag aac aac act ctg atc gaa gag atg ctc tac ctc Asp Val Val Gln Gln Asn Asn Thr Leu Ile Glu Glu Met Leu Tyr Leu 745 750 755	3033
atc atc atg ctt gtg gga gaa aga ttc aac cct ggg gtt gga cag gtg Ile Ile Met Leu Val Gly Glu Arg Phe Asn Pro Gly Val Gly Gln Val 760 765 770	3081
gct gcc aca gat gaa atc aag agg gag att atc cat cag ttg agc atc Ala Ala Thr Asp Glu Ile Lys Arg Glu Ile Ile His Gln Leu Ser Ile 775 780 785	3129
aag cct atg gct cac agt gag ctg gtg aag tct ctg cct gaa gat gag Lys Pro Met Ala His Ser Glu Leu Val Lys Ser Leu Pro Glu Asp Glu 790 795 800	3177

aac aag gag acc ggc atg gag agc gtc atc gag tcc gtt gca cat ttc Asn Lys Glu Thr Gly Met Glu Ser Val Ile Glu Ser Val Ala His Phe 805 810 815 820	3225
aag aaa cct ggg ctc aca ggg cga ggc atg tat gag ctg aag cca gag Lys Lys Pro Gly Leu Thr Gly Arg Gly Met Tyr Glu Leu Lys Pro Glu 825 830 835	3273
tgt gcc aaa gag ttc aac ctg tat ttt tat cat ttc tcc agg gca gag Cys Ala Lys Glu Phe Asn Leu Tyr Phe Tyr His Phe Ser Arg Ala Glu 840 845 850	3321
cag tcc aag gca gag gaa gct cag cgg aaa ttg aaa aga gaa aat aaa Gln Ser Lys Ala Glu Glu Ala Gln Arg Lys Leu Lys Arg Glu Asn Lys 855 860 865	3369
gaa gat aca gca ctc cct cct ccg gct ttg cca ccg ttc tgc cct ttg Glu Asp Thr Ala Leu Pro Pro Ala Leu Pro Pro Phe Cys Pro Leu 870 875 880	3417
ttc gcg agt ctg gtt aac atc ttg cag tgt gac gtc atg ctg tac atc Phe Ala Ser Leu Val Asn Ile Leu Gln Cys Asp Val Met Leu Tyr Ile 885 890 895 900	3465
atg gga acg atc ctg cag tgg gct gta gag cat cac ggg tct gcc tgg Met Gly Thr Ile Leu Gln Trp Ala Val Glu His His Gly Ser Ala Trp 905 910 915	3513
tca gag tcc atg cta cag agg gtg ctg cat ttg atc ggg atg gct ctc Ser Glu Ser Met Leu Gln Arg Val Leu His Leu Ile Gly Met Ala Leu 920 925 930	3561
cag gaa gag aag cac cac ttg gag aac gcc gtg gaa ggg cac gtg cag Gln Glu Lys His His Leu Glu Asn Ala Val Glu Gly His Val Gln 935 940 945	3609
acc ttc acc ttc aca cag aag att tca aag cct ggt gat gca cca cat Thr Phe Thr Phe Thr Gln Lys Ile Ser Lys Pro Gly Asp Ala Pro His 950 955 960	3657
aac tcc ccg agc atc cta gct atg ctg gag acc ttg cag aac gcc ccc Asn Ser Pro Ser Ile Leu Ala Met Leu Glu Thr Leu Gln Asn Ala Pro 965 970 975 980	3705
tcc ctg gaa gcc cac aag gac atg atc agg tgg ttg cta aag atg ttt Ser Leu Glu Ala His Lys Asp Met Ile Arg Trp Leu Leu Lys Met Phe 985 990 995	3753
aat gca att aag aag ata aga gag tgt tca tcc agc agc cct gtg gcc Asn Ala Ile Lys Lys Ile Arg Glu Cys Ser Ser Ser Pro Val Ala 1000 1005 1010	3801
gag gcg gag gga acc ata atg gag gag agc tca aga gac aag gac aaa Glu Ala Glu Gly Thr Ile Met Glu Glu Ser Ser Arg Asp Lys Asp Lys 1015 1020 1025	3849
gca gag agg aaa aga aaa gcc gag atc gcc aga ctg cgc cgq gag aag Ala Glu Arg Lys Arg Lys Ala Glu Ile Ala Arg Leu Arg Arg Glu Lys 1030 1035 1040	3897
atc atg gcc cag atg tct gag atg cag cgq cac ttc att gac gaa aac Ile Met Ala Gln Met Ser Glu Met Gln Arg His Phe Ile Asp Glu Asn 1045 1050 1055 1060	3945

aaa gag ctc ttc cag cag acc cta gag ctg gac acc tct gcc tct gcc Lys Glu Leu Phe Gln Gln Thr Leu Glu Leu Asp Thr Ser Ala Ser Ala 1065 1070 1075	3993
act ctt gac agc agc cct ccc gtt tca gac gca gct ctt aca gca ctg Thr Leu Asp Ser Ser Pro Pro Val Ser Asp Ala Ala Leu Thr Ala Leu 1080 1085 1090	4041
ggc cca gca cag aca cag gtc cct gaa ccg aga cag ttt gtc acc tgt Gly Pro Ala Gln Thr Gln Val Pro Glu Pro Arg Gln Phe Val Thr Cys 1095 1100 1105	4089
ata tta tgt caa gag gag caa gag gtg act gtg gga agc agg gcg atg Ile Leu Cys Gln Glu Glu Val Thr Val Gly Ser Arg Ala Met 1110 1115 1120	4137
gtc ttg gca gcg ttt gtt cag agg tca acg gtt ctg tca aaa gac agg Val Leu Ala Ala Phe Val Gln Arg Ser Thr Val Leu Ser Lys Asp Arg 1125 1130 1135 1140	4185
acg aaa acc atc gcg gac cca gaa aaa tat gat cca tta ttc atg cac Thr Lys Thr Ile Ala Asp Pro Glu Lys Tyr Asp Pro Leu Phe Met His 1145 1150 1155	4233
ccc gat ctg tct tgt ggg aca cac act ggc agc tgt ggg cac gtt atg Pro Asp Leu Ser Cys Gly Thr His Thr Gly Ser Cys Gly His Val Met 1160 1165 1170	4281
cat gcc cat tgt tgg caa agg tat ttt gat tcc gtt caa gcc aag gag His Ala His Cys Trp Gln Arg Tyr Phe Asp Ser Val Gln Ala Lys Glu 1175 1180 1185	4329
cag cga agg cag cag cgg ctg cgc ttg cac act agc tac gat gta gag Gln Arg Arg Gln Gln Arg Leu Arg Leu His Thr Ser Tyr Asp Val Glu 1190 1195 1200	4377
aat ggc gag ttc ctc tgc ccg ctc tgt gag tgc ctg agc aac acg gtg Asn Gly Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu Ser Asn Thr Val 1205 1210 1215 1220	4425
atc ccc ctg ctg ctt cct ccc agg agc atc ctc agc agg agg tta aat Ile Pro Leu Leu Pro Pro Arg Ser Ile Leu Ser Arg Arg Leu Asn 1225 1230 1235	4473
ttt tca gac caa cca gat ctg gca cag tgg acg aga gca gta aca cag Phe Ser Asp Gln Pro Asp Leu Ala Gln Trp Thr Arg Ala Val Thr Gln 1240 1245 1250	4521
cag ata aag gtg gtc cag atg ctg agg aga aag cac aat gct gct gac Gln Ile Lys Val Val Gln Met Leu Arg Arg Lys His Asn Ala Ala Asp 1255 1260 1265	4569
acg tct tct tca gag gac aca gaa gcc atg aat ata ata ccg atc ccc Thr Ser Ser Ser Glu Asp Thr Glu Ala Met Asn Ile Ile Pro Ile Pro 1270 1275 1280	4617
gaa ggc ttc agg cct gat ttt tat cct agg aac cca tat tct gat agc Glu Gly Phe Arg Pro Asp Phe Tyr Pro Arg Asn Pro Tyr Ser Asp Ser 1285 1290 1295 1300	4665
ata aaa gaa atg tta acg aca ttt gga acg gct gct tac aag gtg gga Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Ala Tyr Lys Val Gly 1305 1310 1315	4713

ctg aag gtt cat cct aat gaa ggt gac ccc cgt gtg ccc atc ctg tgc Leu Lys Val His Pro Asn Glu Gly Asp Pro Arg Val Pro Ile Leu Cys 1320 1325 1330	4761
tgg ggg acc tgt gca tac acc atc cag agc ata gaa aga att ttg agt Trp Gly Thr Cys Ala Tyr Thr Ile Gln Ser Ile Glu Arg Ile Leu Ser 1335 1340 1345	4809
gat gag gag aag cct gtt ttt gga cct ctg cct tgt aga ctg gac gac Asp Glu Glu Lys Pro Val Phe Gly Pro Leu Pro Cys Arg Leu Asp Asp 1350 1355 1360	4857
tgt ctc agg tcg tta aca cgg ttt gca gca cat tgg aca gtg gcg Cys Leu Arg Ser Leu Thr Arg Phe Ala Ala His Trp Thr Val Ala 1365 1370 1375 1380	4905
tta ctt cct gtg gta caa gga cac ttc tgt aaa ctc ttt gca tcc ttg Leu Leu Pro Val Val Gln Gly His Phe Cys Lys Leu Phe Ala Ser Leu 1385 1390 1395	4953
gtg cct agt gac agc tat gaa gac ctc ccg tgc ata cta gac atc gac Val Pro Ser Asp Ser Tyr Glu Asp Leu Pro Cys Ile Leu Asp Ile Asp 1400 1405 1410	5001
atg ttt cac ttg ctg gtg ggc ctg gtg ctc gct ttc cca gct ctg cag Met Phe His Leu Leu Val Gly Leu Val Leu Ala Phe Pro Ala Leu Gln 1415 1420 1425	5049
tgt cag gat ttt tca gga agc agc ctg gcc act ggg gac ctg cac atc Cys Gln Asp Phe Ser Gly Ser Ser Leu Ala Thr Gly Asp Leu His Ile 1430 1435 1440	5097
ttc cac ttg gtt acc atg gca cac atc gta cag atc tta ctt acc tca Phe His Leu Val Thr Met Ala His Ile Val Gln Ile Leu Leu Thr Ser 1445 1450 1455 1460	5145
tgt aca gaa gag aat ggc atg gat caa gag aat ccc act ggg gaa gaa Cys Thr Glu Glu Asn Gly Met Asp Gln Glu Asn Pro Thr Gly Glu Glu 1465 1470 1475	5193
gaa ctg gcc att ctc tct ttg cac aaa aca ctt cac cag tat act gga Glu Leu Ala Ile Leu Ser Leu His Lys Thr Leu His Gln Tyr Thr Gly 1480 1485 1490	5241
agt gcc ttg aaa gaa gcc ccc tcc ggc tgg cac ctg tgg agg agc gtc Ser Ala Leu Lys Glu Ala Pro Ser Gly Trp His Leu Trp Arg Ser Val 1495 1500 1505	5289
cgg gcc gcc atc atg cct ttc ctc aag tgc tct gct ttg ttt ttc cac Arg Ala Ala Ile Met Pro Phe Leu Lys Cys Ser Ala Leu Phe Phe His 1510 1515 1520	5337
tat tta aat gga gtc ccg gcc cct cca gac ctt caa gtt tct gga aca Tyr Leu Asn Gly Val Pro Ala Pro Pro Asp Leu Gln Val Ser Gly Thr 1525 1530 1535 1540	5385
agc cat ttt gaa cac tta tgt aac tac ctt tcc cta cca acc aac ctc Ser His Phe Glu His Leu Cys Asn Tyr Leu Ser Leu Pro Thr Asn Leu 1545 1550 1555	5433
att cac ctt ttt caa gaa aac agt gac atc atg aac tcc ctg att gaa Ile His Leu Phe Gln Glu Asn Ser Asp Ile Met Asn Ser Leu Ile Glu 1560 1565 1570	5481

agt tgg tgc cag aac agt gaa gtt aaa cgg tat cta aat ggc gag aga Ser Trp Cys Gln Asn Ser Glu Val Lys Arg Tyr Leu Asn Gly Glu Arg	5529
1575 1580 1585	
gga gcg ata agc tac ccc aga gga gct aac aaa ctg ata gac ctt cca Gly Ala Ile Ser Tyr Pro Arg Gly Ala Asn Lys Leu Ile Asp Leu Pro	5577
1590 1595 1600	
gag gat tac agc agc ctc att aac caa gca tcc aat ttc tcg tgc ccc Glu Asp Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn Phe Ser Cys Pro	5625
1605 1610 1615 1620	
aaa tca ggt ggc gac aag agc aga gct cct act ctg tgc ctc gtg tgt Lys Ser Gly Asp Lys Ser Arg Ala Pro Thr Leu Cys Leu Val Cys	5673
1625 1630 1635	
ggg agt ctc ctc tgc tct cag agt tac tgc tgc caa gct gag ctg gag Gly Ser Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln Ala Glu Leu Glu	5721
1640 1645 1650	
ggt gag gac gtc gga gcc tgc aca gca cac acc tac tcc tgc ggc tcc Gly Glu Asp Val Gly Ala Cys Thr Ala His Thr Tyr Ser Cys Gly Ser	5769
1655 1660 1665	
ggg gcc ggc atc ttc ctg aga gtg cgg gaa tgt cag gtg cta ttt tta Gly Ala Gly Ile Phe Leu Arg Val Arg Glu Cys Gln Val Leu Phe Leu	5817
1670 1675 1680	
gct ggc aaa acc aaa gga tgt ttt tat tct cct cct tac ctt gac gac Ala Gly Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro Tyr Leu Asp Asp	5865
1685 1690 1695 1700	
tat gga gag acc gac cag gga ctc aga cga gga aat cct tta cat tta Tyr Gly Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn Pro Leu His Leu	5913
1705 1710 1715	
tgc caa gag cgg ttt cga aag atc cag aag ctc tgg cag cag cat agt Cys Gln Glu Arg Phe Arg Lys Ile Gln Lys Leu Trp Gln Gln His Ser	5961
1720 1725 1730	
atc aca gag gag atc gga cac gcg cag gag gct aac cag acc ctg gtc Ile Thr Glu Ile Gly His Ala Gln Glu Ala Asn Gln Thr Leu Val	6009
1735 1740 1745	
gga att gac tgg cag cat tta taatcgctcc tctactaaaa acttgacttg Gly Ile Asp Trp Gln His Leu	6060
1750 1755	
gagtttgta acacagctgg cttttccag	6089
<210> 6	
<211> 1755	
<212> PRT	
<213> Mouse	
<400> 6	
Met Ala Ser Glu Met Glu Pro Glu Val Gln Ala Ile Asp Arg Ser Leu	
1 5 10 15	
Leu Glu Cys Ser Ala Glu Glu Ile Ala Gly Arg Trp Leu Gln Ala Thr	
20 25 30	

Asp Leu Asn Arg Glu Val Tyr Gln His Leu Ala His Cys Val Pro Lys
35 40 45

Ile Tyr Cys Arg Gly Pro Asn Pro Phe Pro Gln Lys Glu Asp Thr Leu
50 55 60

Ala Gln His Ile Leu Leu Gly Pro Met Glu Trp Tyr Ile Cys Ala Glu
65 70 75 80

Asp Pro Ala Leu Gly Phe Pro Lys Leu Glu Gln Ala Asn Lys Pro Ser
85 90 95

His Leu Cys Gly Arg Val Phe Lys Val Gly Glu Pro Thr Tyr Ser Cys
100 105 110

Arg Asp Cys Ala Val Asp Pro Thr Cys Val Leu Cys Met Glu Cys Phe
115 120 125

Leu Gly Ser Ile His Arg Asp His Arg Tyr Arg Met Thr Thr Ser Gly
130 135 140

Gly Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Glu Gly
145 150 155 160

Pro Tyr Cys Gln Lys His Lys Leu Ser Ser Ser Glu Val Val Glu Glu
165 170 175

Glu Asp Pro Leu Val His Leu Ser Glu Asp Val Ile Ala Arg Thr Tyr
180 185 190

Asn Ile Phe Ala Ile Met Phe Arg Tyr Ala Val Asp Ile Leu Thr Trp
195 200 205

Glu Lys Glu Ser Glu Leu Pro Glu Asp Leu Glu Val Ala Glu Lys Ser
210 215 220

Asp Thr Tyr Tyr Cys Met Leu Phe Asn Asp Glu Val His Thr Tyr Glu
225 230 235 240

Gln Val Ile Tyr Thr Leu Gln Lys Ala Val Asn Cys Thr Gln Lys Glu
245 250 255

Ala Ile Gly Phe Ala Thr Thr Val Asp Arg Asp Gly Arg Arg Pro Val
260 265 270

Arg Tyr Gly Asp Phe Gln Tyr Cys Asp Gln Ala Lys Thr Val Ile Val
275 280 285

Arg Asn Thr Ser Arg Gln Thr Lys Pro Leu Lys Val Gln Val Met His
290 295 300

Ser Ser Val Ala Ala His Gln Asn Phe Gly Leu Lys Ala Leu Ser Trp
305 310 315 320

Leu Gly Ser Val Ile Gly Tyr Ser Asp Gly Leu Arg Arg Ile Leu Cys
325 330 335

Gln Val Gly Leu Gln Glu Gly Pro Asp Gly Glu Asn Ser Ser Leu Val
340 345 350

Asp Arg Leu Met Leu Asn Asp Ser Lys Leu Trp Lys Gly Ala Arg Ser
355 360 365

Val Tyr His Gln Leu Phe Met Ser Ser Leu Leu Met Asp Leu Lys Tyr
370 375 380

Lys Lys Leu Phe Ala Leu Arg Phe Ala Lys Asn Tyr Arg Gln Leu Gln
385 390 395 400

Arg Asp Phe Met Glu Asp Asp His Glu Arg Ala Val Ser Val Thr Ala
405 410 415

Leu Ser Val Gln Phe Phe Thr Ala Pro Thr Leu Ala Arg Met Leu Leu
420 425 430

Thr Glu Glu Asn Leu Met Thr Val Ile Ile Lys Ala Phe Met Asp His
435 440 445

Leu Lys His Arg Asp Ala Gln Gly Arg Phe Gln Phe Glu Arg Tyr Thr
450 455 460

Ala Leu Gln Ala Phe Lys Phe Arg Arg Val Gln Ser Leu Ile Leu Asp
465 470 475 480

Leu Lys Tyr Val Leu Ile Ser Lys Pro Thr Glu Trp Ser Asp Glu Leu
485 490 495

Arg Gln Lys Phe Leu Gln Gly Phe Asp Ala Phe Leu Glu Leu Lys
500 505 510

Cys Met Gln Gly Met Asp Pro Ile Thr Arg Gln Val Gly Gln His Ile
515 520 525

Glu Met Glu Pro Glu Trp Glu Ala Ala Phe Thr Leu Gln Met Lys Leu
530 535 540

Thr His Val Ile Ser Met Val Gln Asp Trp Cys Ala Leu Asp Glu Lys
545 550 555 560

Val Leu Ile Glu Ala Tyr Lys Lys Cys Leu Ala Val Leu Thr Gln Cys
565 570 575

His Gly Gly Phe Thr Asp Gly Glu Gln Pro Ile Thr Leu Ser Ile Cys
580 585 590

Gly His Ser Val Glu Thr Ile Arg Tyr Cys Val Ser Gln Glu Lys Val
595 600 605

Ser Ile His Leu Pro Ile Ser Arg Leu Leu Ala Gly Leu His Val Leu
610 615 620

Leu Ser Lys Ser Glu Val Ala Tyr Lys Phe Pro Glu Leu Leu Pro Leu
625 630 635 640

Ser Glu Leu Ser Pro Pro Met Leu Ile Glu His Pro Leu Arg Cys Leu
645 650 655

Val Leu Cys Ala Gln Val His Ala Gly Met Trp Arg Arg Asn Gly Phe
660 665 670

Ser Leu Val Asn Gln Ile Tyr Tyr Tyr His Asn Val Lys Cys Arg Arg
675 680 685

Glu Met Phe Asp Lys Asp Ile Val Met Leu Gln Thr Gly Val Ser Met
690 695 700

Met Asp Pro Asn His Phe Leu Met Ile Met Leu Ser Arg Phe Glu Leu
705 710 715 720

Tyr Gln Leu Phe Ser Thr Pro Asp Tyr Gly Lys Arg Phe Ser Ser Glu
725 730 735

Val Thr His Lys Asp Val Val Gln Gln Asn Asn Thr Leu Ile Glu Glu
740 745 750

Met Leu Tyr Leu Ile Ile Met Leu Val Gly Glu Arg Phe Asn Pro Gly
755 760 765

Val Gly Gln Val Ala Ala Thr Asp Glu Ile Lys Arg Glu Ile Ile His
770 775 780

Gln Leu Ser Ile Lys Pro Met Ala His Ser Glu Leu Val Lys Ser Leu
785 790 795 800

Pro Glu Asp Glu Asn Lys Glu Thr Gly Met Glu Ser Val Ile Glu Ser
805 810 815

Val Ala His Phe Lys Lys Pro Gly Leu Thr Gly Arg Gly Met Tyr Glu
820 825 830

Leu Lys Pro Glu Cys Ala Lys Glu Phe Asn Leu Tyr Phe Tyr His Phe
835 840 845

Ser Arg Ala Glu Gln Ser Lys Ala Glu Glu Ala Gln Arg Lys Leu Lys
850 855 860

Arg Glu Asn Lys Glu Asp Thr Ala Leu Pro Pro Pro Ala Leu Pro Pro
865 870 875 880

Phe Cys Pro Leu Phe Ala Ser Leu Val Asn Ile Leu Gln Cys Asp Val
885 890 895

Met Leu Tyr Ile Met Gly Thr Ile Leu Gln Trp Ala Val Glu His His
900 905 910

Gly Ser Ala Trp Ser Glu Ser Met Leu Gln Arg Val Leu His Leu Ile
915 920 925

Gly Met Ala Leu Gln Glu Glu Lys His His Leu Glu Asn Ala Val Glu
930 935 940

Gly His Val Gln Thr Phe Thr Phe Thr Gln Lys Ile Ser Lys Pro Gly
945 950 955 960

Asp Ala Pro His Asn Ser Pro Ser Ile Leu Ala Met Leu Glu Thr Leu
965 970 975

Gln Asn Ala Pro Ser Leu Glu Ala His Lys Asp Met Ile Arg Trp Leu
980 985 990

Leu Lys Met Phe Asn Ala Ile Lys Lys Ile Arg Glu Cys Ser Ser Ser
995 1000 1005

Ser Pro Val Ala Glu Ala Glu Gly Thr Ile Met Glu Glu Ser Ser Arg
1010 1015 1020

Asp Lys Asp Lys Ala Glu Arg Lys Arg Lys Ala Glu Ile Ala Arg Leu
1025 1030 1035 1040

Arg Arg Glu Lys Ile Met Ala Gln Met Ser Glu Met Gln Arg His Phe
1045 1050 1055

Ile Asp Glu Asn Lys Glu Leu Phe Gln Gln Thr Leu Glu Leu Asp Thr
1060 1065 1070

Ser Ala Ser Ala Thr Leu Asp Ser Ser Pro Pro Val Ser Asp Ala Ala
1075 1080 1085

Leu Thr Ala Leu Gly Pro Ala Gln Thr Gln Val Pro Glu Pro Arg Gln
1090 1095 1100

Phe Val Thr Cys Ile Leu Cys Gln Glu Glu Gln Glu Val Thr Val Gly
105 1110 1115 1120

Ser Arg Ala Met Val Leu Ala Ala Phe Val Gln Arg Ser Thr Val Leu
1125 1130 1135

Ser Lys Asp Arg Thr Lys Thr Ile Ala Asp Pro Glu Lys Tyr Asp Pro
1140 1145 1150

Leu Phe Met His Pro Asp Leu Ser Cys Gly Thr His Thr Gly Ser Cys
1155 1160 1165

Gly His Val Met His Ala His Cys Trp Gln Arg Tyr Phe Asp Ser Val
1170 1175 1180

Gln Ala Lys Glu Gln Arg Arg Gln Gln Arg Leu Arg Leu His Thr Ser
185 1190 1195 1200

Tyr Asp Val Glu Asn Gly Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu
1205 1210 1215

Ser Asn Thr Val Ile Pro Leu Leu Leu Pro Pro Arg Ser Ile Leu Ser
1220 1225 1230

Arg Arg Leu Asn Phe Ser Asp Gln Pro Asp Leu Ala Gln Trp Thr Arg
1235 1240 1245

Ala Val Thr Gln Gln Ile Lys Val Val Gln Met Leu Arg Arg Lys His
1250 1255 1260

Asn Ala Ala Asp Thr Ser Ser Ser Glu Asp Thr Glu Ala Met Asn Ile
265 1270 1275 1280

Ile Pro Ile Pro Glu Gly Phe Arg Pro Asp Phe Tyr Pro Arg Asn Pro
1285 1290 1295

Tyr Ser Asp Ser Ile Lys Glu Met Leu Thr Thr Phe Gly Thr Ala Ala
1300 1305 1310

Tyr Lys Val Gly Leu Lys Val His Pro Asn Glu Gly Asp Pro Arg Val
1315 1320 1325

Pro Ile Leu Cys Trp Gly Thr Cys Ala Tyr Thr Ile Gln Ser Ile Glu
1330 1335 1340

Arg Ile Leu Ser Asp Glu Glu Lys Pro Val Phe Gly Pro Leu Pro Cys
345 1350 1355 1360

Arg Leu Asp Asp Cys Leu Arg Ser Leu Thr Arg Phe Ala Ala Ala His
1365 1370 1375

Trp Thr Val Ala Leu Leu Pro Val Val Gln Gly His Phe Cys Lys Leu
1380 1385 1390

Phe Ala Ser Leu Val Pro Ser Asp Ser Tyr Glu Asp Leu Pro Cys Ile
1395 1400 1405

Leu Asp Ile Asp Met Phe His Leu Leu Val Gly Leu Val Leu Ala Phe
1410 1415 1420

Pro Ala Leu Gln Cys Gln Asp Phe Ser Gly Ser Ser Leu Ala Thr Gly
425 1430 1435 1440

Asp Leu His Ile Phe His Leu Val Thr Met Ala His Ile Val Gln Ile
1445 1450 1455

Leu Leu Thr Ser Cys Thr Glu Glu Asn Gly Met Asp Gln Glu Asn Pro
1460 1465 1470

Thr Gly Glu Glu Leu Ala Ile Leu Ser Leu His Lys Thr Leu His
1475 1480 1485

Gln Tyr Thr Gly Ser Ala Leu Lys Glu Ala Pro Ser Gly Trp His Leu
1490 1495 1500

Trp Arg Ser Val Arg Ala Ala Ile Met Pro Phe Leu Lys Cys Ser Ala
505 1510 1515 1520

Leu Phe Phe His Tyr Leu Asn Gly Val Pro Ala Pro Pro Asp Leu Gln
1525 1530 1535

Val Ser Gly Thr Ser His Phe Glu His Leu Cys Asn Tyr Leu Ser Leu
1540 1545 1550

Pro Thr Asn Leu Ile His Leu Phe Gln Glu Asn Ser Asp Ile Met Asn
1555 1560 1565

Ser Leu Ile Glu Ser Trp Cys Gln Asn Ser Glu Val Lys Arg Tyr Leu
1570 1575 1580

Asn Gly Glu Arg Gly Ala Ile Ser Tyr Pro Arg Gly Ala Asn Lys Leu
585 1590 1595 1600

Ile Asp Leu Pro Glu Asp Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn
1605 1610 1615

Phe Ser Cys Pro Lys Ser Gly Gly Asp Lys Ser Arg Ala Pro Thr Leu
1620 1625 1630

Cys Leu Val Cys Gly Ser Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln
1635 1640 1645

Ala Glu Leu Glu Gly Glu Asp Val Gly Ala Cys Thr Ala His Thr Tyr
1650 1655 1660

Ser Cys Gly Ser Gly Ala Gly Ile Phe Leu Arg Val Arg Glu Cys Gln
665 1670 1675 1680

Val Leu Phe Leu Ala Gly Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro
1685 1690 1695

Tyr Leu Asp Asp Tyr Gly Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn
1700 1705 1710

Pro Leu His Leu Cys Gln Glu Arg Phe Arg Lys Ile Gln Lys Leu Trp
1715 1720 1725

Gln Gln His Ser Ile Thr Glu Glu Ile Gly His Ala Gln Glu Ala Asn
1730 1735 1740

Gln Thr Leu Val Gly Ile Asp Trp Gln His Leu
745 1750 1755

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer
-2282-91

<400> 7
ctgctcgagt ctgcgtcaaa c 21

<210> 8
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer -
2385-35

<400> 8
tctcgtatcg ttgcagccctt gcta 24

<210> 9
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 2282-94

<400> 9
gtatgaacctt gccgaggctt tta 23

<210> 10
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 2294-37

<400> 10
caataactttc ccagccctca gaa 23

<210> 11
<211> 18
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 2380-88

<400> 11

atggcgtcgc tagagccaa

18

<210> 12

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 2378-32

<400> 12

caaagcggtt gagcatgatc atc

23

<210> 13

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 2381-48

<400> 13

tgaacagcca atcacactaa gca

23

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 2385-94

<400> 14

ttataaatgc caaatgccaa

20

<210> 15

<211> 1757

<212> PRT

<213> Mouse

<400> 15

Met Ala Asp Glu Glu Met Asp Gly Ala Glu Arg Met Asp Val Ser Pro
1 5 10 15

Glu Pro Pro Leu Ala Pro Gln Arg Pro Ala Ser Trp Trp Asp Gln Gln
20 25 30

Val Asp Phe Tyr Thr Ala Phe Leu His His Leu Ala Gln Leu Val Pro
35 40 45

Glu Ile Tyr Phe Ala Glu Met Asp Pro Asp Leu Glu Lys Gln Glu Glu
50 55 60

Ser Val Gln Met Ser Ile Leu Thr Pro Leu Glu Trp Tyr Leu Phe Gly
65 70 75 80

Glu Asp Pro Asp Ile Cys Leu Glu Lys Leu Lys His Ser Gly Ala Phe
85 90 95

Gln Leu Cys Gly Lys Val Phe Lys Ser Gly Glu Thr Thr Tyr Ser Cys
100 105 110

Arg Asp Cys Ala Ile Asp Pro Thr Cys Val Leu Cys Met Asp Cys Phe
115 120 125

Gln Ser Ser Val His Lys Asn His Arg Tyr Lys Met His Thr Ser Thr
130 135 140

Gly Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu Ala Trp Lys Thr Gly
145 150 155 160

Pro Phe Cys Val Asp His Glu Pro Gly Arg Ala Gly Thr Thr Lys Glu
165 170 175

Ser Leu His Cys Pro Leu Asn Glu Glu Val Ile Ala Gln Ala Arg Arg
180 185 190

Ile Phe Pro Ser Val Ile Lys Tyr Ile Val Glu Met Thr Ile Trp Glu
195 200 205

Glu Glu Lys Glu Leu Pro Pro Glu Leu Gln Ile Arg Glu Lys Asn Glu
210 215 220

Arg Tyr Tyr Cys Val Leu Phe Asn Asp Glu His His Ser Tyr Asp His
225 230 235 240

Val Ile Tyr Ser Leu Gln Arg Ala Leu Asp Cys Glu Leu Ala Glu Ala
245 250 255

Gln Leu His Thr Thr Ala Ile Asp Lys Glu Gly Arg Arg Ala Val Lys
260 265 270

Ala Gly Val Tyr Ala Thr Cys Gln Glu Ala Lys Glu Asp Ile Lys Ser
275 280 285

His Ser Glu Asn Val Ser Gln His Pro Leu His Val Glu Val Leu His
290 295 300

Ser Val Val Met Ala His Gln Lys Phe Ala Leu Arg Leu Gly Ser Trp
305 310 315 320

Met Asn Lys Ile Met Ser Tyr Ser Ser Asp Phe Arg Gln Ile Phe Cys
325 330 335

Gln Ala Cys Leu Val Glu Glu Pro Gly Ser Glu Asn Pro Cys Leu Ile
340 345 350

Ser Arg Leu Met Leu Trp Asp Ala Lys Leu Tyr Lys Gly Ala Arg Lys
355 360 365

Ile Leu His Glu Leu Ile Phe Ser Ser Phe Phe Met Glu Met Glu Tyr
370 375 380

Lys Lys Leu Phe Ala Met Glu Phe Val Lys Tyr Tyr Lys Gln Leu Gln
385 390 395 400

Lys Glu Tyr Ile Ser Asp Asp His Glu Arg Ser Ile Ser Ile Thr Ala
405 410 415

Leu Ser Val Gln Met Leu Thr Val Pro Thr Leu Ala Arg His Leu Ile
420 425 430

Glu Glu Gln Asn Val Ile Ser Val Ile Thr Glu Thr Leu Leu Glu Val
435 440 445

Leu Pro Glu Tyr Leu Asp Arg Asn Asn Lys Phe Asn Phe Gln Gly Tyr
450 455 460

Ser Gln Asp Lys Leu Gly Arg Val Tyr Ala Val Ile Cys Asp Leu Lys
465 470 475 480

Tyr Ile Leu Ile Ser Lys Pro Val Ile Trp Thr Glu Arg Leu Arg Ala
485 490 495

Gln Phe Leu Glu Gly Phe Arg Ser Phe Leu Lys Ile Leu Thr Cys Met
500 505 510

Gln Gly Met Glu Glu Ile Arg Arg Gln Val Gly Gln His Ile Glu Val
515 520 525

Asp Pro Asp Trp Glu Ala Ala Ile Ala Ile Gln Met Gln Leu Lys Asn
530 535 540

Ile Leu Leu Met Phe Gln Glu Trp Cys Ala Cys Asp Glu Asp Leu Leu
545 550 555 560

Leu Val Ala Tyr Lys Glu Cys His Lys Ala Val Met Arg Cys Ser Thr
565 570 575

Asn Phe Met Ser Ser Thr Lys Thr Val Val Gln Leu Cys Gly His Ser
580 585 590

Leu Glu Thr Lys Ser Tyr Lys Val Ser Glu Asp Leu Val Ser Ile His
595 600 605

Leu Pro Leu Ser Arg Thr Leu Ala Gly Leu His Val Arg Leu Ser Arg
610 615 620

Leu Gly Ala Ile Ser Arg Leu His Glu Phe Val Pro Phe Asp Ser Phe
625 630 635 640

Gln Val Glu Val Leu Val Glu Tyr Pro Leu Arg Cys Leu Val Leu Val
645 650 655

Ala Gln Val Val Ala Glu Met Trp Arg Arg Asn Gly Leu Ser Leu Ile
660 665 670

Ser Gln Val Phe Tyr Tyr Gln Asp Val Lys Cys Arg Glu Glu Met Tyr
675 680 685

Asp Lys Asp Ile Ile Met Leu Gln Ile Gly Ala Ser Ile Met Asp Pro
690 695 700

Asn Lys Phe Leu Leu Leu Val Leu Gln Arg Tyr Glu Leu Thr Asp Ala
705 710 715 720

Phe Asn Lys Thr Ile Ser Thr Lys Asp Gln Asp Leu Ile Lys Gln Tyr
725 730 735

Asn Thr Leu Ile Glu Glu Met Leu Gln Val Leu Ile Tyr Ile Val Gly
740 745 750

Glu Arg Tyr Val Pro Gly Val Gly Asn Val Thr Arg Glu Glu Val Ile
755 760 765

Met Arg Glu Ile Thr His Leu Leu Cys Ile Glu Pro Met Pro His Ser
770 775 780

Ala Ile Ala Arg Asn Leu Pro Glu Asn Glu Asn Asn Glu Thr Gly Leu
785 790 795 800

Glu Asn Val Ile Asn Lys Val Ala Thr Phe Lys Lys Pro Gly Val Ser
805 810 815

Gly His Gly Val Tyr Glu Leu Lys Asp Glu Ser Leu Lys Asp Phe Asn
820 825 830

Met Tyr Phe Tyr His Tyr Ser Lys Thr Gln His Ser Lys Ala Glu His
835 840 845

Met Gln Lys Lys Arg Arg Lys Gln Glu Asn Lys Asp Glu Ala Leu Pro
850 855 860

Pro Pro Pro Pro Glu Phe Cys Pro Ala Phe Ser Lys Val Val Asn
865 870 875 880

Leu Leu Ser Cys Asp Val Met Ile Tyr Ile Leu Arg Thr Ile Phe Glu
885 890 895

Arg Ala Val Asp Thr Glu Ser Asn Leu Trp Thr Glu Gly Met Leu Gln
900 905 910

Met Ala Phe His Ile Leu Ala Leu Gly Leu Leu Glu Glu Lys Gln Gln
915 920 925

Leu Gln Lys Ala Pro Glu Glu Val Ala Phe Asp Phe Tyr His Lys
930 935 940

Ala Ser Arg Leu Gly Ser Ser Ala Met Asn Ala Gln Asn Ile Gln Met
945 950 955 960

Leu Leu Glu Arg Leu Lys Gly Ile Pro Gln Leu Glu Gly Gln Lys Asp
965 970 975

Met Ile Thr Trp Ile Leu Gln Met Phe Asp Thr Val Lys Arg Leu Arg
980 985 990

Glu Lys Ser Cys Leu Val Val Ala Thr Thr Ser Gly Leu Glu Cys Ile
995 1000 1005

Lys Ser Glu Glu Ile Thr His Asp Lys Glu Lys Ala Glu Arg Lys Arg
1010 1015 1020

Lys Ala Glu Ala Ala Arg Leu His Arg Gln Lys Ile Met Ala Gln Met
1025 1030 1035 1040

Ser Ala Leu Gln Lys Asn Phe Ile Glu Thr His Lys Leu Met Tyr Asp
1045 1050 1055

Asn Thr Ser Glu Val Thr Gly Lys Glu Asp Ser Ile Met Glu Glu Glu
1060 1065 1070

Ser Thr Ser Ala Val Ser Glu Ala Ser Arg Ile Ala Leu Gly Pro Lys
1075 1080 1085

Arg Gly Pro Ala Val Thr Glu Lys Glu Val Leu Thr Cys Ile Leu Cys
1090 1095 1100

Gln Glu Glu Gln Glu Val Lys Leu Glu Asn Asn Ala Met Val Leu Ser
1105 1110 1115 1120

Ala Cys Val Gln Lys Ser Thr Ala Leu Thr Gln His Arg Gly Lys Pro
1125 1130 1135

Val Asp His Leu Gly Glu Thr Leu Asp Pro Leu Phe Met Asp Pro Asp
1140 1145 - 1150

Leu Ala His Gly Thr Tyr Thr Gly Ser Cys Gly His Val Met His Ala
1155 1160 1165

Val Cys Trp Gln Lys Tyr Phe Glu Ala Val Gln Leu Ser Ser Gln Gln
1170 1175 1180

Arg Ile His Val Asp Leu Phe Asp Leu Glu Ser Gly Glu Tyr Leu Cys
1185 1190 1195 1200

Pro Leu Cys Lys Ser Leu Cys Asn Thr Val Ile Pro Ile Ile Pro Leu
1205 1210 1215

Gln Pro Gln Lys Ile Asn Ser Glu Asn Ala Glu Ala Leu Ala Gln Leu
1220 1225 1230

Leu Thr Leu Ala Arg Trp Ile Gln Thr Val Leu Ala Arg Ile Ser Gly
1235 1240 1245

Tyr Asn Ile Lys His Ala Lys Gly Glu Ala Pro Ala Val Pro Val Leu
1250 1255 1260

Phe Asn Gln Gly Met Gly Asp Ser Thr Phe Glu Phe His Ser Ile Leu
1265 1270 1275 1280

Ser Phe Gly Val Gln Ser Ser Val Lys Tyr Ser Asn Ser Ile Lys Glu
1285 1290 1295

Met Val Ile Leu Phe Ala Thr Thr Ile Tyr Arg Ile Gly Leu Lys Val
1300 1305 1310

Pro Pro Asp Glu Leu Asp Pro Arg Val Pro Met Met Thr Trp Ser Thr
1315 1320 1325

Cys Ala Phe Thr Ile Gln Ala Ile Glu Asn Leu Leu Gly Asp Glu Gly
1330 1335 1340

Lys Pro Leu Phe Gly Ala Leu Gln Asn Arg Gln His Ser Gly Leu Lys
1345 1350 1355 1360

Ala Leu Met Gln Phe Ala Val Ala Gln Arg Ala Thr Cys Pro Gln Val
1365 1370 1375

Leu Ile His Lys His Leu Ala Arg Leu Leu Ser Val Ile Leu Pro Asn
1380 1385 1390

Leu Gln Ser Glu Asn Thr Pro Gly Leu Leu Ser Val Asp Leu Phe His
1395 1400 1405

Val Leu Val Gly Ala Val Leu Ala Phe Pro Ser Leu Tyr Trp Asp Asp
1410 1415 1420

Thr Val Asp Leu Gln Pro Ser Pro Leu Ser Ser Ser Tyr Asn His Leu
1425 1430 1435 1440

Tyr Leu Phe His Leu Ile Thr Met Ala His Met Leu Gln Ile Leu Leu
1445 1450 1455

Thr Thr Asp Thr Asp Leu Ser Pro Gly Pro Pro Leu Ala Glu Gly Glu
1460 1465 1470

Glu Asp Ser Glu Glu Ala Arg Cys Ala Ser Ala Phe Phe Val Glu Val
1475 1480 1485

Ser Gln His Thr Asp Gly Leu Thr Gly Cys Gly Ala Pro Gly Trp Tyr
1490 1495 1500

Leu Trp Leu Ser Leu Arg Asn Gly Ile Thr Pro Tyr Leu Arg Cys Ala
1505 1510 1515 1520

Ala Leu Leu Phe His Tyr Leu Leu Gly Val Ala Pro Pro Glu Glu Leu
1525 1530 1535

Phe Ala Asn Ser Ala Glu Gly Glu Phe Ser Ala Leu Cys Ser Tyr Leu
1540 1545 1550

Ser Leu Pro Thr Asn Leu Phe Leu Leu Phe Gln Glu Tyr Trp Asp Thr
1555 1560 1565

Ile Arg Pro Leu Leu Gln Arg Trp Cys Gly Asp Pro Ala Leu Leu Lys
1570 1575 1580

Ser Leu Lys Gln Lys Ser Ala Val Val Arg Tyr Pro Arg Lys Arg Asn
1585 1590 1595 1600

Ser Leu Ile Glu Leu Pro Glu Asp Tyr Ser Cys Leu Leu Asn Gln Ala
1605 1610 1615

Ser His Phe Arg Cys Pro Arg Ser Ala Asp Asp Glu Arg Lys His Pro
1620 1625 1630

Val Leu Cys Leu Phe Cys Gly Ala Ile Leu Cys Ser Gln Asn Ile Cys
1635 1640 1645

Cys Gln Glu Ile Val Asn Gly Glu Val Gly Ala Cys Val Phe His
1650 1655 1660

Ala Leu His Cys Gly Ala Gly Val Cys Ile Phe Leu Lys Ile Arg Glu
1665 1670 1675 1680

Cys Arg Val Val Leu Val Glu Gly Lys Ala Arg Gly Cys Ala Tyr Pro
1685 1690 1695

Ala Pro Tyr Leu Asp Glu Tyr Gly Glu Thr Asp Pro Gly Leu Lys Arg
1700 1705 1710

Gly Asn Pro Leu His Leu Ser Arg Glu Arg Tyr Arg Lys Leu His Leu
1715 1720 1725

Val Trp Gln Gln His Cys Ile Ile Glu Glu Ile Ala Arg Ser Gln Glu
1730 1735 1740

Thr Asn Gln Met Leu Phe Gly Phe Asn Trp Gln Leu Leu
1745 1750 1755

<210> 16
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<400> 16
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10

<210> 17
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<400> 17
Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10 15

<210> 18
<211> 5205
<212> DNA
<213> Homo sapiens

<400> 18
atggcggacg aggaggctgg aggtactgag aggatggaaa tcagcgccga gttaccccag 60
acccttcagc gtctggcatc ttgggtggat cagcaagttt 120
catcattttgg cacaatttgtt gccagaaaatt tactttgctg aaatggaccc agacttggaa 180
aagcaggagg aaagtgtaca aatgtcaata ttcactccac tggaatggta cttatittgga 240
gaagatccag atatttgctt agagaaattt aagcacagtg gagcatttca gctttgtggg 300
agggtttca aaagtggaga gacaacctat tcttgcaggg attgtgcaat tgatccaaca 360
tgtgtactct gtatggactg cttccaggac agtgttcata aaaatcatcg ttacaagatg 420
catacttcta ctggaggagg gttctgtgac tgtggagaca cagaggcatg gaaaactggc 480
ccttttgtg taaatcatga acctggaaga gcaggtacta taaaagagaa ttcacgctgt 540
ccgttgaatg aagaggtaat tgtccaagcc aggaaaaat ttccttcagt gataaaaat 600
gtcgttagaaa tgactatatg ggaagaggaa aaagaactgc ctcctgaact ccagataagg 660
knryycvndh hsydhgcat atacagccta caaagagctc ttgactgtga gctcgccagag 720
gcccagttgc ataccactgc cattgacaaa gagggtcgtc gggctgttaa agcgggagct 780
tatgctgctt gccaggaagc aaaggaagat ataaagagtc attcagaaaa tgtctctcaa 840

catccacttc atgtagaagt attacactca gagattatgg ctcatcagaa atttgcttg 900
cgtcttggtt cctggatgaa caaaattatg agctattcaa gtgactttag gcagatctt 960
tgccaagcat gccttagaga agaacctgac tcggagaatc cctgtctcat aagcaggta 1020
atgcttggg atgcaaagct ttataaaggt gcccgttaaga tccttcatga attgatctc 1080
agcagtttt ttagggagat ggaatacataaa aaactcttg ctatggatt tgtgaagtt 1140
tataaacaac tgcagaaaga atatatcagt gatgatcatg acagaagtt ctctataact 1200
gcactttcag ttcagatgtt tactgttctt actctggctc gacatcttat tgaagagcag 1260
aatgttatct ctgtcattac tgaaaactctg ctagaagttt tacctgagta cttggacagg 1320
aacaataaaat tcaacttcca gggtatagc caggacaaat tggaagagt atatgcagta 1380
atatgtgacc taaagtatat cctgatcagc aaacccacaa tatggacaga aagattaaga 1440
atgcagttcc ttgaagggtt tcgatcttt ttgaagattc ttacctgtat gcagggaaatg 1500
gaagaaatcc gaagacaggt tggcaacac attgaagtgg atcctgattt ggaggctgcc 1560
attgctatac agatgcaatt gaagaatatt ttactcatgt tccaagagtg gtgtgcttgt 1620
gatgaagaac tcttacttgt ggcttataaa gaatgtcaca aagctgtat gaggtgcagt 1680
accagtttca tatcttagtag caagacagta gtacaatcgt gtggacatag tttggaaaca 1740
aagtcctaca gagtatctga ggatcttcta agcatacatc tgccactctc taggaccctt 1800
gctggcttc atgtacgtt aagcaggctg ggtgctgtt caagactgca tgaatttgt 1860
tctttgagg actttcaagt agaggtacta gtggaaatatc cttacgttg tctgggttt 1920
gttccccagg ttgttgcgtga gatgtggcgaa agaaatggac tgtctttat tagccaggtg 1980
tttattacc aagatgttaa gtgcagagaa gaaatgtatg ataaagatat catcatgctt 2040
cagattggtg catcttaat ggatccaaat aagttcttgt tactggtaat tcagaggtat 2100
gaacttgccg aggctttaa caagaccata tctacaaaag accaggatt gattaaacaa 2160
tataatacac taatagaaga aatgcttcag gtcctcatct atattgtggg tgagcgttat 2220
gtacctggag tggaaatgt gaccaaagaa gaggtcacaa tgagagaaat cattcacttg 2280
ctttgcattt aacccatgcc acacagtgcc attgccaaaa atttacctga gaatgaaaat 2340
aatgaaaactg gcttagagaa tgtcataaac aaagtggcca catttaagaa accaggtgt 2400
tcaggccatg gagtttatga actaaaagat gaatcactga aagacttcaa tatgtacttt 2460
tatcattact ccaaaaccca gcatacgtcaag gctgaacata tgcagaagaa aaggagaaaa 2520
caagaaaaca aagatgtaaatcatttgcgtt ccaccacccctc ctgaattctg ccctgcttc 2580
agcaaagtga ttaacccttctt caactgtatgtt acattctcag gaccgtat 2640
gagcggccaa tagacacaga ttcttaacttg tggaccgaag ggtatgttcca aatggcttt 2700
catattctgg cattgggtttt actagaagag aagcaacagc ttcaaaaagc tcctgaagaa 2760

gaagtaacat ttgacttttcaataaggct tcaagattgg gaagttcagc catgaatata 2820
caaatgcattt tgaaaaaact caaaggaatt ccccgatgt aaggccagaa ggacatgata 2880
acgtggatac ttcatgttt tgacacagt aagcgattaa gagaaaaatc ttgttaatt 2940
gtagcaacca catcaggatc ggaatctatt aagaatgt aagattactca tgataaagaa 3000
aaagcagaac gaaaaagaaa agctgaagct gcttaggtac atcgccagaa gatcatggct 3060
cagatgtctg ctttacagaa aaacttcatt gaaactcata aactcatgt a tgacaataca 3120
tcagaaatgc ctggaaaga agattccatt atggaggaag agagcacccc agcagtcagt 3180
gactactcta gaattgcattt gggcctaaa cggggccat ctgttactgt a aaggaggtg 3240
ctgacgtgca tccttgcca agaagaacag gaggtgaaaa tagaaaataa tgccatggta 3300
ttatcgccct gtgtccagaa atctactgcc ttaaccgc acagggaaa acccatagaa 3360
ctctcaggag aagccctaga cccacttttcaatggatccag acttggcata tggaacttat 3420
acaggaagct gtggcatgt aatgcacgca gtgtgctggc agaagtattt tgaagctgt 3480
cagctgagct ctcagcagcg cattcatgtt gaccttttcaatggatccag acttggcata tggaacttat 3540
ctttgccctc tttgcaaatac tctgtgcaat actgtgatcc ccattattcc tttgcaacct 3600
caaaaagataa acagtggaaa tgcagatgctt ctgtcaac tttgaccct ggcacgggtgg 3660
atacagactg ttctggccag aatatcaggtaataatataa gacatgctaa aggagaaaaac 3720
ccaattccata ttttctttaa tcaaggaatg ggagattcta ctggaggtt ccattccatc 3780
ctgagtttgcgcgttgc ttcgattaaa tattcaataa gcatcaagga aatggittatt 3840
ctcttgccca caacaattta tagaattgga ttgaaagtgc cacctgtatgaa aaggatcct 3900
cgagtccccca tgctgacccgt gggccatgc gctttcaacta tccaggcaat tgaaaatcta 3960
ttgggagatg aaggaaaaacc tctgtttgga gcacttcaaa ataggcagca taatggtctg 4020
aaagcattaa tgcagttgc agttgcacag aggattaccc tgcctcagggt cctgatacag 4080
aaacatctgg ttcgtcttct atcagttgtt ctgccttacaataa taaaatcaga agatacacca 4140
tgccctctgt ctatagatct gtttcatgtt ttgggtgggtg ctgtgttagc atcccatcc 4200
ttgtattggg atgaccctgt tgatctgcag ctttcttcag ttagttcttc ctataaccac 4260
ctttatctct tccatttgat caccatggca cacatgttc agatactact tacagtagac 4320
acaggcctac cccttgcata ggtcaagaa gacagtgaag aggctcattc cgcatcttct 4380
ttcttgccag aaatttctca atatacaatg ggctccattt ggtgtgatat tccctggctgg 4440
tatttggg tctcaactgaa gaatggcatc accccttatac ttcgctgtgc tgcattgttt 4500
ttccactatt tacttgggtt aactccgcct gaggaactgc ataccaattc tgcagaagga 4560
gagttacagt gactctgttag ctatctatct ttacctacaa atttggccct gctctccag 4620
gaatattggg atactgtaa gccccttgctc cagaggcggt gtgcagatcc tgccttacta 4680

aactgtttga agcaaaaaaa caccgtggtc aggtacccta gaaaaagaaa tagtttgata 4740
gagcttcctg atgactatag ctgcctcctg aatcaagctt ctcatttcag gtgcccacgg 4800
tctcgatg atgagcgaaa gcattctgtc ctctgcctt tctgtggggc tatactatgt 4860
tctcagaaca tttgctgcc a gaaattgtg aacgggaaag aggttgagc ttgcatttt 4920
cacgcacttc actgtggagc cgagactgc atttcctaa aaatcagaga atgccgagt 4980
gtcctggttg aaggtaaagc cagaggctgt gcctatccag ctccttactt ggatgaatat 5040
ggagaaacag accctggcct gaagaggggc aaccccttc atttatctcg tgagcggtat 5100
cggaagctcc atttggctcg gcaacaacac tgcattata aagagattgc taggagccaa 5160
gagactaatac agatgttatt tggattcaac tggcagttac tgtga 5205

<210> 19
<211> 1735
<212> PRT
<213> Homo sapiens

<400> 19
Ala Met Glu Gly Asn Met Ala Asp Glu Glu Ala Gly Gly Thr Glu Arg
1 5 10 15
Met Glu Ile Ser Ala Glu Leu Pro Gln Thr Pro Gln Arg Leu Ala Ser
20 25 30
Trp Trp Asp Gln Gln Val Asp Phe Tyr Thr Ala Phe Leu His His Leu
35 40 45
Ala Gln Leu Val Pro Glu Ile Tyr Phe Ala Glu Met Asp Pro Asp Leu
50 55 60
Glu Lys Gln Glu Glu Ser Val Gln Met Ser Ile Phe Thr Pro Leu Glu
65 70 75 80
Trp Tyr Leu Phe Gly Glu Asp Pro Asp Ile Cys Leu Glu Lys Leu Lys
85 90 95
His Ser Gly Ala Phe Gln Leu Cys Gly Arg Val Phe Lys Ser Gly Glu
100 105 110
Thr Thr Tyr Ser Cys Arg Asp Cys Ala Ile Asp Pro Thr Cys Val Leu
115 120 125
Cys Met Asp Cys Phe Gln Asp Ser Val His Lys Asn His Arg Tyr Lys
130 135 140
Met His Thr Ser Thr Gly Gly Phe Cys Asp Cys Gly Asp Thr Glu
145 150 155 160
Ala Trp Lys Thr Gly Pro Phe Cys Val Asn His Glu Pro Gly Arg Ala
165 170 175
Gly Thr Ile Lys Glu Asn Ser Arg Cys Pro Leu Asn Glu Val Ile
180 185 190
Val Gln Ala Arg Lys Ile Phe Pro Ser Val Ile Lys Tyr Val Val Glu
195 200 205

Met Thr Ile Trp Glu Glu Glu Lys Glu Leu Pro Pro Glu Leu Gln Ile
210 215 220

Arg Glu Lys Asn Glu Arg Tyr Tyr Cys Val Leu Phe Asn Asp Glu His
225 230 235 240

His Ser Tyr Asp His Val Ile Tyr Ser Leu Gln Arg Ala Leu Asp Cys
245 250 255

Glu Leu Ala Glu Ala Gln Leu His Thr Thr Ala Ile Asp Lys Glu Gly
260 265 270

Arg Arg Ala Val Lys Ala Gly Ala Tyr Ala Ala Cys Gln Glu Ala Lys
275 280 285

Glu Asp Ile Lys Ser His Ser Glu Asn Val Ser Gln His Pro Leu His
290 295 300

Val Glu Val Leu His Ser Glu Ile Met Ala His Gln Lys Phe Ala Leu
305 310 315 320

Arg Leu Gly Ser Trp Met Asn Lys Ile Met Ser Tyr Ser Ser Asp Phe
325 330 335

Arg Gln Ile Phe Cys Gln Ala Cys Leu Arg Glu Glu Pro Asp Ser Glu
340 345 350

Asn Pro Cys Leu Ile Ser Arg Leu Met Leu Trp Asp Ala Lys Leu Tyr
355 360 365

Lys Gly Ala Arg Lys Ile Leu His Glu Leu Ile Phe Ser Ser Phe Phe
370 375 380

Met Glu Met Glu Tyr Lys Lys Leu Phe Ala Met Glu Phe Val Lys Tyr
385 390 395 400

Tyr Lys Gln Leu Gln Lys Glu Tyr Ile Ser Asp Asp His Asp Arg Ser
405 410 415

Ile Ser Ile Thr Ala Leu Ser Val Gln Met Phe Thr Val Pro Thr Leu
420 425 430

Ala Arg His Leu Ile Glu Glu Gln Asn Val Ile Ser Val Ile Thr Glu
435 440 445

Thr Leu Leu Glu Val Leu Pro Glu Tyr Leu Asp Arg Asn Asn Lys Phe
450 455 460

Asn Phe Gln Gly Tyr Ser Gln Asp Lys Leu Gly Arg Val Tyr Ala Val
465 470 475 480

Ile Cys Asp Leu Lys Tyr Ile Leu Ile Ser Lys Pro Thr Ile Trp Thr
485 490 495

Glu Arg Leu Arg Met Gln Phe Leu Glu Gly Phe Arg Ser Phe Leu Lys
500 505 510

Ile Leu Thr Cys Met Gln Gly Met Glu Glu Ile Arg Arg Gln Val Gly
515 520 525

Gln His Ile Glu Val Asp Pro Asp Trp Glu Ala Ala Ile Ala Ile Gln
530 535 540

Met Gln Leu Lys Asn Ile Leu Leu Met Phe Gln Glu Trp Cys Ala Cys
545 550 555 560

Asp Glu Glu Leu Leu Leu Val Ala Tyr Lys Glu Cys His Lys Ala Val
565 570 575

Met Arg Cys Ser Thr Ser Phe Ile Ser Ser Ser Lys Thr Val Val Gln
580 585 590

Ser Cys Gly His Ser Leu Glu Thr Lys Ser Tyr Arg Val Ser Glu Asp
595 600 605

Leu Val Ser Ile His Leu Pro Leu Ser Arg Thr Leu Ala Gly Leu His
610 615 620

Val Arg Leu Ser Arg Leu Gly Ala Val Ser Arg Leu His Glu Phe Val
625 630 635 640

Ser Phe Glu Asp Phe Gln Val Glu Val Leu Val Glu Tyr Pro Leu Arg
645 650 655

Cys Leu Val Leu Val Ala Gln Val Val Ala Glu Met Trp Arg Arg Asn
660 665 670

Gly Leu Ser Leu Ile Ser Gln Val Phe Tyr Tyr Gln Asp Val Lys Cys
675 680 685

Arg Glu Glu Met Tyr Asp Lys Asp Ile Ile Met Leu Gln Ile Gly Ala
690 695 700

Ser Leu Met Asp Pro Asn Lys Phe Leu Leu Leu Val Leu Gln Arg Tyr
705 710 715 720

Glu Leu Ala Glu Ala Phe Asn Lys Thr Ile Ser Thr Lys Asp Gln Asp
725 730 735

Leu Ile Lys Gln Tyr Asn Thr Leu Ile Glu Glu Met Leu Gln Val Leu
740 745 750

Ile Tyr Ile Val Gly Glu Arg Tyr Val Pro Gly Val Gly Asn Val Thr
755 760 765

Lys Glu Glu Val Thr Met Arg Glu Ile Ile His Leu Leu Cys Ile Glu
770 775 780

Pro Met Pro His Ser Ala Ile Ala Lys Asn Leu Pro Glu Asn Glu Asn
785 790 795 800

Asn Glu Thr Gly Leu Glu Asn Val Ile Asn Lys Val Ala Thr Phe Lys
805 810 815

Lys Pro Gly Val Ser Gly His Gly Val Tyr Glu Leu Lys Asp Glu Ser
820 825 830

Leu Lys Asp Phe Asn Met Tyr Phe Tyr His Tyr Ser Lys Thr Gln His
835 840 845

Ser Lys Ala Glu His Met Gln Lys Lys Arg Arg Lys Gln Glu Asn Lys
850 855 860

Asp Glu Ala Leu Pro Pro Pro Pro Pro Glu Phe Cys Pro Ala Phe
865 870 875 880

Ser Lys Val Ile Asn Leu Leu Asn Cys Asp Ile Met Met Tyr Ile Leu
885 890 895

Arg Thr Val Phe Glu Arg Ala Ile Asp Thr Asp Ser Asn Leu Trp Thr
900 905 910

Glu Gly Met Leu Gln Met Ala Phe His Ile Leu Ala Leu Gly Leu Leu
915 920 925

Glu Glu Lys Gln Gln Leu Gln Lys Ala Pro Glu Glu Val Thr Phe
930 935 940

Asp Phe Tyr His Lys Ala Ser Arg Leu Gly Ser Ser Ala Met Asn Ile
945 950 955 960

Gln Met Leu Leu Glu Lys Leu Lys Gly Ile Pro Gln Leu Glu Gly Gln
965 970 975

Lys Asp Met Ile Thr Trp Ile Leu Gln Met Phe Asp Thr Val Lys Arg
980 985 990

Leu Arg Glu Lys Ser Cys Leu Ile Val Ala Thr Thr Ser Gly Ser Glu
995 1000 1005

Ser Ile Lys Asn Asp Glu Ile Thr His Asp Lys Glu Lys Ala Glu Arg
1010 1015 1020

Lys Arg Lys Ala Glu Ala Ala Arg Leu His Arg Gln Lys Ile Met Ala
1025 1030 1035 1040

Gln Met Ser Ala Leu Gln Lys Asn Phe Ile Glu Thr His Lys Leu Met
1045 1050 1055

Tyr Asp Asn Thr Ser Glu Met Pro Gly Lys Glu Asp Ser Ile Met Glu
1060 1065 1070

Glu Glu Ser Thr Pro Ala Val Ser Asp Tyr Ser Arg Ile Ala Leu Gly
1075 1080 1085

Pro Lys Arg Gly Pro Ser Val Thr Glu Lys Glu Val Leu Thr Cys Ile
1090 1095 1100

Leu Cys Gln Glu Glu Gln Glu Val Lys Ile Glu Asn Asn Ala Met Val
1105 1110 1115 1120

Leu Ser Ala Cys Val Gln Lys Ser Thr Ala Leu Thr Gln His Arg Gly
1125 1130 1135

Lys Pro Ile Glu Leu Ser Gly Glu Ala Leu Asp Pro Leu Phe Met Asp
1140 1145 1150

Pro Asp Leu Ala Tyr Gly Thr Tyr Thr Gly Ser Cys Gly His Val Met
1155 1160 1165

His Ala Val Cys Trp Gln Lys Tyr Phe Glu Ala Val Gln Leu Ser Ser
1170 1175 1180

Gln Gln Arg Ile His Val Asp Leu Phe Asp Leu Glu Ser Gly Glu Tyr
1185 1190 1195 1200

Leu Cys Pro Leu Cys Lys Ser Leu Cys Asn Thr Val Ile Pro Ile Ile
1205 1210 1215

Pro Leu Gln Pro Gln Lys Ile Asn Ser Glu Asn Ala Asp Ala Leu Ala
1220 1225 1230

Gln Leu Leu Thr Leu Ala Arg Trp Ile Gln Thr Val Leu Ala Arg Ile
1235 1240 1245

Ser Gly Tyr Asn Ile Arg His Ala Lys Gly Glu Asn Pro Ile Pro Ile
1250 1255 1260

Phe Phe Asn Gln Gly Met Gly Asp Ser Thr Leu Glu Phe His Ser Ile
1265 1270 1275 1280

Leu Ser Phe Gly Val Glu Ser Ser Ile Lys Tyr Ser Asn Ser Ile Lys
1285 1290 1295

Glu Met Val Ile Leu Phe Ala Thr Thr Ile Tyr Arg Ile Gly Leu Lys
1300 1305 1310

Val Pro Pro Asp Glu Arg Asp Pro Arg Val Pro Met Leu Thr Trp Ser
1315 1320 1325

Thr Cys Ala Phe Thr Ile Gln Ala Ile Glu Asn Leu Leu Gly Asp Glu
1330 1335 1340

Gly Lys Pro Leu Phe Gly Ala Leu Gln Asn Arg Gln His Asn Gly Leu
1345 1350 1355 1360

Lys Ala Leu Met Gln Phe Ala Val Ala Gln Arg Ile Thr Cys Pro Gln
1365 1370 1375

Val Leu Ile Gln Lys His Leu Val Arg Leu Leu Ser Val Val Leu Pro
1380 1385 1390

Asn Ile Lys Ser Glu Asp Thr Pro Cys Leu Leu Ser Ile Asp Leu Phe
1395 1400 1405

His Val Leu Val Gly Ala Val Leu Ala Phe Pro Ser Leu Tyr Trp Asp
1410 1415 1420

Asp Pro Val Asp Leu Gln Pro Ser Ser Val Ser Ser Tyr Asn His
1425 1430 1435 1440

Leu Tyr Leu Phe His Leu Ile Thr Met Ala His Met Leu Gin Ile Leu
1445 1450 1455

Leu Thr Val Asp Thr Gly Leu Pro Leu Ala Gln Val Gln Glu Asp Ser
1460 1465 1470

Glu Glu Ala His Ser Ala Ser Ser Phe Phe Ala Glu Ile Ser Gln Tyr
1475 1480 1485

Thr Ser Gly Ser Ile Gly Cys Asp Ile Pro Gly Trp Tyr Leu Trp Val
1490 1495 1500

Ser Leu Lys Asn Gly Ile Thr Pro Tyr Leu Arg Cys Ala Ala Leu Phe
1505 1510 1515 1520

Phe His Tyr Leu Leu Gly Val Thr Pro Pro Glu Glu Leu His Thr Asn
1525 1530 1535

Ser Ala Glu Gly Glu Tyr Ser Ala Leu Cys Ser Tyr Leu Ser Leu Pro
1540 1545 1550

Thr Asn Leu Phe Leu Leu Phe Gln Glu Tyr Trp Asp Thr Val Arg Pro
1555 1560 1565

Leu Leu Gln Arg Arg Cys Ala Asp Pro Ala Leu Leu Asn Cys Leu Lys
1570 1575 1580

Gln Lys Asn Thr Val Val Arg Tyr Pro Arg Lys Arg Asn Ser Leu Ile
1585 1590 1595 1600

Glu Leu Pro Asp Asp Tyr Ser Cys Leu Leu Asn Gln Ala Ser His Phe
1605 1610 1615

Arg Cys Pro Arg Ser Ala Asp Asp Glu Arg Lys His Pro Val Leu Cys
1620 1625 1630

Leu Phe Cys Gly Ala Ile Leu Cys Ser Gln Asn Ile Cys Cys Gln Glu
1635 1640 1645

Ile Val Asn Gly Glu Glu Val Gly Ala Cys Ile Phe His Ala Leu His
1650 1655 1660

Cys Lys Ala Arg Gly Cys Ala Tyr Pro Ala Pro Tyr Leu Asp Glu Tyr
1665 1670 1675 1680

Gly Glu Thr Asp Pro Gly Leu Lys Arg Gly Asn Pro Leu His Leu Ser
1685 1690 1695

Arg Glu Arg Tyr Arg Lys Leu His Leu Val Trp Gln Gln His Cys Ile
1700 1705 1710

Ile Glu Glu Ile Ala Arg Ser Gln Glu Thr Asn Gln Met Leu Phe Gly
1715 1720 1725

Phe Asn Trp Gln Leu Leu *
1730 1735

<210> 20
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 20
agaaggagag tacagtgcac tc 22

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 21
cgaaagcatc ctgtccctcg 20

<210> 22
<211> 18

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 22
aggaaagctgt ggtcatgt 18

<210> 23
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 23
gttaggaaga actg 14

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 24
aagaacagcg aaggcaacag 20

<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 25
cgcagctacc ccaacacatt ct 22

<210> 26
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 26
tttcttccat tccctgcata ca 22

<210> 27
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 27
caaaaacttta taaaggtgcc cgtaa 25

<210> 28
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 28
attccctgca tgcacttcag taa 23

<210> 29
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 29
cattccctgc atgcacttca g 21